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Abstract 
 
Erosive lichen planus (ELP) is a chronic, inflammatory, scarring skin 
condition that occurs predominantly on the mucosal surfaces of the 
mouth and genital region. It is believed to be an autoimmune 
condition although the exact pathogenesis remains unclear. 
This thesis focuses on ELP affecting the vulvovaginal region (ELPV). 
This is a rare condition with unknown incidence and prevalence. It 
causes painful raw areas at the vaginal entrance and subsequent 
scarring leads to anatomical changes with narrowing of the vaginal 
canal. Symptoms lead to difficulty in normal daily activities such as 
walking/sitting, washing, going to the toilet and can prevent normal 
sexual function. There is risk of cancerous change in affected skin of 
1-3%.  
A Cochrane Systematic Review of interventions for mucosal erosive 
lichen planus, published in 2012, found no randomised controlled 
trials (RCT) on which to base treatment for ELPV. Evidence for 
treatments has historically been based upon retrospective case-
series and case reports. Retrospective case series suggest that 
super-potent topical corticosteroids an effective first-line therapy, 
although one third of patients fail to respond adequately and require 
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escalation of therapy. There is no agreement for which second-line 
agents should be used and this is where the greatest clinical need 
for therapeutic guidance exists. 
The objective of this PhD was to begin to standardise practice for 
the management of people with ELPV and then develop a pragmatic 
protocol for those individuals who had failed to adequately respond 
to first line therapy with super-potent topical corticosteroids. 
 Initial work focused on current practice in the management of 
lichen planus, how response to therapy was documented and which 
outcome measures were routinely used. The following steps were 
taken to finally inform the design of an RCT to determine optimal 
second-line therapy for EVLP resistant to topical steroids 
฀ A multi-centre retrospective review and audit of case notes to 
assess current clinical management in the UK. Variation in 
practice was found and uncertainties were identified. These 
uncertainties comprised methods of diagnosing the condition, 
outcome measures used to assess severity and impact of the 
disease and therapeutic choices. 
฀ A qualitative investigation into UK clinicianV¶views and 
principles of management of vulval erosive lichen planus. This 
involved interviews with 25 UK clinicians and aimed to begin 
to address the uncertainties identified by the retrospective 
case note study. 
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฀ An international multi-disciplinary consensus exercise. This 
was performed to agree a set of diagnostic criteria for ELPV 
that are acceptable to the clinical community. 
฀ A systematic review of the literature to assess existing 
outcome measure tools that have been used in randomised 
controlled trials of vulval skin disorders. 
฀ A survey of a national patient group, the UK Lichen Planus 
Society which identified preliminary information about living 
ZLWK(/39IURPWKHSDWLHQW¶VSHUVSHFWive.  
฀ Focus groups with patients. The themes identified from the 
UK Lichen planus Society survey, plus findings from the 
systematic review of outcome measures, were subsequently 
explored in greater detail through focus group work with 
patients. Focus groups were also used to obtain patient input 
into the proposed future RCT protocol 
Evidence from this work has informed a randomised controlled trial 
(RCT) developed with input from patients and clinicians to 
pragmatically answer an important question of clinical significance  
The resulting trial is a multi-centre, four-armed, open-label, 
pragmatic randomised controlled trial which will run in the 
secondary care setting. The trial will compare the medications 
hydroxychloroquine, methotrexate and mycophenolate mofetil 
against a standard care group of clobetasol propionate 0.05% plus a 
short course of oral prednisolone. These therapies were identified by 
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clinicians as likely to be most effective in clinical practice. However, 
amongst expert clinicians, there was no clearly preferred agent and 
insufficient data existed within the literature to demonstrate efficacy 
of any of these medications. It was therefore impossible to pick one 
comparator alone to test in a two-armed, placebo controlled RCT. As 
the disease is rare but chronic and resources limited in it was 
decided that a four-armed study would be the most appropriate as it 
would conserve patient numbers compared to running separate 
trials, and would give information on the three of the most 
commonly used systemic agents likely to be most effective. The 
primary outcome measure will be the proportion of participants 
responding to therapy at 6 months. This will be measured by a 
Patient Global Assessment score of 0 or 1 on a 4-point scale, and an 
Investigator Global Assessment of improvement from baseline 
judged by clinical images. 
The randomised controlled trial protocol has received ethical 
approval by the National Research Ethics Committee and the 
necessary regulatory documentation has been completed for the 
trial to commence in summer 2014.  
Impact of this research: 
This will be the first randomised controlled trial to test systemic 
agents for patients with vulval erosive lichen planus and will add to 
the existing evidence base. The impact of this work will potentially 
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extend beyond improving care for patients with ELPV as the 
methodologies employed to develop the RCT protocol, and the trial 
design itself, may act as a template for clinical research into the 
therapeutic management of other rare inflammatory conditions.
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Structure of the Skin and mucous membranes 
The skin is an organ that consists of three layers: the epidermis, 
dermis and subcutis. These three structures are represented in 
Figure 1, Page 5. 
i. The epidermis 
The epidermis is the uppermost layer of the skin and is an epithelial 
surface. Squamous epithelium (from Latin squama, "scale") is 
characterised by its most superficial layer consisting of flat, scale-
like cells. In the skin, keratinocytes, which are squamous cells, form 
a stratified epithelium, which consists of four distinct layers. These 
are the stratum basale (basal layer), stratum spinulosum (spinous, 
spiny or prickle cell layer), stratum granulosum (granular layer) and 
stratum corneum (horny layer), which are demonstrated in Figure 1, 
Page 5.  
Stratified squamous epithelium is present on the skin and mucous 
membranes. The keratinocytes undergo a process of maturation as 
they develop from the basal and move outwards towards the skin 
surface. Cells in the basal layer divide and the keratinocytes 
subsequently migrate upwards. They progressively become flattened 
and lose their nuclei as they move towards the stratum corneum. 
Skin, hair and nails are keratinized, which indicates that the 
outermost layer of the epidermis (stratum corneum) is formed by 
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dead, dried out keratinocytes. Figure 2, page 6 shows a 
haematoxylin and eosin stain of a section of normal epidermis. The 
four distinct layers are visible and the stratum corneum has a 
µEDVNHWZHDYH¶DSSHDUDQFH, which confers a hard and impermeable 
surface to the skin. 
In contrast, mucous membranes are non-keratinised. Figure 3, page 
6, demonstrates a typical haematoxylin and eosin stain of non-
keratinising mucosa. There is still differentiation and maturation of 
keratinocytes as they progress upwards from the basal layer, but 
the stratum corneum is absent. Mucous membranes contain more 
glandular structures than keratinized skin, and so remain moist. It is 
glandular secretions, rather than keratin that act to protect mucous 
membranes. 
The differences between keratinized and non-keratinised epithelia 
are important for this thesis on lichen planus as the disease can 
affect either type of surface. However, when it affects mucosal 
surfaces, lichen planus tends to be more resistant to treatment and 
causes greater morbidity. 
Immediately below the basal layer is the basement membrane, a 
specialised structure that links the epidermis and dermis and has a 
vital role in maintaining skin structure. 
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Hair, nails and sweat glands are appendageal structures formed by 
a direct extension of the epidermis. These structures extend down 
into the dermis, but are lined by epidermal cells. 
ii. The dermis 
The dermis is composed of fibrous connective tissue. It contains 
mostly collagen and elastin which provide a supportive structure for 
the skin. Nerves, blood vessels, adnexal structures and cells (mast 
cells, immune cells, fibroblasts and specialised muscle cells) are also 
present in the dermis. When the skin is involved in disease states, 
inflammatory cells transiently infiltrate the dermis, and sometimes 
the epidermis and subcutis. 
iii. The subcutis 
The subcutis is a layer of fat which lies directly below the dermis. It 
consists mainly of adipocytes, nerves and blood vessels.  
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Figure 1: Schematic representation of the three layers of the skin (main diagram) 
and epidermis (insert).  
7DNHQIURP5RRN¶VWH[WERRNRI'HUPDWRORJ\th Edition. 
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Figure 2: High power photomicrograph view of epidermis; keratinised stratified 
squamous epithelium. Haematoxylin and Eosin stain, x 100 magnification. 
The four distinct layers of the epidermis are clearly seen with the hard, 
impermeable keratin layer providing a protective surface to the skin. Image taken 
from ¶www.tissuepath.com.au¶ 
 
Figure 3: Low power photomicrograph of non-keratinising stratified squamous 
epithelium. Haematoxylin and Eosin stain, x 40 magnification. 
In contrast to Figure 2 (above) there is no stratum corneum but there are increased 
glandular secretions that protect mucosal surfaces. Image courtesy of Dr S Deen.
Stratum 
corneum with 
µEDVNHWZHDYH¶
pattern of 
surface keratin 
Granular layer 
Spinous layer 
Basal layer 
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Chapter 1 Introduction - Lichen 
Planus 
Chapter 1: Introduction to lichen planus 
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1.1 What is lichen planus? 
In this chapter, lichen planus, its epidemiology, understood 
pathology, clinical presentations and associations with other medical 
conditions will be discussed in detail. Since this thesis focuses 
predominantly on erosive lichen planus affecting the vulval region, 
whilst all clinical variants are described, greater emphasis is placed 
on vulval erosive lichen planus.  
7KHWHUPµOLFKHQ¶LVXVHGE\GHUPDWRORJLVWVWRGHVFULEHWKHSUHVHQFH
of flat-topped, papular lesions on the skin. Histopathologically, 
µOLFKHQRLG¶UHIHUVWRDFKDUDFWHULVWLFSDWWHUQRILQIODPPDWLRQLQZKLFK
a band-like inflammatory cell infiltrate is seen in the upper dermis. 
This is described in greater detail later in this chapter. 
Lichen planus (LP) was first described by Erasmus Wilson in 1869. It 
is an inflammatory mucocutaneous disorder that may involve any 
surface lined with squamous epithelium. 7KHGHILQLWLRQRIµVTXDPRXV
HSLWKHOLXP¶LVJLYHQLQWKHLQWURGXFWLRQVHFWLRQi (page 2). LP can 
affect both keratinized skin and mucosal surfaces. The structural 
differences in these different types of epithelia are also described in 
the introduction, section i (page 2).  
The regions of the body which can be affected by LP and the typical 
lesions at these sites are illustrated on page 18, which shows a body 
map with some of the common and rarer sites of involvement. The 
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skin and oral mucosa are most frequently affected (Le Cleach 2012). 
Different forms of LP exist and are predominantly the plaque type 
(affecting keratinized skin) and the erosive type (affecting non-
keratinised mucous membranes). Other types such as bullous or 
hypertrophic may also occur. 
1.1.1 Histological changes in lichen planus 
Classical histologic findings are the same in lichen planus, regardless 
of which site is affected. However, the site that a biopsy is taken 
from is important and it may be more difficult to demonstrate 
typical features in mucosal areas if an area of ulceration is sampled. 
Characteristic histologic features of lichen planus are demonstrated 
in Figure 4, page 10 and Figure 5, page 11, and include:  
฀ thickening of the stratum corneum; 
฀ accentuation of the granular-cell layer; 
฀ SRLQWHGµUHWHULGJHV¶DQGZHGJHVKDSHGK\SHUJUDQXORVLV 
(thickening of the stratum granulosum) that gives DµVDZ
WRRWKHG¶SDWWHUQ 
฀ liquefactive degeneration of the basal-cell layer (basal cells 
GHJHQHUDWHDQGIRUPµFROORLGERGLHV¶;  
฀ a band-like inflammatory-cell infiltrate (usually composed of 
lymphocytes).  
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Figure 4: Low power photomicrograph of lichen planus affecting keratinising skin. 
Haematoxylin and Eosin stain, x 40 magnification. 
An inflammatory infiltrate is present in the upper dermis which in some areas 
appears to infiltrate the epidermis. Image tDNHQIURP5RRN¶V7H[tbook of 
Dermatology 8th Edition. 
  
Dense inflammatory cell 
infiltrate in the upper 
dermis 
Inflammatory infiltrate 
extends up to and in some 
areas effaces the epidermis 
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Figure 5: High power photomicrograph of lichen planus on keratinising skin. 
Haematoxylin and Eosin stain, x 100 magnification. 
There is a band-like inflammatory infiltrate, effacement of the epidermis with 
degeneration of the basal cell layer and thickening of the granular cell layer of the 
HSLGHUPLV,PDJHWDNHQIURP5RRN¶V7H[WERRNRI'HUPDWRORJ\th Edition. 
  
Band-like inflammatory 
infiltrate in upper dermis 
(also appreciated in Figure 
4, above) 
Inflammatory infiltrate 
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Thickening of granular cell 
layer 
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1.2 Clinical variants of Lichen Planus 
1.2.1 Classical Lichen Planus 
The most common form or µclassical¶ form of lichen planus affects 
the skin and is termed cutaneous LP. It is estimated to affect 1% of 
the population (Boyd 1991). It presents with characteristic well-
demarcated, polygonal plaques (flat-topped raised lesions) that are 
violaceous in colour. The surface of these plaques often display 
µ:LFNKDP¶VVWULDH¶, which is the clinical finding of white lacy lines 
(Rook 2010). 7KHDSSHDUDQFHRI:LFNKDP¶Vstriae is shown in Figure 
6 (Page 18) where they are present overlying an erythematous 
plaque on the image of cutaneous LP. Plaques of cutaneous LP 
typically occur on the extensor surfaces of the wrists and ankles, 
however, the skin appendegeal structures, the hair and nails, may 
also be affected. The former presents with irregular pits, 
thinning/ridging of the nail plate and distal splitting that leaves a 
scar (pterygium). The latter causes a scarring alopecia (Rook 2010) 
and is shown in Figure 6, page 18, on the image of a scalp. 
Lesions of classical cutaneous LP may also take on different 
morphologies, including papules which appear in groups, lines or 
rings (Rook 2010). In particular, linear lesions may occur following 
WUDXPDWKHVRFDOOHGµ.RHEQHUSKHQRPHQRQ¶&LUFXODUDOVRWHUPHG 
µDQQXODU¶) lesions may be formed by groups of papules arranged in 
rings, or by a single large papule, which clears centrally to leave an 
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active margin (Rook 2010). Annular lesions are most commonly 
seen on the penis (Rook 2010). 
Classical LP can affect any cutaneous surface which includes the 
anogenital skin. When it affects the vulva and/or perianal region, 
presenting features are those of small, intensely itchy violaceous 
papules located on the external genital skin:LFNKDP¶VVWULDHDUH
often seen overlying these anogenital lesions (Goldstein 2005).  
1.2.2 Hypertrophic lichen planus 
If lesions of classical LP persist for a long time, they may enlarge, 
thicken and form a rough surface. This is known as hypertrophic LP, 
which causes severe symptoms of itching. Although hypertrophic 
lesions may eventually resolve they tend to leave considerable 
scarring (Rook 2010). Such lesions are most commonly found on 
the ankles, shins, palms and soles. Malignant transformation has 
been described in this variant (Yesudian 1985). 
1.2.3 Bullous lichen planus 
In bullous (blistering) LP, blisters appear near to, or in within the 
lesions of LP. This is a reflection of severe inflammation occurring in 
the basal cell layer of the skin. Due to destruction of this histologic 
layer, which is represented schematically in Figure 1, page 5, the 
epidermis and dermis separate, which causes bullae (blisters) to 
form. This eruption is usually of short duration but may lead to 
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diagnostic difficulty as other bullous disorders may present similarly. 
Histological and direct immunofluorescence examination of affected 
skin is important in these cases to reach the correct diagnosis. 
1.2.4 Lichen Planus affecting mucous membranes 
Mucous membrane lesions are common and may be present with or 
without concomitant skin lesions. Any mucous membrane may be 
affected by the condition, although the oral and genital mucosa are 
the most common mucosal sites to be involved. More than one 
mucosal site can be affected at any one time. This section is an 
introduction to how lichen planus can affect mucosal surfaces; vulval 
lichen planus, which is the focus of this work is described in much 
greater detail in sections 1.3 (page 19) to 1.12 (page 100). 
1.2.4.1 Oral lichen planus 
Involvement of the oral cavity, oral lichen planus (OLP) is believed 
to the most common presentation of LP worldwide and is sometimes 
the only manifestation of the disease in an individual (Rogers 2003). 
It has been suggested that the prevalence of OLP is 1-2% in people 
over the age of 15 years (Axell 1987). 
The clinical presentation of OLP is often insidious with some patients 
being asymptomatic. Others report roughness of the mouth, 
sensitivity to foods (especially hot and spicy items), pain or 
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ulceration, or a combination of these. Symptoms largely depend 
upon the clinical subtype of disease. 
Several distinct clinical subtypes of OLP are recognized reticulate LP 
(appearing as lacy white lines on the buccal mucosa) may or may 
not be symptomatic. Hypertrophic LP, forms fixed, white plaques on 
the buccal mucosa may be mistaken for candidiasis and is at 
potentially higher risk of malignant transformation than the other 
forms. Erosive lesions are usually highly symptomatic as they leave 
denuded, raw areas of mucosa that are slow to heal. Erosive LP may 
extend to the larynx or oesophagus (Abraham 2000) which leads to 
dyspahgia and formation of strictures. Patients with OLP may also 
have other mucosal sites affected, for example the genital and 
lacrimal mucosa.  
Other clinical forms of OLP include papular, atrophic and bullous. 
1.2.4.2 Genital lichen planus 
Lesions affecting the male and female genitalia (vulva, vagina, 
penis) are well recognized albeit less common than OLP. On the 
penis, classical LP is most often seen. In females, erosions affecting 
the mucosal surface of the vulva are more frequent and it is termed 
erosive lichen planus (ELP). These erosions may extend to affect the 
vagina. Genital lesions are either seen alone or in conjunction with 
OLP. In a large case series of 339 patients with OLP, LP affecting the 
vulva and vagina was identified in 77 (19%) (Eisen 1999).  
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In a specific, severe variant, ELP may concomitantly affect the 
vulva, vagina and oral mucosa. This is known as the vulvovaginal 
gingival (VVG) syndrome and causes considerable morbidity as it is 
resistant to treatment. The equivalent in males is the penogingival 
syndrome. 
1.2.4.3 Other mucous membrane sites 
Other less commonly affected mucosal sites include the eyes 
(Neumann 1993), bladder, larynx, stomach, and anus (Eisen 1999). 
However, relatively little is known about these less common sites, 
especially when compared with the literature available for oral and 
cutaneous LP.   
1.2.5 Who gets lichen planus? 
Oral lichen planus presents at a mean age of 50-60 years (Carbone 
2009, Bermejo-Fenoll 2010). The mean age at diagnosis for 
cutaneous LP is 40-45 years (Irvine 1991). Vulval erosive LP 
primarily affects peri or post menopausal females (Eisen 1999) and 
it is an uncommon condition. 
 Both oral and cutaneous LP have been reported in children, 
although this is usually considered rare, except for the Indian 
subcontinent (Kanwar 2010) where some studies have estimated 
the incidence of LP in childhood to be as high as 11% of all LP cases 
(Kumar 1993). 
Chapter 1: Introduction to lichen planus 
17 
 
1.2.6 Prognosis of the different variants of lichen planus 
Cutaneous LP tends to be self-limiting and is responsive to 
treatment with super-potent topical steroids. Post-inflammatory 
pigmentary changes usually occur, however these fade over time 
and permanent scarring is infrequent. Hair disease (lichen 
planopilaris) also tends to take a self-limiting course but is often 
resistant to treatment and leads to a scarring alopecia which is 
irreversible.  
Nail LP is a scarring, destructive disease causing loss of normal nail 
architecture. It is more likely to require systemic 
immunosuppression, for example, with oral corticosteroids, to which 
response is variable. Hypertrophic LP is also treatment resistant and 
prolonged therapy with super potent topical corticosteroids or 
calcineurin inhibitors is often required. 
In contrast to classical cutaneous LP, disease that affects mucosal 
surfaces such as the oral, genital and other mucosa takes a more 
chronic, relapsing/remitting course (Silverman 1985) and may be 
resistant to treatment. Super potent topical steroids are the widely 
recognised first-line therapy, however, up to one third of patients 
are refractory to these and are likely to have long-term inadequate 
control of their disease.  
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Figure 6: Schematic diagram demonstrating the distribution and type of lichen planus 
lesions on the skin and mucous membranes. 
:LFNKDP¶VVWULDHDUHHDVLO\LGHQWLILHGDWWKHPDUJLQRIWKHOHVLRQVDWWKHODELDPLQRUDDQG
in the buccal sulcus. 
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1.3 Erosive Lichen Planus affecting the Vulva 
This thesis focuses specifically on erosive LP affecting mucosal 
surfaces, specifically the adult female genitalia (erosive lichen 
planus of the vulva, ELPV). It is important though to consider ELPV 
as part of a disease spectrum involving other mucosal surfaces, 
especially the oral mucosa, as described in section 1.2.4. This 
section will therefore at times discuss vulval LP in conjunction with 
other mucosal variants, mainly oral LP. Furthermore as ELPV is 
much less common that oral LP, evidence is lacking in many aspects 
of this subset and at times inferences must be drawn from the oral 
literature.   
1.3.1 Epidemiology of erosive lichen planus affecting the 
vulva 
1.3.1.1 Incidence and prevalence 
The true incidence and prevalence of ELPV is unknown. This is due 
to the variable clinical presentation, lack of clearly defined 
diagnostic criteria and reluctance of women to present to secondary 
care. A formal literature search was not able to identify any 
epidemiological studies that provide these data. 
Studies of patients attending vulval specialty clinics have reported 
variable figures for the number of new patient referrals who were 
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subsequently diagnosed with with ELPV. These are currently the 
best available data and are detailed in Table 1, page 20. 
Study Duration 
of study  
No. of new 
patients 
assessed  
No. of 
patients 
diagnosed 
with ELPV 
Proportion 
of new 
referrals 
diagnosed 
with ELPV 
Hansen 
2002 
4 years 322 25 8% 
Helgesen 
2010 
6 years 989 59 6% 
Kennedy 
2007 
7 years 3983 113 3% 
Table 1: Proportion of new referrals to vulvar specialty clinics who were found to 
have vulval erosive lichen planus. 
 
The largest cohort of patients with vulval disease was described by 
Kennedy (Kennedy 2007) who found that of nearly 4000 patients 
presenting to a specialist clinic in a United States tertiary referral 
centre, 3% were diagnosed with ELPV. Helgesen (Helgesen 2010) 
and Hansen (Hansen 2002) found that in smaller cohorts of new 
referrals to vulval services, 6% and 8% had ELPV respectively.  
A further study by Micheletti et al (Micheletti 2000) found a 
prevalence of 3.7% of ELPV from a case series of 3350 vulval 
biopsies taken between 1986-99 in a specialist vulval clinic.  
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Unfortunately as the size of the population that these cohorts of 
patients were from, it is not possible to calculate incidence and 
prevalence of ELPV. 
However, the figures from these case series suggest that ELPV is 
not as rare as originally thought. Furthermore, the overall problem 
is likely to be underestimated for the following reasons: Genital 
lesions may be subtle (Moyal-Barracco 2004), patients may not 
associate their symptoms with LP elsewhere (Lewis 1996), and there 
remains a culture of patients delaying presentation to medical 
services to seek help for their genital problem (Lawton 2006). 
Therefore, although ELPV has previously been perceived as a rare 
disease, as more clinicians become aware of its existence it is being 
diagnosed more frequently, especially in women (Moyal-Barracco 
2004). 
Erosive lichen planus affecting the vulva often occurs in conjunction 
with other forms of lichen planus. In a study of 37 women with 
cutaneous LP, half had vulval lesions (Lewis 1996). Other studies 
evaluating patients with oral LP have found a prevalence of affected 
vulval skin in 57% (Belfiore 2006) and 19% (Eisen 1999). 
1.3.1.2 Affected age group 
Erosive lichen planus affecting the vulva (ELPV) typically affects 
females of peri- and post-menopausal age (Eisen 1999, Cooper 
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2006) although has been described in patients with ages ranging 
from teens to octogenarians (Micheletti 2000, Helgesen 2010). 
 
1.3.2 Pathogenesis of erosive lichen planus affecting the 
vulva 
The pathogenesis of the disorder is still not entirely clear. It is 
thought though that all types of lichen planus including that 
affecting genital and oral mucosa, have a similar autoimmune 
pathology (Cooper 2008).  
The histology of erosive LP shows features the same as in classical 
LP, with basement membrane zone disruption due to lymphocytic 
infiltration (as demonstrated in the histopathological images in 
Figure 4, page 10, and Figure 5, page 11). The 
immunohistochemistry of cutaneous LP shows widespread changes 
in antigen expression and it is believed that the pathogenesis of 
cutaneous LP is broadly similar to that of ELPV. 
Cooper et al (Cooper 2005) found disruption of major 
hemidesmosomal proteins found at the basement membrane zone in 
a study of 6 patients with ELPV.  In another study (Sander) they 
also found reduced antioxidant defense mechanisms in conjunction 
with increased oxidative damage at the dermo-epidermal junction in 
ELPV patients, suggesting that the accumulation of severely oxidised 
Chapter 1: Introduction to lichen planus 
23 
 
proteins at this site is relevant to the development of scarring and 
skin fragility seen in ELPV. The process of oxidative damage leading 
to T-cell activation and subsequent damage to the basement 
membrane is demonstrated in Figure 7, page 24.  
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Figure 7: Schematic representation of the proposed pathogenesis of erosive lichen 
planus. 
The image shows how in response to oxidative damage, subsequent T-cell 
mediated damage results in disruption of the basement membrane. 
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1.3.3 Aetiological factors in the pathogenesis of erosive 
lichen planus affecting the vulva 
1.3.3.1 Autoimmunity and its association with erosive lichen planus 
affecting the vulva 
Current thinking is that autoimmune mechanisms cause the 
pathological changes in patients with lichen planus affecting mucosal 
surfaces and that the disease is itself an autoimmune condition 
(Cooper 2008, Rook 2010). This is evidenced by studies that 
demonstrate an increased prevalence of other autoimmune 
disorders in patients with vulval erosive lichen planus.  In these 
individuals, circulating autoantibodies targeted towards specific BMZ 
proteins were identified.  Furthermore, oral ELP has been described 
in patients with autoimmune blistering conditions, suggesting 
occurrence of blisters and lichen planus may reflect an extension of 
the immune response to shared antigens (Shipman 2009). 
Cooper et al (Cooper 2005), in a study of 56 cases of ELPV found 
61% to have weakly circulating IgG BMZ antibodies. Of the 11 
samples in this study sent for immunoblotting, the BMZ antibodies 
were found to be predominantly of the BP 180 subtype (8/11). This 
particular antibody is found in the autoimmune blistering skin 
condition, bullous pemphigiod. There were no major differences in 
clinical characteristics between those with positive and those with 
negative BMZ antibodies. It was concluded that the study probably 
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provides evidence for an autoimmune process in ELPV, although the 
detection of these BMZ autoantibodies are more likely a marker for 
disease rather than being directly pathogenic. The same group 
(Cooper 2002), in a study of 37 patients with ELP found that the 
presence of BMZ does not confer adverse prognosis, particularly in 
terms of disease severity and the presence of scarring. 
T cells reactive to the NC16A domain of BP180 were found 2/5 
patients with vulval LP compared with 0/10 controls in a study by 
Baldo in 2010 (Baldo 2010). This was a small study that 
predominantly investigated patients with lichen sclerosus rather 
than LP. It was not specified whether the patients had erosive LP, or 
other subtypes, and diagnostic criteria for inclusion were not 
specifically stated. Terlou et al (Terlou 2012) subsequently 
demonstrated that a high level of pro-inflammatory cytokines in LP 
result in a dense T cell infiltrate in a study involving nine vulval LP 
patients. Although patient numbers were small in both Baldo and 
7HUORX¶VVWXGLHVERWKLPSOLFDWHGDQWLJHQVSHFLILF7FHOOVLQYXOYDO/3
and therefore suggest that treatment of ELPV should be aimed at 
immunosuppression. 
A subsequent cohort study of 126 patients with ELPV (Cooper 2008) 
found 29% to have one or more alternative autoimmune disease, 
compared with 9% in the control group (p<0.001). Thyroid disease 
was most prevalent (15% vs 8%; P<0.001), followed by alopecia 
areata (4% vs 0.1%; P<0.001), and coeliac disease (2% vs 0.2%; 
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P=0.01). 31% ELPV cases had positive family history of one or more 
autoimmune diseases in a first-degree relative. 41% of ELPV cases 
had positive autoantibodies compared with 20% of controls 
(p=0.002). The authors concluded that the results were highly 
suggestive that ELP is associated with autoimmune disease and 
therefore has an autoimmune basis. However, one aspect that was 
not clear from this study is how well matched the control and case 
groups were with regards to ethnicity and this may be relevant as 
certain ethnic groups experience a higher prevalence of autoimmune 
conditions. Setterfield et al (Setterfield 2006) demonstrated similar 
findings in a case series of 40 patients. In this study, 32.5% of 
patients suffering from ELPV, as part of the vulvovaginal syndrome, 
were found to have a first degree relative affected with autoimmune 
disease and 30% had a personal history of autoimmune disease. 
Ebrahimi et al (Ebrahimi 2012) noted 10% of 120 patients with 
mucosal LP had thyroid autoantibodies compared with 6% of 83 
controls. P values for this were not given. 
1.3.3.2 Genetic contribution to the pathogenesis of erosive lichen 
planus affecting the vulva 
Setterfield (Setterfield 2006) found patients with the vulvovaginal 
syndrome to be more likely to possess the HLA DQB1*0201 gene 
than controls (80% versus 41.8%). This particular gene allele has 
been linked to autoimmune disorders, such as thyroid and coeliac 
disease. From this paper it is not clear though whether there is a 
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pathogenic link between this particular HLA or whether its presence 
is a confounding factor due to the increased presence of 
autoimmune conditions in the patient cohort. 
Several familial cases have been reported in  oral LP (Bermejo-
Fenoll 2006), which further adds weight to the role of genetic 
background in all subsets of mucosal LP.  
1.3.3.3 Association of triggers with erosive lichen planus affecting 
the vulva 
Most cases of LP are idiopathic, although some are thought to be 
drug-induced and infections have been implicated in others 
(Sawardekar 2011). Triggers for reticulate LP may be different to 
those of erosive LP. 
1.3.3.4 Infective triggers 
A link between liver disease, in particular infection with the hepatitis 
C virus has been suggested with lichen planus in general, however, 
studies that have demonstrated this were performed by groups from 
countries where there is a higher prevalence of such infections 
(Sanchez-Perez 1996, Mignogna 1998, Nagao 2008).  Reports from 
UK-based populations have found no link to oral (Ingafou 1998), 
cutaneous (Tucker 1999) or vulval (Cooper 2004) LP. It has been 
suggested that although routine serological screening for hepatitis C 
in all patients with LP would not be cost effective, patients should at 
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least be asked about any major or minor risk factors (Bigby 2009). 
If any do exist, then serological testing can then be performed.  
Some authors have putatively suggested a link with herpes simplex 
virus infection (Ebrahimi 2012). There was a statistically significant 
difference in antibodies against herpes simplex virus in mucosal LP 
cases compared with control (60% v 44%, p<0.03). Furthermore, 
patients with significantly higher titres had more oral symptoms 
than the other patients. These figures were from a retrospective 
case series of patients and further work is required to confirm or 
refute this potential association. 
1.3.3.5  Association of lichen planus with specific medications 
Systemic medications have been associated with lichenoid skin and 
mucosal changes (Rook 2010).  One study found increased use of 
beta-blockers and non-steroidal anti-inflammatory agents amongst 
patients with mucosal LP (Clayton 2010) and suggested withdrawal 
of these drugs in such patients. However, this was a retrospective, 
questionnaire based study with high risk of recall bias and little 
theoretical explanation for how these drugs could cause mucosal 
ulceration. However, most of these medications have been found to 
induce reticulate rather than erosive LP. 
Antimalarial drugs, other antihypertensive agents, oral 
hypoglycaemic agents and antiretroviral agents have also been 
reported to cause oral lichenoid eruptions (Ismail 2007). 
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1.3.3.6 Other factors influencing disease presentation 
Exacerbations of LP affecting mucosal sites have been linked with 
periods of psychological stress by some studies. Tobacco chewing 
and  dental materials such amalgam, metals and composite 
restorations  have been associated with oral, but not vulval LP  
(Ismail 2007). 
1.4 Exacerbating factors in erosive lichen planus of 
the vulva 
1.4.1 Oestrogen deficiency 
Vulvovaginal atrophy resulting from oestrogen deficiency in 
postmenopausal females is a common condition. Symptoms include 
dryness, irritation, dyspareunia along with urinary frequency, 
urgency and urge incontinence (Mac Bride 2010). The prevalence of 
vulvovaginal atrophy symptoms is most common in postmenopausal 
females with estimates of prevalence ranging from 4-47% (Mac 
Bride 2010). Given that the peak incidence of ELPV is in this age 
group (Mann 1991, Eisen 1994, Cooper 2006), it may be difficult to 
untangle the symptoms of vulvovaginal atrophy from those of ELPV. 
Physicians treating ELPV should be mindful of this fact, especially if 
ELPV is resistant to first-line therapy as vulvovaginal atrophy may 
be an exacerbating factor. 
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1.4.2 Irritation from urine and faeces 
Irritation (contact irritant dermatitis) secondary to urine and faeces 
is a common cause of vulval symptoms and may worsen the effects 
of a pre-existing vulval skin condition. As the barrier function of the 
skin is impaired in inflammatory conditions, there is greater 
susceptibility to irritant contact dermatitis. History taking for a 
genital skin complaint should specifically include enquiring about 
incontinence of urine or faeces as patients will not usually volunteer 
this information (Lawton 2006). Conversely, patients with ELPV may 
actually present with symptoms of dysuria due to the effects of 
urine burning eroded vulval skin. This in itself may lead to 
secondary incontinence. 
Any patient with a vulval skin disease should have symptoms of 
urinary or faecal incontinence addressed as improving these is likely 
to improve their overall condition. 
1.4.3 Contact irritants 
Contact with irritants in topical agents, particularly cleansing 
products such as bubble bath, soaps, wet-wipes and medicaments 
may all cause an irritant dermatitis (Bunker 2010). Patients with 
vulval skin conditions are more likely to use such products 
frequently in an attempt to cleanse the area as they perceive this to 
be helpful. Unfortunately, the consequence of this is often the 
opposite and worsening of the skin condition may occur. 
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1.4.4 Allergic contact dermatitis 
Allergic contact dermatitis of the vulval area is much less common 
than irritant dermatitis, however, allergy to topical medicaments 
may occur (Lewis 1997) and patch testing is important if signs of 
this are present in surrounding skin. 
1.4.5 Stress 
Stress is anecdotally felt to worsen inflammatory skin conditions and 
studies have shown a positive correlation with stressful events in 
cutaneous LP (Manolache 2008) compared with controls. 
Furthermore, it is felt that stress may contribute to the initiation and 
propagation of oral LP (Ivanovski 2005). Given these findings and 
through anecdotal evidence (personal communication) it is possible 
that ELPV is linked with stress in some way. 
1.5 Clinical subtypes of vulval lichen planus 
There are three distinct clinical patterns  of lichen planus affecting 
the vulval area and more than one variant may be present in any 
given patient (Moyal-Barracco 2004).  
The most common form of LP affecting the vulva is the erosive type, 
vulval erosive lichen planus (ELPV). In ELPV, well demarcated 
erythematous lesions are present (Figure 8, page 34). These 
inflammatory areas often ulcerate, although erosions are not always 
present (Kirtschig 2005). The reticulate pattern (white reticulate 
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lines with a lacy appearance), may be present in conjunction with 
erosions. The vulvo-vaginal gingival syndrome (VVG) is a severe 
variant of ELP encompassing erosions of the vulva, vagina and 
gingiva. This variant was first described in 1982 (Pelisse 1989). 
Classical LP, which is the variant usually seen affecting the skin (as 
described in section 1.1) may be seen solely affecting the vulva. In 
this situation, presenting features are those of small, intensely itchy 
violaceous papules located on the external genital skin, which can 
be seen in Figure 9, page 34:LFNKDP¶VVWULDHDUHRIWHQVHHQ
overlying these lesions (Goldstein 2005).  
The final variant of LP affecting the vulva is hypertrophic LP which 
consists of hyperkeratotic areas with a thickened, irregular surface. 
This is similar to hypertrophic LP affecting the skin (see section 
1.2.2, page 13). 
Of these three subtypes, it is ELPV, particularly the VVG syndrome 
which are typically difficult to treat (Moyal-Barracco 2004) and 
although improvement in the condition is sometimes seen, cure is 
not possible and complete control rarely occurs. Vulval erosive 
lichen planus appears to cause the most suffering in the clinical 
setting.  
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Figure 8: Erosive lichen planus affecting the vulva. 
There is an erythematous area with a slightly hyperkeratotic border at the entrance 
to the vagina. The lesion is surrounded by lacy white lines, particularly in the 
perineal area. Image tDNHQIURP5RRN¶V7H[WERRNRI'HUPDWRORJ\th Edition. 
 
Figure 9: Classical lichen planus affecting the external genitalia.  
There are well demarcated areas of inflammation and post inflammatory 
hyperpigmentation affecting external genital skin. 7DNHQIURP5RRN¶V7H[WERRNRI
Dermatology, 8th Edition. 
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1.5.1 Erosive lichen planus affecting other mucosal sites 
Erosive lichen planus is a multisystem disease (Figure 6, page 18). 
Until 1999, there had been few reports documenting the 
concomitant involvement of other sites in addition to the oral or 
genital mucosa (Eisen 1999). Eisen et al evaluated a case series of 
584 patients with oral LP for extra-oral involvement. They found 
involvement of the skin (16%), genitals (19% of 399 women who 
underwent genital examination), nails (2%), scalp (lichen 
planopilaris, 1%), oesophagus (1%) and conjunctiva (0.02%).  
Subsequent cohort studies involving women with ELPV have 
reported a varying prevalence of LP affecting other skin/mucosal 
sites. The oral mucosa and skin are most commonly associated with 
LP. The scalp may demonstrate a scarring alopecia. The 
oesophagus, outer ear and lacrimal duct are rarer sites of 
involvement. However, it is believed that the prevalence of 
oesophageal disease has been underestimated as patients are 
infrequently asked about symptoms such as dysphagia, or it may be 
asymptomatic (Fox 2011). Dickens et al (Dickens 1990) 
demonstrated that oesophageal LP was present in 5 of 19 patients  
presenting to a dermatology department with cutaneous LP. Four of 
the five patients had concomitant oral disease.  
Furthermore, it is not just the vulvovaginal mucosa that undergoes 
a scarring process. The result of chronic inflammation elsewhere can 
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lead to detrimental effects such as oesophageal strictures and 
lacrimal duct scarring (Webber 2012), which may be bilateral 
(Durrani 2008).  
1.5.2 Differential diagnosis of erosive lichen planus affecting 
the vulva 
Erosive lichen planus affecting the vulva may be difficult to 
diagnose. Conditions which may present in a similar manner include 
vulval squamous cell cancer as seen in Figure 10 (page 37), vulval 
intraepithelial neoplasia, as seen in Figure 11 (page 38) and 
autoimmune bullous disease (e.g. bullous pemphigoid, pemphigus 
vulgaris) as seen in Figure 12 (page 39). These conditions require a 
different management approach to ELPV. In the case of squamous 
cell carcinoma and vulval intraepithelial neoplasia, there is a high 
chance that standard ELPV treatment will progress the neoplasia. It 
is therefore important to use accurate clinical and histopathological 
information to ensure the correct diagnosis is made.  
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Figure 10: Squamous cell carcinoma on the right labia minora 
The malignancy has developed secondary to pre-existing lichen sclerosus. The 
image demonstrates erythematous ulceration with granular morphology which is 
suggestive of malignant or pre-malignant change. Image taken from Rooks 
textbook of Dermatology 8th Edition. 
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Figure 11: Vulval Intraepithelial Neoplasia. 
In this image the disease is presenting as a unilateral eroded plaque on the left 
labia majora. Erosive lichen planus would most likely be bilateral in its appearance. 
Image taken from Rooks textbook of Dermatology 8th Edition 
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Figure 12: Mucous membrane pemphigoid affecting the vulva. 
There is a well demarcated, annular erosion on the right labia minora with a slightly 
hyperkeratotic border. Erosive lichen planus would most likely be bilateral and 
symmetrical in its appearance, although more extensive mucous membrane 
pemphigoid may be difficult to distinguish clinically. Image taken from Rooks 
textbook of Dermatology 8th Edition 
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1.5.2.1 Conditions which co-exist with vulval lichen planus 
Erosive lichen planus may also overlap with other vulval skin 
disorders. Clinicians need to be aware of these as choice of therapy, 
follow up and prognosis may vary depending upon the overlap 
diagnosis. 
1.5.2.1.1 Lichen sclerosus 
Lichen sclerosus (LS) was previously considered the same entity as 
vulval LP, however, clinicians now recognise these as separate 
diseases. Both LS and LP may co-exist in a single patient (Marren 
1994), however, personal communication with experts suggests this 
is a rare occurrence. LS is believed to be an autoimmune condition 
driven by T lymphocyte activity. Histological features differ from LP 
as there is atrophy (rather than thickening) of the epidermis and 
sclerotic changes occur in the papillary dermis. Patients with an 
overlap LS/LP diagnosis are more likely to respond poorly to 
treatment  than if they have pure LS (Marren 1994). 
1.5.2.1.2 Plasma cell vulvitis 
Plasma cell vulvitis is a condition which causes erythematous/orange 
glazed lesions in the vulval introital area. It is usually asymptomatic. 
Histological features consist of a thinned epidermis and a plasma 
cell rich infiltrate in the dermis in association with dilated blood 
vessels. There is controversy as to whether plasma cell vulvitis is a 
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distinct clinical entity (Scurry 1993). There has been separation into 
primary plasma cell vulvitis (probably related to vulvovaginal 
atrophy due to lack of oestrogen) or plasma cell vulvitis that is 
secondary in nature (Wendling 2011). Cases that are secondary 
usually have an unrecognised inflammatory skin condition such as 
LP or LS present. 
1.5.2.1.3 Desquamitive inflammatory vaginitis 
Desquamitive inflammatory vaginitis is another presentation of 
vulvovaginal disease that is a result of an underlying inflammatory 
process, most commonly ELP. Desquamitive inflammatory vaginitis 
is not in itself a condition, but a symptom/clinical presentation that 
consists of discomfort, irritation, painful intercourse and copious 
vaginal discharge (Murphy 2004). Vulval examination is often 
normal, except for the presence of vaginal discharge, and vaginal 
examination with a speculum is necessary to elicit clinical signs. 
ELP, pemphigus vulgaris and mucous membrane pemphigoid may all 
cause this presentation. There is controversy whether an idiopathic 
subset exits, with some authors believing that cases without an 
obvious diagnosis are all due to underlying vaginal ELP (Edwards 
1992). 
1.5.2.1.4 Vulval pain 
Vulval pain, particularly provoked pain (e.g. during sexual 
intercourse) may occur as a result of the inflammation in ELP and is 
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discussed in section 1.8.2. This is another way in which ELP may 
present rather than with more typical presenting features that are 
described in section 1.5. 
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Figure 13: Relationship of vulval erosive lichen planus with other vulval conditions 
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1.6 The management of vulval skin disease in the 
UK 
In this section the current UK pathways for managing patients with 
vulval skin diseases are explained. 
1.6.1 Infrastructure of services for patients with vulval skin 
disease  
Symptoms and signs of vulval skin disorders are common. Data 
regarding the incidence and prevalence of these conditions are not 
available in the literature, however U.S based community surveys 
suggest that one-fifth of women have significant vulval symptoms 
that last for longer than 3 months (Harlow 2001). In the UK, women 
will usually present first to their general practitioners but may 
subsequently be referred to a range of health care services 
including, dermatology, gynaecology or genitourinary medicine. 
There is no common pathway for GPs to follow in terms of referral 
and so the specialist to whom they refer will depend upon the GPs 
assessment of the problem. Common causes for referral to 
secondary care are dermatitis, lichen simplex, candidiasis, lichen 
sclerosus and lichen planus (RCOG 2011). 
An estimated 80 specialist vulval clinics are present in the UK. The 
configuration of these is mixed, with approximately one third being 
single discipline and two thirds multi discipline. However, little more 
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is known about the structure and running of these clinics, including 
the quality of care offered (Nunns 2012).  
Given the sensitive nature of the subject matter, it is preferable for 
women to be managed by a dedicated vulval service or a vulval 
clinic rather than a general outpatient clinic. Vulval clinics, although 
not always multidisciplinary, are usually set up to allow more time 
per appointment than a general outpatient appointment. This 
enables a detailed history and examination to be taken in a non-
rushed environment and helps the patient to feel more comfortable 
discussing her sensitive condition with the clinician.  
$µYXOYDOVHUYLFH¶LVGHILQHGDVDQPXOWLGLVFLSOLQDU\WHDP of health 
professionals interested in vulval disorders across different 
specialties (Nunns 2012) . In addition to the previously mentioned 
medical specialties, the MDT may include specialist nurses, 
physiotherapists and sexual therapists. Many consider such services 
to be the gold standard way of managing patients with vulval skin 
disease. The model provides the patient rapid access to relevant 
specialists and the joint expertise provided is important for effective 
management of those with complex conditions.  
Both the Royal College of Obstetrics and Gynaecology (RCOG 2011) 
and the British Association for Sexual Health and HIV (HIV. 2007) 
have published individual guidelines for the for the management of 
vulval skin conditions, however, guidelines and standards of care for 
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vulval services have not been addressed until recently (Nunns 
2012).  
1.6.2 Teaching of vulval skin disorders 
Teaching and training opportunities for practitioners with an interest 
in vulval disorders have historically been suboptimal, as evidenced 
by a survey of the British and International Societies for the Study 
of Vulval Disease (see section 1.7.1, page 47) (Murphy 2007). In 
this survey 37/107 (29%) respondents had been self-taught in the 
specialty. The curriculum for dermatology trainees now includes 
compulsory modules for training in vulval disease. Gynaecology and 
Genitourinary medicine trainees have the opportunity to take up a 
specialist interest in vulval skin disorders and may complete a 
specialist rotation in this field. It is therefore hoped that knowledge 
and competence in managing vulval skin disorders will improve 
considerably amongst these specialties. 
1.7 Professional societies dedicated to the care of 
women with vulval skin conditions 
There are national and international professional societies dedicated 
to the care of women with vulval skin conditions. Vulval medicine is 
a relatively new branch of medicine and has traditionally been 
practiced by multiple specialties. It is important that there is 
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collaboration between these groups to enable physicians to share 
expertise, which will ultimately improve knowledge and patient care.  
1.7.1 The International Society for the Study of Vulvovaginal 
Disease 
The International Society for the Study of Vulvovaginal Disease 
(ISSVD) was founded in 1970 with the goal: 
³7RSURPRWHLQWHUQDWLRQDOFRPPXQLFDWLRQDPRQJJ\QHFRORJLVWV
pathologists, dermatologists, and related disciplines and to establish 
international agreement on terminology and definitions of 
YXOYRYDJLQDOGLVHDVHV´ 
The ISSVD has 280 members from different specialist areas 
including Dermatology, Gynaecology, Genitourinary Medicine, 
Histopathology and Sexual Health. Of note, terminology is slightly 
different in the United States ZKHUHµYXOYDUGLVHDVH¶LVXVHG
FRPSDUHGZLWKµYXOYDOGLVHDVH¶(XURSH 
1.7.2 The British Society for the Study of Vulval Disease 
The British Society for the Study of Vulval Disease (BSSVD) was 
founded in the 1990s and currently has over 160 members. It 
comprises a similar mix of specialist groups to the ISSVD. 
In addition, to aiding communication between specialties, the 
BSSVD and ISSVD promote research (basic and clinical) and 
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dissemination of knowledge in the field of vulval skin disorders. The 
Societies attain these goals through regular meetings, publications 
and communication with their members. Furthermore, patient 
information leaflets are freely available in the public domain from 
WKH6RFLHWLHV¶ZHEVLWHVDQGWKH\SURYLGHOLnks with patient support 
groups. 
1.7.3 Support groups for patients with vulval skin disorders 
There are many support groups that have been set up to support 
patients with skin diseases. They are often run by volunteers who 
suffer from the disease themselves, and many patients find it 
valuable to have such contact with others both for support and for 
practical help ("British Association of Dermatologists website section 
on patient information"  2012). Such groups often support research 
efforts and are an effective way for researchers to engage with the 
patient community, promote ongoing research projects and 
disseminate findings. 
1.7.3.1 The UK Lichen Planus Society 
UK Lichen Planus (UKLP) ("UK Lichen Planus (UKLP) Society 
website"  2012) is a support group that was set up in 2007 to help 
people who live with LP. UKLP is run by those living with LP for 
those living with LP, and helps patients to cope with the diagnosis, 
as well as offering practical tips and ideas on how to manage their 
condition. The support group is available for people with all subtypes 
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of LP. It has a number of patrons, who are practicing clinicians and 
experts in this field, who approve information which is posted on the 
UKLP website. In addition to electronic patient information, the 
group holds a regular workshop with guest speakers to encourage 
networking and communication between members. 
1.7.4 Information available to patients diagnosed with vulval 
erosive lichen planus 
Information is an important part of the patient journey and is 
SDUDPRXQWWRLPSURYLQJPRVWSDWLHQWV¶H[SHULHQFHRIWKHLU
management. Good information enables people to be involved in 
their conditions and its treatment, especially as it reinforces 
information given in the clinical setting and provides them with the 
power to make informed decisions about their healthcare, should 
they wish. A high quality patient information leaflet written in clear 
and simple language will help to ensure that standard of care is as 
high as possible in a health care setting. 
Unfortunately, for ELPV, relevant patient information is not easy to 
locate. Most information identified was web-based only which is only 
relevant if the patient population in question has a confident grasp 
of internet use. This includes information by the UK Lichen Planus 
Society, the BSSVD and the British Association of Dermatologists 
(BAD). Many patients with ELPV are from an older generation, many 
of whom do not have computers or the internet at home. According 
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WRµ2IFRP¶Fompared to the general adult population, adults aged 
60 and over are less likely to live in households with the internet 
and are less likely to regularly use newer media devices such as 
mobile phones (Ofcom 2009). 
The ISSVD have produced a comprehensive patient information 
leaflet about vulval lichen planus ("Vulval Lichen Planus"  2010) 
(Appendix 1), however, other relevant societies have scarce 
information available in the public domain. Indeed, many sources 
only describe ELPV in brief within information about lichen planus in 
general. This is insufficient for patient needs given the severity and 
nature of the condition. 
Relevant, up to date patient information sources appear to be an 
area that needs improving as a matter of urgency in this field. 
1.8 Managing erosive lichen planus: How the 
diagnosis of erosive lichen planus affecting the 
vulva is made 
1.8.1 History 
The diagnosis of ELPV is primarily clinical with the appropriate 
histological confirmation (Ball 1998). The symptoms described by 
the patient vary according to clinical subtype of disease. The 
predominant symptoms described by females with ELPV are 
soreness and burning (Eisen 1999, Micheletti 2000, Anderson 2002, 
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Cooper 2006, Kennedy 2007, Santegoets 2010) with associated 
dyspareunia (Micheletti 2000, Anderson 2002, Cooper 2008, 
Helgesen 2010). Itch and irritation occur less frequently. Post coital 
bleeding, difficulty in urination and vaginal discharge are variably 
present (McPherson 2010). It is possible that ELPV may present with 
isolated vulval splitting. In a case series of nine patients presenting 
to a specialist vulval clinic with vulval splitting, eight were found to 
have features of LP on biopsy (Wong 2004). Although this is not the 
usual presentation of the disease, it should certainly be considered 
in new patients presenting to the outpatient clinic. 
 In contrast, reticulate vulval LP may be asymptomatic (Lewis 1996, 
Eisen 1999, Micheletti 2000, Belfiore 2006), or mildly pruritic, 
although this subset occurs less frequently than erosive vulval 
disease. 
Patients may have symptoms for many years before presenting to 
medical services (Helgesen 2010) and may not link genital 
symptoms to a diagnosis of LP elsewhere (e.g. on the skin or mouth 
as depicted in Figure 6, page 18 ). 
1.8.2 Diagnostic Data Set for erosive lichen planus affecting 
the vulva 
Early recognition of vulvovaginal lichen planus is important to 
minimise unnecessary medical or surgical procedures and to 
instigate prompt treatment and alleviation of symptoms (Pelisse 
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1989, Eisen 1999). However, the clinical diagnosis of ELPV can be 
challenging as it may mimic other conditions such as lichen 
sclerosus (also overlapping histpoathologically (Marren 1994, Niamh 
2009, McPherson 2010)), autoimmune bullous disorders and 
intraepithelial carcinoma (McPherson 2010).  As LP is not a common 
disease for non-dermatologists, e.g. gynaecologists, to recognise 
and treat (Belfiore 2006), a set of criteria for physicians to follow in 
making the diagnosis is important. 
Oral lichen planus has a set of diagnostic criteria which was 
published by the World Health Organisation in 1978 (Kramer 1978) 
and subsequently modified in 2003 (van der Meij 2002). However, 
the equivalent does not exist for ELPV.  
In 2007 the ISSVD developed new nomenclature for vulval 
dermatoses (Lynch 2007) and placed vulval LP under the pathologic 
VXEVHWRIGHUPDWRVHVZLWKDµOLFKHQRLGSDWWHUQ¶+RZHYHUWKH\GLG
not expand its classification in any further detail than this. 
Following a review of the literature for studies involving case series 
of patients with ELPV, the clinical and pathological features of ELPV 
used in these reports have been summarised in the following 
sections. 
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1.8.2.1 Clinical features of vulval erosive lichen planus  
The clinical features of ELPV, as documented by previous studies of 
the condition are summarised in Table 2 on page 57.  
As its name suggests, erosive lichen planus typically shows well 
demarcated erythematous areas or erosions as seen in Figure 14 
(p55). These are usually located at the entrance to the vagina (the 
µYDJLQDOLQWURLWXV¶. Erosions, when seen are actually secondary to 
intense inflammation and it is therefore considered by some that the 
WHUPµHURVLYH/3¶LVLQDFFXUDWH(Kirtschig 2005). Hyperkeratosis is 
often present (Pelisse 1989, Santegoets 2010) and the erosions are 
usually edged by a hyperkeratotic white border as seen in Figure 14 
(p55). Features of classical OLFKHQSODQXVVXFKDV:LFNKDP¶VVWULDH
may also be present (Eisen 1994, Santegoets 2010). Biopsy from 
WKHHGJHRUDUHDVFRQWDLQLQJ:LFNKDP¶VVWULDHLV most likely to yield 
classical pathological features of LP (as described in section 1.1.1, 
page 9). 
Vaginal manifestations of ELP include appearances of a diffuse 
erosive vaginitis (Edwards 1989, Pelisse 1989, Eisen 1994) which 
may, or may not be superimposed on a white reticular network 
(Pelisse 1989). Patients may present with symptoms of 
desquamative inflammatory vaginitis (described in section 1.5.2, 
page 41). In one case series (Helgesen 2010) where vaginal 
examination was performed in 58 patients with vulval signs of LP, 
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involvement of the upper vagina was found in over two thirds. 
Vaginal examination, however, is often difficult to perform due to 
adhesions, pain and bleeding on insertion of the speculum (Pelisse 
1989). Examination may need to be performed under general 
anaesthesia (Helgesen 2010).  
A significant complication of the inflammation caused by ELP is 
scarring (Figure 15, p55), which manifests as loss of normal 
architecture through the formation of adhesions, also known as 
µsynechiae¶. Narrowing of the vaginal introitus (Pelisse 1989, 
Santegoets 2010), vulval adhesions (Pelisse 1989) and loss of the 
labia minora (Pelisse 1989) are frequently described anatomical 
changes caused by the disease and are demonstrated in Figure 15, 
page 55.  
Scarring is present to some extent in most patients with ELPV. 
Cooper et al reported 95% of 114 patients to have scarring, 73% 
were graded moderate or severe. Scarring is often present at the 
time of diagnosis. It is believed that prompt recognition of the 
condition with appropriate treatment can prevent this complication 
(Eisen 1999). 
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Figure 14: Well demarcated vaginal introital erosions in vulval erosive lichen planus 
  
Figure 15: Advanced vulval erosive lichen planus with scarring 
There is destruction of the normal vulval anatomy. Compared with Figure 14, there 
is loss of the labia minora, clitoral burying and vaginal introital narrowing. Images 
courtesy of Dr Ruth Murphy
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Author Clinical Features (% of participants with feature) 
Erythematous 
erosions/areas 
Hyperkeratosis tŝĐŬŚĂŵ ?Ɛ^ƚƌŝĂĞ Lesions located 
at vaginal 
introitus 
Erosive vaginitis Scarring 
Pelisse  
1989 
94.7% WƌĞƐĞŶƚŝŶ ‘ŵŽƐƚ
ĐĂƐĞƐ ? ?ĨŝŐƵƌĞƐŶŽƚ
given) 
Not commented Not commented Present but 
numbers not 
given 
 ‘sƵůǀĂůĂƌĐŚŝƚĞĐƚƵƌĂůĐŚĂŶŐĞ ?ŝŶ ? ? ? ?й
 ‘^ĞǀĞƌĂů ?ĐĂƐĞƐƵŶĂďůĞƚŽƉĂƐƐƐƉĞĐƵůƵŵ 
Eisen  
1994 
62.5% Not commented  37.5% Not commented 31% Present in 31% 
Lewis  
1996 
Not commented Not commented Not commented Not commented Not commented Not commented 
Anderson 
2000 
Erythema 97.7% 
Erosions 65.1% 
Not commented Not commented Not commented 
 
81.4% vaginal 
lesions 
37.2% vaginal stenosis 
Mitcheletti 
2000 
Erosive 17.6%  ‘tŚŝƚĞ ? ? ? ? ?й
 ‘tŚŝƚĞ-ĞƌŽƐŝǀĞ ? ? ?й 
Not commented Not commented Not commented Not commented 
Kirschig 2005 100% Not commented Not commented  100% Not commented Vaginal fusion in 45% patients but not clear 
how many had gynaecological examination. 
Cooper  
2006 
97% 22% 82% reticulation Not commented Not commented 95% 
Kennedy 2007 Inclusion criteria not stated 
Kennedy 2008 Not commented Not commented Presence on 
mucous 
membranes 
Not commented Not commented Not commented 
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Table 2: Summary of clinical features adopted for the diagnosis of ELPV used by published case series in the literature. 
N.B. These case series were identified through a systematic review of the literature. All studies that explained how they made the 
diagnosis were included in this table.  
Cooper  
2008 
Erosion 74% 
Erythema 66% 
Not commented 56% Not commented 34% discharge 63% 
Santegoets 
2010 
81.1% 14.7% 35.8% 69.5% Not commented Vaginal narrowing in 16.8% 
Helgesen 
2010 
Erythema 100% 
Erosions 81% 
Not commented Not commented 74% lower vagina 67% lesions 
upper vagina 
Vulval scarring 36% 
Vaginal scarring 50%  
Vaginal obliteration 15.5% 
Fischer 
2013 
Not commented Not commented 7.6% 90.1% 38.2% Labial fusion in 42% 
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1.8.2.2 Pathological features of vulval erosive lichen planus 
The histopathological features of ELPV, as documented by previous 
studies of the condition are summarised in (Table 3, page 63). 
Many case series reporting patients with ELPV have not documented 
the specific histopathological features which they sought to make 
the diagnosis (Lewis 1996, Micheletti 2000, Anderson 2002, Cooper 
2006, Cooper 2008). In contrast to classical cutaneous LP which has 
characteristic histological findings (Figure 4 and Figure 5, page 11), 
the findings in ELPV are often inconclusive (Pelisse 1989, Ball 1998, 
Kirtschig 2005, Cooper 2006). Biopsy specimens are found to be 
most characteristic when taken from the white hyperkeratotic 
margin of erosions (Figure 16, Figure 17, page 62) (Pelisse 1989). 
Assessment of vulval biopsies should be by a dermato- or gynae-
pathologist. Changes of LP seen in specimens taken from ELPV are 
often subtle and there is a possibility of an incorrect diagnosis being 
made by pathologists who are inexperienced in this field (Bowen 
2008). 
In a study to investigate histopathological findings of 31 vulval 
biopsies (from patients with a range of different diagnoses), Leonard 
et al (Niamh 2009) found that 10 of the reviewed specimens were 
from patients with vulval LP. They found the most powerful predictor 
of LP to be the presence of an inflammatory band at the dermo-
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epidermal junction (present in 9/10 specimens). They also stated 
WKDWµEDVDOVTXDPDWLVDWLRQ¶ZDVDSUHGLFWRURIYXOYDO/3EXWGLGQRW
explain what this term meant, nor did they provide data for the 
frequency of this feature in assessed specimens. Characteristic 
features of LP that are often seen on biopsies from non-vulval skin 
were seen infrequently; pointed rete ridges (2/10), wedge-shaped 
hypergranulosis (3/10), and civatte bodies (4/10). These features of 
classical LP have already been described and are demonstrated in 
Figure 4 and Figure 5 on page 11 (section 1.1.1, page 9).  
Belfiore (Belfiore 2006) and DiFede (Di Fede 2006) adapted the pre-
existing World Health Organisation criteria proposed in 2002 (van 
der Meij 2002) for the diagnosis of OLP, to extend to vulval LP. They 
looked for the presence of basal cell layer degeneration, a well-
defined cellular infiltrate confined to the superficial connective tissue 
layer and the strong predominance of lymphocytes in the infiltrate. 
When all of these features were present, the case was categorised 
DV¶KLVWRORJLFDOO\GLDJQRVWLFRIYXOYDO/3¶LIRQO\WZRIHDWXUHVZHUH
present, a histologicDOGLDJQRVLVRIµFRPSDWLEOHZLWKYXOYDO/3¶ZDV
PDGH$OORWKHUFDVHVZHUHFODVVHGDVµQRQ-FRQVLVWHQW¶ZLWKYXOYDO
LP. Immunohistochemical staining was subsequently performed on 
DOOµGLDJQRVWLF¶DQGµFRPSDWLEOH¶FDVHVWRORRNIRUDSUHGRPLQDQFHRI
T-lymphocytes, which would confirm the diagnosis. 
Kirtschig et al (Kirtschig 2005) in a retrospective study of 44 
females with ELPV diagnosed clinically found that of 38 who were 
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biopsied from the edge of an erythematous area, 18 showed 
diagnostic features for LP, including wedge-shaped hypergranulosis, 
civatte bodies and band-like inflammation at the DEJ. A further 7 
patients showed features consistent with ELPV (band-like 
inflammation at the DEJ only). The remainder of biopsies showed 
non-specific inflammation only. 
Eisen (Eisen 1994) IRXQGµFKDUDFWHULVWLFFKDQJHVRIOLFKHQSODQXV¶LQ
all 100% vulvar biopsies taken from a series of patients with the 
vulvovaginal-gingival syndrome (n=6). 22 patients in the full series 
had undergone oral biopsy showing ELP. 
Helgesen et al (Helgesen 2010) in a retrospective analysis of 58 
females with genital ELP found that 14/ 49 biopsies were diagnostic 
and 21/49 were µconsistent¶ with lichen planus. 14/49 showed non-
specific features, of which 4 were concluded to be plasma cell 
vulvitis (>50% infiltrate was plasma cells). They looked for specific 
IHDWXUHVRIOLFKHQSODQXVLQWKHPXFRVDOVLWHVDVLQ.LUWVFKLJ¶VVWXG\
These authors also performed direct immunofluorescence (IMF) on 
22 samples and concluded 7/22 were consistent with lichen planus. 
The remaining 15/22 were non-specific. However, the authors did 
not stipulate which IMF features they were specifically looking for. 
It is clear that that diagnosing ELPV is difficult and varying 
clinicopathological features may be present in any one case. Clinical 
and pathologic features need to be standardised to prevent the 
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misdiagnosis of ELPV and to ensure prompt management of the 
condition where possible. A way of ensuring this would be to reach a 
consensus opinion with expert physicians from the BSSVD and 
ISSVD. Usually a biopsy in this condition serves as much to exclude 
other pathologies such as vulval or vaginal intra epithelial neoplasia 
or pemphigus as the standard treatments for EVLP would not be 
appropriate for these conditions. 
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Figure 16: Low power histopathological image from erosive lichen planus affecting 
the vulva. Hematoxylin and Eosin stain x 5 magnification. 
This biopsy specimen has been taken from from non-keratinined squamous 
epithelium. A lichenoid infiltrate is present in the superficial dermis and along the 
basement membrane. The epidermis is missing on the right hand side due to 
erosion. Courtesy of Dr S. Deen 
 
Figure 17: High power histopathological image from erosive lichen planus affecting 
the vulva. Hematoxylin and Eosin stain x 40 magnification. 
This biopsy specimen has been taken from from non-keratinined squamous 
epithelium. The image demonstrates complete effacement of the basement 
membrane by lymphocytes, degeneration of the basal cell layer and the presence of 
civatte bodies. Courtesy of Dr S. Deen 
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Author Number of patients in series 
(number of patients with 
biopsies taken) 
Biopsies consistent 
with ELPV (%) 
Other histopathological findings (n) 
Eisen 1994 22 (6) 100% - 
Pelisse 1989 19 (16 patients had a total of 20 
vulvar biopsies taken) 
65% Lichenoid features (2) 
Non-specific inflammation (5) 
Kirschig 2005 44 (38) 65.7% Non-specific chronic inflammation (13) 
Belfiore 2006 32 (32) 75% LS (5) 
Other dermatitis (3) 
Cooper 2006 114 (97)  ? ?йŐƌĂĚĞĚ ‘ĚŝĂŐŶŽƐƚŝĐ ?
Žƌ ‘ƉƌŽďĂďůĞ ? 
 ? ?й ‘ƉŽƐƐŝďůĞ ?>W 
 ‘EŽŶ-ĚŝĂŐŶŽƐƚŝĐ ? ? ?) although alternative diagnoses not given 
Santegoets 2010 95 (93) 75.8%  Chronic non-specific inflammation (16) 
Lichen sclerosus (1) 
Uncertain (4) 
Helgesen 2010 58 (49) 71.4% 8.1% plasma cell vulvitis (4) 
Non-specific (10) 
Fischer 2013 131 (62) 21%  ? ? ? ?йƌĞƉŽƌƚĞĚĂƐ ‘ůŝĐŚĞŶŽŝĚ ? ?ĂůƚŚŽƵŐŚŶŽƚƐƉĞĐŝĨŝĐĂůůǇƐƚĂƚĞĚĂƐ
being consistent with LP 
3.2% full thickness vulval intraepithelial neoplasia 
Table 3: Summary of histopathological features adopted for the diagnosis of ELPV used by published case series in the literature. 
NB These case series were identified through a systematic review of the literature. All studies that explained how they made the diagnosis were included 
in this table. 
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1.9 Therapy for vulval erosive lichen planus 
The management of erosive lichen planus affecting any surface is 
challenging and there is no clear agreement with respect to the best 
first-line management in oral or genital disease or indeed as to 
whether first-line therapy should be the same at both sites (Cheng 
2012). The commonly accepted first-line therapy for ELP is super-
potent topical corticosteroids, however, patients often respond 
poorly. There is no standardisation in second-line therapy and a 
variety of other topical agents (alternative topical corticosteroids, 
topical immunomodulators) or systemic immune suppressants (oral 
corticosteroids or steroid sparing agents) may be used. There is no 
clinical agreement on which therapy is optimum for patients who 
have failed super-potent topical corticosteroids.    
Treatments for both oral and genital LP are similar and it is likely 
that effective treatment for ELP in the oral region would be 
beneficial in the genital region and vice versa, however, there is no 
evidence to demonstrate this (Cheng 2012).  
A Cochrane Systematic Review of Interventions for ELP affecting 
mucosal sites (Cheng 2012) found no RCT evidence for the 
treatment of genital ELP. Fifteen RCTs met inclusion criteria and 
were included in the Cochrane review, but all of these studies 
involved patients with oral disease. These studies had a total of 473 
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patients with oral ELP, and found only weak evidence for the effects 
of topical treatments in this subset, including topical corticosteroids. 
The authors were not able to pool data due to heterogeneity in the 
interventions, design methods, and outcome variables used between 
studies. The two main recommendations were that more RCTs on a 
larger scale are required for the oral and genital ELP populations, 
and that standard outcome variables need to be used in such 
studies. 
Subsequently, Davari et al (Davari 2012) in a conference abstract 
published in 2012, presented a systematic review and meta-analysis 
of treatments for LP (both cutaneous and mucosal subsets). Of 54 
identified RCTs involving mucosal LP, only 1 was for vulval disease, 
the remainders were performed in patients with oral disease. Again, 
these authors commented upon the lack of clear and accurate 
measurements of disease outcome or severity. With their findings 
they were able to perform a meta-analysis which showed that the 
potent topical corticosteroids, betamethasone valerate and 
fluocinolone are more beneficial than placebo in oral ELP. However, 
as this is only a conference abstract, it is not been possible to 
assess the methods used for the search and meta-analysis. 
In general, there is a dearth of evidence for the management of 
ELPV with the majority of studies being retrospective case series 
and case reports.  
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The results of a systematic review of the literature performed for 
this thesis that followed publication of the Cochrane systematic 
review identified two randomised controlled trials; these consisted of 
a poorly designed and poorly reported RCT comparing aloe vera gel 
against placebo (Rajar 2008), and a conference abstract describing 
the use of topical photodynamic treatment against high-potent 
steroid cream (Helgesen 2013). The literature search also identified 
two cohort studies (Lonsdale-Eccles 2005, Cooper 2006) that 
prospectively assessed treatments in ELPV.  
A wide range of treatment strategies have been described for the 
management of ELPV and are summarised in tables 3-13  (pages 
78-89). This summary has been formulated through a systematic 
literature review with databases last searched on 9th March 2014. In 
total, treatment of ELPV in 1126 patients (from a mixture of case 
reports, case series and two RCTs) have been described in the 
literature and are described below. 
1.9.1 Topical treatments 
1.9.1.1 Topical corticosteroids 
The greatest evidence is available for the use of super-potent topical 
steroids (clobetasol propionate 0.05%) with the level of response 
EHLQJGHHPHGDVµJRRG¶RUµSDUWLDO¶LQDUHODWLYHO\KLJKQXPEHURI
patients in published studies (Table 4, page 78). These were, 
however, case series, not RCTs. Cooper et al (Cooper 2006) 
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reported that of 89 women treated with superpotent topical steroids, 
71% (63/89) became symptom free whilst on treatment. This 
response in general continued with longer-term maintenance 
therapy. Santegoets et al (Santegoets 2010) reported 64 women 
treated with clobetasol proprionate 0.05%, and suggest 
DSSUR[LPDWHO\VKRZHGµVOLJKWWRPRGHUDWHLPSURYHPHQW¶7KH
remainder showed no improvement at all. Outcome measures to 
assess the cases were not specified. In keeping with these studies, 
Maor et al (Maor 2013) report in a conference abstract documenting 
the results of a retrospective case note review found 72.5% of 80 
women to have improvement following superpotent topical steroid 
use. 
Potent topical corticosteroids (Table 4, page 78) in the form of 
suppositories or enemas may be used to treat vaginal disease. In a 
study of 60 women with vaginal ELP, hydrocortisone suppositories 
over a mean duration of treatment of 28.1 +/- 38.5 months, 
relieved symptoms but did not improve the complications of scarring 
or vaginal stenosis (Anderson 2002). 
 A variety of lower strengths of topical steroids have also been 
reported upon (Table 4, page 78), however, the number of patients 
assessed were small, reported response rates were mixed, and 
method of data collection was largely retrospective. Cooper et al 
(Cooper 2006) did find a good response to a combined moderate 
potency topical steroid/anti fungal/antibiotic preparation (Table 11, 
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page 86 ) with 13/14 patients treated with this showing good and 
1/14 showing partial response. No other studies have commented 
upon this preparation.  
1.9.1.2 Aloe vera gel 
One RCT comparing aloe vera gel against placebo in 34 patients 
with ELPV has been published (Rajar 2008). This was poorly 
reported and as a result appeared methodologically flawed. As the 
authors included a variety of participants (i.e. erosive and non 
erosive LP) it was not included in the Cochrane review (Cheng 
2012). Although the authors report a statistically significant result in 
favour of aloe vera with a good response seen in 85% versus 4% 
(P<0.001), it was not clear how patients were randomised, what 
their baseline characteristics were, how allocation was concealed or 
whether an intention to treat analysis was used. Furthermore, the 
outcome scale used in this study is non-validated and was devised 
for oral QRWYXOYDO/3WKHµ7KRQJSUDVRP¶VFRUH(Thongprasom 
1992)). 
1.9.1.3 Topical immunomodulators 
Topical immunomodulators are steroid-sparing agents that are 
prescribed as second-line therapy for many skin conditions. Topical 
tacrolimus and pimecrolimus are licensed for use in atopic dermatitis 
that has not responded to first-line treatments. These agents inhibit 
T-cell activity and also cause downregulation of inflammatory 
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cytokines, hence regulating the local immune response in the skin. 
Topical ciclosporin is a calcineurin inhibitor which also leads to down 
regulation of inflammatory cytokines on keratinocytes and causes 
local immunosuppression. 
In general, case series of patients using topical tacrolimus, 
pimecrolimus and ciclosporin, have reported a good or partial 
response (Table 6, page 80). The greatest numbers of patients 
reported are those who were treated with tacrolimus, but the ways 
in which response was assessed in the studies reviewed is not clear.  
Theoretical concerns have been raised about the use of topical 
immunomodulators in conditions which may have pre-malignant 
potential as they suppress the local immune system. Furthermore, 
these agents, particularly topical tacrolimus are often poorly 
tolerated as they cause sensations of stinging, burning and 
irritation. Interestingly, a patient satisfaction questionnaire survey 
comparing patients treated with topical clobetasol against those 
treated with topical tacrolimus, found tacrolimus use to be more 
satisfactory than clobetasol (Jensen 2004). The authors also 
reported a similar level of side effects to be experienced between 
the two groups, this differs from what is usually observed in clinical 
practice (Simpson 2012). This particular study does have some 
severe limitations, as acknowledged by the authors, such as non-
random subject allocation, potential recall bias, open-label 
treatment and small numbers of patients (n=17) (Jensen 2004). 
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Additionally, inclusion and exclusion criteria were not stated and the 
questionnaire used not validated. In the absence of any other 
similar studies, and in the light of personal clinical experience, it is 
probably best to reject these findings at present.  
Concerns have also been raised about the potential development of 
infections of skin treated with topical immunomodulators. The 
development of vulval warts have been described in a female using 
0.1% tacrolimus ointment to treat genital psoriasis (Amstey 2003). 
It is important to bear such potential complications in mind when 
using such treatments. 
1.9.1.4 Topical oestrogens 
Given that ELPV is a disease mainly of post menopausal women, 
some studies have utilized topical oestrogens in conjunction with 
topical steroids to treat ELPV (Table 7, page 81). Kennedy et al 
(Kennedy 2007) reported 39/114 women in a retrospective case 
series having been treated with topical oestrogens, however, they 
did not comment upon the outcome of therapy. Santegoets 
(Santegoets 2010)used hydrocortisone acetate 10% in oestrogen 
cream intravaginally but again did not specifically comment on the 
effectiveness of this regimen. 
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1.9.2 Systemic treatments 
The overall number of patients treated with systemic agents, as 
described in the literature, are small.  
1.9.2.1 Oral corticosteroids 
Oral prednisolone has been described in the greatest number of 
patients, and in general a good response has been reported (Table 
8, page 82). It works as an immunosuppressant, however, if used 
long-term carries the risk of considerable side effects such as 
hypertension, diabetes, osteoporosis and weight gain. Therefore oral 
corticosteroids are not an appropriate long-term management 
strategy for a chronic disease such as ELPV.  
1.9.2.2 Other systemic immunosuppressants 
Azathioprine, ciclosporin, methotrexate and mycophenolate mofetil 
are all immunosuppressant agents that are used frequently in 
dermatological practice. They have been described as treatments for 
ELPV but definitive evidence for their efficacy is lacking (Table 8, 
page 82). 
1.9.2.3 Systemic antibiotics 
Systemic antibiotics, particularly those in the tetracycline group, 
have additional functions to treating bacterial infections. In fact, 
tetracycline antibiotics are rarely the drug of choice for skin 
conditions with an infective component, except for acne vulgaris 
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(Rook 2010). However, tetracyclines have been studied as agents 
with anti-inflammatory properties and there is evidence that they 
inhibit the T-lymphocyte response (Sapadin 2006) and are therefore 
utilised in a range of inflammatory skin conditions, including LP, 
although an open-label study reported disappointing results in 14 
cutaneous LP patients (Hantash 2007). When used in this capacity, 
antibiotics are used on a long-term basis, for example 6 months. 
Small numbers of patients with ELPV have been reported in case-
series following treatment with antibiotics (Table 9, page 83), but 
the overall response was poor. 
1.9.2.4 Other systemic agents 
A range of other systemic agents have been reported as treatments 
for ELPV (Table 10, page 83).  
1.9.2.4.1 Hydroxychloroquine 
Hydroxychloroquine, a non-steroidal systemic agent which 
traditionally has been used as an anti-malarial medication, is also 
used as an anti-inflammatory agent in dermatological and 
rheumatological conditions. Its mechanism of action in the latter 
role is not fully understood. The largest case series of ELPV patients 
treated with hydroxychloroquine included 15 patients (Hubbard 
2003). This was a retrospective review of clinical notes and a good 
response to hydroxychloroquine was reported (Table 10, page 83). 
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A severity index to score the degree and extent of LP was devised, 
although the methodology of this was not specified. At a dose of 
200mg twice daily, 13/15 patients showed improvement at six-
months, with a mean improvement of 64.2% in severity score. The 
authors concluded that hydroxychloroquine is an effective treatment 
for vulval LP. However, due to the retrospective nature of the study, 
unclear assessment methods and brief nature of the conference 
abstract report, it is impossible to make a full critical assessment of 
their findings. 
1.9.2.4.2 Retiniods 
Systemic retinoids are principally used for psoriasis and disorders of 
keratinisation. One double-blind RCT involving 65 patients showed 
Acitretin to be efficacious in cutaneous LP (Laurberg 1991). Smaller 
case series have shown a good outcome with the retinoid Etretinate 
in oral LP patients, however, these studies were found difficult to 
assess in a systematic review duHWRµODFNRISUHFLVHFULWHULD¶(Cribier 
1998). Studies reporting systemic retinoids in ELPV, in general, did 
not find good effect (Table 10, page 83). 
1.9.2.4.3 Griseofulvin 
Griseofulvin is an oral anti-fungal agent that has received mixed 
reviews for its efficacy in oral LP as assessed by a review article 
(Eisen 1993). Three case series with a total of 6 ELPV patients 
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treated with griseofulvin have reported poor results overall with this 
systemic medication (Table 10, page 83). 
1.9.2.4.4 Anti-neutrophilic agents 
Colcichine, an agent traditionally used to treat gout, and Dapsone, 
an anti-leprosy medication are both used within dermatology for 
inflammatory skin conditions. It is thought that they possess anti-
neutrophilic properties (Debol 1997) (Altinor 2003) and may be 
useful in treating recurrent mucosal apthous ulceration (Lynde 
2009). Dapsone has been reported useful in isolated cases of oral LP 
(Cribier 1998) but this is not the case for ELPV (Table 10, page 83). 
In their case series, Cooper et al (Cooper 2006) treated 1 patient 
with ELPV with colchicine but poor result was noted.  
1.9.2.4.5 Other agents 
Rituximab, an interleukin-1 inhibitor was used to treat a patient with 
concurrent ELPV and pyoderma gangrenosum (McAleer 2010). 
Complete resolution of ELPV was reported, however, Rituximab was 
primarily administered to manage therapy-resistant pyoderma 
JDQJUHQRVXPDQGLPSURYHPHQWRIWKHSDWLHQW¶V(/3ZDVD
coincidental effect. Rituximab is an unlikely treatment of choice for 
pure ELP as it is a relatively new biologic therapy, has potential 
serious side effects and is subject to strict prescribing regulations. 
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Thalidomide has immunomodulatory and anti-inflammatory effects. 
It has demonstrated good response isolated cases of oral lichen 
planus, but has not seemed effective in ELPV (Table 10, page 83). 
Sulpiride, which is usually an antipsychotic agent, was reported to 
KDYHµUHPDUNDEOHHIIHFWV¶RQ(/39E\3HOLVVH(Pelisse 1989), 
however, no information was given as why this treatment was 
chosen or how efficacy was measured. 
1.9.3 Combined treatments 
It is of note that patients who have inadequate response to topical 
therapy will usually be given additional systemic treatment (Table 
13, page 89). Theoretically, systemic agents may take a period of 
time to reach maximum therapeutic response. Even though by 
definition, the topical treatment has had inadequate effect, it is 
likely that a baseline level of control will occur and stopping the 
topical agent whilst waiting for the systemic to take effect, may 
cause rebound of symptoms. Therefore physicians will use both in 
combination and the topical can be weaned down gently depending 
upon response. 
Bradford et al (Bradford 2013) in a retrospective case note review 
described that 48 out of 131 patients who achieved induction of 
remission with superpotent topical corticosteroids (+/- an initial 
course of oral corticosteroids), required multimodal therapy to 
maintain disease control. Combination therapies included tacrolimus 
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plus topical corticosteroid (n=15), tacrolimus plus methotrexate 
(n=7), regular courses of oral prednisolone in conjunction with 
topical treatment (n=7) and low dose methotrexate in conjunction 
with usual topical treatment (n=11). See Table 12, page 87 and 
Table 13 page 89 
1.9.4 Surgical treatments 
Surgical intervention is sometimes required in patients who develop 
severe scarring secondary to ELPV. It is of note that all patients 
undergoing surgical intervention were given concurrent topical (+/- 
systemic therapy) to reduce postoperative inflammation and prevent 
early recurrence of synechiae formation (table 13, page 89). 
Bradford et al recommended doubling of the frequency of 
preoperative topical therapy (Bradford 2013). 
Numbers of patients described having been treated by surgical 
division of adhesions were again small and follow up duration not 
specified by the reports. The largest number of patients were 
documented by Helgesen (Helgesen 2010) ZKRUHSRUWHGµJRRG¶
response in 13/17 patients who underwent dilatation procedures in 
conjunction with topical steroids. However, relief was to a varying 
degree, often with some recurrence. Combining surgical dilatation 
with methotrexate seemed to reduce the rate of re-stenosis in a 
case series of 5 patients (Kortekangas-Savolainen 2007). 
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In conclusion, the evidence for the optimal first and second-line 
therapies used in the management of ELPV is lacking. However, 
since erosive lichen planus is a chronic disease, it is important to 
choose therapies which can be used long-term with minimal side 
effects.
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Medical Therapy 
Table 4: Topical corticosteroids for the treatment of ELPV 
Treatment Author Type of study Outcomes of treatment No. of patients 
assessed 
Clobetasol 
proprionate 0.05% 
(Santegoets 2010) Retrospective case series Partial response 64 
(Cooper 2006) Prospective cohort Good  89 
(Kirtschig 2005) Retrospective case series Mixed  32 
Hydrocortisone 10% 
foam 
(Cooper 2006) Part of prospective cohort Partial  1 
Hydrocortisone 
suppositories 
(Anderson 2002) Cohort (unclear if 
retrospective or 
prospective) 
Symptoms improved, 
scarring/stenosis did not 
60 
Betamethasone 
Valerate 0.1% 
(Borrego 1993) Case report No benefit 1 
(Cooper 2006) Prospective cohort study Partial response 3 
Mometasone 
furoate 0.1% 
(Cooper 2006) Part of prospective cohort 
study 
Good  1 
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Beclomethasone 
diproprionate 
0.025% 
(Kirtschig 2005) Retrospective case series Good  11 
(Cooper 2006) Prospective cohort study Partial response 5 
Fluticasone 
proprionate 0.05% 
(Santegoets 2010) Retrospective case series Partial response 27 
Hydrocortisone 1% (Cooper 2006) Part of prospective cohort 
study 
Good response 1 
 ?hůƚƌĂƉŽƚĞŶƚƚŽƉŝĐĂů
ƐƚĞƌŽŝĚƐ ?
(formulation not 
specified) 
(Helgesen 2010) Retrospective case series Partial response 56 
(Maor 2013) Retrospective case series Good response 80 
(Bradford 2013) Retrospective case series Response not specified 72 
 ?WŽƚĞŶƚƚŽƉŝĐĂů
ƐƚĞƌŽŝĚƐ ?
(formulation not 
specified) 
(Lewis 1996) Case series (unclear if 
prospective or 
retrospective) 
Poor response 19 
Corticosteroids 
(Potency not 
specified) 
(Kennedy 2007) Case series Long term maintenance 
treatment required. Response 
not specified 
108 
(Eisen 1994) Retrospective case series Partial response 22 
(Pelisse 1989) Retrospective case series Poor 19 
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Table 5: Intralesional corticosteroids for the treatment of ELPV 
Treatment Author Type of study Outcomes of treatment No. of patients assessed 
Intralesional 
corticosteroid 
(Borrego 1993) Case report No benefit 1 
Table 6: Topical Immunomodulators for the treatment of ELPV 
Treatment Author Type of study Outcomes of treatment No. of patients assessed 
Topical ciclosporin (Borrego 1993) Case report Remission after 4 months 
(relapse 8 months after 
cessation) 
1 
Topical tacrolimus 
(Bradford 2013) Retrospective case series Response not specified 1 
(Helgesen 2010) Retrospective case series Partial  22 
 (Cooper 2006) Prospective cohort Partial  7 
(Byrd 2004) Retrospective case series Good  16 
(Lotery 2003) Case report Good  3 
(Kirtschig 2002) Case report Good  2 
Topical 
pimecrolimus 
(Cooper 2006) Part of prospective cohort Partial response 1 
(Lonsdale-Eccles 2005) Prospective case series  Complete resolution 55%, 
Partial response 27% 
11 
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Intolerable 18% 
 ?dŽƉŝĐĂůŝŵŵƵŶĞ
ƐƵƉƉƌĞƐƐĂŶƚƐ ? 
(Kennedy 2007) Retrospective case series Mixed response 47 
 
Table 7: Other topical treatments for the treatment of ELPV 
Treatment Author Type of study Outcomes of treatment No. of patients assessed 
Topical 
photodynamic 
therapy 
(Helgesen 2013) Randomised controlled 
trial 
No significant difference 
from clobetasol propionate 
comparator group 
19 (38 included in whole 
trial) 
Topical oestrogens 
(in combination 
with topical 
steroid) 
(Santegoets 2010) Prospective cohort Not specified 4 
(Kennedy 2007) Retrospective case series Not specified 39 
Aloe vera gel (Rajar 2008) Randomised controlled 
trial 
Good response compared 
with placebo 
17 (34 included in whole 
trial) 
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 Systemic Therapy 
Table 8: Systemic immunosuppressants for the treatment of ELPV 
Treatment Author Type of study Outcomes of treatment No. of patients assessed 
Azathioprine (Cooper 2006) Part of prospective case 
series 
Poor 1 
Ciclosporin (Cooper 2006) Prospective case series Poor 2 
(Eisen 1994) Retrospective case series Complete Resolution 2 
Methotrexate (Genadry 2006) Case report Mixed response 2 
Mycophenolate 
mofetil 
(Frieling 2003) Case report Good 3 
Oral prednisolone (Bradford 2013) Retrospective case series Response not specified 22 
(Cooper 2006) Prospective cohort Resolution 3 
(Eisen 1994) Retrospective case series Good 6 
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(Borrego 1993) Case report No benefit with 20mg/d 
over 4 months 
1 
(Pelisse 1989) Retrospective case series Good 10 
Table 9: Systemic antibiotics for the treatment of ELPV 
Treatment Author Type of study Outcomes of treatment No. of patients assessed 
Doxycycline (Eisen 1994) Retrospective case series Poor 3 
Erythromycin (Cooper 2006) Prospective cohort Mixed response 6 
Minocycline and 
nicotinamide 
(Cooper 2006) Prospective cohort Poor  5 
Table 10: Other systemic agents for the treatment of ELPV 
Treatment Author Type of study Outcomes of treatment No. of patients assessed 
Acitretin (Cooper 2006) Prospective case series Poor 4 
(Eisen 1994) Retrospective case series Partial 4 
Colchicine (Cooper 2006) Part of prospective cohort Poor 1 
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Dapsone (Eisen 1994) Retrospective case series Poor 4 
(Pelisse 1989) Part of retrospective case 
series 
Poor 1 
(Edwards 1988) Case report Poor 1 
Etretinate (Pelisse 1989) Retrospective case series Poor 3 
Griseofulvin (Eisen 1994) Retrospective case series Poor  4 
(Pelisse 1989) Part of retrospective case 
series 
Poor 1 
 (Edwards 1988) Case report Partial 1 
Hydroxychloroquine (Cooper 2006) Prospective cohort Poor 2 
(Hubbard 2003) Retrospective case series Good 15 
Rituximab (McAleer 2010) Case series Good 1 
Sulpiride (Pelisse 1989) Part of retrospective case 
series 
Complete Resolution 1 
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Thalidomide (Cooper 2006) Part of prospective cohort Poor 1 
(Borrego 1993) Case report No benefit 1 
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Combined Treatments 
Table 11: Combined topical therapy in the treatment of ELPV 
Treatment Author Type of study Outcomes of treatment No. of patients assessed 
Topical ciclosporin 
plus topical 
corticosteroids 
(Eisen 1994) Retrospective case series Partial  5 
Clobetasone 
butyrate 0.05%, 3% 
oxytetracycline plus 
nystatin 
(Cooper 2006) Prospective cohort study Good  14 
Topical 
corticosteroid plus 
topical tacrolimus 
(preparations not 
specified) 
(Bradford 2013) Retrospective case series Response not specified 2 
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Table 12: Combined topical and systemic therapy for the treatment of ELPV 
Treatment Author Type of study Outcomes of treatment No. of patients assessed 
Topical 
corticosteroids 
(superpotent or 
potent) and 
systemic 
immunosuppressant 
(prednisolone) 
(Bradford 2013) 
Retrospective case series 
 
Response not specified 31 
Topical 
corticosteroids 
(Clobetasol), 
immnosuppressants 
(Tacrolimus) and 
systemic 
immunosuppressant 
(Methotrexate) 
(Jang 2008) Case report Good  4 
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Topical 
corticosteroids 
(regimen not 
stated) and 
systemic 
immunosuppressant 
(Methotrexate) 
(Nylander Lundqvist 2002) Case report Good  3 
Topical 
corticosteroid 
(superpotent or 
potent) and 
systemic 
immunosuppressant 
(methotrexate) 
(Bradford 2013) Retrospective case series Response not specified 1 
Hydroxychloroquine
, 25mg 
hydrocortisone 
suppositories , 
mycophenolate 
mofetil 1g BD 
(Genadry 2006) Case report Good  1 
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Methotrexate, 
hydroxychloroquine
, 25mg 
hydrocortisone 
suppositories 
(Genadry 2006) Case report Good  1 
Mild topical steroids 
and oral 
corticosteroids 
(Mann 1991) Case series Good  9 
Griseofulvin and 
clobetasol 
(Edwards 1988) Case report Good  1 
Dapsone and topical 
hydrocortisone 
(Edwards 1988) Case report Good  2 
Table 13: Combined systemic treatment for ELPV 
Treatment Author Type of study Outcomes of treatment No. of patients assessed 
Oral prednisolone 
plus oral 
methotrexate  
(Bradford 2013) Retrospective case series Response not specified 1 
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Table 14: Combined medical and surgical intervention for the treatment of ELPV 
Treatment Author Type of study Outcomes of treatment No. of patients assessed 
Topical 
corticosteroids (+/- 
oral prednisolone) 
plus surgical 
division of 
adhesions 
(Bradford 2013) Retrospective case series Adequate 8 
Topical 
corticosteroids 
(preparation not 
specified) plus 
surgical division of 
adhesions 
(Santegoets 2010) Retrospective case series Not commented 9 
Topical steroids plus 
dilatation 
(Helgesen 2010) Retrospective case series Partial response 17 
Topical steroids 
(diflucortolone 
valerate 0.3%, 
prednisolone foam) 
and surgical division 
of adhesions 
(Panagiotopoulou 2010) Case report Good  1 
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Topical 
corticosteroids 
(Clobetasol), 
immunosuppressant
s (Tacrolimus), oral 
Methotrexate 
(7.5mg weekly) and 
surgical dilation 
(Kortekangas-Savolainen 2007) Case series Good  5 
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1.10 Complications of vulval erosive lichen planus 
1.10.1 The risk of malignant transformation with ELPV 
The risk that ELPV lesions increase the risk of squamous cell 
carcinoma (SCC) in the vulval area has been reported in case series 
(Lewis 1994, Dwyer 1995, Franck 1995, Ramos-e-Silva 2010), but 
larger-scale studies are lacking. A recently published critically 
appraised topic to evaluate whether ELPV is associated with an 
increased risk of vulval SCC did not find conclusive evidence to 
confirm or refute these reports (Simpson 2012). The critically 
appraised topic analysed case series with five or more consecutive 
patients to reduce reporting bias. 
Identified were 4 case series (Kirtschig 2005, Cooper 2006, Kennedy 
2008, Santegoets 2010) that described the long-term follow up of a 
total of 366 patients with ELPV. A further 2 case series (Zaki 1996, 
Derrick 2000) of patients with anogenital carcinoma were found 
whereby the authors investigated the underlying aetiology of the 
malignancy. Combining findings from the 4 case series, vulval SCC 
occurred in 5 of 366 patients. The overall duration of ELPV was only 
reported for 1 of these incident cases (3 years)(Kennedy 2008). 
Mean follow up time was only documented by 2 studies (60 months 
(Kennedy 2008) and 72 months (Cooper 2006)). There were 3 
retrospective and 1 prospective studies. These studies are 
summarized in Table 15, page 95. 
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Squamous cell carcinoma may also occur in other sites affected by 
ELP. Studies included in the review also documented SCC 
developing in the oral mucosa and the oesophagus (Table 15, page 
95). Vulval intraepithelial neoplasia (VIN) was documented in a total 
of 6 women. It is not clear from the reports whether these cases 
were due to ELP or not. The most common cause of VIN is known to 
be preceding infection with the human papilloma virus but viral 
status was not discussed in the patients who developed VIN. 
Other malignancies that occurred within the case series of patients 
discussed were cervical adenocarcinoma and rectal adenocarcinoma. 
These are unlikely related to ELP itself as the cell type of the tumour 
is different to what would be seen with ELP. Therefore, it is most 
likely that an alternative aetiology was underlying these cases. 
There is clear evidence that certain vulval inflammatory disorders, 
such as lichen sclerosis predispose to the development of 
malignancy. However, at present there is only a suggested 
increased prevalence of vulval SCC in patients with ELPV. The only 
way to clarify whether there is a real risk is for long-term follow up 
data of the disease and its complications to be recorded in a multi-
centre registry. 
1.10.1.1 Malignant transformation of ELP affecting other sites 
The development of SCC has been described most commonly in oral 
LP. The World Health Organisation considers oral LP as a 
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premalignant condition, however, there remains controversy 
whether oral LP is an intrinsically premalignant condition, a 
facilitator of the action of carcinogenic agents, or simply a 
coincidental (and therefore confounding) factor (Ramos-e-Silva 
2010). Two analyses of the literature, one including 223 cases 
(reported between 1950 and 1977) (Krutchkoff 1978) and the other 
98 cases (reported between 1977 and 1999) (van der Meij 1999) of 
SCC arising in oral LP concluded that there was not enough evidence 
to settle the debate. These reviews have been subject to criticism, 
particularly due to the selection criteria used for included cases and 
it is felt that bias has influenced their findings (Lodi 2005).  
 There have been isolated case reports of SCC developing within 
oesophageal LP (Moncarz 1993, Shenfine 2006, Zvidi 2012), but no 
case series or longitudinal studies. 
Malignant transformation of cutaneous LP (non-erosive) is rare and 
tends to be in longstanding hypertrophic lesions located on the 
lower limbs (Sigurgeirsson 1991, Singh 2006). 
Therefore, as for vulval LP, long-term prospective studies are 
required to determine whether lichen planus is a truly pre-malignant 
condition, or not.
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Table 15: Summary of included studies for critically appraised topic performed to assess the relationship between ELPV and the 
development of SCC 
Author Study type 
(Level of 
evidence) 
Study period No. of 
patients 
Mean follow up 
period 
(months) 
No. of patients with malignancy 
(duration of preceding ELPV if known) 
Santegoets 
(2010)  
Retrospective 
case series 
May 1995- Dec 
2002 
95 ? 2 (unclear) 
Kennedy  
(2008)  
Retrospective 
case series 
Jan 1995  W Dec 
2002 
113 60 Vulvar SCC - 1 (3 years after diagnosis of ELPV; 1 yr after 
treatment for cervical carcinoma) 
Oral SCC -1 (2 years) 
Oesophageal SCC - 1 (7 years) 
Cervical adenoca - 1 (5 years) 
Rectal adenoca -1  (14 years) 
Cooper  
(2006)  
Prospective 
cohort study 
5-year study 
period, unclear 
timeline 
114 72  Oral SCC  W 1 
Perianal SCC  W 1 
Vulval SCC  W 1 (on background of VIN 3) 
VIN in further 6 patients 
Duration of ELPV preceding malignancy not stated in this 
study 
Kirtschig  
(2005)  
Retrospective 
case series 
1997-2000 44 ? 1 (not stated) 
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1.10.2 Scarring 
Scarring is frequently observed in patients with ELPV (Table 2, page 
57). Cooper et al, in their prospective study of 114 females with 
ELPV specifically commented that µVRPHGHJUHHRIVFDUULQJZDV
present in almost all women (95%), with 73% having moderate or 
VHYHUHVFDUULQJ¶(Cooper 2006). 
The degree of and location of scarring can be variable, however, it 
seems to typically affect the vaginal introitus (to cause a 
fused/semi-fused vagina), the labia (causing loss of the labia 
minora) and the clitoral hood (to cause burying of the clitoris). The 
resulting physical morbidity from vulvovaginal scarring includes 
urinary outflow obstruction and loss of ability for sexual activity. 
Psychological effects due to this loss of function, not to mention the 
altered anatomical appearance can be profound. In advanced cases, 
scarring needs to be treated with division of adhesions, either 
manually or under general anaesthesia, depending upon the level of 
scarring that is to be addressed. 
 It is logical to presume that early effective treatment of ELPV would 
prevent progression to scarring, however, data demonstrating this 
are lacking. Interestingly though, Cooper et al found that a delay in 
diagnosis of ELPV (and therefore delay in treatment) was not 
associated with worse scarring at the time of presentation. 
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1.10.3 The development of neuropathic pain 
Vulvodynia is the term given to vulval discomfort, most often 
described as a burning pain, occurring in the absence of relevant 
visible findings or a specific, clinically identifiable, neurological 
disorder. It is a form of neuropathic pain. Similar symptoms of 
vulval pain may develop as a result of inflammatory skin disease, 
such as ELPV. In this context it may be either an acute, or a chronic 
symptom. In one study, 89 patients who had vulval pain that was 
either unresponsive to initial treatment or who had an unclear initial 
diagnosis, underwent biopsy of the vulval area (Bowen 2008). 
Lichen planus was found to be present in four of these cases. 
Therefore, clinicians should be mindful of this potential complication 
in patients with ELPV whose symptoms appear out of keeping with 
the clinical severity of ELPV. In particular, point tenderness on 
examination with a Q-tip in a patient with ELPV may represent 
secondary vulvodynia and this should be managed appropriately. 
Amitriptyline, a tricyclic antidepressant, is the treatment of choice in 
these patients (Nunns 2010). 
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 Study N in 
series 
Anatomical Site 
Oral mucosa 
(%) 
Skin  
(%) 
Perianal 
skin/mucosa (%) 
Scalp  
(%) 
Nails 
(%) 
Oesophagus (%) External 
Auditory 
meatus (%) 
Lacrimal 
duct (%) 
Lewis  
1996 
37 54 68 - - - - - - 
Anderson 2002 60 40 7 - - - - - - 
Byrd 2004 16 - 31 12 - - 12 19 - 
Cooper 2006 114 59 - 28 8 4 3 2 1 
Kennedy 2007 113 17 - - - - - - - 
Cooper 2008 161 48 14 17 1 2 2 - - 
Ebrahimi 2012 120 80 30 - - - 5% (symptoms only- not 
confirmed by OGD) 
- - 
Table 16: Frequency of concomitant sites affected by lichen planus as reported by published studies- = Site not commented upon in paper 
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1.11 Measuring the clinical severity of vulval 
erosive lichen planus  
Accurate assessment of disease severity is essential to enable 
clinicians to deliver optimal patient care. However, there are no 
tests of clinical significance that are available to measure the 
severity of erosive lichen planus or indeed, other vulval skin 
conditions. A clinician managing ELPV must take into account both 
objective (clinician assessed) and subjective (patient reported) 
outcomes when measuring severity and response to treatment. 
1.11.1 Clinician assessed outcomes in vulval erosive 
lichen planus 
A scoring system has been validated for the clinical assessment of 
oral LP (Escudier 2007), which is a composite score taking into 
account extent of site involvement, disease activity at each site and 
an overall pain level as reported by the patient. This score provides 
an objective view of disease severity and is used in both clinical 
practice and clinical trials. However, this outcome measure tool has 
been relatively recently devised, and heterogeneity for outcome 
measures in oral LP still exists (Cheng 2012). 
The same is true for vulval ELP, in which there are no published or 
validated outcome measure scales to document its severity. 
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Reported case series of ELPV patients have used a heterogeneous 
selection of methods to assess the disease.  
1.12 Measuring the impact of vulval erosive lichen 
planus on the patient 
1.12.1 Impact of vulval erosive lichen planus on the 
patient 
Patients with chronic skin diseases ± in line with other chronic 
physical conditions- report lower levels of psychological and social 
well-being (Evers 2008). Vulval skin disorders are no exception as 
they cause significant distress and can affect both physical and 
psychological well-being. Previous qualitative studies have 
demonstrated how genital skin disease causes a reduction in quality 
of life (QoL) (Sargeant 2007, Hickey 2010). The existing literature 
has tended to focus on gynaecologic malignancies and their 
treatment, with little having been published on inflammatory vulval 
conditions. A systematic review of health related QoL measurement 
for patients with benign gynaecologic conditions (Jones 2002) 
concluded that few questionnaires have been used to evaluate 
treatment outcomes in terms of subjective health status.  
A study of patients with oral and genital LP (Lundqvist 2006) has 
demonstrated that depression, anxiety and increased levels of stress 
are distinctly more prominent compared to a matched group of 
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healthy controls. Furthermore, the loss of function caused by ELPV 
(due to pain and scarring) interferes ZLWKSDWLHQWV¶ personal and 
working lives. It is likely that involvement of increasing number of 
mucocutaneous sites will have proportionally greater effect on QoL. 
A number of outcome measure tools exist within dermatology to 
assess the impact of disease on QoL, however, none have been 
specifically devised with vulval skin conditions in mind. Therefore, 
the instruments used in studies and clinical practice tend to be a 
combination tools which are SHUFHLYHGWRµEHVW-ILW¶WKHFRQGLWLRQ,Q
DZRUOGZKHUH4R/DQGFRQVLGHUDWLRQRIWKHSDWLHQW¶VSHUVSHFWLYH
plays a major role in the provision of services, current methods of 
assessing vulval skin disease seem inadequate. This dissertation will 
detail later the results of a systematic review analysing published 
outcome measures for patients with vulval disease. 
1.13 Economic consequences of vulval erosive 
lichen planus 
The economic consequences of ELPV, although never formally 
assessed, are likely to have considerable impact on those affected, 
their families and the health system as a whole.  
The only work to look at the economic evaluation of ELP was a study 
from an Italian group comparing topical clobetasol proprionate 
against topical ciclosporin in the treatment of oral lichen planus 
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(Conrotto 2006). This study was summarised by the Cochrane 
FHQWUHIRUUHYLHZVDQGGLVVHPLQDWLRQDVDµ&ULWLFDOOy Appraised 
Economic Evaluation.  
In this study both drugs were mixed separately with 4% 
hydroxyethyl cellulose gel to obtain a final concentration of 0.025% 
for clobetasol and 1.5% for ciclosporin. Forty patients were enrolled 
in the study, 20 being allocated to each group. There was a 
statistically significant difference in improvement of clinical signs 
(95% improvement in clobetasol-treated patients versus 65% of 
ciclosporin-treated patients) after 2 months of therapy, but there 
was not a statistically significant improvement in symptoms, with 
both groups showing high levels of improvement (95% clobetasol 
group versus 85% ciclosporin group). Ciclosporin seemed to 
produce a statistically significant improvement of stability in clinical 
scores. 
No total costs of the interventions were reported but the daily cost 
of ciclosporin treatment was EUR 1.82 compared with EUR 0.35 for 
clobetasol therapy. Therefore the cost of topical ciclosporin was 5.2 
times greater than clobetasol. The authors concluded that clobetasol 
propionate in 4% hydroxyethyl cellulose gel was to be more 
costǦeffective than topical 1.5% ciclosporin in the same medium for 
the treatment of oral lichen planus. The main drawback of using 
ciclosporin routinely was its high cost. 
Chapter 1: Introduction to lichen planus 
103 
 
The sources of the cost data were not fully reported and the price 
year was also not reported. Even though this study is a start to 
estimating the economic burden of ELP it does not investigate the 
vulval subset and it is not possible to directly extrapolate the 
findings to a genital population. Therefore these data in the 
literature are lacking and steps should be taken to rectify this.  
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1.14 Chapter 1 Summary 
Vulval erosive lichen planus (ELPV) is a rarer variant of lichen planus 
and is an inflammatory dermatosis causing painful erythema and/or 
erosions of the vulva and vagina. Scarring can cause burying of the 
clitoris and narrowing of the vaginal introitus/vaginal canal, which 
may alter sexual function and make intercourse impossible. ELPV 
has a significant negative impact on QoL as it affects day to day 
function and there is a reported risk of malignant progression.  
There is no randomised controlled trial evidence (RCT) on which to 
base treatment for ELPV, including no evidence for the efficacy of 
very potent topical steroids, which are used by most clinicians as 
standard first-line therapy. Approximately 25% of patients with 
ELPV are resistant to the accepted first-line therapeutic agents as 
defined by crudely reported patient and clinician outcome measures, 
and there is considerable variation in second-line agents used. Since 
the condition is chronic, any therapies used need to be safe for long 
term use. 
There is a general lack of standardisation of management in terms 
of diagnostic criteria, methods of assessing disease severity and 
treatment. To improve the care pathway for patients with this 
distressing condition, these issues need to be addressed. 
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This PhD will outline a number of steps that have been taken to 
reduce these uncertainties to improve understanding about how the 
how the disease is currently defined and treated and to review the 
evidence for the best outcome measures to use when assessing the 
condition. This will lead to the design of randomised controlled trial 
protocol for a study that is designed to identify interventions that 
are effective in improving disease control in patients with ELPV who 
have failed first-line therapy. The structure of this thesis and aims of 
each chapter are outlined below: 
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Overview of Chapters  Aims 
1 - Introduction Background to project, clinical features and impact of vulval erosive lichen planus plus description of the 
problems in management and gaps in knowledge which need to be addressed. 
2  W Determining current clinical practice in the 
management of vulval erosive lichen planus 
A retrospective study to assess current clinical management in the UK. Variation in practice was found and 
a number of uncertainties were highlighted, including methods of diagnosing the condition, outcome 
measures used to assess severity and impact of the disease and therapeutic choices. 
3  W A qualitative investigation into UK clinician 
views and principles of management of vulval 
erosive lichen planus 
This qualitative study involving interviews with 25 UK clinicians aimed to clarify the uncertainties 
identified by the retrospective case note study. Subsequent chapters are aimed at reducing the identified 
uncertainties. 
4  W Diagnostic criteria for erosive lichen planus 
affecting the vulva : An international electronic-
Delphi exercise 
An international consensus exercise to agree a set of diagnostic criteria that are acceptable to the clinical 
community. The resulting diagnostic dataset can be applied to clinical practice and future studies. 
5  W Outcome measures for vulval skin disorders A systematic review of the literature to assess outcome measure tools that have been used in randomised 
controlled trials of vulval skin disorders. The findings were subsequently discussed with patients to 
ascertain which measures are most appropriate to use in the context of vulval erosive lichen planus.  
6. Patients views on vulval erosive lichen planus A survey of a national patient group, the UK Lichen Planus Society identified early information about living 
ǁŝƚŚƚŚĞĚŝƐĞĂƐĞĨƌŽŵƚŚĞƉĂƚŝĞŶƚ ?ƐƉĞƌƐƉĞĐƚŝǀĞ ?dŚĞƐĞƚŚĞŵĞƐ ?ƉůƵƐĨŝŶĚŝŶŐƐĨƌŽŵƚŚĞƐǇƐƚĞŵĂƚŝĐƌĞǀŝĞǁŽĨ
outcome measures described in Chapter 5, were then explored in greater detail through focus group work 
with patients. 
7 WA randomised controlled trial of adjunctive 
systemic therapy for vulval erosive lichen planus  W 
The hELP Trial. 
Information from the previous chapters was brought together to design a randomised controlled trial that 
aims to improve practice by identifying effective treatments for patients with severe disease. The chapter 
concludes with a fully developed multi-centre randomised controlled trial protocol for ƚŚĞ ‘Ś>W ? ?ƐǇƐƚĞŵŝĐ
tHerapy for vulval Erosive Lichen Planus) Trial.  
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2 Determining current clinical 
practice in the management of 
vulval erosive lichen planus: A 
case-based review and UK 
multi-centre case note audit. 
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2.1 Introduction 
Chapter 1 outlined current knowledge about the epidemiology, 
aetiology, clinical presentation and outcome of erosive lichen planus. 
It also reviewed the treatment options that are presently available 
to offer patients with the condition. The 2012 Cochrane systematic 
review of interventions for mucosal lichen planus, and subsequent 
search of case series of ELPV patients discussed in Chapter 1 
identified a significant lack of evidence for the management of ELPV, 
poor consensus upon disease definition and diagnostic criteria, and 
deficiencies in methods of assessment of the condition (outcome 
measures).  
In order to progress this work in the light of these deficiencies, it 
was important to investigate and GHILQHZKDWµQRUPDO¶care that is 
followed in day to day clinical practice. This was achieved through 
collaborating with UK physicians to perform a multi-centre case-
based audit and review of practice. The process of this audit and 
review study is described in Chapter 2. 
The work in this thesis is building towards a randomised controlled 
trial. For the findings from a clinical trial to be adopted into clinical 
SUDFWLFHLWLVLPSHUDWLYHWKDWWKHWULDOGHVLJQUHVHPEOHVµXVXDO¶FDUH
as closely as possible. A trial using treatments or demanding follow 
up arrangements that are not practicDOLQµUHDOOLIH¶LVQRWUHOHYDQW
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and not going to be followed by the clinical community. The 
development of a pragmatic study which reflects usual practice will 
be the end point of this thesis. 
 Until this point, it was not clear how ELPV was managed by 
different centres. The goal of this exercise was WRDVFHUWDLQµXVXDO¶
clinical practice and determine current standards of care. 
2.2 Aims 
The aims of this national multi-centre audit were to compare real-
life clinical practice to a proposed standard of optimal care for ELPV, 
as well as collecting additional data about the condition.  In the 
absence of national/international guidance, audit standards were set 
following agreement with expert clinicians from the British Society 
for the Study of Vulval Disease (BSSVD), a multi-disciplinary 
national specialist group (See Section 1.7.2, p2).  
2.3 Materials and Methods  
This study was coordinated centrally from the Centre of Evidence 
Based Dermatology, University of Nottingham. Proposed audit 
standards were set following communication with experts from the 
British Society for the Study of Vulval Disease in the context of a 
questionnaire survey and subsequent discussion at the VRFLHW\¶V
biennial meeting. Derived standards are detailed in Figure 18, p112, 
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and were circulated to the involved clinicians for approval prior to 
conducting the audit.  
A data abstraction form (Appendix 2) was used for data to be 
extracted from casenotes to compare current UK practise as against 
the agreed audit standards(Figure 18, p112) for the management of 
ELPV. Data that were also collected in addition to the audit 
standards included: 
฀ Co-morbidities 
฀ Concurrent medications 
฀ Disease duration 
฀ Result of biopsy 
฀ Documentation of other affected sites 
฀ Duration and side effects of therapy 
Lead consultants from multiple UK centres were identified through 
the BSSVD. These included nine dermatologists and one 
gynaecologist. Each centre identified consecutive patients with a 
clinical diagnosis of ELPV who were seen in the outpatient clinic over 
a six-month period. For each patient the notes were reviewed back 
to the time of presentation to secondary care. Since the histology of 
ELPV is variable (Pelisse 1989), histological confirmation of ELPV 
was not considered mandatory, for inclusion to the study patients 
only required a clinical diagnosis of ELPV to have been made.  
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To maintain anonymity, each patient was assigned a study identity 
code number and participating centres were asked to maintain a 
separate confidential list of participants to permit identification of all 
included patients in case additional follow-up should be later 
required. 
Data were inputted it into an Excel spread sheet for analysis. Data 
were of mixed type; categorical data were summarized as 
percentages with numerator and denominator indicated. Numerical 
results were summarized by the mean and median values. 
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Diagnosis of ELPV:  
 Biopsy should be performed in cases of 
diagnostic uncertainty to exclude other 
pathology 
 Other skin sites and the oral cavity should be 
examined for evidence of lichen planus 
 
Documentation of severity and impact of ELPV: 
 Assessment of disease should include: 
 Documented evidence of disease severity 
and disease extent as assessed by the 
clinician 
 Impact of disease on quality of life as 
completed by patient (e.g. visual analogue 
scale for pain, Dermatology Life Quality 
Index) 
 Consideration of interference with 
functional activity such as sexual activity 
 
Provision of care: 
 Patients with multi-site or complex disease 
should be managed by a multidisciplinary 
approach involving the relevant specialties 
 
Treatment for ELPV: 
 A very potent topical steroid should be used as 
first-line treatment 
 Patients who fail first-line treatments should be 
changed to an alternative agent (although there 
is no evidence to determine optimum second-line 
therapy) 
 
Figure 18: Multi-centre case note audit: Agreed audit standards for the 
management of vulval erosive lichen planus 
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2.4 Results 
Participating clinicians included nine dermatologists and one 
gynaecologist. A total of 172 case notes were reviewed by the ten 
participating centres.  The number of patient notes reviewed by the 
centres ranged from 4 to 37. Data were recorded from under 10 
patients in three centres, 10-20 patients in four centres and over 20 
patients in three centres. 
All patients were female and their ages ranged from 34-94 years 
(mean 66.5 years, median 68 years). Duration of disease ranged 
from six months to more than 20 years (median range 1-5 years) 
with nearly half, 49% (85/172) having disease documented for 
more than five years (Table 17, page 113). 
  
Duration of ELPV (years) Number of patients 
<1 10 
1-5 77 
6-10 45 
11-15 19 
16-20 11 
>20 7 
Unclear 3 
TOTAL 172 
Table 17: Multi-centre case note audit results: Duration of vulval erosive lichen 
planus 
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The individual audit standards set for this study (Figure 18, p112) 
were assessed individually and a summary of how well the 
standards were met is detailed at the end of the results section 
(Table 21, page 124). 
2.4.1 Diagnosis 
Biopsy of the vulval region was taken as part of the initial diagnosis 
in 77% of patients (132/172); oral mucosal biopsy had been 
performed in a further 2% (3/172). It was recommended  in the 
audit standards that biopsy should be performed in cases of 
diagnostic uncertainty or resistant disease; this did not occur in 5 
such cases. These cases were all patients with disease that was 
resistant to first line therapy.  
The majority of histology results reported were consistent with a 
diagnosis of erosive lichen planus (71%, 96/135). The remainder 
either ruled out any other significant pathology (10%, 14/135) or 
were inconclusive (16%, 22/135). The result could not be located in 
two cases, and one was not answered. 
Since erosive lichen planus may occur at other sites it was 
recommended as a standard that clinicians examine other areas that 
might be affected. Documentation of examination of other skin sites 
occurred in 60% (104/172) of patients and 62% (106/172) had 
recorded oral cavity examination. 
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2.4.2 Documentation of disease severity/impact 
A description of symptoms and clinical findings were documented for 
nearly all of the patients whose data contributed to this study. 
Severity of disease was documented in 99% (170/172) of notes and 
87% (150/172) displayed a schematic diagram of the vulva 
indicating disease location and scarring. However, less than half of 
patients (42%, 72/172) had evidence about ability for sexual 
function documented.  Assessment of disease impact using the 
Dermatology Life Quality Index (DLQI) was performed in 3% (6/172) 
and only 1% (2/172) had pain/discomfort recorded by a visual 
analogue scale. 
2.4.3 Affected sites and provision of care 
The vulva was affected exclusively in 44% (75/172) of patients. The 
most commonly affected other sites were oral mucosa, skin and 
vagina, with anal and oesophageal mucosa being affected least 
frequently (Table 18, p117). One patient had lacrimal duct 
involvement. 
In considering provision of care, nearly all patients with skin 
involvement had input from a dermatologist (95%, 35/37), which 
reflected the speciality of recruiting clinicians. Of patients with oral 
disease, only 54% (40/74) were also managed by oral medicine or 
maxillofacial surgery. Half of patients with vaginal disease (51%, 
18/35) were under the care of a gynaecologist. All patients with 
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unusual site involvement (oesophagus, lacrimal duct) received input 
from the relevant specialities. 
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Site Number of patients 
(%) 
Vulva only 75 (44) 
Vulva plus: 
Oral mucosa 74 (43) 
Skin/scalp 37 (22) 
Vagina 35 (20) 
Anus 9 (5) 
Oesophageal mucosa 2 (1) 
Lacrimal duct 1 (0.6) 
Table 18: Multi-centre case note audit results: Anatomical sites affected by lichen 
planus 
2.4.4 Treatment 
Topical treatment alone was received by 78% (134/172) and 
additional systemic treatment was used in 21% (37/172) of patients. 
One patient did not receive any treatment as their condition 
improved spontaneously.  
As recommended by the audit standard, first-line treatment with a 
very potent topical steroid was received in 75% (129/172) with the 
remainder being given alternative topical or systemic treatments 
(Table 19, page 121). The most common alternative first-line 
therapies were potent topical steroids (i.e. one class of potentcy 
down from the recommendation) or topical immunomodulators. 
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Of the patients who received first-line therapy with a very potent 
topical steroid, 66% (85/129) were documented to have responded 
but it was unclear what methods had been used to assess response. 
First-line treatment failure occurred in 11% (14/129) and it was 
unclear how well the patient responded in 10% (13/129) of cases. A 
number of cases (13% (17/129)) who were new referrals to the 
clinic had recently commenced treatment and were awaiting further 
follow up.  
Of those who failed first-line very potent topical steroids (n=14), 
second-line agents used were topical tacrolimus (4/14), intravaginal 
steroids (enemas 2/14, suppositories 2/14), oral 
hydroxychloroquine (2/14) and less-potent topical steroids (3/14). 
One patient continued on the same very potent topical steroid. 
Therefore 71% (10/14) of this group were appropriately given a 
more potent therapy. 
In 24 patients who had initially responded to a very potent topical 
steroid, intra-vaginal steroid enemas or systemic agents were 
required at a later stage due to relapsing-remitting disease. 
A total of 66 treatment episodes (in 37 patients) with systemic 
agents were recorded and 16 different systemic agents had been 
used (Table 20, p122). There was no demonstrable consistency in 
approach. The most frequently used agents were oral corticosteroids 
(15 patients) and, hydroxychloroquine (11 patients). These agents 
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were given simultaneously in one further patient. Acitretin, 
methotrexate, mycophenolate mofetil and minocycline were each 
used a total of six times. A number of other agents were used less 
frequently (Table 3). 
Prednisolone (13/37) and hydroxychloroquine (8/37) were the most 
frequently used initial systemic agents after failure of topical 
treatment. The systemic therapies recorded as being most effective 
were oral prednisolone (7/15), which was withdrawn once disease 
remission was obtained and hydroxychloroquine (4/11) which 
tended to be used longer-term to maintain disease control.  Though 
again, as with the topical agents, there was no clear methodology 
though for recording disease severity or induction of remission.  
Reported side effects varied according to the therapy used. The 
most frequent was burning/irritation secondary to topical 
immunomodulators (21/45). Irritation occurred infrequently from 
very potent topical steroids (4/229), potent topical steroids (2/60), 
topical lidocaine (1/8), zinc (1/1) and topical isotretinoin (1/1). Skin 
atrophy or local steroid effect on the skin was only documented in 2 
cases.  
Intravaginal steroid enemas caused bleeding in 2 cases. Side effects 
from systemic agents were seen most commonly with 
hydroxychloroquine (4/11 ± rash in three patients, joint 
pain/headache in one patient) and oral prednisolone (4/15 ± weight 
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gain and low mood in two patients, hypertension in one patient and 
agitation in one patient). 
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Treatment Number of patients Outcome 
Mild potency topical steroid 
/antimicrobial preparation 
2 2 successful for >12 months 
then failed 
Moderate potency topical 
steroids /antimicrobial 
preparation 
5 4 successful 
1 failed 
Potent Topical steroid 
 
10 7 successful  
2 successful for > 12 months 
then failed 
1 failed: non-compliance 
Potent Topical steroids/ 
antimicrobial preparation 
4 1 successful for > 12 months 
then failed  
3 failed 
Topical immunomodulators 
 
6 
 
3 Stopped as side effects 
1 successful 
1 failed 
1 unclear 
Intravaginal steroid enemas 
 
5 2 successful 
2 stopped due to patient 
choice 
1 Failed 
Topical antibiotics 1 Successful 
Topical oestrogens 3 3 failed 
Oral antibiotics 2 1 Stopped as side effects 
1 Successful 
Oral corticosteroids 1 Successful 
Dapsone 1 Unknown 
No treatment 1 N/A 
Unclear 2 N/A 
TOTAL 43  
Table 19: Multi-centre case note audit results: Other first-line treatments if super-
potent topical steroid not initially used to treat vulval erosive lichen planus.
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Systemic agent Total times used* Total used as first 
systemic agent$ 
Patients on treatment currently 
(duration of treatment in months) 
Patients failed 
treatment 
Patients successfully 
responded  to treatment 
Prednisolone 15 13 3 (1,6,12) 5  7  
Hydroxychloroquine 11 8 4 (1, 12, 36,240) 5 2 
Acitretin 6 3 0 4 2 
Methotrexate 6 2 3 (1,3,18) 3 0 
Minocycline 6 4 2 (6, 6) 2  2  
Mycophenolate 6 1 4 (1,7, 12,13) 2  0 
Ciclosporin 3 0 0 1 2 
Erythromycin 3 1 1 (3) 1  1  
Azathioprine 1 0 1 (96) 0 0 
Dapsone 1 0 0 1  0 
Efalizumab 1 0 0 Drug withdrawn 0 
Imipramine 2 2 0 2  0 
Isotretinoin 1 0 0 1  0 
Metronidazole 1 0 0 1  0 
Prednisolone + HCQ 1 1 0 1  0 
Sulfasalazine 1 0 0 1  0 
Thalidomide 1 0 0 1  0 
Table 20: Multi-centre case note audit results: Systemic agents used (+/- concomitant topical steroids) when other first-line treatments 
failed to provide adequate disease control. 
Key: * - number of times agent used in total accounting all treatment episodes with systemic agents; $ - number of times agent was used 
as the first systemic treatment after failure of topical treatments
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2.4.5 Complications of disease 
Additional information about long term sequelae of ELPV was 
collected. Vulval squamous cell carcinoma (SCC) occurred in two 
patients, both of whom had preceding vulval intraepithelial 
neoplasia (VIN). One of these patients was documented to have 
differentiated VIN and had been under the care of vulval 
dermatology for one year with the disease. She had been managed 
by maxillofacial surgery for a number of years due to oral ELP with 
associated dysplasia.  The second patient had been diagnosed with 
grade 3 VIN, (this was prior to publication of the updated 
International Society for the Study of Vulvovaginal Disease 
classification system for VIN (Heller 2007) in which terminology was 
changed from WRµXVXDO¶RUGLIIHUHQWLDWHG¶9,1UDWKHUWKDQJUDGLQJ
the severity of dysplasia on a scale of 1, 2 or 3) and had been under 
the care of vulval dermatology for over 10 years with ELPV. 
$KLVWRORJLFDOGLDJQRVLVRIµXVXDO¶9,1ZDVVHHQLQWZRIXUWKHU
patients. Oral SCC occurred in two patients; it is unknown whether 
these had dysplastic changes diagnosed histologically before the 
diagnosis of SCC was made. 
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Agreed Standard Number of patients in 
category 
Number of patients 
meeting standard 
n (%) 
Biopsy to exclude other 
diagnoses  
55 5 (19) 
Evidence of other affected sites 
examined? 
172 104 (60) 
Oral cavity examined?  172 106 (62) 
Evidence of documentation of 
disease severity? 
172 170 (99) 
Evidence of disease extent using 
schematic diagram 
documented? 
172 150 (87) 
Evidence of documentation of 
disease impact? (e.g. DLQI and 
VAS) 
172 6 (3) 
Interference with functional 
activity documented (e.g. sexual 
activity)? 
172 72 (42) 
Evidence of multiple 
site/complex disease managed 
by multidisciplinary approach?  
155 101 (65) 
Documentation of first line 
treatment super-potent topical 
steroid 
172 129 (75) 
Evidence of second-line 
treatment given very potent 
topical steroid not effective? 
14 10 (71) 
Table 21: Multi-centre case note audit results: Summary of compliance against 
agreed audit standards 
N.B. Diagnostic uncertainty was defined as complicated disease (atypical 
presentation or features suggesting neoplasia), or disease resistant to very potent 
topical steroids/requiring systemic treatment defined as no documented response 
over a three-month period. DLQI = Dermatology Life Quality Index; VAS = Visual 
Analogue Scale 
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2.5 Discussion 
This audit provided a comprehensive insight into current UK 
dermatological practice for the management and treatment 
response of a large cohort of patients with ELPV. Patient 
demographics were consistent with previous studies that have found 
that ELPV is most common in women of menopausal age (Mann 
1991, Eisen 1999, Cooper 2006) and follows a chronic course 
(Bidarra 2008), with half of our patient cohort experiencing disease 
lasting five years or longer. 
2.5.1 Main findings 
The findings were particularly relevant to further work in this field as 
a number of uncertainties were highlighted; these are considered in 
the discussion section and mainly include assessment of appropriate 
outcomes, treatment algorithms and methods of diagnosis. 
2.5.1.1 Outcome measures 
When taking into account the method of assessing and 
documentating outcomes, it was found that although clinicians were 
thorough in taking a description (99%) and recording severity with a 
diagram (87%), a measure of disease impact to assess how the 
condition affects the patient, such as assessment of quality of life, 
was performed in fewer than 50% cases. In even fewer 
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circumstances was the patient asked about impact on sexual 
functioning.  
2.5.1.2 Diagnosis of the disease 
In terms of accurately diagnosing ELP, it has been recognised that 
definite histological evidence of the disease in mucosal sites is more 
difficult to confirm than it is for classical cutaneous lichen planus 
(Pelisse 1989). The majority of patients in this study (79%) had a 
diagnostic biopsy and histological findings consistent with ELPV were 
present in 71% of these. An alternative diagnosis was ruled out in a 
further 10%. This indicates that diagnostic biopsy is a worthwhile 
investigation and appears to be part of normal care for most 
clinicians. 
2.5.1.3 Other involved mucocutaneous sites 
Mucocutaneous sites were frequently affected in addition to the 
vulva. Vaginal disease was present  in 20% of patients with ELPV, 
which is in keeping with the results of Cooper (26%) (Cooper 2006), 
but lower than in other published series (58% (Pelisse 1989); 100% 
(Bermejo 1990)). The findings for skin/scalp involvement (22%) 
were similar to previously published data (17% (Eisen 1999)), but 
may be an underestimate as not all patients received formal 
cutaneous examination. Anal mucosal, oesophageal and lacrimal 
duct involvement were found to be present in 5%, 1% and 0.5% of 
patients respectively.  
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2.5.1.4 Complications of the disease 
Malignancy developed in four (2.3 %) patients; two patients had 
vulval SCC (both occurred on a background of VIN and one also had 
oral dysplasia) and two patients had developed oral SCC. Three 
further patients developed VIN. We know that vulval SCC developed 
after disease duration of >10 years in one patient and after several 
years in the other, although this study was not designed to elucidate 
the exact timings. 
2.5.1.5 Treatment algorithms 
A very potent topical steroid was  received as first-line treatment in 
75% (129/172) of patients, which was successful in 66% (85/129) 
of these cases. Although there was no consensus as to how this was 
determined.Treatment regimens were variable, although a reducing 
regimen over 3 months was most frequent. 
The 66% success rate of very potent topical steroids as determined 
retrospectively in this audit was lower than the 75% improvement in 
a previous report (Cooper 2006). One quarter of patients (24/ 85) 
who experienced initial good symptomatic response to treatment 
required further treatment with a second line agent. This 
demonstrates the relapsing, remitting nature of the disease.  
For the remaining 25% (43/172) of patients who did not receive 
very potent topical steroids, a wide range of other first-line topical 
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treatments were used with varying success. Due to the small 
numbers that were treated in each category we do not feel that it is 
possible to draw any conclusions regarding efficacy. One patient did 
not require any specific treatment for their disease and received 
only physiotherapy; this is an unusual finding and is not typical for 
ELPV. 
 For patients with severe recalcitrant disease requiring systemic 
treatment, a variety of agents had been used. Although oral 
corticosteroids were the most frequently used agent, they are not 
the treatment of choice for long-term control of a chronic disease 
due to the potential side effect profile. In some centres it is standard 
practice to initially use oral corticosteroids to induce remission, or 
µVZLWFKRII¶WKHLQIODPPDWRU\SURFHVVEHIRUHPRYLQJWRDPRUHORQJ-
term systemic treatment, but this is not the case in all centres. 
Hydroxychloroquine was the second most frequently used first 
systemic agent after failure of topical treatment, however, side 
effects were seen in four patients resulting on discontinuation of the 
drug in three of these.  
The numbers of patients on other systemic agents - 
immunosuppressants (e.g. mycophenolate mofetil, methotrexate), 
anti-inflammatory antibiotics (e.g. minocycline, erythromycin) or 
other agents (e.g. acitretin, dapsone) were relatively few, and 
varied responses were documented. A small number of patients had 
been treated with methotrexate, mycophenolate mofetil or 
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azathioprine for over 12 months, but in other cases these agents 
were unhelpful indicating the need for more therapeutic evidence in 
this area (Table 20, page 122).  
2.5.1.6 Side effects of therapies 
The greatest frequency of side effects, in nearly half with 
documented use, was seen with the topical immunomodulators - 
tacrolimus and pimecrolimus. Reports have been published 
regarding the efficacy of these in ELPV (Kirtschig 2002, Lonsdale-
Eccles 2005, Cooper 2006) and oral LP (Volz 2008), although no 
comparative studies between topical immunomodulators and topical 
steroids have been reported. The frequency of side effects found by 
this audit therefore suggests that these may not be a suitable 
second-line agent for ELPV due to their poor tolerance. Surprisingly 
few side effects were seen with the potent and very potent topical 
steroids despite being by far the most frequently used agents. This 
is reassuring, especially for non-dermatologists managing ELPV 
patients who may feel less confident in prescribing topical steroids. 
2.5.2 Implications for clinical and research practice 
Health-related QoL measures as scored by the patient (known as 
µ3DWLHQW5HSRUWHG2XWFRPH0HDVXUHV¶are important for therapeutic 
decision-making. They are also fundamental in developing service 
provision, particularly in smaller subspecialty areas such as vulval 
dermatology. As vulval diseases cause a reduction in QoL (Sargeant 
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2007, Hickey 2010) it is necessary that clinicians use patient based 
assessment tools as part of their monitoring of ELPV. 
The fact that ELP is a multisystem disease demonstrates the 
importance of the managing clinician having a good understanding 
of its effects so that management of other affected sites is 
considered where necessary. Although vulval disease is rarely 
asymptomatic (Cooper 2006), oral and oesophageal involvement 
(Dickens 1990, Eisen 1999) may be. It is therefore pertinent that 
physicians perform an oral examination and ask screening questions 
about dysphagia in all patients.  
The development of SCC secondary to LP has been previously 
documented (Ruocco 1989, Lewis 1994, Dwyer 1995, Cooper 2006, 
Kennedy 2008) although a formal consensus on whether ELPV is a 
premalignant condition does not yet exist (Ramos-e-Silva 2010). 
None the less, these previous reports in conjunction with our 
findings reinforce the need to discuss potential complications of ELP 
with patients and their primary health care practitioners.  
There is considerable variation in second-line therapy if a patient 
fails superpotent topical steroids. The findings for the types of 
systemic agent used are similar to a previously published 
international survey of ELPV treatments where data were collected 
in 2004 (Cooper 2008). That survey prospectively collected data 
from 161 patients by nine physicians in three countries; the United 
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States (n=106), UK (n=48) and Brazil (n=7). They found that oral 
prednisolone (12/161) and hydroxychloroquine (7/161) were the 
most frequently used systemic agents with others such as 
ciclosporin, methotrexate, doxycycline and minocycline only being 
used each in 4 patients. The use of systemic treatments was much 
more common in the USA (29%) than in the UK (8%) and Brazil 
(0%).  
These audit data suggests that clinicians in the UK may now be 
treating ELPV more aggressively than previously as higher numbers 
of systemic agents were used. An alternative explanation would be 
that we have a more representative sample of UK practice by 
auditing multiple centres. 
2.6 Chapter 2 Summary 
This audit has provided a comprehensive overview with respect to 
the current management of ELPV in the UK; results of usual care 
against the agreed standards are summarized in Table 21 (p124). A 
wide variation in practice reflected the shortage of published 
evidence, and subsequent absence of guidance for clinicians when 
treating ELPV. Although the majority of clinicians used very potent 
topical steroids as first-line treatment, there was no clear consensus 
for which second-line treatment was best to use. There was a lack 
of appropriate documentation of outcome measures in ELPV (and 
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likely vulval disease in general) and impact of disease on the patient 
did not appear to be adequately addressed. 
Following on from this work, these  findings can be used to help the 
design of a multi-centre randomised controlled trial of treatments 
for ELPV. A clinical trial is required to addresses the lack of evidence 
in this neglected area. However, the issue of appropriate outcome 
measures, participant inclusion criteria and medications to use in a 
future  trial need to be formally addressed prior to protocol 
preparation.
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3 Reducing uncertainties in the 
management of vulval erosive 
lichen planus: A qualitative 
investigation into UK clinician 
views and principles of 
management of erosive lichen 
planus affecting the vulva 
Chapter 3: Reducing uncertainties 
134 
 
3.1 Introduction 
Early feasibility work through the multi-centre case note audit 
described in Chapter 2 showed general agreement on appropriate 
first-line therapy and recording of clinical findings in ELPV, but there 
were shortfalls in assessing disease impact, inconsistencies in 
determining response to treatment and variation in choice of 
second-line therapies. 
The qualitative work described in this chapter involved structured 
interviews with clinicians.  This work sought to reduce treatment 
uncertainties and was also an opportunity to engage with UK 
clinicians to increase awareness of this project and assess potential 
willingness to participate in a future trial. This qualitative work 
involved collaboration with clinicians from a variety of different 
settings, ranging from tertiary referral centres to district general 
hospitals. The reason for this was to determine whether the case 
note audit findings were representative of UK management as a 
whole and to obtain further information to inform the design a 
pragmatic RCT protocol. 
3.2 Aims 
To assess how clinicians make the diagnosis of ELPV, prescribe 
therapies, record therapeutic responses and make the decision to 
escalate therapy.  
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The overall purpose was to assess feasibility and inform the design 
and conduct of a future RCT of treatments for ELPV.  
The structured interviews were designed to assess the diagnostic 
criteria and outcome measures that other clinicians employ in usual 
practice and to help define which treatments should be assessed in 
the planned RCT. Furthermore, engaging with other UK clinicians 
was a method to improve collaborative links and identify potential 
recruitment sites for the eventual trial. 
The objectives of the study were to ascertain: 
฀ How clinicians make the diagnosis of ELPV; 
฀ Which outcome measures (Clinical and patient oriented) are 
perceived as important for use in a clinical trial; 
฀ Which first and second-line treatment approach do the 
clinicians take for ELPV; 
฀ Which factors make a clinician move to a second line therapy; 
฀ Which doses of systemic agents tend to be used; 
฀ Which, if any, restrictions are there in individual centres for 
using certain systemic agents. 
฀ Which medications clinicians feel comfortable in prescribing 
for patients with ELPV; 
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฀ Would clinicians be willing to randomise patients to a trial 
where that includes a control arm? 
3.3 Materials and methods 
This was a multi-centre study involving clinicians from secondary 
care settings who regularly treat patients with vulval disease. 
Participants were asked to take part in a one-off structured 
telephone interview lasting 15-20 minutes. Interviews were 
recorded manually. The questionnaire proforma is in Appendix 3. 
Research participants were all members of NHS staff, and so ethical 
approval was not required as participation in research is considered 
part of their professional role. Interviews specifically did not discuss 
any personal or identifiable patient information and only theoretical 
issues regarding management of ELPV were covered. 
3.3.1 Recruitment 
Clinicians were recruited from secondary care settings. As ELPV is a 
rare condition that requires specialist management, patients with 
ELPV are predominantly managed in secondary care. The initial 
approach was through the departmental secretary where 
information about the study was verbally communicated. A 
subsequent email/fax documenting the purpose of the study and 
inviting the clinician to participate was then sent. 
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Clinicians who have dedicated outpatient services, as well as those 
who treat vulval patients as part of their general outpatient practice 
were approached. Participants were identified from multiple 
disciplines including dermatology, gynaecology and genitourinary 
medicine.  
3.3.2 Interview conduct 
An appropriate date and time was arranged and the telephone 
interview was performed using a structured method with a 
standardised proforma to ensure that all relevant areas were 
covered. The interviewer asked a range of open and closed 
questions that explored FOLQLFLDQV¶EDFNJURXQG beliefs, experiences 
and opinions regarding aspects of ELPV and its management. 
3.3.2.1 Analysis 
Recorded notes were transcribed. Transcriptions of open questions 
were typed in full and analysed thematically. Questions with a 
choice of answers were inputted into an Excel spreadsheet and 
analysed quantitatively. 
3.4 Results 
The telephone numbers of 80 departments were identified using the 
NHS choices website (Figure 19, page 138). Thirty of these numbers 
were either incorrect or not answered, despite leaving answer phone 
messages where possible. Of the remaining 50 centres that were 
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successfully contacted, 44 agreed for an explanatory email/facsimile 
to be sent to the relevant consultant. Of these, 25 agreed to 
participate in the study, which represented a wide geographical area 
(Figure 20, p139). Interviews were carried out from December 
2011-March 2012. 
 
 
 
 
 
Telephone calls made (n=80) 
 
Spoke to secretary (n=50) 
 
Email/facsimile sent (n=44) 
 
Clinicians willing to participate 
(n=25) 
 
Incorrect number 
(n=8) 
 
No answer/message 
left (n=22) 
 
 
 
Figure 19: Structured interview Results: Flow chart demonstrating 
recruitment process 
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Figure 20: Structured interview Results: Map of United Kingdom demonstrating 
location of participating centres. 
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3.4.1 Demographic details 
Respondents were dermatologists (22/25, 88%) and gynaecologists 
(3/25, 12%). Of these, 15/25 (60%) were members of the British 
Society for the Study of Vulval Disease (BSSVD) and 3/25 (12%) 
were also International Society for the Study of Vulvovaginal 
Disease (ISSVD) members. There was a combination of those who 
worked in Teaching (14/25, 56%) and in District General Hospitals 
(11/25, 44%). The majority of participants worked in specialist 
vulval disease clinics (19/25, 74%. Four of these were 
multidisciplinary clinics). Most participants saw more than 20 
patients per month with vulval skin disease (Table 22, page 141) 
although the number of patients with ELPV varied (Table 23, p141). 
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Vulval patients seen/month Number of centres 
0-10 1 
11-20  4 
21-30 6 
31-40 2 
>40 5 
Unsure 7 
Table 22: Structured interview Results: Number of vulval patients seen per month 
by participants (estimate) 
 
ELPV patients (approx. total  number) Number of centres 
0-5 5 
6-10 3 
11-15 0 
16-20 4 
>20 1 
Unsure  12 
Table 23: Structured interview Results: Number of ELPV patients managed by 
participants (estimate) 
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3.4.2 Initial thoughts on treating ELPV 
The overwhelming theme was that ELPV is a difficult disease to treat 
and patients are often resistant to therapy.  
Other themes that emerged were regarding the poor prognosis, 
difficulty in making a diagnosis and potential complications 
from the disease, including scarring and sensory problems such as 
vulval pain syndromes. 
3.4.3 Follow up arrangements 
The majority of clinicians followed up patients long-term (18/25, 
72%). The reasons for this were that this is a chronic disease which 
is often difficult to control (8/18, 44%), risk of malignancy (1/18, 
6%), and a combination of poor treatment response/concerns about 
malignancy (9/18, 50%).  
The remainder of clinicians would only follow up long-term if control 
was poor and the patient required ongoing support (6/25, 24%). 
One respondent did not follow up long-term as they believed the 
disease responded to treatment given and therefore follow up was 
not required.  
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3.4.4 Clinical and histological features required to make the 
diagnosis 
A number of clinical criteria were given with most respondents 
wanting to see a combination of diagnostic features to make a 
clinical diagnosis. The most commonly sought characteristics were 
erosions (10/25, 40%), specifically vaginal introital erosions (5/25, 
20%), scarring/architectural change (7/25, 28%) and presence of a 
white hyperkeratotic edge to lesions or :LFNKDP¶VVWULDH
20%). Other clinical features cited were a glazed appearance to the 
vaginal mucosa (3/25, 12%), excruciating pain (3/25, 12%) and 
vaginal involvement (2/25, 8%). Two respondents were not willing 
to commit to specific clinical criteria. 
A biopsy was performed as part of routine practice by 16/25 (56%) 
of clinicians and in cases of diagnostic doubt/poor treatment 
response by 9/25 (36%). In addition some clinicians recommended 
that a specimen should be sent for direct immunofluorescence 
(3/25, 12%). 
Respondents were more hesitant to commit to specific pathological 
criteria. Over half (13/25, 52%) commented that typical features 
are not often seen on biopsy and  felt that clinical findings are the 
most important factor in making a diagnosis. The most common 
diagnostic histological feature sought was the presence of a 
lichenoid infiltrate on biopsy (10/25, 40%). The role of a 
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multidisciplinary approach with specific pathology review was 
highlighted by 4 clinicians. Three respondents were not willing to 
commit to histopathological features. 
3.4.5 Assessment of severity in clinical practice 
None of the respondents used a specific tool for assessing severity 
in clinical practice. The most common clinical method was through 
drawing a diagram in the notes (9/25, 36%). A broad physician 
assessment of severity using a global measure 
(mild/moderate/severe) was used by 20% (5/25) and clinical 
images by a further 20%. In addition a further four clinicians would 
preferably use medical photography if they had access to this 
resource in their department. 
Only 5/25 (20%), used a specific tool to assess impact of disease on 
the patient (Dermatology Life Quality Index (DLQI) 3/25, Hospital 
Anxiety and Depression Scale (HADS) 2/25). The main focus of 
management was to preserve an acceptable level of functioning 
(18/25, 72%) and respondents specifically identified sexual 
function, micturition, defecation and ability to wash as important 
outcomes to assess. Disease impact was not routinely assessed by 
8/25 respondents (32%). 
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3.4.6 Assessment of severity for clinical trial purposes 
The majority of respondents felt that the most important clinical trial 
outcome (Table 24, page 146) should be an assessment of function 
(13/25, 52%) and the most popular tool to measure this was 
suggested as the DLQI (11/25, 44%). An objective clinical outcome 
was suggested by 28% (7/25) and a combination of function/clinical 
signs was suggested by 16% (4/25). A variety of other outcomes 
were suggested. In particular two FOLQLFLDQVVWDWHGWKDWWKH\µZRXOG
OLNHWRVHHDVSHFLILFYXOYDORXWFRPHVFDOH¶GHYHORSHG 
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Table 24: Structured interview Results: Outcomes considered to be measured as a 
minimum requirement for patients with vulval erosive lichen planus. 
  
Outcome measures N 
Clinician-assessed:  
Reproducible objective clinical 
outcome  measures e.g. Physician 
Global Assessment, Clinical Images 
8 
Topical steroid usage 2 
Number of other sites involved by 
lichen planus e.g. oral cavity 
2 
Time to heal 1 
Presence of malignant/pre-malignant 
change 
1 
Patient-assessed:  
Functional ability e.g. sexual function 13 
Specific validated scales 
suggested: 
 
Dermatology Life Quality 
Index 
11 
Visual Analogue Scale of 
symptoms 
6 
Hospital Anxiety and 
Depression Scale 
3 
Female Sexual Function Index 2 
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3.4.7 Treatment approach 
3.4.7.1 First-line therapy 
In keeping with the case note audit results, the majority of 
respondents used super-potent topical steroids as first-line therapy 
(96%, 24/25). One used an alternating regimen of a super-potent 
topical steroid with a less potent topical steroid/antimicrobial 
preparation. Intravaginal steroids were specifically used by 44% 
(11/25) for vaginal disease and 4% (1/25) additionally used topical 
anaesthetic as part of their standard practice. 
3.4.7.2 Second-line therapy 
Considerable variation occurred with the use of second-line 
therapies. A change of topical steroid preparation was suggested by 
8/25 (32%) before moving onto a systemic treatment. Prednisolone 
was used by 8/25 (32%) to achieve remission before converting to 
an alternative systemic agent, whereas 4 /25 (16%) used an 
alternative systemic agent immediately post topical treatment. One 
VWDWHGWKDWWKH\KDGµQRVHWUHJLPHQ¶DQGRQHVWDWHGWKDWV\VWHPLc 
treatment was not effective or required in ELPV as topical therapy 
always gave success. 
Gynaecology respondents (3/25) all stated they would refer onto 
their dermatology colleagues following failure of first-line therapy.  
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3.4.7.3 Follow up arrangements 
Follow up arrangements were variable depending upon severity of 
disease and the treatments being used. In general, initial follow up 
between 2-3 months was acceptable for 16/25 (56%) clinicians. One 
hospital used a telephone follow up two weeks after commencing 
therapy which was followed up by an outpatient appointment at the 
three-month time point. 4/25 (16%) followed up at one month and 
4/25 (16%) stated it depended entirely on the treatment being 
prescribed. One respondent made no comment. 
3.4.7.4 Factors for escalating treatment 
The main reason for escalating treatment was based on symptoms 
alone (14/25, 56%) and a combination of symptoms and 
appearance in 5/25 (20%). No comment was made by 3/25 (12%), 
and a further 2/25 (8%) stated that they µGRQRWHVFDODWHFDUH¶.The 
final participant stated that HVFDODWLRQZDVGXHWRDµFOHDUODFNRI
UHVSRQVH¶ Since the second-line medical treatment for EVLP is 
usually prescribed by physicians it is unlikely that gynaecologists 
would escalate care and it is possible there is also some reluctance 
with GUM physicians. 
3.4.7.5 Systemic treatments for potential use in RCT 
The multi-centre case note audit (Chapter 2) identified a number of 
systemic treatments that were used more frequently than others in 
ELPV resistant to topical therapy. These were prednisolone, 
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hydroxychloroquine, methotrexate, mycophenolate mofetil, acitretin 
and minocycline (+/- nicotinamide). It is important to reiterate that 
prednisolone is not appropriate for long term management of a 
chronic disease due to its side effect profile. 
Gynaecologists were not comfortable prescribing any of the systemic 
agents as they do not use these in day to day practice. Of the 
remaining 22 respondents who were dermatologists, 10 did not use 
minocycline/minocycline and nicotinamide in their usual 
dermatological practice due to potential side effects.  
None of the clinicians had witnessed patients with unexpected 
adverse effects from any medications on the list; all had been 
SUHGLFWDEOHGXHWRWKHGUXJV¶GRFXPHQWHGVLGHHIIHFWSURILOH$OO
respondents prescribed these treatments according to national 
guidelines (British Association of Dermatologists or British National 
Formulary). The only restrictions in usage of the systemic 
treatments were of mycophenolate mofetil (n=1) and minocycline 
(n=1) in individual centres. 
For the treatment of ELPV, respondents would not routinely use 
acitretin (6/25, 24%), hydroxychloroquine (1/25, 4%) or 
minocycline (2/25, 8%)) as a treatment. For clinical trial purposes, 
four respondents would be put off recruiting patients into a RCT if 
acitretin was one of the trial arms and one would be put off if 
hydroxychloroquine was being used. One clinician commented that 
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the costs of the trial treatments would be a potential barrier for 
recruitment and one stated that they would not participate into a 
trial using systemic treatments for ELPV. 
All clinicians prescribed the relevant systemic medications according 
to national guidelines from the British Association of Dermatologists 
and the British National Formulary. The only variation was with 
Acitretin, which was often commenced at a low dose due to its 
potential mucocutaneous side effects. 
3.4.7.6 Washout period for systemic therapy 
In practice, 15/22 (65%) dermatologists did not leave a specific 
washout period when transitioning between systemic agents. 17% 
(4/22) stated that the washout would depend upon the specific 
agent. The remaining respondents stated they leave a period of 4 
weeks (1/22, 5%) or made no comment (2/22, 9%). 
For clinical trial purposes, there was no agreement on the optimum 
washout period required, however five respondents stated that to be 
pragmatic, treatment should be transitioned as quickly as possible. 
Many (11/22, 50%) were not willing to give a definite answer, 6/22 
(27%) felt it depended entirely upon the drug, 2/22 (9%) stated 
one-month should be left and 1/22 (5%) stated that three-months 
should be left as washout period. 
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3.4.7.7 Vulval skin care regimen 
All clinicians agreed that topical and systemic therapy should be 
administered in conjunction with a vulval skin care regimen. There 
were a range of emollient and soap substitute regimens adopted by 
the respondents in their normal practice. The majority (18/25, 72%) 
felt that the specific regimen should not be prescribed for a trial and 
the recommended agent should be at the discretion of the managing 
consultant. 
3.4.7.8 Trial design and participation 
Almost all respondents (21/25, 84%) were willing to be consulted 
regarding a RCT protocol. If one of the trial arms was placebo (but 
continuing topical steroids), 17/25 (68%) would be willing to recruit 
to such a trial. A further three stated that their decision would 
depend upon the overall trial design. However, three stated that 
they would not be willing to recruit if this were the case. One 
participant gave no comment and one would not consider recruiting 
to a trial involving systemic therapy at all. 
3.5 Discussion 
3.5.1 Main findings 
Most physicians diagnosed ELPV based upon clinicopathological 
correlation. Features including vaginal introital erosions with a white 
edge, scarring and architectural change, were frequently sought 
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clinical features. Most physicians in this sample performed a biopsy 
as part of routine clinical practice, although there was recognition 
that pathognomonic histological findings are not always found. 
Those who did not perform biopsy as routine practice did so to 
exclude other vulval pathology. Since the histology is often non-
specific, it may be beneficial for clinicians to discuss their cases with 
a histopathologist in a multidisciplinary setting, as was described by 
several participants. 
In the absence of vulval-specific outcome measure tools, methods of 
recording severity vary.  One third of participants did not formally 
assess the impact of disease on the patient, although the patient 
symptoms were reported to drive the escalation of treatment. This 
suggests that physicians are thinking about impact of disease, even 
if it is not formally documented. Of those who did assess impact, the 
most common method was to assess functional impairment with a 
DLQI (Finlay 1994, www.dermatology.org.uk/quality/dlqi). Although 
the DLQI is a commonly used and convenient dermatological health-
related QoL tool, recent studies have suggested it is suboptimal in 
assessing individuals with mild disease (Fernandez-Penas 2012, 
Twiss 2012) and in comparing different diseases and different 
patient populations (Twiss 2012). Furthermore, the DLQI does not 
assess micturition, defecation or washing ability, all items that were 
identified as important functional outcomes by respondents. 
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Overall, patient-reported outcomes were a popular method for 
assessing disease severity. This is most likely because anecdotally, 
clinical signs lag behind symptomatic recovery.  Hence, the main 
driver for escalation of therapy is patient-reported symptoms, not 
clinical appearance.  
The use of super-potent topical steroids as first-line therapy and 
lack of agreement for second-line therapy was in keeping with the 
published literature (Cooper 2006, Simpson 2012). For patients 
resistant to super-potent topical steroids, some clinicians use an 
alternative topical agent, some attempt remission with oral 
corticosteroids and some move straight to longer term anti-
inflammatory/ immunosuppressant systemic medications. 
3.5.2 Strengths and weaknesses 
This study takes into account the views of 22 dermatologists and 
three gynaecologists working in UK secondary care. These numbers 
are only a small sample of the total number of physicians who make 
up these groups. In order to obtain a broad idea of whether practice 
was the same in different environments, physicians from different 
specialties and settings were invited to participate. Three quarters of 
those who responded managed patients in a specialist vulval disease 
clinic.  Therefore, data obtained are likely representative of those 
who feel confident in managing vulval skin disease and see such 
patients on a regular basis, rather than representing the wider 
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clinical community.  Gynaecology participant numbers were small, 
but their practice was similar to that of dermatologists in that they 
were confident in diagnosing ELPV clinically and commencing 
therapy, however, patients who did not respond to initial therapy 
were referred onto dermatology colleagues.  
3.5.3 Implications for clinical practice 
As it is a chronic disease with poor response to treatment and 
perceived risk of malignant transformation, most clinicians follow up 
their patients long-term. Therefore, clusters of patients with ELPV 
are likely to be found at centres across the UK.  
Pitfalls in managing difficult cases were highlighted, in particular, 
the need to look out for secondary vulvodynia as a cause of ongoing 
pain in patients whose clinical signs are improving. This should 
clearly be managed in a different way to ELPV. 
3.5.4 Implications for this research project 
For clinical trial purposes, patient-related outcomes were the most 
favoured method of assessment with an objective method of clinical 
assessment being rated less important. This is most likely because 
clinical signs do not always match symptoms, and improvement of 
visual appearance often lags behind symptomatic recovery. Of 
interest, the main driver for escalation of treatment was described 
as patient-reported symptoms, not clinical appearance. However, 
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thorough clinical assessment to exclude secondary infection, allergy 
and malignant transformation, and exclusion of secondary 
vulvodynia are always needed before there is any escalation of 
treatment. 
It is important that when determining appropriate outcome 
measures for this condition this is taken into account.  
3.6 Chapter 3 Summary 
Having engaged with clinicians from a variety of different clinical 
settings, it was clear that treating ELPV is difficult, but there was a 
collective sense of enthusiasm to provide good quality RCT evidence 
for treating resistant cases.  
To further knowledge about treatment of ELPV, a collaborative 
approach will be required to run multicentre studies. It is apparent 
that management differs between centres, and a pragmatic 
approach needs to be adopted for studies to be successfully run 
amongst busy outpatient clinics.  
A set of diagnostic criteria acceptable to the clinical community for 
inclusion into a trial and outcome measures that are relevant to 
patient and clinician needs should be devised before definitive 
therapeutic randomised controlled trials can be performed. 
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4 Diagnostic Criteria for Erosive 
Lichen Planus Affecting the 
Vulva: An international 
electronic-Delphi Consensus 
Exercise. 
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4.1 Introduction 
Published literature suggests that most clinicians managing vulval 
diseases would diagnose ELP affecting the vulva (ELPV) following 
careful clinico-pathological correlation (Ball 1998). This was 
reinforced by findings from the structured interview process 
described in Chapter 3. 
Oral lichen planus, has a defined set of diagnostic criteria that was 
set out by the World Health Organisation in 1978 (and subsequently 
modified in 2003 (van der Meij 2002)), but the same does not exist 
for vulval erosive lichen planus.  
ELPV may mimic other conditions such as lichen sclerosus (for which 
it may overlap clinically and histopathologically (Marren 1994, 
Niamh 2009, McPherson 2010)), autoimmune bullous disorders and 
intraepithelial carcinoma (McPherson 2010). The diagnosis can 
therefore be challenging (see section 1.5.2, page 36). 
Early recognition of ELPV is important to minimise unnecessary 
medical or surgical procedures and to instigate prompt treatment 
and alleviation of symptoms (Pelisse 1989, Eisen 1999). However, 
ELPV may present to a range of specialties such as general 
dermatology, gynaecology and genitourinary medicine, where 
variation in diagnosis and management exists (Simpson 2012). An 
agreed diagnostic dataset would be valuable to standardise practice, 
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assist non-experts in making a correct diagnosis and to regulate 
inclusion into clinical trials.  
4.2 Aims 
The purpose of this international, multiperspective, electronic-Delphi 
(e-Delphi) consensus exercise was to reach agreement on a 
diagnostic dataset for ELPV that is acceptable to the international 
clinical community.  
4.3 Materials and methods 
4.3.1 Study type 
This was a three-stage, international electronic-Delphi exercise that 
was conducted between October 2012 and December 2012. A 
formal feedback process was undertaken and results generated from 
the process were circulated to participants for comments.  All 
communication occurred electronically and the process was 
moderated by a single central coordinator (RS). 
The Delphi process is widely used in clinical and health services 
research (Vernon 2009); it is an iterative technique based upon the 
scoring of a series of structured statements which are revised and 
repeated until consensus has been reached amongst a panel of 
expert participants (Murphy 1998). It is a method that has been 
used for establishing diagnostic criteria (Turoff 1970, Graham 
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2003). This study was conducted as an electronic-Delphi (e-Delphi) 
process.  
4.3.2 Participants 
A letter of invitation was emailed to all members of the International 
Society for the Study of Vulvovaginal Disease (ISSVD, see section 
1.7.1, page 47) and members of the British Society for the Study of 
Vulval Disease (BSSVD, see section 1.7.2, page 47). These 
multidisciplinary societies enabled international collaboration with 
experts from different stakeholder groups who manage vulvovaginal 
disorders. Members of these societies were identified as ideal 
participants of this e-Delphi study as they represent professionals 
with a specialist interest in vulval skin conditions who would adopt 
the outcomes of the Delphi study in their daily practice and they 
were capable of making an insightful, well-informed contribution to 
the exercise. 
4.3.3 Study procedures 
Findings from the literature review (Chapter 1) and structured 
interviews (Chapter 3) were used to provide an evidence base for 
the consensus process. Results from the two exercises were collated 
to form a structured questionnaire that contained a list of 12 
potential diagnostic criteria required for the diagnosis of ELPV. The 
study protocol was finalised in September 2012.  
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An invitation letter containing background information, study aims 
and an explanation of how to participate was sent out via email to 
all members of the ISSVD and BSSVD. Recipients were asked to 
declare an expression of interest, via email, to the study 
coordinator. No inconvenience allowance was offered and response 
to the initial invitation was taken as implied consent to participate in 
the study. The coordinator was UHTXLUHGWRNQRZSDUWLFLSDQWV¶GHWDils 
for administrative purposes. The exercise was otherwise conducted 
anonymously. Participants were asked specifically for their consent 
to be acknowledged in future presentation or publication. 
Questionnaires were completed using the online tool µ6XUYH\
0RQNH\¶(www.surveymonkey.com). A two-week period for each 
round was given in which participants could submit their responses 
(Hsu 2007). Reminders for each round were sent at seven, 10 and 
14 days to those that had not responded to the surveys. 
4.3.3.1 Round 1 
In the first round of the e-Delphi exercise (Appendix 4), participants 
were asked to rate the importance of the selected 12 diagnostic 
criteria on a five-point Likert scale. The scale¶VILYHFDWegories 
consisted of µYHU\LPSRUWDQW¶¶LPSRUWDQW¶¶OHVVLPSRUWDQW¶µQRW
LPSRUWDQW¶DQGµQRWVXUH¶:KHQGLVFXVVLQJKLVWRORJLFDOFULWHULDLW
was specified that biopsy samples should be taken from the edge of 
an erosion where more representative histology would more likely 
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be present. Contributors were then asked to list any additional 
diagnostic features that they considered relevant that were not in 
the original list.  
4.3.3.2 Round 2 
Following analysis of round one, the survey instrument was 
amended to create the round two questionnaire (Appendix 5). 
'LDJQRVWLFLWHPVWKDWZHUHUDWHGE\FRQVHQVXVDVµnot important¶
were removed and additional diagnostic items were incorporated 
into the questionnaire. Due to a number of comments regarding 
nomenclature of the condition, a question on disease terminology 
was also included in round two. Participants received feedback on 
WKHJURXS¶VRYHUDOOVFRUHVIURPWKHSUHYLRXVURXQG,QWKHVHFRQG
round, respondents could submit new answers, or leave their 
original responses unchanged. The same process of analysis and 
amendment of survey instrument occurred to create the round three 
questionnaire (Appendix 6).  
4.3.3.3 Round 3 
In the third round participants were asked to rate the diagnostic 
criteria that had reached consensus as importanWDVµHVVHQWLDO¶, 
µVXSSRUWLYH¶ RUµneither¶µ(VVHQWLDO¶ was defined as a diagnostic 
feature that must be present to make a diagnosis of ELPV. 
µ6XSSRUWLYH¶ was defined as a feature that does not have to be 
present, but adds weight to other diagnostic features that are 
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present. Participants were also asked how many essential and/or 
supportive diagnostic criteria should be present to make a diagnosis 
of ELPV. 
It was made clear throughout all rounds if questions had been 
amended, added or excluded following analysis of previous rounds. 
Participants were given the opportunity to comment on any of these 
amendments. 
4.3.3.4 Feedback 
After completion and analysis of all three rounds, the findings were 
circulated for formal feedback and comments from the participants 
(Appendix 7). The feedback round was not mandatory although 
participants were encouraged to complete the questionnaire. 
4.3.4 Definition of consensus 
Consensus was defined as being where 75% of participants agreed 
RQWKHLPSRUWDQFHRIDQLWHPLHUDWHGµvery importanW¶ or 
µimportant¶RQWKH/LNHUWVFDOHRUDJUHHGZKHWKHUDQLWHPVKRXOGEH
µHVVHQWLDO¶ or VXSSRUWLYH¶ . As a soft measure of consensus to avoid 
premature exclusion of diagnostic items, we also carried through 
LWHPVWKDWOHVVWKDQSDUWLFLSDQWVUDWHGµnoWLPSRUWDQW¶or 
¶XQVXUH¶. Diagnostic criteria that did not achieve consensus in this 
way were excluded from subsequent rounds of the exercise. 
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4.4 Results 
4.4.1 Demographic data 
The letter of invitation was circulated to 283 members of the 
International Society for the Study of Vulvovaginal Disease and 175 
members of the British Society for the Study of Vulval Disease. 
Some physicians were members of both societies but for 
confidentiality reasons these data are unknown. An expression of 
interest was received by 87 physicians; a total of 73 individuals 
participated in the first round. Of these, 71 (97.2%) completed the 
second round and 69 (95%) completed the final round. The formal 
feedback survey, which was optional, was completed by a total of 54 
participants.  
Participants represented four distinct stakeholder groups and were 
from 14 different countries. Characteristics of participants are in 
Table 25, p166. The majority had over ten years¶ experience in 
managing patients with vulval skin disease and 88% respondents 
were either Professors or Consultants in their field.
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 No. participated in 
Round 1 (%) 
No. participated in 
Round 2 (% 
response rate) 
No. participated in 
Round 3 (% response 
rate) 
Total participants in round 73 71 69 
Stakeholder group 
Dermatology 30 (41.7) 30 (42.3) 30 (43.5) 
Gynaecology (+/- Obstetrics) 30 (41.7) 28 (39.4) 26 (37.7) 
Histopathology/ 
Dermatopathology 
7 (9.7) 7 (9.9) 7 (10.1) 
Genitourinary 
medicine/venereology 
6 (8%) 6 (8.5) 6 (8.7) 
Grade 
Professor/Associate Professor 19 (26) 18 (25.3) 17 (24.6) 
Consultant 45 (61.6) 45 (63.3) 45 (65.2) 
Associate Specialist 6 (8.2) 5 (7) 4 (5.8) 
Resident/Specialist Registrar 2 (2.7) 2 (2.8) 2 (2.9) 
Specialist Nurse 1 (1.4) 1 (1.4) 1 (1.4) 
Country 
Argentina 2 2 2 
Australia 7 7 7 
Canada 3 3 3 
Denmark 1 1 1 
France 2 2 1 
Germany 1 1 1 
Israel 1 1 1 
Italy 2 2 2 
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Netherlands 3 3 3 
New Zealand 1 1 1 
Portugal 1 1 1 
UK 34 33 32 
US 14 13 12 
Uruguay 1 1 1 
Duration of Experience 
< 5 years 11 (15.3) 8 (11.3) 7 (10.1) 
6-10 years 12 (16.7) 13 (18.3) 12 (17.4) 
11-15 years 15 (20.8) 15 (21.1) 14 (20.3) 
16-20 years 18 (25) 18 (25.4) 22 (31.9) 
> 20 years 17 (23.6) 17 (23.9) 14 (20.3) 
Table 25: Characteristics of participants in the e-Delphi exercise
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4.4.2 Refinement of diagnostic criteria 
Following the first round, two additional clinical and three additional 
histopathological items were added to the second round 
questionnaire. In addition, the wordings of four questions needed to 
be amended for clarity. 
After the first and second rounds, six potential diagnostic criteria 
were removed from the final dataset as participants answers 
indicated these were not important features in diagnosing ELPV 
(Table 26, p169). 
There were ten diagnostic features (six clinical and four 
histopathological) that reached consensus, or soft consensus, and 
were carried through for final approval in the third round (Table 27, 
p171).  
In the third and final round, participants were asked to rank items 
DVµHVVHQWLDO¶RUµVXSSRUWLYH¶GLDJQRVWic criteria, or neither (Table 28, 
p172). No diagnostic indicator reached consensus as being 
µHVVHQWLDO¶7KHUHZHUHWKUHHGHILQLWHµVXSSRUWLYH¶FULWHULDZKHUH
>75% respondents agreed on the same answer. One item was not 
IDYRXUHGDVEHLQJLQWKHILQDOGLDJQRVWLFGDWDVHWWKLVZDVµthe 
absence of dermal hyalinisation¶RQKLVWRSDWKRORJLFDOH[DPLQDWLRQ
ZKHUHRIUHVSRQGHQWVFODVVLILHGLWDVQHLWKHUDQµHVVHQWLDO¶
QRUDµVXSSRUWLYH¶GLDJQRVWLFIHDWXUH7KHUHPDLQLQJILYHGLDJQRVWLF
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items were recommended as being supportive diagnostic criteria 
(Table 28, p172). The resulting diagnostic dataset therefore 
consisted of nine criteria that represent the clinicopathological 
features of erosive lichen planus. Of the 54 participants who 
provided feedback 92.6% were in agreement with this dataset. 
When asked how many diagnostic features should be present to 
diagnose ELPV, consensus was reached for three supportive features 
needing to be present. However, results from participant feedback 
were not so decisive and opinion was divided between three or four 
of the nine supportive features being required (Table 29, page 173). 
Some participants also suggested that clinical and histological 
criteria should be separate, or that criteria should be weighted as 
some are considered more important than others. 
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Diagnostic item 
Responses 
Number of responses (%) 
Very 
important 
Important Less important 
Not 
important 
Not sure 
Excluded after Round 1 
Presence of 
symmetrical lesions 
2 (2.7) 9 (12.3) 30(41.1) 30 (41.1) 2 (2.7) 
Presence of vaginal 
discharge 
1 (1.4) 10 (13.7) 30 (41.1) 30 (41.1) 2 (2.7) 
Presence of pain on 
Q-tip pressure 
2 (2.7) 8 (11) 21 (28.8) 38 (52.1) 4 (5.5) 
Excluded after Round 2 
Findings on wet 
mount preparation 
2 (2.8) 5 (7) 27 (38) 28 (39.4) 9 (12.7) 
Presence of 
epidermal changes 
on histopathological 
examination 
5 (7) 20 (28.2) 25 (35.2) 8 (11.3) 13(18.3) 
Direct 
immunofluorescence 
3 (4.2) 12 (16.9) 29 (40.8) 20 (28.2) 7 (9.9) 
Table 26: Diagnostic criteria excluded after the first and second e-Delphi rounds. 
1%&ULWHULDZHUHH[FOXGHGLI!SDUWLFLSDQWVFRQVLGHUHGWKHPDVµQRWLPSRUWDQW¶RUµQRWVXUH¶  
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Diagnostic item Responses 
Very important Important Less important Not important Not sure 
Clinical 
Presence of well demarcated 
erosions or glazed erythema 
at the vaginal introitus 
41 (57.7) 26 (36.6) 0 (0) 1 (1.4) 3 (4.2) 
Scarring/loss of normal 
architecture 
13 (18.3) 46 (64.8) 10 (14.1) 0 (0) 2 (2.8) 
Presence of a hyperkeratotic 
white border to erythematous 
areas/erosions +/- 
:LFNKDP¶VVWULDHLQ
surrounding skin 
9 (12.7%) 37 (52.1) 21 (29.6) 2 (2.8) 2 (2.8) 
Presence of vaginal 
inflammation +/- vaginal 
scarring 
7 (9.9) 20 (28.2) 34 (47.9) 8 (11.3) 2 (2.8) 
Involvement of other mucosal 
sites e.g. mouth, oesophagus 
13 (18.3) 31 (43.7) 21 (29.6) 4 (5.6) 2 (2.8) 
Symptoms of pain/burning 16 (22.5) 32 (45.1) 18(25.4) 28 (39.4) 9 (12.7) 
Findings on wet mount 
preparation 
2 (2.8) 5 (7) 27 (38) 28 (39.4) 9 (12.7) 
Histopathological 
Presence of a well-defined 
inflammatory band in the 
superficial connective tissue 
that involves the dermo-
epidermo junction 
27 (38) 40 (56.3) 3 (4.2) 0 (0) 1 (1.4) 
Presence of an inflammatory 
band that consists 
6 (8.5) 60 (84.5) 3 (4.2) 0 (0) 2 (2.8) 
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predominantly of 
lymphocytes 
Signs of basal cell layer 
degeneration e.g. Civatte 
bodies, abnormal 
keratinocytes or basal 
apoptosis 
13 (18.3) 47 (66.2) 7 (9.9) 0 (0) 4 (5.6) 
Absence of dermal 
hyalinisation 
8 (11.3) 17 (23.9) 29 (40.8) 3(4.2) 14 (19.7) 
Epidermal changes e.g. 
wedge shaped 
hypergranulosis, saw toothed 
acanthosis 
5 (7) 20 (28.2) 25 (35.2) 8 (11.3) 13 (18.3) 
Findings on direct 
immunofluorescence 
3 (4.2) 12 (16.9) 29 (40.8) 20 (28.2) 7 (9.9) 
Table 27:  e-Delphi round two results.  
N.B Items that reached consensus as important (i.e. where >75% participants rated µYHU\LPSRUWDQW¶RUµLPSRUWDQW¶) were carried through 
into the final round (white background). Items which did not meet this cut-off, but where <25% participants UDWHGµQRWLPSRUWDQW¶RUµQRW
VXUH¶ZHUHDOVRFDUULHGWKURXJKDVDPHDVXUHRIµVRIWFRQVHQVXV¶blue background). The remaining items were dropped following round 2 
(red background). 
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Diagnostic item Essential Supportive Neither 
Presence of well demarcated erosions or glazed erythema at the 
vaginal introitus 
44 (63.8) 24 (34.8) 1 (1.4) 
Presence of a hyperkeratotic white border to erythematous 
areas/erosions +/- :LFNKDP¶VVWULDHLQVXUURXQGLQJVNLQ 
8 (11.6) 57 (82.6) 4 (5.8) 
Symptoms of pain/burning 13 (18.8) 47 (68.1) 9 (13) 
Scarring/loss of normal architecture 10 (14.5) 55 (79.7) 4 (5.8) 
Presence of vaginal inflammation 7 (10.1) 48 (69.6) 14 (20.3) 
Involvement of other mucosal sites 1 (1.4) 66 (95.7) 2 (2.9) 
Presence of a well-defined inflammatory band in the superficial 
connective tissue that involves the dermo-epidermo junction 
37(53.6) 32 (46.4) 0(0) 
Presence of an inflammatory band that consists predominantly of 
lymphocytes 
30 (43.5) 37 (53.6) 2 (2.9) 
Signs of basal cell layer degeneration e.g. Civatte bodies, abnormal 
keratinocytes or basal apoptosis 
24 (34.8) 43 (62.3) 2 (2.9) 
Absence of dermal hyalinization 11 (15.9) 38 (55.1) 20 (29) 
Table 28: e-Delphi round three results - essential and supportive diagnostic criteria and final diagnostic dataset.  
N.B. Items that reached agreement to be in the final diagnostic dataset are with a white background. The item that did not reach 
consensus and was subsequently has a red background. 
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Number of criteria from 
final diagnostic dataset 
Response count Response percent (%) 
 1 3 5.8 
 3 5.8 
 15 28.8 
 17 32.7 
 7 13.5 
 5 9.6 
 1 1.9 
 0 0 
9 1 1.9 
TOTAL 52 100 
Table 29: e-Delphi feedback survey ± number of diagnostic criteria needed to confirm vulval erosive lichen planus 
Categories with the greatest number of responses were  DQGDQGDUHhighlighted in red  
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4.4.3 Requirement for histopathological examination of 
affected tissue 
During the exercise, participants were also asked about the 
importance of performing a diagnostic biopsy for ELPV. The majority 
(36/69, 52.2%) responded that a diagnosis of ELPV does not always 
have to satisfy clinical and histopathological criteria. However, 
63/69 (93.1%) acknowledged that a biopsy should be performed if 
there was diagnostic uncertainty or concern of neoplastic change. 
During group feedback, the main differential diagnoses that could 
potentially cause diagnostic difficulty were identified as lichen 
sclerosus and mucosal autoimmune bullous disorders (Table 30, 
p175).  
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Differential Diagnosis Number of participants 
Lichen Sclerosus 27 
Autoimmune blistering diseases 
(MMP, PV, BP) 
22 
3ODVPD&HOO9XOYLWLV=RRQ¶VYXOYLWLV 9 
Eczema/contact dermatitis 6 
Atrophic vaginitis 5 
Cancer/VIN 5 
Desquamitive Inflammatory Vaginitis 5 
Drugs/Fixed Drug Eruption 5 
µ9XOYRYDJLQLWLV¶ 3 
Infection 3 
SLE 3 
HSV infection 2 
Psoriasis 2 
Vulvodynia 2 
Amyloidosis 1 
Behcets disease 1 
Crohns disease 1 
([WUDPDPPDU\3DJHW¶V'LVHDVH 1 
GVHD 1 
Lichen Simplex chronicus 1 
Pyoderma Gangrenosum 1 
Table 30: Differential diagnoses for ELPV that were offered by the 54 participants in 
the e-Delphi Feedback Round.  
N.B. 47 participants offered more than one differential. MMP = mucous membrane 
pemphigoid; PV = pemphigus vulgaris; BP = bullous pemphigoid 
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4.4.4 Nomenclature 
Anxiety regarding nomenclature of the condition was expressed in 
the first round. This led to the addition in the second round of a 
VSHFLILFTXHVWLRQDERXWWHUPLQRORJ\3DUWLFLSDQWVZHUHDVNHG³what 
is the best nomenclature for the finding of painful erosions/glazed 
erythematous lesions at the vaginal introitus (+/- vaginal 
LQYROYHPHQW´ Based upon comments from the first round, three 
options were given: i) Vulval erosive lichen planus; ii) vulvovaginal 
erosive lichen planus and iii) vulvovaginal lichen planus. These 
scored 29.6%, 52.1% and 18.3% of responses respectively. 
Therefore consensus was not reached and many commented that 
the nomenclature should depend upon the individual clinical context. 
For the purposes of the exercise the original phrase µerosive lichen 
planus of the vulva (ELPV¶ was used, although it was acknowledged 
that not all patients have true erosions and some may have more 
extensive mucosal involvement. In practice it seems that physicians 
will use the diagnostic expression µHURVLYHOLFKHQSODQXVRIWKH
DIIHFWHGVLWHVHJµ(URVLYHOLFKHQSODQXVRIWKHYXOYDDQGYDJLQD¶ or 
µerosive lichen planus of the vulva and gingiva¶ etc. 
4.5 Discussion 
4.5.1 Main findings 
This exercise enabled the collation of a set of nine diagnostic criteria 
defined by experts as supportive of the diagnosis of ELPV (Figure 
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21, p183). It was agreed at the third round that three or more of 
these supportive features were required to diagnose ELPV and these 
can be a combination of both histological and clinical features. 
However, feedback from participants suggested that more focused 
work is required to determine whether this is the optimum number 
of features and whether the individual features should be weighted.  
The consensus exercise did not identify any essential diagnostic 
FULWHULD7KHWHUPµHVVHQWLDO¶LVDSRZHUIXOZRUGDQGPD\KDYHEHen 
LQWHUSUHWHGE\SDUWLFLSDQWVDVEHLQJV\QRQ\PRXVZLWKµDOZD\V¶7KH
diagnostic feature that was closest to reaching consensus as 
µHVVHQWLDO¶ZLWKRIUHVSRQVHVZDVZHOO-demarcated 
erosions/glazed erythema at the vaginal introitus. In some cases 
patients may have only vaginal disease without any external signs. 
It was commented by some physicians that this was the reason they 
did not rate introital erosions as essential. 
As ELP can affect a variety of mucosal surfaces one nomenclature 
does not necessarily fit all presentations of the disease. 
Furthermore, erosions are secondary to intense inflammation and in 
some cases only glazed erythematous areas are seen (Kirtschig 
2005). This caused debate amongst participants as to whether the 
WHUPµHURVLYH¶ZDVWHFKQLFDOO\FRUUHFW7KHILQDOGDWDVHWWRRNWKLV
discrepancy into account by wording the relevant diagnostic criteria 
as µZHOOGHPDUFDWHGHURVLRQVor glazed HU\WKHPD¶  
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The nomenclature of this condition is likely to remain controversial; 
DOWKRXJKWKHWHUPµerosive lichen planus¶ZDVFRQVLGHUHGLQDFFXUDWH
E\VRPHµOLFKHQSODQXV¶ as a standalone saying is usually reserved 
for disease affecting keratinising epithelium, which has a very 
different natural history and response to therapy than the mucosal 
variant (as described in section 1.2.1, page 12). 
4.5.2 Strengths and limitations of the study 
The µH-'HOSKL¶ method was used to answer a research question that 
required specialist input from the clinical community as these data 
were not available in the existing literature. This was a modification 
of the original description of the Delphi method that was first used 
in the 1950s (Murphy 1998). The present study involved 
communication with participants electronically rather than by post. 
The Delphi technique is characterised by four core features: 
involvement of an expert panel, multiple iterations, feedback 
between rounds and anonymity (Holloway 2012).  The latter is 
particularly important as in face to face group-based processes, the 
presence of dominant individuals can have a large influence on the 
results (Hsu 2007). Each of these features were embodied by this 
study. 
Due to the study conduct being via web-based communication, 
geographical constraints were overcome and anonymity of 
participants was maintained. There was a high degree of experience 
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and skill level within the recruited group, with the majority of those 
who completed all three rounds practicing as a Professor or 
Consultant having greater than ten years of experience in their field. 
All participants were members of specialist societies with a specific 
interest in vulvovaginal disease. The demographics of the group 
indicate that respondents had the necessary skills and experience to 
contribute to the derived diagnostic dataset. 
Three rounds of the Delphi exercise were performed which enabled 
the study to be completed in a timely manner without participants 
developing VXUYH\µIDWLJXH¶)eedback indicated that three rounds 
were sufficient to formulate a list of clinicopathological features that 
are suggestive of ELPV but further work is needed to determine the 
exact number of these criteria required.  
Important considerations when interpreting the results of this 
exercise are that two of the stakeholder groups, dermatopathology 
and genitourinary medicine were underrepresented.  Reliability of 
responses from individual groups diminishes with numbers of less 
than 12 and are considered to be unreliable with 6 or less (Murphy 
1998). Whilst dermatology and gynaecology expertise was 
adequately represented by respondents (Table 25, p166), 
histological opinion was not as only seven dermatopathologists took 
part. Individual histopathologists did comment that epidermal 
changes such as saw toothed acanthosis and hypergranulosis, and 
dermal changes of lack of hyalinisation, were important. These 
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comments were not sufficient to alter the results, however, it is 
possible that the views of the seven dermatopathologists were not 
representative of the profession as a whole, and findings may be 
different with larger numbers. Unfortunately it was beyond the 
scope of this exercise to investigate further. 
4.5.3 Implications for clinical and research practice 
It was important to do this exercise for two reasons, firstly to 
improve the diagnosis of an uncommon condition and improve 
patient care, and secondly to define stringent diagnostic criteria so 
that robust clinical trials can be carried out to improve current 
patient management (Simpson 2012).  This is particularly crucial as 
patients with ELPV may present to various specialty groups. 
Participants agreed that ELPV can be diagnosed clinically and a 
biopsy does not always need to be taken. Biopsy should however, 
be performed in cases of diagnostic doubt or if there is suspicion of 
malignancy.  
The site of biopsy is important as histological features described in 
the diagnostic dataset are more likely to be present at the edge of 
an erosion than centrally. Classical lichenoid features are most likely 
to be found when taken from the white margin of erosions (Pelisse 
1989). Assessment of vulval biopsies should be by a specific 
dermatological or gynaecological pathologist as changes of LP are 
often subtle and there is a possibility of an incorrect diagnosis being 
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made by pathologists who are inexperienced in this field (Bowen 
2008).  
The interest and high fidelity demonstrated in all three rounds 
shows that physicians internationally are motivated to advance 
practice in this area of vulvovaginal disease; 73 experts participated 
in the first round and only four dropped out during the nine-week 
study period. 
It should be realised that this is just one utility of the Delphi process 
and the methodology can be translated to other areas of healthcare 
where information in the scientific literature is lacking and therefore 
needs to be generated using expert opinion, for example in 
establishing core outcome sets (Schmitt 2011). 
4.6 Chapter 4 Summary  
The result of this consensus exercise represents the views of a 
group of experts and provides a list of supportive features that they 
consider important to diagnosing ELPV. The next steps are to 
validate the diagnostic criteria in the clinical setting by applying 
them to patients managed during normal practice. It is anticipated 
that the diagnostic criteria will guide physicians in their daily 
practice but more importantly, this dataset can be utilized in the 
conduct of my future clinical trial criteria to ensure inclusion of 
comparable participants. As practicing clinicians were participants in 
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the e-Delphi exercise, a trial protocol incorporating the results 
should provide a sense of ownership for those who participate in the 
main study.
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฀ Presence of well demarcated erosions or glazed erythema at the 
vaginal introitus 
฀ Presence of a hyperkeratotic white border to erythematous 
areas/erosions +/- :LFNKDP¶VVWULDHLQVXUURXQGLQJVNLQ 
฀ Symptoms of pain/burning 
฀ Scarring/loss of normal architecture 
฀ Presence of vaginal inflammation 
฀ Involvement of other mucosal sites 
฀ Presence of a well-defined inflammatory band in the superficial 
connective tissue that involves the dermo-epidermo junction 
฀ Presence of an inflammatory band that consists predominantly of 
lymphocytes 
฀ Signs of basal cell layer degeneration e.g. Civatte bodies, abnormal 
keratinocytes or basal apoptosis 
Figure 21: Final diagnostic dataset agreed through the e-Delphi consensus process. 
Diagnosis of erosive lichen planus affecting the vulva requires three out of the nine criteria 
listed in this table. 
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5 Outcome measures for vulval 
skin disorders: A systematic 
review of randomised 
controlled trials 
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5.1 Introduction 
5.1.1 The concept of an outcome measure 
The concept of an outcome measure is important for patient care. It 
is a way of assessing the health status (or disease-specific aspect of 
health) of a defined population, or a method to measure the effects 
of disease before and after an intervention to determine the 
effectiveness of that intervention.  
In many areas of medicine, bedside or laboratory tests are available 
to determine response to an intervention. For example, the use of a 
sphygmomanometer in primary care to assess hypertension. 
However, it is more difficult to assess disease severity for conditions 
where adequate laboratory tests are not available. Specific tools 
that serve the purpose of an outcome measure in these 
circumstances are available and can be categorized as demonstrated 
in Figure 22, below. 
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Figure 22: Different categories of outcome measure 
 
µ*HQHUDO¶RXWFRPHPHDVXUHVDUHWKRVHWKat have been designed for 
use in patients with any type of condition. They are useful in 
comparing different populations and diseases, particularly for health 
economic purposes. An example of a general outcome measure tool 
is the Short Form-36 questionnaire, which is a patient-reported 
health related quality of life, (HRQoL) measure.  
µDisease specific¶RXWFRPHPHDVXUHVDUHGHVLJQHGWRDVVHVVFHUWDLQ
aspects of named conditions and cannot be translated to other 
conditions. An example of a disease specific measurHLVWKH¶32(0¶
(Patient Oriented Eczema Measure) which is a patient-reported 
eczema severity measure. 
Clinician-rated outcome measures tend to assess impairments, 
whereas patient-rated measures evaluate the impact of disease on a 
SDWLHQW¶VGDLO\DFWLYLWLHs, work, and recreation.  
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5.1.2 Outcome measures for vulval skin conditions 
The work described in Chapter 1 (literature review), Chapter 2 
(multicentre case note audit and review of current clinical practice) 
and Chapter 3 (structured interviews with clinicians) of this thesis 
have all indicated that there are no outcome measures specifically 
designed for use in ELPV, or vulval skin disorders as a whole.  
The work in this chapter aimed to elucidate outcome measures that 
were already being used in for vulval skin conditions through a 
systematic review of the literature.   
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5.2 Aims 
The aim of this systematic review was to identify the outcome 
measures reported in published RCTs that had investigated the 
treatment of vulval diseases, and to determine whether any vulval-
specific scales existed. 
As it had been established that there were no RCTs and only a few 
large case series for ELPV, it was decided that RCTs of all vulval skin 
conditions should be included in the review. The rationale for this 
was that the goal of therapy for vulval dermatoses, regardless of 
underlying aetiology, is similar. Physicians aim to i) reduce 
symptoms that are of most importance to affected patients and ii) 
prevent secondary complications such as scarring or malignancy. 
5.3 Materials and methods 
The study protocol was finalised in July 2012 and published on the 
COMET Initiative database ("COMET Initiative"  2013). The protocol 
was also available in the public domain through the Centre of 
Evidence Based Dermatology website ("CEBD"  2012). 
The Medline, EMBASE and Cochrane Central Register of Controlled 
Trials (CENTRAL) databases were searched from the time of 
inception to the 17th July 2012, to identify all interventional RCTs of 
vulval skin conditions where the full text was available in English. 
The search strategy combined the free text terms µYXOYDO¶µYXOYDU¶
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DQGµYXOY¶ZLWKWKHPHGLFDOVXEMHFWKHDGLQJVµ9XOYLWLV¶, 
µ([WUDPDPPDU\3DJHW'LVHDVH¶µ9XOYDU1HRSODVPV¶µ9XOYRG\QLD¶ 
and µ9XOYDU9HVWLEXOLWLV¶7KH&RFKUDQH&ROODERUDWLRQ¶VVHDUFKILOWHU
for RCTs was then applied to select all RCTs categorised under those 
search terms. The full search strategy for the Medline database is in 
Appendix 8. There was no time limit on the searches. All types of 
topical, systemic, surgical and psychological intervention were 
considered. 
5.3.1  Inclusion criteria for studies assessed in systematic 
review 
i. RCTs of vulval skin conditions that included a clinical 
assessment of disease impact and severity of disease.  
5.3.2 Exclusion criteria for studies assessed in systematic 
review  
i. Non-randomised studies; 
ii. Papers where the outcomes were  
a. determined wholly by laboratory tests (e.g. 
histopathological specimens, microbiological tests) 
b. determined by survival rates 
c. pertaining to cervical disease 
d. pertaining to menopausal symptoms 
e. pertaining to infective conditions.  
iii. Reports that did not have clinically assessed or patient-
reported outcomes in the title or abstract 
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5.3.3 Data extraction 
Data were double-extracted by two researchers (RS and RM). All of 
the papers were reviewed independently by the data extractors. 
Data were entered onto a standardised proforma that was designed 
specifically for this study. Any difference in opinion was adjudicated 
by a third researcher (KT).  
Data collected included: 
i. The vulval condition being investigated 
ii. The study interventions 
iii. Whether the primary outcome measure was specified in the 
abstract or main text 
iv. Which primary and secondary outcomes were measured 
v. Which scales were used to assess the outcome 
vi. The method of assessment (i.e. assessed by physician, 
patient or other means). N.B. When the primary outcome was 
not specified, the first reported outcome in the results section 
was taken to be the primary outcome measure. 
A Microsoft Access 2007 database was designed to enter and 
process data from the paper extraction forms. 
5.4 Results 
5.4.1 Included studies 
A total of 1,613 articles were retrieved by the search strategy. The 
full texts of 67 articles were reviewed, of which 28 were eligible for 
inclusion into the study in line with selection criteria stated in the 
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eligibility criteria. A flow chart of included articles is shown in Figure 
23, page 193.  
The disorders reported by the included studies were vulvodynia 
(localised provoked, n=12 (Bornstein 1995, Weijmar Schultz 1996, 
Bornstein 1997, Bornstein 2000, Bergeron 2001, Nyirjesy 2001, 
Munday 2004, Danielsson 2006, Murina 2008, Petersen 2009, 
Bornstein 2010, Foster 2010); generalised provoked, n=1 (Brown 
2009); type not specified, n=1 (Masheb 2009)), lichen sclerosus 
(n=9) (Paslin 1991, Bracco 1993, Sideri 1994, Cattaneo 1996, 
Origoni 1996, Paslin 1996, Burrows 2011, D'Antuono 2011, 
Goldstein 2011), vulval intraepithelial neoplasia (VIN, n=2) (Naik 
2006, van Seters 2008), vulval pruritus (n=2) (Origoni 1990, Lagro-
Janssen 2009) and lichen planus (n=1) (Rajar 2008). 
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Figure 23: Articles identified for systematic review of outcome measures used in 
RCTs of vulval skin disorders 
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5.4.2 Outcomes identified from included studies 
The 28 studies measured 25 different types of outcome using 49 
different scales (Table 31, page 201). One study reported as many 
as 13 outcomes in their results. Only 6/28 (21%) studies clearly 
stated the primary outcome measures in the abstract or in the main 
text (Bornstein 1995, van Seters 2008, Bornstein 2010, Foster 
2010, Burrows 2011, Goldstein 2011).  
Of the total number of outcomes measured by the studies, those 
reported by patients were most common (69/103, 67%), followed 
by physician-reported outcomes (21/103, 20%). Histological 
assessment was used on eight occasions and digital images on four. 
The histological assessments identified were secondary outcomes 
and were always measured in conjunction with either physician or 
patient-reported outcome measures, or both. 
Some studies measured an outcome type more than once using 
different methods of assessment. The most commonly assessed 
outcomes were patient-rated improvement in pain (15/103, 15%), 
clinician-rated improvement in appearance (13/103, 13%) and 
patient-rated improvement in overall symptoms (11/103, 11%).  
Of the 49 different scales listed in Table 31, only one-third of these 
referenced previously used methods. Very few of these were specific 
to vulval disease; four were relevant to vulvodynia and five were 
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relevant to sexual functioning. The remaining eight were general 
QoL scales that were not specific to vulval disease. 
5.4.2.1 Patient reported symptoms 
Patient-reported improvement in pain was the most commonly 
reported outcome (n=15). It was almost exclusively used in the 
context of vulvodynia with only one study reporting its utility in 
lichen sclerosus. The McGill pain questionnaire (n=7) and a visual 
analogue scale (VAS, n=6) were the tools most commonly used to 
assess pain. The VAS was used with scales of 0-10 and 0-100.  
Improvement in overall symptoms was assessed by 11 studies 
investigating several different disorders, lichen sclerosus (n=5), 
vulvodynia (n=3), VIN (n=2) and pruritus (n=1).  Of these, there 
were three different ways of measuring µSDWLHQWJOREDODVVHVVPHQW¶
(PGA). As with the investigator-reported outcome measures, no two 
PGA scales were the same. Scales for PGA included 0-3 scale of 
severity, a 1-5 scale of severity and a scale of complete/partial/no 
response compared to baseline 
A composite scale of patient-assessed severity was used by five 
studies. Each study asked the patient to score the severity of 
various symptoms on a pre-defined scale. Symptoms included a 
combination of itch, burning, pain, dyspareunia (painful sexual 
intercourse), dryness and dysuria (pain on passing urine). These 
varied depending on the condition under investigation. They all used 
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a scale of 0-3 for a variety of symptoms. A VAS was used to 
measure overall symptoms by three studies, two of which measured 
on a 0-10 (Naik 2006, van Seters 2008) scale and one on a 0-100 
scale (Nyirjesy 2001).  
5.4.2.2 Clinician reported measures 
Clinician-rated improvement in appearance was reported in 13 
studies; these were investigating lichen sclerosus (n=8), vulvodynia 
(n=2), lichen planus (n=1), vulval pruritus (n=1) and vulval 
LQWUDHSLWKHOLDOQHRSODVLDQ 2IWKHVHVL[XVHGDQµLQYHVWLJDWRU
JOREDODVVHVVPHQW¶,*$WKDWLV, clinician assessed overall severity 
of disease. However, the specific IGA scales varied with no 
concordance between the different investigators and studies.   
A composite score of clinician-assessed severity was used in five 
studies, various component parts were used to form the composite 
score. For example, one study investigating lichen sclerosus 
(Cattaneo 1996) scored clinical features of hyperkeratosis, atrophy 
and sclerosis in terms of severity (0-3), summed these scores and 
then adjusted depending upon the extent of disease. Another study 
investigating lichen sclerosus (Munday 2004) scored pain, 
tenderness and erythema on a 0-3 scale and summated these; the 
total score was used as the outcome. 
A single study investigating vulval lichen planus (Rajar 2008) scored 
clinical severity according to criteria used by Thongprasom 
Chapter 5: Outcome measures 
197 
 
(Thongprasom 1992), which assesses the disease severity on a 
scale of 0-5. However, Thongprasom originally described this scale 
for oral lichen planus and it has never been validated in the 
assessment of vulval disease. 
5.4.2.3 Measures to assess disease impact on function and quality 
of life 
Sexual function was specifically addressed by 61% of studies 
(17/28). The different aspects of sexual function measured were i) 
the presence of dyspareunia (n=7); ii) improvement in sexual 
function (n=6); iii) severity of dyspareunia (n=5); iv) frequency of 
intercourse (n=3); v) sexual distress (n=2); vi) capability of 
completing intercourse (n=1) and vii) sexual satisfaction (n=1). 
A large number of different scales were used to assess these 
aspects of sexual function, as outlined in Table 31, page 201. 
Otherwise, other than one study that assessed dysuria as part of a 
composite assessment (Origoni 1990), day to day functioning 
including passing urine, defecation and washing was not assessed 
by the studies. 
Only 14% (4/28) of studies reported QoL or general health state 
(Danielsson 2006, van Seters 2008, Lagro-Janssen 2009, Petersen 
2009). The scales used to assess these were the Short Form 36 
6)Q DQGWKHµ'DUWPRXWK3ULPDU\&DUH&RRSHUDWLYHDQG
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World OrgDQLVDWLRQRI)DPLO\'RFWRUV¶&223:21&$TXHVWLRQQDLUH
(n=1).  
5.4.2.4 Other outcomes 
Side effects of treatment were only measured by one study (Origoni 
1990), treatment satisfaction by two (Masheb 2009, Bornstein 
2010) and treatment acceptability by two studies (Origoni 1990, 
Masheb 2009). 
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Method of outcome 
assessment 
Outcome measured Times outcome 
measured by the 
studies (n) 
Scales used to measure the outcome type  
(number of times scale used) 
References * 
Patient-rated Pain reduction  15  McGill Pain Questionnaire (7) 
VAS (6) 
Brief Symptom Inventory (1) 
Neuropathic Pain Index (1) 
(Bergeron 2001, Murina 2008, Brown 
2009, Masheb 2009, Petersen 2009, 
Bornstein 2010, Foster 2010, Goldstein 
2011) 
Improvement in overall 
symptoms  
11 Composite score, comprising various 
components (5) 
PGA (various scales) (3) 
VAS (3) 
(Origoni 1990, Bracco 1993, Sideri 
1994, Cattaneo 1996, Origoni 1996, 
Weijmar Schultz 1996, Nyirjesy 2001, 
Naik 2006, van Seters 2008, D'Antuono 
2011) 
Dyspareunia 7 Yes/no (1) 
Satisfactory/Unsatisfactory (1) 
Complete/partial/no response (1) 
0-4 scale (1) 
Marinoff Dyspareunia scale (1) 
(Paslin 1991, Bornstein 1995, 
Bornstein 1997, Bornstein 2000, 
Murina 2008, Bornstein 2010, Foster 
2010) 
Improvement in itch 6 PGA, various scales (3) 
Frequency, intensity and duration of itch 
(1) 
(Origoni 1990, Paslin 1991, Origoni 
1996, Paslin 1996, Lagro-Janssen 2009, 
Goldstein 2011) 
Improvement in sexual 
function 
6 FSFI (3) 
Sexual History Form (1) 
Derogatis Sexual Functioning Index (1) 
(Paslin 1996, Bergeron 2001, Murina 
2008, Masheb 2009, Petersen 2009) 
Psychological impact of 
disease 
5 Beck Depression Inventory (2) 
Profile of Mood States (1) 
Brief Symptom Inventory (1) 
Structured Questionnaire (1) 
(Bergeron 2001, Danielsson 2006, 
Masheb 2009, Foster 2010) 
Frequency of intercourse 3 Frequency/week or month (2) 
Once weekly yes/no (1) 
(Bergeron 2001, Bornstein 2010, 
Foster 2010) 
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Treatment acceptability 3 VAS (1) 
0-5 Scale (1) 
Consistency/absorbance/skin colour (1) 
 
(Origoni 1990, Masheb 2009) 
General health state 2 SF 36 (1) 
COOP/WONCA (1) 
(Lagro-Janssen 2009, Petersen 2009) 
Sexual distress 2 FSDS (2) (Petersen 2009, Burrows 2011) 
Treatment satisfaction 2 VAS (1) 
Excellent/Good/Low (1) 
(Masheb 2009, Bornstein 2010) 
Quality of life 2 SF 36 (1) (Danielsson 2006, van Seters 2008) 
Capability of completing 
intercourse 
1 Yes/No (1) (Bornstein 2010) 
Relationship with partner 1 Excellent/Good/Mediocre/Poor (1) (Bornstein 2010) 
Side effects of treatment 1 No description given (1) (Origoni 1990) 
Sexual satisfaction 1 Index Sexual satisfaction (1) (Foster 2010) 
Tampon test 1 Tampon Test (1) (Foster 2010) 
Clinician-rated Global assessment of 
appearance  
13 IGA, various scales used (6) 
Composite score, comprising various 
components (5) 
Thongprasom score (1) 
No description given (1) 
(Origoni 1990, Paslin 1991, Bracco 
1993, Sideri 1994, Cattaneo 1996, 
Origoni 1996, Nyirjesy 2001, Munday 
2004, Naik 2006, Rajar 2008, Masheb 
2009, D'Antuono 2011, Goldstein 
2011) 
Improvement/reduction in 
pain  
6 Vulval algesiometer, pain rated on VAS (1) 
Vulval algesiometer (1) 
Speculum rating (1) 
Cotton swab test (2) 
(Bergeron 2001, Danielsson 2006, 
Masheb 2009, Foster 2010) 
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Table 31: Outcome measures used in the 28 studies included in the systematic review of interventional trials for vulval skin conditions 
*N.B some studies measured an outcome type more than once (using different assessment methods); COOP/WONCA- Dartmouth Primary 
Care Cooperative and World Organisation of Family Doctors questionnaire; FSFI ± Female Sexual Function Index; FSDS ± Female Sexual 
Dysfunction Scale; PGA ± Patient Global Assessment; IGA ± Investigator Global Assessment; SF36 ± Short Form 36; VAS ± Visual 
Analogue Scale. 
Digital palpation of muscle groups (1) 
Vestibular pain index (1) 
Ulceration 1 IGA (1) (Goldstein 2011) 
Lichenification 1 IGA (1) (Goldstein 2011) 
Histological 
assessment 
Pathological-reported 
changes in histology 
8 No description given (3) 
Complete/partial/no response (1) 
Yes/no (1) 
Improvement in elastic fibres (1) 
Atrophy/Fibrosis/Oedema/Inflammatory 
infiltrate on 0-3 scale (1) 
Inflammation 0-4 scale (1) 
(Paslin 1991, Bracco 1993, Sideri 1994, 
Cattaneo 1996, Paslin 1996, Naik 2006, 
van Seters 2008) 
Digital image Improvement in 
appearance (photograph) 
2 No specific description of how images used 
(2) 
(Paslin 1996, Goldstein 2011) 
Lesion size 2 Method of measuring not given (1) 
Lesion measured with calipers and 
calculated by computer program (1) 
(Naik 2006, van Seters 2008) 
Assessment unclear Vestibular pressure 
sensitivity 
1 No description given (1)  
TOTAL 25 different outcome types 103 outcomes 
were measured by 
the included 
studies 
49 different outcome measure scales  
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5.5 Discussion 
5.5.1 Main findings 
There was little consistency in the way that studies assessed 
outcomes in trials of vulval skin conditions. Although outcome 
measure tools for the assessment of sexual function and pain were 
identified we did not find any global vulval-specific outcome 
measures. 
Symptoms and signs of disease were most commonly assessed 
using composite scores, physician or patient global assessments or 
visual analogue scales. However, scales and categories of 
assessment varied widely. The studies that measured pain were 
almost exclusively those investigating vulvodynia despite the fact 
that many vulval disorders are considered painful, such as erosive 
lichen planus. 
Outcome measures can be categorised into patient and physician-
reported measures which may be either general or disease-specific 
(Figure 22, page 187).  The review identified eight measures that 
were specific to vulval pain ± the vestibular pain index (Bergeron 
2001), the vulval algesiometer (Curnow 1996) and the Marinoff 
dyspareunia scale (Marinoff 1992). There were five measures 
specific to sexual function ± the Female Sexual Functioning Scale 
(Rosen 2000), the Sexual History Form (Nowinski 1979), the 
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Derogatis Sexual Function Index (Derogatis 1979), the Female 
sexual Distress Scale (Derogatis 2002) and the Index of Sexual 
Satisfaction (Hudson 1998). There was only one disease-specific 
measure, the Thongprasom score (Thongprasom 1992), which is 
specific to lichen planus. However, this has previously been 
described for oral, not vulval lichen planus and has not undergone 
validation in either subtype. There were no disease-specific 
measures for lichen sclerosus or premalignant disease. 
Studies were inconsistent in terms of measuring impact of disease 
on day to day function and on QoL. Whereby nearly two thirds of the 
included studies specifically asked about sexual function, other 
functional aspects of daily life were not considered, with the 
exception of one study reporting dysuria (Origoni 1990). We did not 
find any specific reference to bowel habit, washing, wearing specific 
clothing, walking, sitting or physical activity, despite patients with 
vulval problems commonly describing an impact on all these 
functions. Furthermore, only five studies specifically evaluated 
psychological impact of the vulval skin condition, which is an 
important factor when considering overall quality of life (Chen 
2007). 
It is disappointing that only four studies assessed quality of life 
since the majority of the conditions studied were chronic and 
clinically are known to affect daily life in affected individuals (Hickey 
2010, Lawton 2013).  
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5.5.2 Strengths and weaknesses of the study 
The strengths of this review were that it identified RCTs involving a 
range of vulval conditions ± vulvodynia, lichen sclerosus, pre-
PDOLJQDQWGLVHDVHOLFKHQSODQXVDQGµSUXULWXV¶(YHQWKRXJKWKH
aetiology of these conditions is different, their symptoms and effect 
on quality of life are comparable, as is the general clinical approach 
to initial disease assessment and response to therapy. It was 
therefore possible to collate the outcome measures that had been 
used in a range of clinical and research environments in the context 
of vulval disease. 
Potential limitations are that non-RCTs and trials without full text 
available in English were excluded. It is possible that some studies 
were not identified due to the latter, however, there are many 
hundreds of case series and pragmatically it would not have been 
possible to include all of these.  
A formal critical assessment of the quality of included studies was 
not undertaken as this was not the primary aim of the review. 
Overall, it appeared that many studies were poorly reported. Details 
about randomisation, blinding and concealment of allocation were 
frequently omitted.  These factors are important in assessing risk of 
bias in a study design (Moher 2010). Stringency of disease definition 
was also a problem in some cases, and two studies investigated 
µSUXULWXV¶, which is a symptom rather than a diagnosis and can be 
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the result of varying pathologies, rather than specific diagnoses. 
However, it was beyond the scope of this review to examine these 
issues in greater detail. 
5.5.3 Clinical and research implications 
For most skin conditions it is not possible to assess disease response 
on the basis of laboratory tests. Therefore, monitoring disease in 
RCTs and in clinical practice requires the use of reliable and relevant 
tools to assess clinical outcomes. Such measures are a necessary 
prerequisite for good evidence-based practice (Chren 2000) and are 
paramount in clinical trial research.  
The most commonly reported outcomes in the included studies were 
patient-led, which fits with standard clinical practice as described in 
Chapter 3 following structured interviews with clinicians. Therapeutic 
decision making for disease management is predominantly driven by 
SDWLHQWV¶V\PSWRPUHVSRQVHWRWKHUDS\(Simpson 2013). This is 
because with many vulval skin conditions, the appearance of vulval 
skin does not necessarily mirror the patient symptoms and the 
clinicians treating them are aware that adequate treatment must 
reflect the aspects of disease that particularly affect the patient. 
There is currently a movement towards core outcome sets for trials 
of specific conditions, as detailed by the COMET Initiative, which 
aims to standardise practice and enable comparison of the results of 
different treatment modalities in meta-analyses. Groups such as 
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OMERACT (outcomes in rheumatologic conditions) (Tugwell 2007), 
HOME (outcomes in eczema) (Schmitt 2011) and IMMPACT 
(outcomes in chronic pain) (Turk 2003), are disease or specialty-
specific projects striving to reach concordance so that the same 
disease specific outcome measures are adopted in therapeutic 
intervention studies . 
As vulval skin conditions affect patients in a multidimensional 
manner, outcome measures used in trials and clinical practice need 
to provide a holistic assessment of disease status encompassing 
emotional and social interactions, symptoms and functional 
impairment. Further work is required to identify what aspects of 
vulval disease are most important to patients, and to establish 
which aspects they would most like to see improved by therapy. 
 
5.6 Chapter 5 Summary 
This systematic review has highlighted the lack of outcome 
measures for chronic inflammatory vulval skin diseases and in 
particular, for erosive lichen planus. Patient and physician global 
assessments and visual analogue scales were commonly used to 
measure symptoms and signs, but there was no standardization in 
the scales used. Assessment of sexual function is clearly important 
when managing vulval skin conditions, however, a variety of scales 
had been used without agreement on which one(s) are most 
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appropriate. Finally, quality of life was poorly assessed and limited 
validated tools were used to assess this aspect of vulval skin 
disease. 
However, this is evidence on which to base further work with 
patients and clinicians. The most relevant outcomes to be measured 
in a randomised controlled trial of ELPV should be established and 
the following chapter (chapter 6) will describe qualitative work 
which was carried out to identify the treatment outcomes which 
patients consider most important.  
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6 3DWLHQWV¶YLHZVRQYXOYDO
erosive lichen planus 
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6.1 Introduction 
+DYLQJHVWDEOLVKHGFOLQLFLDQV¶SHUVSHFWLYHVRQWUHDWLQJ(/39 (Chapter 
3) and subsequently demonstrating the lack of clinically appropriate 
outcome measures for the condition (Chapter 5), it was important to 
DVFHUWDLQSDWLHQWV¶YLHZVRQ(/39 and assess which outcomes were 
most relevant from their perspective. For any clinical research 
patient involvement is paramount to ensure that the work and end 
results are relevant and important to the population affected. This 
chapter aimed to provide evidence through patient input that would 
build upon the work described in the previous chapters. 
6.2 UK Lichen Planus Society Survey  
6.2.1 Aims 
In order to supplement the systematic review of outcome measures 
in Chapter 4, members of the UK Lichen Planus Society (UKLP, see 
section 1.7.3.1, p48) were approached to obtain qualitative 
information about the aspects of ELPV and its treatment that are 
important from DSDWLHQW¶VSHUVSHFWLYH Specifically investigated 
were aspects of disease that have the greatest impact upon quality 
of life, and SDWLHQWV¶SULRULWLHVIRUWUHDWPHQW 
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6.2.2 Materials and methods 
The UKLP society membership consists of people who suffer from 
lichen planus. Members were contacted by electronic mail and 
invited to complete a questionnaire that was posted on the website. 
Forms were completed anonymously and returned electronically to 
the study coordinator (RS) via the UKLP website lead. As this was a 
voluntary survey which was completed anonymously without any 
information to link back to an individual, ethical approval was not 
required. 
The questionnaire was devised to obtain the following information: 
฀ basic demographic data; 
฀ medical care received for treating lichen planus 
฀ specific details about the disease itself (i.e. site, duration); 
฀ DVSHFWVRIGLVHDVHWKDWµERWKHU¶SDWLHQWVWKHPRVW 
฀ priorities for treatment. 
To ascertain impact on quality of life caused by ELP, patients were 
asked to complete a Dermatology Life Quality Index questionnaire 
(Finlay 1994). 
7KHWHUPµERWKHU¶ZDVXVHGDVLWKDVEHHQVKRZQWREHHDVLO\
understood by patients when developing symptom-based outcome 
measures in other disease areas, such as eczema (Charman 2004). 
Chapter 6: WĂƚŝĞŶƚƐ ?ǀŝĞǁƐ 
212 
 
Data from forms received were entered data entered into a 
Microsoft Excel spreadsheet for qualitative and quantitative analysis. 
6.2.3 Results 
6.2.3.1 Demographic data 
At the time of the survey 234 people were a member of the UKLP 
support group, but it was not possible to identify how many of these 
were active website users. There was an 18% (42/234) response 
rate. Of these, 35/42 had genital or oral disease, or both; the 
remainder did not have LP affecting mucosal surfaces. Respondents 
with mucosal LP consisted of 26 females and 9 males.  
The mean duration of disease was 5.2 years (range 0.5-20 years). 
The majority of respondents were aged between 35 and 65 years.  
Patients were asked to indicate which anatomical sites were affected 
by lichen planus (Figure 24, p213); most had more than one site 
affected. The oral cavity was most commonly involved, followed by 
the vulva and vagina. Other mucosal sites such as the anus and 
penis were affected, but much less commonly. These are 
demonstrated in the bar chart below. 
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More than one anatomical site was involved in the majority of 
respondents; 71% (25/35) patients having two or more sites and 
43% (15/35) had over 3 different anatomical sites affected by LP.  
6.2.3.2 Effect of ELPV of quality of life 
Results for female respondents with ELPV were separated from the 
remainder of the group as these were of greatest relevance to this 
project. Dermatology life quality index scores (DLQI) ranged from 0-
22 (Figure 25, page 215). It has been shown that a score of 10 or 
PRUHRQWKH'/4,UHSUHVHQWVWKHGLVHDVHDVKDYLQJDµODUJHHIIHFW¶
on quality of life (Basra 2008). For this group of females, 44% 
scored 10 or more on the DLQI scale. Furthermore, when mapped to 
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Figure 24: Bar chart showing the results of UKLP survey - body sites affected by lichen 
planus 
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number of anatomical sites affected by LP, there was a directly 
proportional relationship with the DLQI score (Figure 26, page 215).  
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Figure 25: Scatter plot from the UKLP survey showing the dermatology life quality 
index scores of participants. 
N.B DLQI scores are for females with orogenital erosive lichen planus (n=26) 
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Figure 26: Scatter plot from the UKLP survey showing the correlation between 
numbers of sites affected with lichen planus and dermatology life quality index. 
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6.2.3.3 Symptoms of ELPV that bother people the most 
Patients were asked to list the top two aspects of disease that 
bothered them the most and were therefore priorities for treatment 
(Table 32, 217), not all patients filled in two answers. Symptoms 
(pain/discomfort/itch) were the most common response, followed by 
functional impairment (sexual problems/difficulty in passing 
urineµ2ther¶UHVSRQVHV were a heterogeneous group with no 
distinct themes, ranging from the possibility of malignant 
transformation to having a smear test under general anaesthetic. 
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Disease aspect that bothers the most N (%) 
Pain/discomfort 12 
Sexual problems 8 
Appearance 5 
Difficulty eating 3 
Itch 2 
Scarring 2 
Other 12 
Table 32: UKLP survey - Aspects of mucosal lichen planus that 
bother patients the most
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Other themes that emerged from the questionnaire were that: 
฀ there is a lack of understanding of ELP and its management 
amongst primary care practitioners; 
฀ definitive treatment pathways are not currently available and 
therefore management of ELP is suboptimal; 
฀ existing quality of life assessment tools were not specific 
enough to PHHWWKHSDWLHQWV¶ needs. 
6.2.4 Discussion 
Despite the relatively low number of resonses, this questionnaire 
survey of patients with lichen planus demonstrated that when the 
disease affected mucosal surfaces, it has a considerable effect on 
quality of life. This was evidenced by the fact that nearly half of 
patients scored greater than 10 on the DLQI, indicating that the 
condition has a large impact upon quality of life. Furthermore, this 
study showed a convincing positive correlation between number of 
sites affected and DLQI value. 
7KHHPSKDVLVRISDWLHQWV¶concerns were symptoms, functional 
impairment and the physical appearance of lesions. However, there 
was also dissatisfaction with current treatment, disease specific 
outcome measures and level of understanding of the disease from 
the wider medical community.  
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To explore these themes further and to demonstrate their validity, 
patient-oriented focus groups that were subsequently performed 
(Section 6.3). 
6.3 Erosive Lichen Planus Focus Groups 
6.3.1 Introduction 
Following on from the questionnaire work described in section 6.1 
the next natural step was to engage directly with patients to verify 
and consider in more details some of the findings of these studies. 
It was felt that interaction on a group level using focus groups, 
rather than individual structured interviews, would provide a more 
appropriate environment and peer support to explore this sensitive 
and potentially difficult topic. In addition, it was felt that this group 
setting would help individuals to verbalise feelings that they might 
find difficult to express alone.  
This type of interaction was also intended to obtain patient input 
into the design of the future trial, for which the work in previous 
chapters has been building towards. 
As has already been  alluded, in order to design an RCT for patients 
with ELPV a number of steps need to be taken to ensure the trial is 
pragmatic, answers clinical questions that are important to patients 
and doctors, and measures clinically relevant outcomes. The 
primary aims of these focus groups were to obtain this information, 
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however, they were also an opportunity to perform an exploratory 
evaluation of how ELPV affects peoples lives. 
6.3.2 Aims 
This study had a number of aims relating to patienWV¶H[SHULHQFHVRI
living with ELPV and to obtaining patient input into the RCT design. 
฀ To identify the most important aspects of ELPV from the 
patients¶ perspective. 
฀ To ascertain outcome measures that might be appropriate for 
use in a future RCT 
฀ To determine whether the overall design of the planned RCT 
is acceptable to patients with ELPV and if they would be 
willing to take part; 
฀ To understand the potential barriers to recruitment and 
consider ways to overcome these; 
฀ To explore factors that will make the RCT attractive to 
participants including: content of patient information sheets, 
discussing the potential treatments/regimens to be used, 
willingness to be randomised to a new treatment, follow up 
timings and monitoring investigations.  
฀ To explore the effeFWVRI(/39RQSHRSOHV¶OLYHVDQGDVFHUWDLQ
VSHFLILFSUREOHPVHQFRXQWHUHGIURPWKHSDWLHQWV¶SHUVSHFWLYH 
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6.3.3 Materials and methods 
6.3.3.1 Ethical approval 
The focus group study proposal underwent a full ethical review and 
was approved by the Nottingham Research Ethics Committee on 27th 
December 2012 (REC Reference 12/EM/0462). 
6.3.3.2 Participants 
Participants were enrolled from  a single centre. Focus groups were 
held on two occasions two weeks apart. The same participants were 
involved in both sessions. As there was a considerable amount of 
information to process and understand it was decided that two 
sessions would be preferable to one. The first session covered the 
concept of outcome measures and most bothersome symptoms with 
the second session covering trial design. Participants therefore had 
the opportunity to reflect upon issues brought up in the initial 
discussion prior to attending the second session.  
(DFKSDUWLFLSDQW¶VLQYROYHPHQWZDVOLPLWHGWRWKHWZRIRFXVJURXSV
The study duration, from time of sending out invitation letters to 
completing the second focus group was three months from January 
2013 to March 2013.  
All participants provided written informed consent for their 
involvement in this study. 
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6.3.3.3 Recruitment 
Participants were recruited from Nottingham University Hospitals, 
which runs a dedicated vulval dermatology clinic.  
Participants were identified through outpatient clinic lists and invited 
to join through a letter from by their usual treating clinician. A full 
patient information sheet (PIS) was enclosed with the invite letter. 
Patients who were interested in taking part were asked to contact 
the study co-ordinator by either return of a response slip or by 
telephone. A follow-up telephone call subsequently took place to 
discuss the PIS prior to attending the focus group. The patients 
were counselled on all aspects relating to participation in the study 
and given the opportunity to ask questions before deciding whether 
to participate or not. 
6.3.3.4 Moderators 
Two moderators were present to lead the sessions and each had 
distinct roles. A clinical researcher (RS) provided clinical input into 
the discussion, introduced the concept of a future trial and its design 
DQGH[SODLQHGWKHFRQFHSWRIµRXWFRPHPHDVXUHV¶$QLQGHSHQGHQW
moderator was present to facilitate the discussion in a non-biased 
manner (CL).  
6.3.3.5 Inclusion criteria 
฀ Clinical diagnosis of ELPV as made by a Dermatologist;  
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฀ Capability to give informed consent and to attend focus group 
meetings; 
฀ Fluent in written and spoken English language; 
฀ Age >18 years. 
6.3.3.6 Exclusion criteria 
฀ Age < 18 years; 
฀ Not willing/ unable to give informed consent/unable to attend 
focus group meetings; 
฀ Alternative/unclear clinical diagnosis. 
6.3.3.7 Focus group session 1 format 
At the beginning of Focus Group 1, introductions took place and the 
function of the day was reiterated. Consent forms were signed prior 
to starting of recording of the first session. 
Participants were encouraged to discuss their experiences of living 
with ELPV and the impact it has had on their lives. After this initial 
open discussion the session focused on assessing what might be 
important outcomes for patients being treated for ELPV as well as 
exploring the appropriateness of outcome measure tools that are 
commonly used in clinical practice. Patients were asked specifically 
to comment upon  the tools that had been identified by the 
systematic review (section 5.4.2, page 194). Prompts used for this 
part of the session can be seen in appendix 9. 
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7KHFRQFHSWRIDQµRXWFRPHPHDVXUH¶ZDVLQWURGXFHGEHIRUH
patients were asked to give their opinion on the relevance of the 
tools. These had been identified by the systematic review and are 
outlined in Table 33, page 225.  
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Aspect of disease 
measured 
Tools discussed 
Health related quality of 
life 
COOP/WONCA questionnaire 
Short Form-36 questionnaire 
Overall disease score (e.g. 
bother) 
Visual Analogue Scale 
Likert Scale (3- and 5-point scales 
presented) 
Pain Visual analogue scale (0-10) 
McGill pain Questionnaire 
Psychological effects Hospital Anxiety and Depression Scale 
Sexual function Female Sexual Functioning Index 
Female Sexual Distress Scale 
Derogatis Sexual Function score 
Skin related quality of life DLQI 
Skindex-29 (vulval specific version) 
Table 33: Outcome measure tools discussed in Erosive Lichen Planus Focus Groups 
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Patients were asked which of the tools they felt were relevant to 
their needs and accurately provide a reflection of their disease 
severity. Discussion also took place around other aspects of disease 
(or its treatment) that the patients felt should be asked about as an 
outcome.  
Participants were then given a 2-week period in which to reflect 
upon the discussion and to complete some example  questionnaires 
at home, before attending Focus Group 2. 
6.3.3.8 Focus group session 2 format 
A summary of findings from the first session was given in order to 
reiterate and clarify the important points that had been identified 
from the first focus group. 
The proposed future RCT plan was subsequently presented, focusing 
on aspects of the study that have most impact on patients. 
Participants were encouraged to give their honest opinion on the 
overall study concept i.e. proposed trial medications, timing of 
follow up visits, and were asked to highlight any aspects that would 
prevent or discourage them from entering the study, as well as 
aspects that they particularly liked. 
Focus group sessions one and two each  lasted two hours. This 
included a refreshment break and the sessions were followed by 
lunch. 
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6.3.3.9 Data management 
The sessions were audio-recorded using two devices (one for 
backup). The recordings were copied onto DVD and transcription 
occurred within two weeks of the second session. The recordings 
and their transcriptions were stored securely on a password-
protected computer and the recordings were deleted once 
transcription was complete. The resulting documentation did not 
contain any identifiable patient information. Formal analysis (section 
6.3.3.10, page 227) was performed using NVivo 10 software. 
6.3.3.10 Analysis 
Although the focus groups were carried out at two different time 
points, data were considered as one set as the same group of 
participants were involved in both. There were two main aims to the 
analysis:  
1. to obtain information relevant to designing a future 
randomised controlled trial; 
2. to perform an exploratory analysis and identify key features 
RISDWLHQWV¶H[SHULHQFHVRI(/39 
Data were analysed thematically using a multi-stage process as 
described by Braun and Clarke in 2006 (Braun 2006). Thematic 
analysis is a method of identifying, analysing and reporting patterns 
WKHPHVZLWKLQGDWD$µWKHPH¶FDStures something that is 
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important about the data in relation to the research question and 
represents a degree of patterned response or meaning within a 
dataset (Braun 2006). Researcher judgement and discretion is 
necessary to define and determine what themes exist within the 
dataset. Thematic analysis is a flexible and organic process that 
evolves as data is repeatedly analysed and greater familiarisation 
with the content occurs (Braun 2006).  
The steps taken to analyse data resulting from the ELPV focus 
groups were as follows: 
Stage 1: Familiarising with the data 
This stage was performed to generate preliminary thoughts on what 
might be interesting or important about the data. Firstly, recordings 
from the sessions were listened to in order to understand the 
breadth and content of the data. Brief notes of initial thoughts and 
ideas were recorded as well as postulating broad categories of how 
the data could later be organised.  
As data were transcribed by an external typist, it was important to 
check the transcript against the original audio recording for accuracy 
and become more familiar with the data. 
Stage 2: Generation of initial broad codes 
The full dataset was then assessed and sections of text were 
systematically coded; a code represents the most basic segment of 
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the raw data that at a later stage can be organised to find meaning 
within the data (Boyatzis 1998). Coded data were in much broader 
categories than postulated in phase one of analysis resulting in a 
larger number of codes being generated. It was important in this 
stage to code for as many potential themes and patterns as possible 
and to keep the data in context. Therefore coded sections of text 
were taken with relevant surrounding data to maintain the full 
meaning of the selection. It was possible that an individual extract 
of data could fit into more than one category if the content was 
relevant to a number of different issues. Furthermore, as this was a 
fluid process, data could be un-coded if it later became apparent 
that it was not important or if it did not fit within its initial 
designated category.  
Finer analysis of the coding then took place and items that had been 
broadly coded were considered in greater detail with the initial codes 
being broken down into smaller subcategories. 
Stage 3: Organising codes and searching for themes 
During this stage coded data were organised so that the original raw 
data took on a more structured format.  The codes were then used 
to find themes, which is a way that the codes are organised in a 
systematic fashion. In this stage an early look at the relationship 
between the codes and the themes took place. 
Stage 4: Rationalising and refining themes 
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Themes were then rationalised through assessing the data contained 
within each category. It became evident if there was not enough 
data to support a theme that it should not be a feature of the end 
results whereas other themes were too diverse and needed to be 
restructured. 
Following this process it was then possible to organise the themes 
into a hierarchical model, to assess links and associations between 
WKHWKHPHVDQGWRFUHDWHDWKHPDWLFµPDS¶WKDWDGHTXDWHO\
represents the original data set (Appendices 9 and 10). 
 
Stage 5: 
This final stage was to identify the key themes and features 
resulting from the data, these are presented as the main findings of 
this work. This is the information which will help us to understand 
ZRPHQ¶VH[SHULHQFHVRIOLYLQJZLWKDQGEHLQJWUHDWHGIRUHURVLYH
lichen planus affecting the vulva. 
6.3.4 Results 
Invitation letters were sent out to 31 patients identified from the 
specialist vulval clinic at Nottingham University Hospitals. Responses 
were received from 14/31 (45%) with 11/14 agreeing to participate 
in the sessions. Due to various reasons, six participants were able to 
attend both sessions. In addition, one patient who was unable to be 
Chapter 6: WĂƚŝĞŶƚƐ ?ǀŝĞǁƐ 
231 
 
present at the focus groups attended a structured interview to 
discuss the focus group findings. Participants were aged 42-76 
(mean 64.1) years, with six being in the post-menopausal range. All 
were white British females. 
The total study period from sending out invitation letters to 
completing the two focus groups and structured interview lasted 
from January 2013 to March 2013.  
As discussed in the methods (section 6.3.3, page 221), these focus 
groups were analysed with two different purposes -practical 
considerations for a future trial design and thematic analysis of 
SDWLHQWV¶H[SHULHQFHV7KHVHZLOOEHSUHVHQWHGVHSDUDWHO\7KH
structured interview was analysed in a similar way and any findings 
additional to the focus group data were incorporated into the main 
results. 
6.3.4.1 Practical consideration for a future randomised controlled 
trial 
6.3.4.1.1 Outcome measures 
The outcomes that are most important to assess from the patients 
SHUVSHFWLYHDUHRYHUDOOµERWKHU¶RIGLVHDVHVRUHQHVVSV\FKRORJLFDO
impact, impact on quality of life and sexual function. People were 
keen for all of these to be assessed in some way as ELPV has a 
greater impact than on just physical symptoms as discussed in the 
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thematic analysis of these data. Through assessing these different 
HIIHFWVRIWKHGLVHDVHRQSHRSOHV¶OLYHVWKH\IHHOWKDWGRFWRUVDUH
considering them as a whole person, not just a condition affecting 
one part of them. 
Having discussed the tools that can be used to measure the 
outcome domains there were some clear preferences. These are 
tabulated alongside the reasons for patients preferring these to the 
other options (Table 33 and Table 34 pages 225 and 233 
respectively). Examples of the questionnaires described in Table 33 
are in appendix 10. 
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Outcome measure to assess Preferred tool Comments 
Overall disease control  ‘ŽƚŚĞƌ ?Ɛcore on 5 
point Likert scale 
dŚĞǁŽƌĚ ‘ďŽƚŚĞƌ ?ǁĂƐĐŽŶƐŝĚĞƌĞĚ
the most appropriate term to assess 
overall control. A Likert scale was 
preferable to a VAS 
Symptoms Soreness measured by 
10-point VAS 
VAS preferred to a Likert scale as 
people felt it gave them the greatest 
flexibility given that their symptoms 
are variable day to day  
Psychological impact HADS People felt this was a very good way 
of considering them as a whole 
person and liked the questions 
asked 
Quality of life (Skin specific) Vulval Skindex-29 
scale 
This was preferred over the DLQI as 
it was in greater depth and asked 
questions of more relevance to their 
condition 
Quality of life (General) SF-36 This was the preferred tool, 
although people were not 
particularly supportive of a general 
QoL tool and preferred the skin-
specific measures 
Sexual function Derogatis sexual 
functioning scale 
Although people did not mind the 
more in depth scales (FSFI and FSDS) 
they felt the Derogatis scale was 
simpler to complete and was in 
sufficient detail for their needs  
Table 34: Outcome measure tools preferred by patients in focus groups.  
DLQI- Dermatology Life Quality Index; FSDS- Female Sexual Distress Scale; FSFI ± 
Female Sexual Functioning Index; HADS ± Hospital Anxiety and Depression Scale; 
SF-36 ± Short Form-36; VAS ± Visual analogue scale 
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6.3.4.1.2 Trial design 
The focus group participants were extremely supportive of a future 
RCT, despite two of them already having taken the proposed trial 
medications with resulting poor effects. People were positive about 
the fact that the study would improve knowledge about treatments 
for ELPV and would help patients to understand that there are other 
people out there with the same condition. Although the monitoring 
and follow up schedule proposed is the same for any patient on a 
systemic therapy, people felt that clinic visits being increased 
slightly from when on topical therapy alone were reassuring and 
would encourage their participation in a trial. 
The main concerns expressed about the study were the fact that 
people with ELPV are likely to be on other medications and that 
there is a risk of drug interactions. There was some worry about 
taking medications for six-months in case the disease worsened, or 
the treatment caused side effects or was intolerable. Furthermore, 
comments were made about the potential size of tablets and the 
fact that they may be difficult to take. 
These are all understandable fears, particularly from a slightly older 
age group who may have previously experienced adverse effects 
from medications. Such responses are witnessed in the clinical 
environment and are an indication that extra time will need to be 
spent to allay these fears before the randomisation process. 
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Furthermore, a telephone help line to discuss any problems related 
to the medication was suggested by the participants. 
Hypothetically, five of the seven participants were willing to take 
part in the proposed trial. The remaining two had well-controlled 
disease and therefore would not have been eligible for the trial, they 
were therefore more hesitant. However, if their condition did get 
significantly worse, they would be willing to consider entering into a 
trial of systemic therapy.  
6.3.4.2 Thematic analysis of the exploratory data generated by the 
focus groups 
Thematic analysis of data from these exploratory focus groups was 
broken down into an hierarchical structure consisting of a number of 
categories with numerous subcategories. These are demonstrated in 
Appendix 11. It became apparent that there were interlinking 
themes between all of these categories and none were mutually 
exclusive. The categories and subcategories were used to create a 
thematic map, which demonstrates the complexity of issues 
identified during the focus groups (Appendix 12).  
This thematic map was reduced down into four main themes that 
from this early work appeared to underpin the experiences faced by 
patients with ELPV. These themes can be broken down further to 
give a fuller understanding of why they are important (Table 35, 
page 237). These four main themes have been interpreted as areas 
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in which healthcare professionals need to work to improve 
management, increase awareness of the condition and develop 
opportunities for supporting patients.  
Chapter 6: WĂƚŝĞŶƚƐ ?ǀŝĞǁƐ 
237 
 
Main theme Major category within 
theme 
Effect on management/patient 
Symptoms Soreness Profound effect on daily activities and 
function 
Psychological effect Low mood 
Anxiety 
Distress 
Fear 
Guilt 
Stigma 
Embarrassment 
Effect on relationships Impact on other people 
Negative 
experiences 
Community management Time taken to diagnosis 
Lack of understanding/lack of faith in 
non-specialists 
Secondary care Inconsistency in care received 
Poor handling of clinical examination 
and diagnostic tests 
Lack of communication between 
doctors 
Lack of understanding  
Misunderstandings Patient misunderstandings 
Health care professional 
misunderstandings 
Treatments Feeling unsupported when on systemic 
treatment 
Difficulty in using treatments as 
requested by the clinician 
Support 
networks 
Poor information 
available 
Dearth of information available on the 
internet and from doctors 
Value of reassurance Patients needing someone to talk to 
Positive 
outcomes 
Stoicism Coping mechanism 
Trust in specialist doctors Improves perception of management 
Table 35: Four main themes identified by the ELP focus groups 
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6.3.4.2.1 Symptoms 
Symptoms caused by ELPV are the main factor that seems to lead to 
a number of secondary problems. 
The predominant symptom caused by ELPV is soreness. Although 
patients described the unbearable sensation of itch in the early 
stages, this quickly turned into soreness, which has significant 
sequelae. Doctors often ask patients about the level of pain that 
they are experiencing from their condition; a term that GRHVQ¶W
always accurately describe the symptom that people face. From 
these focus groups people talked predominantly about soreness: 
 “&ŽƌŵĞŝƚŝƐƚŚĞƐŽƌĞŶĞƐƐƚŚĂƚŐĞƚƐŵĞĚŽǁŶ ?/ƚŝƐŶŽƚĂƐŝƚĐŚǇŶŽǁĂƐŝƚǁĂƐ ?ǀĞŶũƵƐƚ
sitting causes it. ? 
Symptoms of soreness have an impact in the following ways; there 
is considerable interlinking between these categories: 
6.3.4.2.1.1 Soreness 
Soreness and discomfort caused by ELPV has a substantial effect 
upon performing day to day activities and should not be 
underestimated. It causes difficulty in most routine tasks that are 
otherwise taken for granted. The most notable effects seemed to be 
upon mobility, sitting, urination, choice of clothing and eating. Even 
those without oral ELP found that certain food types they ate 
impacted on their vulval symptoms due to changes in their urine. 
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The following comments demonstrate the ways in which people are 
affected: 
 “/ŬŶŽǁŝƚƐŽƵŶĚƐƐŽƐŝůůǇďƵƚũƵƐƚŐĞƚƚŝŶŐŝŶƚŽĂĐĂƌ ?ŝĨ ǇŽƵŝŵĂŐŝŶĞũƵƐƚŐĞƚƚŝŶŐŝŶƚŽĂ
car, you open your legs and you sit down and then it hits you then when you out the 
ŽƚŚĞƌůĞŐŝŶ ?ŝƚŚƵƌƚƐ ? ? 
 “^ŽŵĞƚŝŵĞƐĞǀĞŶũƵƐƚǁĂůŬŝŶŐŝƐƐŽƵŶĐŽŵĨŽƌƚĂďůĞ ?zŽƵũƵƐƚŐĞƚƐŽƐŽƌĞĂŶĚƚŚĞŶǇŽƵ
ƚƌǇƚŽƐŝƚĚŽǁŶƚŚŝŶŬŝŶŐ ? ‘ǁĞůů/ǁŽŶ ?ƚĚŽƚŚĂƚ ? ?ďƵƚƐŝƚƚŝŶŐĐĂŶďĞĂƐďĂĚ ? “
 “/ƐŝƚŽŶƚŚĞƚŽŝůĞƚĂŶĚďĞŶĚĨŽƌǁĂƌĚŝŶƚŚĞŚŽƉĞŝƚǁŽŶ ?ƚƚŽƵĐŚŝƚĂŶĚǁŽŶ ?ƚŚƵƌƚ ? ? 
 “/ĨǇŽƵŐŽŽƵƚĨŽƌĂŵĞĂů ?ŝĨŝƚŝƐƐůŝŐŚƚůǇƐƉŝĐǇ/ƐƚŝůůƚƌǇĂŶĚŐĞƚŵŽƌĞĂŶĚŵŽƌĞǁĂƚĞƌ
ďĞĐĂƵƐĞƚŚĞƐƉŝĐĞĐĂŶĂůƐŽĂĨĨĞĐƚƵƌŝŶĂƚŝŶŐƐŽ ?/ƚƌǇƚŽ ?ĚŝůƵƚĞŝƚĂŐĂŝŶ ? ?
 “/ĐĂŶŶŽt wear trousers very often. If I do it has to be cotton or loose fitting. In the 
ƐƵŵŵĞƌƚŝŵĞ/ĐĂŶŶŽƚǁĞĂƌƐŚŽƌƚƐďĞĐĂƵƐĞ/ĨŝŶĚŝŶƚŚĞƐƵŵŵĞƌ/ĐĂŶŐĞƚƌĞĂůůǇƐŽƌĞ ? ?
6.3.4.2.1.2 Psychological effects 
The symptoms of ELPV and its effects on daily activities contribute 
extensively towards a range of psychological consequences. All of 
the patients had experienced a variety of emotions when coming to 
terms with dealing with the condition. Predominantly people feel low 
in mood, distressed or anxious, fearful, guilty and embarrassed or 
ashamed by their condition. In particular, one participant described 
the psychological side of things as the worst aspect of disease. This 
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is important as doctors often do not spend much, if any, time 
exploring the emotional impact of disease. 
 “/ĨŝŶĚŝƚĂůůǀĞƌǇĚŝƐƚƌĞƐƐŝŶŐ ?/ƚũƵƐƚŵĂŬĞƐǇŽƵĨĞĞůĐŽŵƉůĞƚĞůǇŵŝƐĞƌĂďůĞ ? ?
 “/ǁŽƌƌǇďĞĐĂƵƐĞŽĨƚŚĞƉƐǇĐŚŽůŽŐŝĐĂůƐŝĚĞǁŚĞƌĞŝƚŵĂǇŐĞƚǁŽƌƐĞ ? “
 “/ĨĞĞůŐƵŝůƚǇĂƐŝƚŝƐŵǇƉƌŽďůĞŵ ?tĞůůŝƚŝƐŵǇƉƌŽďůĞŵďƵƚ/ĐĂŶŶŽƚĚŽĂŶǇƚŚŝŶŐĂďŽƵƚ
ŝƚ ? ? 
 “/ĚŽŶŽƚůŝŬĞ ƚŽĞǀĞŶůŽŽŬĂƚŝƚ ? ? ? 
6.3.4.2.1.3 Effects on relationships 
ELPV has a significant effect on relationships with other people, 
particularly intimate relationships and has subsequent impact upon 
partners as well as the patient. This is a particular problem for 
patients as ELPV is a chronic disease and the situation is unlikely to 
improve much over time. Many people developed ELPV in their 
SHULPHQRSDXVDO\HDUVDQGIHHOWKDWWKHFRQGLWLRQKDVµUREEHGWKHP¶
of their ability to have a relationship with their partner. This is again 
contributory to the psychological consequences of the disease. 
 “ ?ŝĨŵǇŚƵƐďĂŶĚŶŽǁ ?/ŵĞĂŶŐŽĚďůĞƐƐŚŝŵŚĞŝƐƐŽŐŽŽĚ ?ŝĨŚĞƐƵĚĚĞŶůǇƐƚĂƌƚĞĚ
ƐŚŽǁŝŶŐĂŶŝŶƚĞƌĞƐƚŝŶĞǀĞƌǇƚŚŝŶŐĞůƐĞ/ƚŚŝŶŬ/ǁŽƵůĚďĞŵĂĚďĞĐĂƵƐĞ/ĂŵƐŽƐĐĂƌĞĚ ? ?
 “zŽƵŬŶŽǁƚŚŝƐďƵƐiness of intimacy that plays on your mind, it plays on my mind. 
ŽŶ ?ƚŐĞƚŵĞǁƌŽŶŐ/ĂŵŶŽƚǁĂŝƚŝŶŐƚŽũƵŵƉŽŶŵǇŚƵƐďĂŶĚĂƚĂůůďƵƚũƵƐƚƚŚĞƐŚĞĞƌ
ĨĂĐƚƚŚĂƚǇŽƵŬŶŽǁƚŚĞƌĞŝƐŶŽƚŚŝŶŐǇŽƵĐĂŶĚŽĂďŽƵƚŝƚƉůĂǇƐŽŶŵǇŵŝŶĚ ? ?
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 “ůŽƚŽĨŵǇƉƌŽďůĞŵŝƐƚŚĂƚ ?ŵǇŚƵƐďĂŶĚƚĞůůƐŵĞ/ĂŵũƵƐƚƐŝůůǇ ? ?ďƵƚŝƚŝƐƚŚĞŐƵŝůƚŽĨ
ŶŽƚďĞŝŶŐĂďůĞƚŽĚŽĂŶǇƚŚŝŶŐ ?ĂƐŝŶŐĞŶĞƌĂůƉĞƌƐŽŶĂůƚŚŝŶŐƐǁŝƚŚŵǇŚƵƐďĂŶĚ ? ?
 
However, some people felt that it had taken the pressure off their 
relationships, particularly if their partners had problems of their own 
that prevented them from sexual activity: 
 “/ŵĞĂŶƚŚĞƉŚǇƐŝĐĂůƐŝĚĞŽĨŵĂƌƌŝĂŐĞŚĂƐŐŽŶĞĂůŽŶŐǁŚŝůĞĂŐŽďƵƚ/ĂŵƐƵƌĞŚĞ
ǁŽŶ ?ƚŵŝŶĚŵĞƚĞůůŝŶŐǇŽƵĂƚƚŚĞƚŝŵĞƚŚĂƚŚĞŚĂĚĂĨĞǁƉƌŽďůĞŵƐƐŽŚĂǀŝŶŐŵǇ
problem took the pressure off him. ? 
6.3.4.2.2 Negative experiences 
There were numerous occasions on which people felt subject to 
negative medical experiences. These meant that overall care was 
often considered unsatisfactory and was contributory towards the 
psychological effects of ELPV. These negative experiences were 
witnessed at all stages of care and are attributable to both 
community and hospital environments. 
6.3.4.2.2.1 Community management 
People experienced numerous incidences of misdiagnosis and a 
subsequent delay in referral to secondary care. Most common was 
the misdiagnosis of thrush. It took several years for most 
SDUWLFLSDQWV¶FRQGLWLRQWREHFRUUHFWO\GLDJQRVHGEXWHYHQWKHQWKH\
Chapter 6: WĂƚŝĞŶƚƐ ?ǀŝĞǁƐ 
242 
 
found that there was poor understanding from the wider medical 
community about ELPV. This led to a lack of faith in non-specialists. 
 “/ĚŽŶ ?ƚĨŝŶĚƚŚĂƚǇŽƵƌ'ĞŶĞƌĂůŽĐƚŽƌƋƵŝƚĞƵŶĚĞƌƐƚĂŶĚƐďĞĐĂƵƐĞƚŚĞƌĞĂƌĞƚŚĂƚŵĂŶǇ
ĚŝĨĨĞƌĞŶƚŽŶĞƐĂƚŽƵƌƉƌĂĐƚŝĐĞ ? ?
 “/ƵƐĞĚƚŽŚĂǀĞƚŚƌƵƐŚƋƵŝƚĞĂďŝƚĂŶĚƐŽǇŽƵŐŽƚŽƚŚĞŽĐƚŽƌĂŶĚ/ŚĂĚĂƐƉĂƚĞŽĨŶŽƚ
having it for quite a while and then /ǁĞŶƚďĂĐŬĂŐĂŝŶĂŶĚƚŚĞŽĐƚŽƌƐĂŝĚǁĞůůŝƚ ?Ɛ
thrush so I felt pretty silly about that but anyway I got some creams and then I was 
getting some other creams and then it got to the stage where it was getting worse 
and I went back to the Doctors, broke doǁŶŝŶƚŚĞƌŽŽŵĂŶĚ/ƐĂŝĚŝƚŝƐŶŽƚǁŽƌŬŝŶŐ ? ? ? 
 “/ŚĂĚďĞĞŶƚŽŵǇ'WĨŽƌ ?ǇĞĂƌƐĂŶĚĞǀĞƌǇƚŝŵĞ/ǁĂƐƚŽůĚŝƚǁĂƐƚŚƌƵƐŚĂŶĚŝƚǁĂƐĂ
fluke there was a lady Doctor just standing in who said to me I do not think this is 
ƚŚƌƵƐŚ ? ? ? 
 “dŚĞǇƉƵƚŵĞŽŶ,ZdĨŽƌĂďŽƵt 5 years which seemed to help at one time but then 
got very sore and I looked one day and there was this little red spot about the size of 
a 5p, it got bigger and so I went to the Doctor and was given various creams and it 
was a long while before it was dŝĂŐŶŽƐĞĚ ? ?
6.3.4.2.2.2 Secondary care 
Within the hospital environment there was also inconsistency in care 
received with incidences of misdiagnosis and poor continuity and 
communication between specialties. It seems that other specialties 
GLGQ¶WQHFHVVDULO\PDQDJH(/3 as a multisystem disease, which led 
to patients visiting numerous different departments. Once the 
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correct diagnosis was made, patients felt that on occasion there was 
lack of consideration of the severity of symptoms by doctors, 
particularly when it came to clinical examination and invasive 
diagnostic procedures. This again contributed towards psychological 
effects particularly those of fear and anxiety. 
 “/ŚĂǀĞƐƚĂƌƚĞĚƚŽĐŽƵŶƚŚŽǁŵĂŶǇƉĞŽƉůĞ/ŚĂǀĞƐĞĞŶǁŚĞŶ/ŐŽƚƚŽ ? ?ĂŶĚƚŚĂƚǁĂƐ
years ago and I must have seen at least 30 since. All different people were looking at 
ĚŝĨĨĞƌĞŶƚďŝƚƐŽĨŵĞĂŶĚŝƚǁĂƐŶ ?ƚƵŶƚŝů/ŐŽƚƚŽƌyĂŶĚ/ƐĂǁŚĞƌƚŚĂƚǁĂƐĨŽƌƚŚĞ
vulva I thought and then I was there one day and I said there is some in my mouth but 
/ĚŽŶ ?ƚƚŚŝŶŬǇŽƵ ǁĂŶƚƚŽŚĞĂƌƚŚĂƚĂŶĚƐŚĞƐĂŝĚ ‘ǇĞƐ/ĚŽ ? ?,ĞƌũƵƐƚƐĂǇŝŶŐǇĞƐ/ǁĂŶƚ
ƚŽŚĞĂƌĂďŽƵƚĞǀĞƌǇƚŚŝŶŐǁĂƐƐƵĐŚĂƌĞůŝĞĨ ? ?
 “/ĞǀĞŶŚĂĚĂ and ĂŶĚ/ƚŚŽƵŐŚƚƚŚĞ'ǇŶĂĞĐŽůŽŐŝƐƚǁŽƵůĚƐƵƌĞůǇŶŽƚŝĐĞƚŚŝŶŐƐ ? ?
he did not say anything and nothing ever happened so I tŚŽƵŐŚƚŝƚŵƵƐƚďĞĂůƌŝŐŚƚ ? ? “ 
 “zŽƵĐĂŶ ?ƚƚŽƵĐŚĂĐĞƌƚĂŝŶĂƌĞĂ ?/ŵĞĂŶƌzĚŝĚĂƐǁĂďĂƚŝŵĞŽƌƚǁŽĂŐŽĂŶĚ/ŶĞĂƌůǇ
ƐŚŽƚŽĨĨƚŚĞƚĂďůĞ ? ? 
 “ƚƚŚĞŵŽŵĞŶƚ/ŚĂǀĞŐŽƚĂƚŚŝŶŐƚŽŐŽĨŽƌĂĐĂŶĐĞƌƐŵĞĂƌ ?/ũƵƐƚĚƌĞĂĚƚŚĞƚŚŽƵŐŚƚ ?
/ƚŝƐůŝŬĞďĞŝŶŐƚŽƌƚƵƌĞĚ ? ?
 “ƌX sent me for a biopsy a couple of times previously to me seeing her and I was 
ĂďƐŽůƵƚĞůǇĚŝƐƚƌĂƵŐŚƚďĞĐĂƵƐĞŝƚǁĂƐƐŽƉĂŝŶĨƵů ? ?
 “,ĞĐƵƚŝŶƚŽŵĞĂŶĚŚĞŚĂĚŶŽƚŶƵŵďĞĚŵĞĂŶĚ ? ?/ŐŽƚƚĞĂƌƐƌŽůůŝŶŐĚŽǁŶŵǇĨĂĐĞ
and the nurse was apologizing because he had noƚĐŚĞĐŬĞĚ ? ?
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6.3.4.2.2.3 Misunderstandings 
A number of factors seemed responsible for patients 
misunderstanding certain aspects of their condition, its management 
and pathways that they have followed. Predominantly, the 
psychological effects of anxiety, distress, fear and stigmatisation 
seem to feed into patient misunderstanding, which in turn links back 
to the lack of information and support that is available. 
 “/ŚĂĚŐŽƚŝƚŝŶƚŽŵǇŚĞĂĚ ?ƚŚĂƚǁŚĞŶƚŚĞǇĨŝƌƐƚƚŽůĚŵĞŝƚǁĂƐůŝĐŚĞŶƉůĂŶƵƐƚŚĂƚ/ŚĂĚ
not been clean enough ĂŶĚ/ŚĂĚƉĂƐƐĞĚŝƚƚŽŵǇŵŽƵƚŚ ? ?
 “dŚĂƚŝƐǁŚǇ/ĚŝĚŶŽƚǁĂŶƚƚŽŐŽ ?ƚŽƚŚĞ'ĞŶŝƚŽƵƌŝŶĂƌǇDĞĚŝĐŝŶĞĐůŝŶŝĐ ?ďĞĐĂƵƐĞ/ĚŝĚ
ŶŽƚŚĂǀĞĂƉƌŽďůĞŵŝŶƚŚĂƚĂƌĞĂ ? ? ?ĂƚŵǇĂŐĞƚŚĂƚ/ŚĂĚŐŽƚŝƚŝŶƚŽŵǇŚĞĂĚƚŚĂƚ/ĚŝĚ
ŶŽƚǁĂŶƚƚŽŐŽƚŽĂĐůŝŶŝĐůŝŬĞƚŚĂƚ ? ?
 “ ?ĂŶĚǁŚĞther you would still be able to wee. Will that bit close up? Does it close up? 
/ĚŽŶ ?ƚŬŶŽǁĞŶŽƵŐŚĂďŽƵƚŝƚƌĞĂůůǇ ? “ 
6.3.4.2.2.4 Treatments 
People found that they often had difficulty in managing their 
condition in the way that their specialist doctor had advised, and 
when on systemic therapy felt quite frightened and unsupported. 
This led to non-compliance and stopping therapy early on some 
occasions. 
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 “ƐƚŚĞĞŶƚƌĂŶĐĞƚŽƚŚĞǀĂŐŝŶĂŚĂĚŶĂƌƌŽǁĞĚĂŶĚƚŚĞŶǁŚĞŶƐŚĞŐĂǀĞŵĞ
ƚŚĞƐĞ ?ƚŚĞƐĞ ? ?ĚŝůĂƚŽƌƐ ?ĂƐƐŽŽŶĂƐ/ƐƚĂƌƚĞĚƚŽuse them it was just as if I was on a 
ƉĞƌŝŽĚĂŶĚŝƚƚŽƌĞ ? ?
 “/ƚǁĂƐƌyƚŚĂƚƉƌĞƐĐƌŝďĞĚŝƚ ?DǇĐŽƉŚĞŶŽůĂƚĞ ?ĨŽƌŵĞĂŶĚƚŚĞŶ/ŶĞǀĞƌƐĂǁƚŚĞŵ
ĂŐĂŝŶĂŶĚ/ǁĂƐŚĂǀŝŶŐďůŽŽĚƚĞƐƚƐŚĞƌĞĂŶĚ/ƚŚŽƵŐŚƚ ? ? ?/ǁĂƐĂďŝƚĂĨƌĂŝĚŽĨǁŚĂƚ
the tablets were doing to me, you know what I mean, because you go to the clinic and 
ŝƚŝƐǀĞƌǇƌĂƌĞƚŚĂƚǇŽƵƐĞĞƚŚĞƐĂŵĞŽĐƚŽƌƚǁŝĐĞ ? ?
 “/ǁŝůůďĞǀĞƌǇŚŽŶĞƐƚďĞĐĂƵƐĞƚŚĞůĂƐƚŽŶĞ/ƚŽŽŬ ?DǇĐŽƉŚĞŶŽůĂƚĞ ?ŝƚǁĂƐŶ ?ƚƐŽŵƵĐŚ
ƚŚĞǇǁĞƌĞǀĞƌǇůĂƌŐĞŚĂƌĚ ?ŵƵĐŚůĂƌŐĞƌƚŚĂŶĂWĂƌĂĐĞƚĂŵŽůĂŶĚ/Śad to take 3 at 
night, 3 at lunch and 3 at bedtime and I just could not cope with it, I just could not get 
ƚŚĞŵĚŽǁŶĂƚĂůů ? ?
6.3.4.2.3  Support networks 
All of the participants expressed the need for reassurance about 
their condition and expressed comfort in being able to talk to about 
their experiences. They were all appreciative of the opportunity to 
take part in the focus groups as this was a way of sharing their 
experiences and voicing their feelings in a way which had not been 
possible previously. This seemed to stem from  information being 
poorly available from doctors, a lack of support groups in the 
community and little  patient information being available on the 
internet. 
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6.3.4.2.3.1 Poor information available to patients 
People felt that even when the correct diagnosis had been made 
their General Practitioners did not have the knowledge to provide 
them with any information and although they had confidence in 
vulval disease specialists, they still found that information available 
was limited. When people used the internet they were unable to find 
reputable sources and found themselves frightened by what they 
read. Furthermore, lack of information had led to uncertainty and 
misunderstandings about the condition with people showing concern 
that they developed the disease due to something they have done. 
 “/ƐĞĞƐŽŵĞďŽĚǇĚŝĨĨĞƌĞŶƚƌĂƚŚĞƌƚŚĂŶŵǇŽǁŶŽĐƚŽƌďĞĐĂƵƐĞ/ĚŽŶŽƚƚŚŝŶŬǇŽƵƌŽǁŶ
ŽĐƚŽƌŬŶŽǁƐĞŶŽƵŐŚĂďŽƵƚƚŚĞĐŽŶĚŝƚŝŽŶ ? ?
 “/ĂŵƐĐĂƌĞĚĂŶĚ/ŵĂĚĞƚŚĞŵŝƐƚĂŬĞŽĨŐŽŝŶŐŽŶƚŚĞ/ŶƚĞƌŶĞƚǁŚĞŶ/ĨŝƌƐƚŐŽƚŝƚĂďŽƵƚ
the fusion oĨƚŚĞůĂďŝĂĂŶĚƚŚŝŶŐƐůŝŬĞƚŚĂƚĂŶĚŝƚƌĞĂůůǇƐĐĂƌĞĚŵĞǁŚĞŶ/ƌĞĂĚƚŚĂƚ ? ?
 “ŶŽƚŚĞƌƚŚŝŶŐ/ǁĂŶƚĞĚƚŽĂƐŬŝƐ ?/ŚĂǀĞŚĂĚĞǀĞƌǇƚŚŝŶŐŝŶŵǇŚĞĂĚ- ŝƐŝƚĐĂƚĐŚŝŶŐ ? ? 
6.3.4.2.3.2 The need for reassurance 
It became clear that in dealing with this chronic condition, people 
require reassurance from vulval disease specialists, particularly in 
terms of checking for malignant progression. They value follow up 
appointments even if these are only 6 monthly so that they remain 
µLQWKHV\VWHP¶ have a point of contact and receive continuity of 
care. People also appeared reassured by talking with others in the 
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group and sharing their experiences, which were all relatively similar. 
To this end, the group exchanged contact details so that they could 
keep in touch after the focus groups had ended. 
 “/ƚŚŝŶŬŝƚŝƐŐŽŽĚƚŽŬŶŽǁƚŚĂƚǇŽƵĂƌĞŶŽƚƚŚĞŽŶůǇŽŶĞǁŝƚŚƚŚĞĐŽŶĚŝƚŝŽŶ ? ? 
 ? ‘dŚĞĨĂĐƚĂůƐŽŝƐƚŚĂƚǁŚĞŶǇŽƵƐƚĂƌƚƚŽƌĞĂĚĂďŽƵƚŝƚƚŚĞƌĞŝƐĂůǁĂǇƐƚŚŝƐƉŽƐƐŝďŝůŝƚǇŽĨ
cancer later on.  At least with the six monthly check ups you are in the system and so 
ƚŚŝŶŐƐĐĂŶďĞŬĞƉƚĂŶĞǇĞŽŶ ? ?
 “ ?ĞǀĞƌǇƚŝŵĞ/ŐŽ ?ƚŽƚŚĞĐůŝŶŝĐ ?/ƚŚŝŶŬŽĨŝƚƐĨŝŶĞďƵƚƚŚĞƌĞŵŝŐŚƚďĞƐŽŵĞƚŚŝŶŐƐŽŝƚŝƐ
that kind of fear. That is why it is so reassuring to be able to see someone every six 
ŵŽŶƚŚƐ ? 
 “/ƚŚŝŶŬŝƚŝƐŶŝĐĞƚŽďĞ ĂďůĞƚŽŽĨĨůŽĂĚŝƚĂůů ?ƚŽĚŝƐĐƵƐƐŝƚǁŝƚŚƉĞŽƉůĞǁŚŽƵŶĚĞƌƐƚĂŶĚ
ŝƚĂŶĚǇŽƵĂůůƵŶĚĞƌƐƚĂŶĚĞĂĐŚŽƚŚĞƌƐ ?ƉƌŽďůĞŵƐ ? ? 
6.3.4.2.4 Positive experiences 
Although negative experiences did seem to predominate in the 
discussions, there were positive aspects that came apparent during 
the focus groups. 
6.3.4.2.4.1 Stoicism 
All participants showed an enormous level of stoicism that had 
developed as a coping mechanism to dealing with the condition. 
Whilst the psychological aspect of disease was critical for the 
patients and they found this difficult to come to terms with, people 
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were able to accept and carry on with their symptoms, no matter 
how uncomfortable. This is a real testament to these patients and 
should not go unmentioned. Examples of people demonstrating 
stoicism are: 
 “zŽƵũƵƐƚŐĞt on with it  W ǇŽƵŚĂǀĞƚŽĚŽŶ ?ƚǇŽƵĂŶĚ/ŚĂǀĞďĞĞŶůŝǀŝŶŐǁŝƚŚŝƚĨŽƌ ? ?
ǇĞĂƌƐŶŽǁ ? ?
 “ĞĐĂƵƐĞǁĞŚĂǀĞďĞĞŶƚŚƌŽƵŐŚĂůůƚŚĞŝŶŝƚŝĂůĂǁĨƵůŶĞƐƐŽĨŝƚŚĂǀĞŶ ?ƚǁĞ ?ǁĞŚĂǀĞĂůů
done that and been frightened and then passed from pillar to post, then getting a bit 
of treatment which helps a bit and then you look at other people who cannot walk or 
ŚĂǀĞŽƚŚĞƌĚŝƐĂďŝůŝƚŝĞƐ ?ǁĞůůǇŽƵƚŚŝŶŬ ?ĂƚůĞĂƐƚ/Ăŵ ? ?  ? ? 
 “/ŶĂǁĂǇĂƐƚŚŝŶŐƐĂƌĞĂƚƚŚĞŵŽŵĞŶƚǁŝƚŚŶŽĐƵƌĞŝƚŝƐŐŽŽĚƚŚĂƚǁĞŚĂǀĞĂĐĐĞƉƚĞĚ
ŝƚ ? ? 
 “/ŵĞĂŶǇĞĂƌƐĂŐŽďĞĨŽƌĞĂůůƚŚŝƐ/ŚĂĚŝƚĂŶĚ/ĚŝĚƌĞĂůůǇƐƵĨĨĞƌƚƌǇŝŶŐƚŽŚĂǀĞƐĞǆ ? ?
6.3.4.2.4.2 Trust in doctors 
Whilst there was an apparent lack of faith in generalists and non-
specialist doctors, patients were extremely loyal to the Consultants 
who managed their condition in the specialist vulval clinic. It 
appears that patients feel they can trust a doctor who is confident in 
managing the condition and this reduces their fear and anxiety. 
 “ƌyĂŶĚƌzŚĂǀĞďĞĞŶƐŽŐŽŽĚ ?zŽƵĨĞĞůĐŽŶĨŝĚĞŶƚƐŽǇŽƵĂƌĞŶŽƚĂŶƚŝĐŝƉĂƚŝŶŐƚŚĞ
pain so ŵƵĐŚ ? ? 
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 “zŽƵŐŽƚŽĂůůƚŚĞƐĞƉůĂĐĞƐĂŶĚƐŚĞǁĂƐŝŶƚĞƌĞƐƚĞĚŝŶƚŚĞǁŚŽůĞƚŚŝŶŐ ?ĞƌŽƐŝǀĞůŝĐŚĞŶ
ƉůĂŶƵƐĂƚĂůůƐŝƚĞƐ ? ?ŝƚǁĂƐũƵƐƚĂŵĂǌŝŶŐ ? ? 
6.3.5 Discussion 
6.3.5.1 Main Findings 
The key areas highlighted by these focus groups were the effects of 
WKHGLVHDVHRQSDWLHQWV¶Oives, particularly the psychological and 
functional impact, which for most of the participants were marked. 
These problems were further compounded by perceived substandard 
care with poor understanding and lack of communication between 
primary and secondary care professionals. Support networks were 
lacking and sources of information available to patients were difficult 
to identify. 
The findings of the focus groups confirmed the results of the UKLP 
survey described in Section 6.2 with the themes identified being 
extremely similar.  
6.3.5.2 Strengths and weaknesses of the study  
Whilst it is important to remember these qualitative findings from 
this early exploratory exercise are preliminary as they represent the 
views of a small group of patients, some provisional lessons can still 
be learnt.  Furthermore, the findings corroborate those from the 
earlier work involving UKLP society members (section 6.2). Patient 
experience needs to be improved and although these patients were 
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all from one geographic area, given the lack of national guidance for 
ELPV and in context with the UKLP society survey findings, it is 
possible that experiences are similar across the country. 
6.3.5.3 Clinical and research practice implications 
Symptom control is extremely important but there are currently no 
randomised controlled trials to guide treatment, particularly for 
those patients with severe disease. Therefore the planned RCT for 
second-line therapy will address this. 
As psychological effects were identified as being significant, it would 
be appropriate if all patients (and potentially their partners) should 
be offered links to psychological support. The British Association of 
Dermatologists is currently setting up an online support system for 
people with chronic skin conditions, which may be of interest to 
ELPV patients; however, as this is a particularly sensitive and 
specialised area psychological support should be integrated into the 
vulval multidisciplinary team clinic where possible. 
There are a number of ways in which management of ELPV can be 
improved. Education is paramount as are the introduction of 
management pathways including national guidelines for the 
management of ELPV. Communication between specialties needs to 
be enhanced; this can be achieved through the use of a 
multidisciplinary team. 
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Finally, existing support and information available to patients needs 
to be highlighted (e.g up to date information leaflet on the ISSVD 
website, the UK Lichen Planus support group) and developed. Better 
information sheets should be available in clinic, support groups that 
are not necessarily web-based could be set up (bearing in mind the 
demographic of patients means that many are not comfortable 
internet users) and potentially short educational videos could be 
made (although these would most likely be web-based). 
6.4 Chapter 6 Summary 
This chapter has addressed a number of concepts that are important 
for clinical practice and research into erosive lichen planus affecting 
the vulva.  
The aspects of disease that matter the most to patients were 
identified by the by the UKLP survey as discomfort and functional 
difficulty, including sexual problems. The survey also demonstrated 
that the quality of life of patients with orogenital erosive lichen 
planus is significantly affected. In-depth discussion in the focus 
groups reinforced these findings and also suggested that 
psychological aspects of disease are often neglected.  
These studies have provided information to inform a RCT protocol. 
That is, a list of suitable outcome measure tools and an idea of what 
the primary outcome in a future study should measure. 
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Furthermore, aspects of study design were discussed with patients 
and areas which will need specific attention, such as reassurance 
about taking systemic medications and potential side effects, have 
been highlighted. Patients were supportive of a future RCT in this 
area and showed enthusiasm to take part if eligible. 
The focus groups highlighted that there seem to be shortfalls in the 
management of ELPV in primary and secondary care. It is likely that 
these experiences will be shared by patients with other vulval 
diseases. These findings are a basis on which clinicians can start to 
build and improve the patient journey for what is a distressing, 
chronic disease. However, it should be realized that further focus 
group sessions are required to draw more evidenced based 
conclusions. 
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7 A Randomised Controlled Trial 
of Adjunctive Systemic Therapy 
for Vulval Erosive Lichen 
Planus7KHµK(/3¶7ULDO 
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7.1 Introduction 
Chapters 1 to 6 of this thesis describe what is known about the 
epidemiology, aetiology, clinical presentation HIIHFWVRQSDWLHQWV¶
lives and treatment of erosive lichen planus affecting the vulval area 
(ELPV). 
There is no high quality randomised controlled trial evidence on 
which to base treatments for ELPV. The only RCTs identified (Rajar 
2008, Helgesen 2013) were of poor quality with inadequate 
information on included patients, weak description of study 
methodology and inappropriate outcome measures. 
As demonstrated in Chapters 2 and 3, first-line therapy is usually 
with a super-potent topical steroid, usually clobetasol propionate 
0.05% (Simpson 2012, Simpson 2013). Non-randomised studies, 
mainly retrospective case series, have suggested that these can be 
an effective first-line therapy (Lewis 1996, Cooper 2006, Helgesen 
2010, Bradford 2013, Maor 2013). Therefore, evidence to date 
suggests that super-potent topical steroids are a reasonable first-
line therapeutic choice and the qualitative and quantitative work 
demonstrated in Chapters 2 and 3 has shown that they are 
ingrained into clinical practice as an initial therapy for ELPV.  
However, the only prospective published case series (Cooper 2006) 
identified in this field showed that up to one-third of patients had 
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unsatisfactory response to super-potent topical steroids. The case 
note review (Chapter 2) and structured interviews with clinicians 
(Chapter 3) indicated that there is no agreement for which second-
line agents should be used (Simpson 2012, Simpson 2013),  
Most second-line therapies are used based upon expert opinion. In 
Chapter 1, a wide range of systemic agents were identified from the 
literature for treating ELPV, although these were described by case 
series and case reports rather than randomised controlled trials. The 
Cochrane Systematic review of interventions for mucosal lichen 
planus confirmed that there were no quality RCTs in this field. 
Providing an evidence base for the treatment of ELPV has been 
prioritised by the British and International Societies for the Study of 
Vulval Disease and the most important question clinically is to 
determine the most effective second-line therapy for ELPV. Patients 
with disease that does not respond to standard first-line therapy 
with a super potent topical corticosteroid undergo the most suffering 
and are in the greatest need of help. 
Collaboration with expert clinicians throughout the duration of this 
PhD has indicated that the systemic treatments with the greatest 
success rates (anecdotally) when used in clinical practice are 
hydroxychloroquine, methotrexate, mycophenolate mofetil and 
prednisolone. It is these agents that clinicians have prioritised to 
compare in a randomised controlled trial.  
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7.2 Aims 
7KLVFKDSWHUGHVFULEHVWKHDJUHHGSURWRFROIRUWKHµK(/3¶(systemic 
tHerapy for vulval Erosive Lichen Planus) Trial. This is to be a four-
armed, open label, multi-centre, pragmatic randomised controlled 
trial to compare three systemic treatments (hydroxychloroquine, 
methotrexate and mycophenolate mofetil) against a control group 
who will receive clobetasol proprionate 0.05% in conjunction with an 
initial short course of oral corticosteroids.  
This methodology will allow information about the four treatments 
that are favoured by clinicians to be acquired more quickly 
compared with separate trials and will require smaller patient 
numbers than three separate placebo controlled RCTs. This 
approach is important to maximise information about ELPV which is 
a rare disease. 
This RCT of second-line therapy for ELPV will contribute towards 
future evidence-based management guidelines and will help to 
standardise practice. 
7.2.1 Purpose 
The RCT is designed to identify interventions that are effective in 
improving disease control in patients with erosive lichen planus 
affecting the vulva (ELPV). 
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7.2.2 Primary Objective 
To assess whether adjunctive systemic therapies are better than 
topical treatment (in conjunction with a short course of oral 
corticosteroids) in treating patients with ELPV that is refractory to 
standard first-line topical therapy. The trial will be powered to 
assess whether each of the three agents are more effective than the 
control treatment, it will not be powered to assess which of the 
three is the most effective, because numbers needed to recruit to 
answer the latter would be prohibitive in this rare disease. 
 
7.2.3 Secondary Objective 
To assess the tolerability of the systemic therapies in patients with 
ELPV. 
 
7.3 Materials and Methods 
7.3.1 Trial configuration 
A four-armed, open label, multi-centre, pragmatic randomised 
controlled trial. 
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7.3.2 Participants, settings and outcomes 
7.3.2.1 Recruitment 
Up to 96 female participants will be recruited from secondary care 
clinics. The trial will aim to recruit up to a maximum of 96 
participants into the trial in order to have a clinically relevant 
outcome.  
The initial approach will either be during the clinic, or from the 
SDUWLFLSDQW¶V usual care team via post to participants identified from 
existing confidential participant lists.  
If a participant is believed to be eligible a patient information sheet 
(PIS) will be provided and any questions answered by the 
investigator or their designated nominee.  
If needed, the usual hospital interpreter and translator services will 
be available to assist with discussion of the trial and the participant 
information sheets as consent forms will not be available printed in 
other languages.  
It will be explained to the potential participant that entry into the 
trial is entirely voluntary and that their treatment and care will not 
be affected by their decision. It will also be explained that they can 
withdraw at any time but attempts will be made to avoid this 
occurrence. In the event of their withdrawal it will be explained that 
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their data collected so far cannot be erased and we will seek 
consent to use the data in the final analyses where appropriate. 
7.3.2.2 Participants 
Participants will be patients with ELPV who satisfy the following 
criteria. Eligibility criteria have been determined through 
collaboration with expert clinicians in the structured interviews 
(Chapter 3), the e-Delphi consensus exercise (Chapter 4) and 
through personal communication with future recruiting clinicians. 
7.3.2.2.1 Inclusion criteria 
฀ Clinical diagnosis of erosive lichen planus affecting the 
vulvovaginal region; 
฀ Histological examination within the past 12 months to exclude 
malignant/pre-malignant disease;  
฀ Inadequate disease control despite first-line therapy with 
clobetasol propionate 0.05%; 
฀ Disease severity of moderate-severe on Investigator Global 
Assessment 
฀ Negative microbiological swabs at study entry; 
฀ Willing and capable of giving informed consent; 
฀ Willing to have clinical images taken; 
฀ Female aged 18 years or over (there is no upper age limit); 
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฀ Use of effective contraceptive methods in females of 
childbearing age for the duration of treatment and for 6 
weeks following the end of treatment. 
 
7.3.2.2.2 Exclusion criteria 
฀ Cases of lichen sclerosus/lichen planus overlap; 
฀ Patients taking Beta Blockers or non-steroidal anti-
inflammatory medications; 
฀ Received one or more of the trial drugs within the last one 
month (excluding clobetasol propionate 0.05%); 
฀ Previous/current diagnosis of malignant disease (skin or 
internal); 
฀ Pre-malignant vulval skin or cervical disease; 
฀ Receiving concurrent medications (as listed in the BNF) that 
would preclude the use of any of the trial medications in 
normal practice; 
฀ History of clinically significant renal or liver impairment or 
other pre-existing medical conditions that would preclude the 
use of any of the trial medications in normal practice; 
฀ Administration of a live vaccine (BCG, Measles, Mumps, 
Rubella, Yellow Fever, Oral Polio, Oral Typhoid) within the last 
2 weeks; 
฀ Pregnancy (to be confirmed by testing) or breast-feeding; 
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฀ Known sensitivity to any of the trial medications. 
7.3.2.3 Informed consent 
All participants will provide written informed consent. The Consent 
Form will be signed and dated by the participant before they enter 
the trial. The Investigator will explain the details of the trial and 
provide a PIS, ensuring that the participant has sufficient time to 
consider participating or not. The Investigator will answer any 
questions that the participant has concerning study participation.  
Informed consent will be collected from each participant before they 
undergo any interventions (including physical examination and 
history taking) related to the study. One copy of this will be kept by 
the participant, one will be kept by the Investigator, and a third will 
be retained in the participant¶VKRVSLWDOUHFRUGV 
Should there be any subsequent amendment to the final protocol, 
ZKLFKPLJKWDIIHFWDSDUWLFLSDQW¶VSDUWLFLSDWLRQLQWKHWULDO
continuing consent will be obtained using an amended Consent form 
which will be signed by the participant. 
 
7.3.3 Outcome measures 
The outcomes for this study have been discussed at length by the 
trial development group taking into consideration the information 
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obtained from earlier work (Structured Interviews, Chapter 3, 
6\VWHPDWLFUHYLHZ&KDSWHU3DWLHQWV¶YLHZV&KDSWHU. 
7.3.3.1 Primary outcome measure  
The proportion of patients achieving treatment success at 6 months. 
Treatment should be classed as successful if both Patient Global 
Assessment and Investigator Global Assessments are met (for 
definitions of scales see Figure 27, page 263):  
฀ Patient Global Assessment of disease severity of 0 or 1 on 
a 4-point scale 
฀ Assessment of improvement from baseline  using blinded 
clinical images 
As identified in the systematic review (Chapter 5), these outcomes 
are not validated. Following discussion with clinicians (Chapter 3) it 
was apparent that the primary driver for therapeutic decision 
making in ELPV is patient reported symptoms. However, in the 
clinical setting the FOLQLFLDQ¶V judgment will also form part of that 
assessment. Furthermore, as this is an open-labelled trial, there is a 
possibility of bias being introduced if the patient global assessment 
only was used as the primary outcome. 
Therefore, this composite primary outcome measure was devised to 
take into consideration both patient and clinician judgment of 
disease severity. It is intended that the investigator global 
assessment is performed using blinded clinical images taken at 
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baseline and at the end of the treatment period. This way, any bias 
from the patient-reported outcome should be minimised as both 
patient and clinician outcomes have to have shown improvement to 
confirm treatment success. 
 
Figure 27: Patient and Investigator Global Assessment categories or hELP trial 
primary outcome 
Patient Global Assessment: 
 
How much bother is the erosive lichen planus 
causing the patient TODAY? 
 
0 -No bother at all/not much bother 
1 - A little 
2 - A lot 
3 - Very much 
Investigator Assessment of vulval 
disease:  
 
+RZGR\RXFOLQLFDOO\UDWHWKLVSDWLHQW¶V
VULVAL erosive lichen planus at THIS visit? 
 
0 - Clear/almost clear 
1 - Mild  
2 - Moderate 
3 - Severe 
 
7.3.3.2 Secondary outcome measures 
1. Reduction in soreness throughout the 6 month treatment 
period compared with baseline using a visual analogue scale. 
2. Global assessment of disease assessed by:  
a. Patient Global Assessment at baseline, 3, 6 and 12 
months 
b. Investigator Assessment by treating clinician at 
baseline, 3 and 6 months 
3. Assessment by blinded assessor using clinical images at 
baseline and 6 months 
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4. Assessment of severity of other oral and vaginal sites if 
affected ± Investigator assessment by physician at baseline, 
3 and 6 months. 
5. Psychological assessment using the Hospital Anxiety and 
Depression Scale at baseline, 6 and 12 months. 
6. Assessment of sexual function at baseline, 6 and 12 
months. 
7. Impact on health-related quality of life ±using a 
GHUPDWRORJ\VSHFLILFWRROµ6NLQGH[-¶(Ponte 2009) and a 
JHQHUDOXWLOLW\PHDVXUHWKHµ6KRUW)RUP¶(Brazier 1992) at 
baseline, 6 and 12 months. 
8. Days of topical steroid use (as a surrogate marker of 
control in each of the groups) as documented in patient diary. 
9. Overall treatment satisfaction assessed by 
a. overall satisfaction 
b. number of patients continuing treatment post the 
primary endpoint 
10. Economic considerations: Average cost of 
intervention in each treatment group per participant based on 
prescribed medication. 
 
As with the primary outcome measure, the secondary outcome 
measures are not standardised. These assessments have been 
derived from the systematic review for all outcome measures used 
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for vulval disease (Chapter 5), the UK Lichen Planus Society survey 
and the subsequent patient focus group sessions (Chapter 6). 
Outcomes 1-LQWKHOLVWUHIOHFWSDWLHQWV¶YLHZVRQOLYLQJZLWK(/39
and assess the main aspects of life that are affected by the disease. 
Outcome 9 is important as the economic impact of ELPV has not 
previously been investigated. 
 
7.3.3.3 Safety endpoints 
All of the investigational medications are familiar to Dermatology 
and have been used as part of routine clinical practice for years. It 
is not anticipated that these agents will have any greater side-
effects in this population. Structured interviews (Chapter 3) showed 
that clinicians were confident in prescribing the proposed 
medications and had not encountered any unexpected adverse 
events n their daily practice. 
Safety endpoints will be adverse events (AEs) reported during the 
study, and discontinuation of medications due to AEs. 
 
7.4 Trial procedures 
Participants will undergo 5 study visits in the clinic environment over 
a six-month treatment period. There will subsequently be a long-
term follow up communication 12 months after entering the trial. A 
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summary of assessments to be made at each trial visit is 
summarized in Table 37, page 275. A flow diagram of the trial is 
shown in Figure 28, page 276. 
Trial visits are to be as follows: 
7.4.1 Pre-screening 
Participants with ELPV will be identified by their usual care teams 
through the outpatient clinic and databases held by the recruiting 
centres.  
Participants with ELPV will be under the care of the PI, or a delegate, 
at the individual recruiting centres. Identified participants will be 
provided with a hELP Trial PIS at their outpatient clinic appointment 
or by post prior to their next appointment.  
If the participant has received clobetasol propionate 0.05% for 3 
months or more at any time during the management of their ELPV 
and still has moderate or severe disease as judged by Investigator 
Global Assessment, the following should be checked: 
฀ That a biopsy has been performed within the last 12 months 
to rule out any other pathology that would make non-
response to treatment more likely (It may be clinically 
indicated to repeat the biopsy if unusual clinical features are 
present for example if the diagnosis was in doubt before 
commencing immunosuppressive therapy due to the risk of 
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malignant transformation. This will be a decision made by the 
clinician on a case by case basis as part of normal care); 
฀ That microbiological swabs are negative (as infection can 
worsen disease severity). Swabs would only be repeated if 
there was a clinical need to do so as part of normal care. 
The rationale for 3 months duration of clobetasol proprionate 0.05% 
is based upon the practice described by Cooper et al in their 
prospective case series of treatment for patients with ELPV (Cooper 
2006). Furthermore, it the recognised standard for patients with 
lichen sclerosus, which is managed similarly in the initial stages 
(Neill 2010). 
A screening visit appointment will be made for all potentially eligible 
participants. The screening visit may be on the same day as pre-
screening depending upon individual circumstances.  
If the above criteria (i.e. biopsy and swabs) are not satisfied the 
relevant tests should be carried out and the participant reviewed 
with the results before being given a screening appointment. 
 
7.4.2 Baseline visit (Study visit 1) 
It may be possible to combine the baseline and safety screening 
visits (visits I and 2) for participants who have already had the 
relevant screening investigations done within the past month (this 
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could be the case for participants under long-term care who were 
already been considered for systemic therapy) or those randomised 
to the control group, who do not need any safety screening 
investigations.  
In some cases it may be considered clinically appropriate to 
commence treatment immediately and this will be at the discretion 
of the treating clinician provided they feel they have all of the 
relevant information to safely commence therapy and the 
participant has had enough time to consider their participation in the 
trial. 
 
Procedures to be carried out at baseline: 
฀ Informed consent 
฀ Confirmation of eligibility criteria. 
฀ Pregnancy test for women of child bearing potential 
฀ Assessment of patient and clinician reported outcome 
measures 
฀ Pain/soreness using a visual analogue scale. 
฀ Patient Global Assessment at baseline 
฀ Investigator Global Assessment by treating clinician at 
baseline 
฀ Investigator Global assessment by physician of other oral and 
vaginal sites  
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฀ Hospital Anxiety and Depression Scale 
฀ Assessment of sexual function 
฀ Vulval µ6NLndex-¶(Ponte 2009) DQGµ6KRUW)RUP¶(Brazier 
1992)  
฀ Digital images to be taken.  
฀ Randomise patient 
฀ Perform safety screening investigations 
 
Once eligibility is confirmed at this visit, participants will be 
randomised. Only once treatment allocation is known will the 
relevant safety screening investigations be performed. These will be 
standard care safety baseline investigations specific to the 
treatment allocation as recommended through national guidance. As 
this is a pragmatic trial, it is only appropriate to perform the safety 
baseline investigations post randomisation as each treatment 
requires a different set of tests. To perform all of these tests on all 
of the patients pre-randomisation would be costly and in some 
aspects, unethical, particularly as a chest x-ray would be required to 
cover the methotrexate group (but is not required in any of the 
other groups). In usual practice the investigations would only be 
performed once a decision has been made about treatment for the 
patient, and so this is what will happen in the trial. 
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7.4.3 Safety Screening Visit (Visit 2) 
At this visit the results of the safety baseline investigations will be 
reviewed and if satisfactory, treatment will be commenced. 
Participants will be randomised to one of four treatment groups as 
outlined in Table 36, page 271. The treatment regimens are those 
that were agreed during structured interviews with clinicians 
(Chapter 3) and subsequent discussion with collaborators on the 
trial. 
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Table 36: Table of treatment groups for hELP trial 
Trial treatment arm Dose summary 
Control group: Clobetasol 
propionate 0.05% ointment 
alone plus initial reducing 
course of oral prednisolone 
Clobetasol propionate 0.05% once daily for one 
month followed by alternate day application for 
one month then twice weekly application. Increase 
to daily during times of flare and then gradually 
reduce as before. A course of oral prednisolone 
starting at 20mg OD for 1 week then reduce by 
5mg/week until stop. Oral prednisolone should be 
used as per usual practice following national 
guidelines; use of bone protection and gastro 
protection is not prohibited by this study. 
Group A: Hydroxychloroquine 
plus clobetasol propionate 
0.05% ointment 
Hydroxychloroquine 400mg p.o. daily. May be 
reduced to 200mg daily depending upon clinical 
response. Maximum dose 6.5mg/kg/d. 
Oral hydroxychloroquine should be used as per 
usual practice following national guidelines 
including and appropriate safety monitoring. 
Clobetasol propionate 0.05% ointment to be used 
as in control group. 
Group B: Methotrexate plus 
clobetasol propionate 0.05% 
ointment 
Methotrexate starting dose 5-10mg p.o. weekly, 
increase by 2.5-5mg every 2 weeks until disease 
stabilised. Maximum dose 25mg weekly. 
Oral methotrexate should be used as per usual 
practice following national guidelines including 
and appropriate safety monitoring; use of folic 
acid is not prohibited by this study. 
Clobetasol propionate 0.05% ointment to be used 
as in control group. 
Group C: Mycophenolate 
mofetil plus clobetasol 
propionate 0.05% ointment 
Mycophenolate mofetil starting dose 500mg p.o. 
daily for the first week, 500mg twice daily for the 
second week then increase by 500mg each week 
until maximum dose reached. Maximum dose 3g 
daily (in divided doses). 
Oral Mycophenolate mofetil should be used as per 
usual practice following national guidelines 
including and appropriate safety monitoring. 
Clobetasol propionate 0.05% ointment to be used 
as in control group. 
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7.4.4 1 month clinic visit (Study visit 3) 
Outcomes will not be formally assessed at this stage. 
Procedures to be carried out during this 1 month clinic visit are: 
฀ Samples taken as required for standard care safety 
monitoring according to the national guidelines for each 
specific treatment.  
฀ Pregnancy test for women of child bearing potential who are 
sexually active. 
฀ Check treatment adherence. 
฀ Document current dosage of therapy and adjust treatment 
dose as required;  
฀ Check for adverse events. 
 
7.4.5 3 month clinic visit (Study visit 4) 
The purpose of this visit will be to perform an interim assessment of 
response and side effects, to assess tolerance and adjust trial 
medication dosage as necessary. This is normal follow up practice 
when these therapies are commenced in standard care. 
Procedures to be carried out during this 3 month clinic visit are: 
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฀ Samples taken as required for standard care safety 
monitoring according to the national guidelines for each 
specific treatment.  
฀ Pregnancy test for women of child bearing potential who are 
sexually active. 
฀ Check treatment adherence. 
฀ Document current dosage of therapy and adjust treatment 
dose as required;  
฀ Check for adverse events. 
฀ Assess patient and clinician reported outcome measures 
 
7.4.6 6 month clinic visit (Study visit 5) 
During this visit the clinician and participant should make a 
pragmatic decision about ongoing treatment. If adequate control or 
disease tolerability is considerably improved, the medication should 
be continued for as long as is clinically indicated, as per local 
guidelines.  
Medication should be stopped at this visit if they have poor ongoing 
control of disease despite good adherence to the treatment regimen 
or if the side effects indicate that the participant should not carry on 
with the designated treatment. This will be a pragmatic decision by 
the treating physician according to local guidelines; there will be no 
study specific guidelines as this is a pragmatic study.  
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Procedures to be carried out during this 6 month clinic visit are: 
฀ Samples taken as required for standard care safety 
monitoring according to the national guidelines for each 
specific treatment.  
฀ Pregnancy test for women of child bearing potential who are 
sexually active. 
฀ Check treatment adherence. 
฀ Document current dosage of therapy and adjust treatment 
dose as required;  
฀ Check adverse events. 
฀ Assess patient and clinician reported outcome measures 
฀ Repeat digital photograph to be taken.  
 
7.4.7 12 month follow-up 
This will be done by telephone, email or letter. Its purpose will be to 
assess long term use and efficacy. 
Procedures to be carried out during this 12 month follow up are: 
฀ Assess patient and clinician reported outcome measures 
฀ Assess current medication usage
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Table 37: Summary table of assessments for hELP trial 
Assessment 
0 months 
(baseline 
and safety 
screening) 
1 
month 
3 
months 
6 
months 
12 
months 
(by 
telephone, 
letter or 
email) 
 
Informed consent  ¥     
Eligibility checks ¥     
Medical history ¥    ¥ 
Demographics ¥     
Randomisation ¥     
Standard safety monitoring ¥ ¥ ¥ ¥  
Pregnancy test # ¥ ¥ ¥ ¥  
Prescription given ¥ ¥ ¥ ¥  
Digital images$ ¥   ¥£  
Pain/Soreness VAS * ¥  ¥ ¥  
Patient Global Assessment 
(PGA) * ¥  ¥ ¥
 
¥ 
Investigator Global 
assessment of vulva ¥  ¥ ¥ 
 
Investigator Global 
assessment of other sites ¥  ¥ ¥ 
 
Anxiety and depression scale 
score* 
¥   ¥ ¥ 
Assessment of sexual function* ¥   ¥ ¥ 
Vulval Skindex 29* ¥   ¥ ¥ 
SF36* ¥   ¥ ¥ 
Patient diary* ¥ ¥ ¥ ¥  
Adverse Events  ¥ ¥ ¥  
# For women of child bearing potential who are sexually active 
$
 Images do not need to be taken by medical photography. Images are to assess general 
improvement and detail is not required. 
£
 Analysis by blinded assessor 
*
 Assessment completed by the participants 
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Figure 28: hELP Trial flow chart 
  
Identification of 
participants 
Baseline/screening clinic visit 
Informed consent, eligibility, digital photo 
Randomisation 
Prednisolone + 
clobetasol 
propionate 0.05% 
Hydroxychloroquine 
+ clobetasol 
propionate 0.05% 
 Methotrexate + 
clobetasol 
propionate 0.05% 
Clinic visit  (1 months) 
Standard safety monitoring and adherence, 
titrate medications if indicated 
 
Clinic visit  (3 months) 
Standard safety monitoring and 
adherence, titrate medications if indicated, 
record assessment parameters 
 
Clinic visit  (6 months) 
Primary and secondary outcomes 
measures including digital photo 
Medication specific safety assessments 
prior to start of treatment 
 
Final follow-up contact (12 months from randomisation) 
Contact by telephone, letter, online to assess long term 
efficacy 
Treatment 
phase 
Follow-up 
phase 
Mycophenolate 
mofetil + clobetasol 
propionate 0.05% 
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7.4.8 Ongoing monitoring investigations 
7.4.8.1 All participants  
As part of usual practice biopsy should be repeated during the trial if 
the clinical appearance of the vulva changes and there is suspicion 
of premalignant/malignant change.  
7.4.8.2 Control group: 
As part of usual practice no ongoing monitoring investigations are 
required. 
7.4.8.3 Active interventions:  
As part of usual practice participants receiving hydroxychloroquine, 
methotrexate or mycophenolate mofetil require monitoring 
investigations. Monitoring of these should follow national 
recommendations from the BSR/BHPR guideline for disease-
modifying anti-rheumatic drug therapy in consultation with the 
British Association of Dermatologists (Chakravarty 2008) and the 
individual medication SmPCs . Communication with clinicians 
(Chapter 3) indicated that these are the guidelines followed in 
normal daily practice 
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7.5 Concomitant and Rescue Medications and 
Treatments 
All medications being continued by a participant on entry to the 
study and all medication given in addition to the study treatment 
during the study will be documented on the CRF and also in the 
participant's medical records. Any changes to these treatments and 
dosage will be documented.  
All concomitant medications present at baseline and which do not 
interfere with the assessments should, where possible, be kept 
constant from screening throughout the study. 
7.5.1 Non-permitted concomitant treatment and 
medications: 
Participants will not be entered into the intervention phase if 
randomisation could potentially result in the combinations 
documented in Table 38, page 279. 
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Table 38: Contraindicated medications for hELP Trial 
Trial medication Contraindicated medications 
Hydroxychloroquine Amiodarone 
Artemether (anti-malarial) 
Droperidol 
Histamine 
Laronidase 
Lemefantrine (antimalarial) 
Mefloquine 
Moxifloxacin 
Quinine 
Methotrexate Acitretin 
Clozapine  
Live vaccines 
Mycophenolate mofetil Live vaccines 
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7.5.2 Concomitant treatment and medications to be used 
with caution due to possibility of interaction 
A list of medications which should be used with caution in 
conjunction with the trial medications are listed in the individual 
summery of medical characteristic (SmPC) documents. Medications 
to be taken with caution in conjunction with the trial medications 
should not prevent a patient from entering the trial if eligibility 
criteria are met and the clinician is happy that systemic therapy is 
indicated. Participants should continue to take their medications for 
other conditions as normal. 
 
7.5.3 Rescue therapy 
If the trial treatments appear to be ineffective, in the first instance 
compliance with study medications should be checked and 
concomitant complications (e.g. infection and malignancy) should be 
ruled out. The frequency of topical clobetasol propionate 0.05% 
should then be increased to once daily, if not already. If no 
improvement in disease control is seen within one month, the 
clinician and the participant should decide whether to carry on with 
the trial treatment, or whether different/additional therapy e.g. oral 
corticosteroids are required. If this is decided to be the case then 
the participant will be classified as a treatment failure and will be 
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withdrawn from the treatment (although they will continue to be 
followed up where possible). 
7.5.4 Compliance 
As this is a pragmatic study, it will seek to reflect current practice as 
far as possible (regardless of whether or not the drugs have been 
taken appropriately). Adherence will be assessed by the managing 
physician and through self-assessment as reported by the 
participants at outpatient visits. Acceptable adherence is defined as 
a participant taking their medication as instructed and partaking in 
the necessary monitoring investigations. 
 
7.6 Trial management 
The trial will have a Chief Investigator who will have overall 
responsibility for the study and will oversee all study management. 
The trial will be coordinated centrally from the Centre of Evidence 
Based Dermatology by the Trial Manager. 
There will be a Trial Management Group, a Trial Steering Committee 
and a Data Monitoring Committee in place to ensure the safe and 
transparent running of the trial. 
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7.7 Interventions 
The chosen investigational products have been shown through the 
work in chapters 2 and 3, plus the literature review in chapter 1, to 
be part of normal practice when treating ELPV and anecdotally have 
the greatest success rates. However, as there is currently no RCT 
evidence for any of the trial interventions it was impossible to pick 
one alone to test in a traditional two-armed, RCT. As patient 
numbers are scarce and resources limited in this population it was 
decided to design a four-armed study which will efficiently assess 
the medications in this group of patients and will give an indication 
of which one of these interventions is the most effective. 
The treatment regimens to be used are as per usual practice 
following national guidelines for the individual medications. In 
addition, the regimens have been agreed with collaborators who will 
be recruiters for the trial. 
As this is an open-label trial all of the investigational medical 
products will be prescribed as normal by the treating clinician and 
will be dispensed from the SDUWLFLSDQW¶V usual pharmacy with 
labelling in accordance with the dispensed medicines regulations. 
7.7.1 Treatment groups  
Participants will be randomised to one of four treatment groups: 
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Control group: standard care of topical clobetasol propionate 0.05% 
plus a short course of oral prednisolone. N.B Ointment format is 
preferred for the study. Topical clobetasol propionate 0.05% will be 
used once daily for one month, alternate days for 1 month then 
twice weekly thereon. This is in conjunction with an initial reducing 
course of oral prednisolone (20mg per day to reduce by 5mg per 
week over 4 weeks until stop (i.e. 20mg/day for 1 week, then 
15mg/day for 1 week, then 10mg/day for 1 week, then 5mg/day for 
1 week then stop)  
Research arm 1: Oral hydroxychloroquine (up to 200mg twice 
daily) PLUS topical clobetasol propionate 0.05% in the same 
regimen as in the control group. The exact dose will be decided by 
the treating physician according to clinical requirement. Oral 
hydroxychloroquine should be used as per usual practice following 
national guidelines including appropriate safety monitoring. 
Research arm 2: Oral methotrexate (starting at 5mg weekly 
titrated upwards over 3-4 months to a ceiling dose of 25mg weekly) 
PLUS topical clobetasol propionate 0.05% in the same regimen as in 
the control group. Oral methotrexate should be used as per usual 
practice following national guidelines including appropriate safety 
monitoring. 
Research arm 3: Oral mycophenolate mofetil (starting at 500mg 
OD titrated upwards over 3-4 months to a ceiling dose of 3g/day) 
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PLUS topical clobetasol propionate 0.05% in the same regimen as in 
the control group. Oral mycophenolate mofetil should be used as per 
usual practice following national guidelines including appropriate 
safety monitoring. 
 
All participants will receive an emollient to be used as soap 
substitute and moisturiser. This was demonstrated as standard care 
in Chapter 3. The choice of emollient will be usual medical practice 
for that recruiting site.  
 
7.7.2 Detailed information about the investigational products 
7.7.2.1 Clobetasol propionate 0.05% 
Clobetasol propionate 0.05% will be used by all of the treatment 
groups. Clobetasol propionate 0.05% is available by the topical 
route only. It is a highly active corticosteroid with topical anti-
inflammatory activity. The major effect of clobetasol propionate 0.05% 
on skin is a non-specific anti-inflammatory response, partially due to 
vasoconstriction and decrease in collagen synthesis. 
Standard practice for ELPV has been shown to be the use of 
clobetasol propionate 0.05% on a reducing regimen over three 
months. It is typically used once daily for one month (to try and 
induce remission of ELPV) and then weaned to alternate days for 
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one month then twice weekly for maintenance therapy. If this 
regimen is ineffective then a patient is likely to be asked to use 
clobetasol propionate 0.05% at the minimum frequency that 
maintains symptoms at a tolerable level. If a patient commences 
systemic therapy they will use clobetasol propionate 0.05% 
concurrently as systemic therapies can take weeks to months to 
produce optimum effect and although clobetasol propionate 0.05% 
is not effective by itself, it is likely to have at least some suppressive 
disease activity if stopped ELPV may flare severely. As the systemic 
therapies take effect, disease control will improve and patients will 
find that they can reduce the frequency of application of clobetasol 
propionate 0.05% without experiencing flares. If the condition is not 
controlled by the systemic agent they will continue to use clobetasol 
propionate 0.05% on a more frequent basis. Therefore the 
frequency of application of clobetasol propionate 0.05% will act as a 
surrogate marker of disease control achieved by the systemic 
agents. 
 
7.7.2.2 Prednisolone 
Prednisolone is a highly potent glucocorticoid steroid which has an 
anti-inflammatory effect. 
Prednisolone will be taken by the control group only (standard care) 
as a short course for the first four weeks of treatment. Participants 
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will be treated with 20mg reducing by 5mg per week over a 4 week 
period. It will be used as per usual practice following national 
guidelines which will include the use of bone and gastro-protection 
where necessary. 
Prednisolone is included in the control group on the basis that 
clobetasol propionate 0.05% has failed WRFRQWUROWKHSDWLHQW¶V(/39 
thus far and that it would be unethical to continue this completely 
by itself. Therefore standard care comprising a short course of oral 
prednisolone for the first month was decided following discussion 
with collaborators. 
7.7.2.3 Hydroxychloroquine sulfate (HCQ) 
Hydroxychloroquine will be used up to a dose of up to 200mg twice 
daily. 
Hydroxychloroquine has several pharmacological actions which may 
be involved in its clinical effects, but the role of each action is not 
known. These include interaction with sulphydryl groups, 
interference with enzyme activity, DNA binding, stabilisation of 
lysosomal membranes, inhibition of prostaglandin formation, 
possible interference with interleukin 1 production from monocytes 
and inhibition of neutrophil superoxide release. 
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7.7.2.4 Methotrexate (MTX) 
Methotrexate will be prescribed by the oral route for this study. It is 
available as 2.5mg and 10mg tablets, the 2.5mg strength will be 
used (which is standard practice within dermatology). Methotrexate 
is taken on a once weekly basis.  
Oral methotrexate should be used as per usual practice following 
national guidelines in conjunction with folic acid to reduce the 
incidence of side effects. 
Methotrexate is a folate antagonist and its major site of action is the 
enzyme dihydrofolate reductase. Its main effect is inhibition of DNA 
synthesis but it also acts directly both on RNA and protein synthesis. 
 
7.7.2.5 Mycophenolate mofetil (MMF) 
Mycophenolate mofetil in both 250mg and 500mg strengths will be 
required for this study as the dose is gradually titrated to the 
maximum tolerated amount that is therapeutic for the participant. If 
a participant is intolerant to the tablet form of mycophenolate 
mofetil the prescriber may consider prescribing an oral suspension 
which anecdotally causes fewer gastrointestinal symptoms.  
Oral mycophenolate mofetil will be used as per usual practice 
following national guidelines including appropriate safety monitoring. 
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Mycophenolate mofetil is an ester of mycophenolic acid. 
Mycophenolic acid is a potent, selective, uncompetitive and 
reversible inhibitor of inosine guanosine nucleotide synthesis without 
incorporation into DNA. T and B lymphocytes are dependent for their 
proliferation on de novo synthesis of purines. Mycophenolic acid 
(and therefore mycophenolate mofetil) therefore has potent 
cytostatic effects on lymphocytes (but not on other cells which are 
not critically dependent upon the synthesis of purines). 
 
7.8 Sample size and justification 
For the sample size calculation, assumptions for the success rate in 
the control and intervention arms, and potential loss to follow up 
rate, had to be made. As there are limited data in the literature to 
draw conclusions from, these assumptions were based upon expert 
opinion and clinical experience. 
Assuming a control success rate of 10% for the primary outcome, 
17 patients per arm are required to detect a 40% absolute increase 
in the proportion of treatment successes in an experimental arm, 
with 80% power at the two-sided 5% significance level and using a 
1:1:1:1 allocation ratio. The target difference between the groups is 
based upon data collected from patients and clinicians and is the 
minimally important clinical difference required to make taking one 
of the investigational medicinal products worthwhile. 
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To account for a loss-to-follow-up rate of 10% a total of 76 patients 
are required. To control the familywise error rate (probability of any 
type I, false positive, error) at the 5% level and maintain the power 
of each pairwise comparison at 80%, 96 patients will be required 
A staged approach to recruitment will be taken for the trial. After six 
months, or the recruitment of 40 participants (whichever comes first) 
it will be assessed whether with the time and resources remaining 
the target of 76 or 96 patients (as per the sample size calculation 
for a definitive trial) can be achieved. On the basis that ELPV is a 
rare condition and the pool of eligible patients limited, two sample 
sizes have been given. The power of the trial will ultimately be 
determined by the number of patients that can be recruited with the 
resources available. 
 
7.9 Randomisation and blinding 
Randomisation will be based on minimisation criteria on recruiting 
centre and disease severity (moderate or severe on the Investigator 
Global assessment scale, Figure 27, page 263). The randomisation 
sequence will be concealed until interventions are all assigned and 
recruitment, data collection, and data cleaning are complete. 
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Randomisation will be used for allocation to study groups but as this 
is an open-label RCT treatments will not be blinded to the 
researcher, patient participant or local pharmacist.  
The trial statistician and assessor of clinical images taken at baseline 
and at 6 months will both be blinded.  
The reason for designing an open-label trial is that because of the 
widely differing treatment regimes, complete participant blinding will 
be prohibitively expensive and impractical as each participant would 
need to take multiple tablets every day. Furthermore, it was felt 
that with so many different regimens and the potential side effects 
of some of the treatments it could be potentially dangerous to blind 
the participant and investigator to the intervention.  
Although it is an open-label trial, the participants will be randomised 
to receive one of the four interventions and therefore a large 
proportion of biases that could be introduced through a non-
randomised open trial will be removed. 
 
7.10 Adverse events 
One of the secondary endpoints will be cessation of medication due 
to adverse events. As this study is designed to reflect normal 
practice, adverse events are most likely to be detected in one of 
three ways: 
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฀ Patient-reported side effects at the time of their clinic 
consultation; 
฀ The managing clinician detecting abnormalities in monitoring 
blood tests; 
฀ The participant contacting the managing clinician in between 
clinic appointments to state any problems. 
Adverse events will be collected if they are considered secondary to 
the study drug. All serious events will be collected. 
7.10.1 Reporting of adverse events 
Participants will be asked to contact the study site immediately in 
the event of any serious adverse event. All adverse events will be 
recorded and closely monitored until resolution, stabilisation, or until 
it has been shown that the study medication or treatment is not the 
cause.  
In the event of a pregnancy occurring in a trial participant 
monitoring shall occur during the pregnancy and after delivery to 
ascertain any trial related adverse events in the mother or the 
offspring.  
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7.11 Stopping of the trial/discontinuation of 
medications 
An individual participant will stop treatment (but continue follow up) 
if: 
 they have poor ongoing control of disease despite good 
adherence to the treatment regimen and optimising topical 
clobetasol propionate 0.05% use and the clinician feels it 
is unethical to continue; or 
 side effects indicate that the participant should not carry 
on with the designated treatment regimen. 
If participants stop the study treatment they will continue to be 
followed up. 
Participants may stop the trial early either at their own request or at 
WKH,QYHVWLJDWRU¶VGLVFUHWLRQ (for example due to severe secondary 
infection, pregnancy and development of malignancy). If possible 
data will continue to be collected. The participants will be made 
aware that this will not affect their future care. Participants will be 
made aware (via the information sheet and consent form) that 
should they stop the trial, data collected to date cannot be erased 
and will still be used in the final analysis.  
Participants who are randomised but are subsequently found to be 
ineligible will be replaced and will not be included in the intention to 
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treat analysis. Participants who are randomised but choose not to 
start their medication (i.e. change their mind re: participation) will 
be followed up and will be included in the intention to treat analysis. 
 
7.12 Duration of the trial 
The overall duration of trial is expected to be 24 months. 
The recruitment period is anticipated to last for 12 months. If the 
number of participants entering the trial is low, then recruitment 
may be extended. 
Each participant will participate in the trial for 12 months (treatment 
period: 6 months, follow-up phone call 12 months after 
randomisation). Her participation will commence upon signing the 
consent form. 
7.13 Ethics Committee and regulatory Approvals 
The trial will be conducted in accordance with the ethical principles 
that have their origin in the Declaration of Helsinki, 1996; the 
principles of Good Clinical Practice, in accordance with the Medicines 
for Human Use Regulations, Statutory Instrument 2004, 1031 and 
its subsequent amendments and the Department of Health Research 
Governance Framework for Health and Social care, 2005. 
Chapter 7: Randomised controlled trial protocol 
294 
 
The trial will not be initiated before the protocol, informed consent 
forms and participant and GP information sheets have received 
approval from the Medicines and Healthcare products Regulatory 
Agency (MHRA), Research Ethics Committee (REC), and the 
respective National Health Service (NHS) Research & Development 
(R&D) department.  
 
7.14 Publication and Dissemination 
Following the analysis of the trial, it is of paramount importance that 
the findings are disseminated appropriately. The specialties that 
manage ELPV include dermatologists, gynaecologists, genitourinary 
physicians and specialist nurses. The optimal way to reach these 
groups, in addition to publications in peer reviewed journals, will be 
through the British and International Societies for the Study of 
Vulval Disease (BSSVD and ISSVD, section 1.7, page 46). These 
multidisciplinary groups each hold a biennial conference at which the 
findings will be presented. It would also be planned to present at 
the British Association of Dermatologists (BAD) Annual meeting. 
It is intended that ultimately results from the definitive trial will 
stimulate further research into ELPV. Findings from this and other 
research studies can then be combined to develop evidence based 
guidelines for treating ELPV which is urgently needed. 
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Further collaboration with the BAD will be sought to update their PIS 
on Lichen Planus as the current version does not cover the erosive 
subtype. Other groups that have collaborated with, or have links 
with the trial team include: 
 The UK Dermatology Clinical Trials Network 
 The UK Lichen Planus Society (UKLP) 
 NHS Choices 
 Nottinghamshire Collaboration for Leadership in Applied 
Health Research and Care (CLAHRC) 
These groups will be engaged to produce patient-oriented 
information that can be accessed through their online resources and 
can be generated into PISs for use in the clinic environment. In this 
way patients who have been directly involved in the research can 
benefit from their contribution. The UK DCTN and Centre of 
Evidence Based Dermatology (where this project is being co-
ordinated) have a reputation for producing research newsletter 
updates and keeping their trial websites up to date. We will follow 
this lead and do the same for our project, hence keeping members 
of the public informed. 
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7.15 Chapter 7 Summary 
This chapter describes the protocol for a future randomised 
controlled trial to assess four of the most commonly used treatment 
regimens for ELPV that is resistant to standard first-line therapy. 
The trial has been developed with input from patients, clinicians and 
members of expert specialist societies in the field of vulval skin 
disease. Work described in the earlier chapters of this thesis has 
informed many aspects of the protocol and has ensured that the end 
result is pragmatic, answers a question of clinical relevance and 
measures outcomes that are important to patients and clinicians. 
The trial has received the relevant regulatory approvals and is 
planned to commence in 2014.   
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8 Impact of this research and 
next steps
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8.1 Introduction 
Vulval skin disorders have long been underfunded and under-
researched. This thesis began by demonstrating that vulval erosive 
lichen planus, as a rare disease has very little evidence base to 
support current treatment regimens (Chapter 1), resulting in 
considerable variation in practice. In addition, this research 
identified that diagnostic criteria for the disease were not 
standardised, that there were no accepted outcome measures for 
the condition and that there was little known about the patient 
experience of living with the disease. 
In identifying these issues, this thesis has evolved. A pragmatic trial 
needs to follow usual clinical practice, ensure that the included 
patients are correctly diagnosed with the disease and measure 
outcomes that are clinically relevant to patients and clinicians. It 
was therefore important that these areas which were uncertain 
previously were addressed in order to develop the randomised 
controlled trial. 
Each of the individual studies that comprise this thesis have added 
to the existing evidence base for vulval erosive lichen planus and 
work has been well received the clinical community. The following is 
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8.2 Case-based review and UK multi-centre case 
note audit. 
This study was published in the British Journal of Dermatology in 
June 2012. It highlighted to the clinical community that: 
 Management and assessment of ELPV in the UK is variable 
and needed be standardised. 
 Both objective and subjective assessments of disease severity 
and impact should be considered when treating vulval disorders 
such as ELPV. 
 A number of systemic treatments may be used for patients 
with ELPV resistant to first-line therapy but formal assessment of 
their efficacy needed to be determined through well designed 
randomised controlled trials. 
In the absence of evidence-based guidance for the management of 
ELPV, the audit standards used in this study, which had been agreed 
by the members of the British Society for the Study of Vulval 
Disease, were suggested be used as an interim guide to patient care 
and as predetermined standards for clinical audit purposes in other 
centres to assess their practice. In 2013 an abstract was published 
by an Australian group who have adopted these audit standards 
(Maor 2013). 
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8.3 Qualitative investigation into UK clinician views 
and principles of management of erosive lichen 
planus affecting the vulva 
This study, which consisted of structured interviews with clinicians, 
was published in the British Journal of Dermatology in July 2013.  
It demonstrated a need to consolidate diagnostic criteria and 
develop outcome measures relevant to both patients and clinicians. 
It also backed up the results of the case note audit by hearing from 
clinicians that evidence towards treatment strategies, especially for 
patients not responding to first-line therapy, was needed. 
 
8.4 International electronic-Delphi Consensus 
Exercise 
This study was published by the British Journal of Dermatology in 
August 2013. It was also presented to the British Association of 
Dermatologists in the Plenary session at their annual meeting in July 
2013, and to the University of Nottingham School of Medicine 
Postgraduate Research Forum in June 2013. The work was well 
received by the scientific and clinical community and the 
presentations were awarded first prize at both meetings. 
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Using the e-Delphi technique a set of diagnostic criteria were 
internationally agreed by physicians with expertise in the diagnosis 
and management of vulval disease including ELPV. The diagnostic 
dataset is intended to guide the clinical diagnosis of ELPV and to 
help standardise the inclusion of patients into clinical trials. Other 
research groups have already begun to validate these criteria, the 
work of which is currently in progress. 
The e-Delphi methodology used is not restricted to diagnostic 
criteria or to skin disorders, and can be translated to other fields of 
medicine where expert opinion is required to answer a question 
which cannot be answered using the existing evidence base. The 
audiences to which the work was presented were very interested in 
the wider applications of the e-Delphi method resulting and have 
asked for advice on how to utilize the process in their own fields of 
medicine. 
  
8.5 Systematic review for outcome measures in 
vulval skin disorders 
This systematic review was published by the British Journal of 
Dermatology in September 2013. It was also presented as a poster 
DWWKHµ&20(7¶&RUH2XWFRPH0HDVXUHVLQ(IIHFWLYHQHVV7ULDOV
meeting in June 2013. 
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The study highlighted that interventional trials of vulval skin 
conditions have used multiple different scales to measure the same 
outcome. Furthermore, despite being a major cause of morbidity, 
functional impairment was rarely assessed by trials of vulval skin 
conditions. It was recommended that in line with the COMET 
Initiative a move to standardise outcomes for vulval skin conditions 
was made. 
8.6 3DWLHQWV¶YLews 
This exploratory study investigated WKHHIIHFWVRI(/39RQSHRSOHV¶
lives and ascertained specific problems encountered from the 
SDWLHQWV¶SHUVSHFWLYH. The four main themes identified from the 
focus groups were i) symptoms experienced by patients and 
subsequent consequences from these symptoms such as effect on 
quality of life, impact on daily functioning, and psychological 
distress; ii) negative experiences of management in primary and 
secondary care due to lack of understanding, poor continuity of care 
and inadequate communication between specialties; iii) lack of 
support networks and information available to patients; iv) positive 
experiences including coping mechanisms and faith in expert 
clinicians.  
The findings have provided a framework on which to base future 
qualitative investigations in this field and also guide areas for 
improvement in the clinical care. 
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Furthermore, patients were consulted upon the proposed 
randomised controlled trial design. The resulting protocol has 
therefore been developed with active patient involvement to ensure 
it is relevant and acceptable to them as service users.  
 
8.7 Randomised controlled trial 
This will be the first therapeutic trial of systemic therapy in ELPV 
and as such will contribute to the existing therapeutic evidence 
base. The study will investigate whether any of the three 
investigational agents are better than topical treatment in the 
management of ELPV resistant to first-line therapy. This four-armed 
study will guide future research in this field, particularly in 
identifying which, if any, of the systemic agents should be further 
investigated in a two-armed randomised controlled trial. 
Furthermore, it is hoped that the methodology employed will be 
translated to randomised controlled trials of other rare conditions. In 
disease areas where evidence for treatments is lacking and there 
are a number of possible interventions to test in a controlled trial 
setting, this multi-armed methodology has the potential to reduce 
research waste by comparing multiple therapies in one trial. It 
therefore will provide an answer more quickly and require fewer 
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patient numbers than performing multiple randomised controlled 
trials. 
8.8 Future research direction 
This thesis has made steps to improve care for patients with vulval 
erosive lichen planus. The randomised controlled trial, which is 
planned to start recruitment in spring 2014, will provide much 
needed information on systemic treatments for the condition and 
the results will guide researchers for future therapeutic trials. 
The agreed diagnostic criteria should be formally validated to assess 
their sensitivity and specificity in diagnosing cases of ELPV. As 
previously discussed, other research groups have already begun to 
action this. 
As suggested by the systematic review, outcome measures for 
vulval skin disorders urgently need to be standardised. The 
outcomes decided for use in the randomised controlled trial are the 
µEHVW-ILW¶RIH[LVWLQJFXUUHQWPHDVXUHV+RZHYHUWLPHVKRXOGEH
dedicated to devising a vulval-specific outcome measure tool. 
Furthermore, in line with the COMET Initiative, core-outcomes for 
vulval skin conditions should be agreed on an international level. 
The electronic-Delphi process would be ideal for use in this setting. 
Agreed outcomes should then be used in all trials of vulval skin 
conditions going forward. 
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Themes identified from the focus group should be further explored 
on a larger scale. The findings represent a small group of patients 
from one geographical location. Although they were in keeping with 
results from the UK Lichen Planus survey, the focus group only 
provided preliminary in-GHSWKGDWDRQSDWLHQWV¶H[SHULHQFHVDQGWKH
impact of the disease on their lives. Through involving a greater 
number of patients from more diverse settings, richer data will be 
obtained and will provide more substantial evidence on which to 
base changes in care structure that will ultimately enrich the patient 
experience. 
Our understanding of vulval erosive lichen planus could be improved 
by future research addressing the following questions: 
฀ What is the true incidence and prevalence of vulval erosive 
lichen planus? 
฀ Which regimen of super-potent topical corticosteroids is 
optimum to use as first-line therapy? 
฀ Which regimen of super-potent topical corticosteroids is 
optimum to maintain remission in those who have responded 
to first-line therapy? In particular, whether proactive 
treatment with super-potent topical corticosteroids once or 
twice weekly is more efficacious than reactive treatment on 
an as and when basis 
฀ Whether early aggressive therapy reduces progression to 
scarring and malignant change  
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8.9 Concluding remarks 
Research invariably produces further questions that need to be 
answered, as demonstrated by this thesis. The cycle of identifying 
and prioritising research agendas, carrying out research to answer a 
question and subsequently identifying further areas for exploration 
is paramount to moving practice forward, regardless of disease 
area. For patients who suffer the distressing condition of vulval 
erosive lichen planus this is only the beginning and it is with great 
hope that this project will stimulate others to take an interest in this 
condition and help to make a difference through continuing the 
research cycle.
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10 Appendices 
Appendix 1:
ISSVD Patient Information Leaflet on Vulval Erosive Lichen Planus
 
 
VULVAR LICHEN PLANUS 
  
What is it? 
Lichen planus (LP) is a disease of the skin caused by inflammation. It occurs 
most commonly in women 50-60 years old.  It can affect the genital area, 
including both the vulva and the vagina. The most common symptoms are 
burning and soreness. Some women describe itching as well.  Lichen planus 
causes a rash of small purplish bumps, often on the arms, legs or back. It can 
affect the mouth (oral disease) with a whitish eruption or ulcers. In some cases, 
the nails and the scalp are also involved.  It is possible to have the disease in 
one area without ever having a problem elsewhere.  Many patients with vulvar LP 
have LP in the mouth as well and sometimes on the skin.   
 
How common is it? 
It is estimated that 1 in 4000 women will have vulvar or vaginal LP compared to 1 
in 100 who may have oral LP. About 50% of women who have oral lichen planus 
may have vulvar or vaginal LP but the diagnosis may be missed as dentists do 
not generally enquire about genital symptoms and the mouth may not be 
routinely examined in those presenting with genital disease. 
 
  
What causes LP? 
The cause of LP is unknown. There may be a problem with the immune system, 
the system that protects a person from diseases.  In LP the system is overactive 
and can act against itself (this is called an auto-immune reaction).  In some 
cases, it is possible that an infection or medication can start this reaction.  We do 
not know why the lesions develop in some places and not others. LP may be 
associated with other auto-immune conditions such as vitiligo (white patches on 
the skin), thyroid disease and alopecia areata (patches of hair loss).  
  
Lichen planus is NOT contagious and cannot be passed to a sexual partner or to 
another part of your body. 
  
 
 
 
 
 
 
What are the symptoms and what do I see?   
¥ Soreness, burning and rawness are very common symptoms.  Less 
commonly there may be itching. If the outer layers of the skin break down 
(erosions), these areas appear moist and red.  
¥ There may be a white lacy pattern on the vulva.  This pattern can also be 
seen around the edges of the erosions  
¥ The vulva may appear pale white or pink/red.  Scarring with loss of the 
inner lips (labia minora) may be seen.  The clitoris may be buried under 
scar tissue. There may be shiny, red, raw areas. 
¥ Intercourse can be painful if the vagina is involved or there is scar tissue 
narrowing the entrance of the vagina.  
¥ Erosions can occur inside the vagina in a patchy or generalized pattern.  
Some women have a sticky, yellow or yellow-green discharge, which can 
be bloodstained, especially after intercourse.  The vaginal entrance may 
become smaller if the inner walls of the vagina or the skin around the 
entrance sticks together when it heals. This is one reason why intercourse 
can be painful or even impossible. Sometimes it is difficult for a doctor to 
perform an internal examination.  
¥ On rare occasions, the skin may have thickened areas.  These may have 
a warty appearance.  
 
If the skin is affected in other parts of the body, the rash is usually on the inside 
of the wrist, the forearms and the ankles.  The spots are a purple color and you 
may see some fine white streaks on the top of the spots.  A similar white, lacy 
streaking may be seen inside the mouth, but there may not be any symptoms.  
There may be sore, red, ulcerated areas around the gum margins, tongue and 
inside of cheeks. Occasionally LP can affect the tear ducts and oesophagus (the 
tube that carries food from the mouth to the stomach). If you experience 
excessive watering of the eyes, difficulty in swallowing or it feels as if food gets 
stuck, you should tell your doctor about this.  
 
  
How is LP diagnosed? 
Doctors familiar with the condition may diagnose it by looking at the skin and 
seeing the characteristic appearance.  The diagnosis is usually confirmed by 
taking a small piece of skin to be sent to the laboratory and then looked at under 
a microscope.  This is called a biopsy.  This is a simple procedure that can be 
done in the doctorÕs office after numbing with an anesthetic given on the skin or 
injected under the skin to be biopsied. 
 
 
How is LP treated? 
There are many treatments used to treat lichen planus.  Treatment needs to be 
selected to fit your problem.  Different people respond to different things.  The 
medications will control but often will not cure the LP. Treatment is a long 
process and close follow up with you and your care-giver is important.    
 
Lichen planus is often managed with medication as there is no absolute cure for 
LP.  However, in some cases, LP seems to come and go of its own accord and it 
is possible that it will disappear completely.  All irritating products must be 
stopped.  Avoid using soap or perfumed products in the area.   
 
As the activity of the immune system is increased in LP, the treatments aim to 
slow it down. The usual treatment for LP is a strong topical steroid also known as 
cortisone. The ointment form (petrolatum like) is generally used rather than the 
cream (white, like thick plain yogurt). This strong cortisone is very safe to use in 
this condition, and it is safe to use 30 grams in 3 months. This is used once a day 
for about a month and then on alternate days and eventually as needed. 
Occasionally, ointments containing calcineurin inhibitors are used (tacrolimus, 
pimecrolimus). These are treatments that are used to treat other types of 
inflammation on the skin such as eczema. These will help some people but may 
sting when they are first applied. 
 
If the vagina is involved, then a vaginal preparation containing cortisone can be 
inserted into the vagina. For scarring and narrowing of the vagina and/or the 
entrance into the vagina, physiotherapy of the pelvic floor or dilators are advised. 
Only rarely is surgery needed. 
 
If the ointments do not control the inflammation, then cortisone tablets taken 
orally or some types of cortisone injection can be helpful.  Medication to lower the 
overactive immune system may be needed. Examples of these are methotrexate 
or ciclosporin (Cyclosporine). These are medications that require blood tests to 
monitor their side-effects and this will all be discussed with you if you require 
them. Women on cortisone can have a safe pregnancy. However, it is very 
important that you do not become pregnant if you are taking any of the other 
drugs discussed above, as they can be harmful to the baby.  
 
 
What should I watch for? 
As LP is a long lasting inflammatory skin condition, there is a very slight 
increased risk of developing local types of skin cancer in the area compared to 
women without LP.  The risk is about 3%. Any new raised, bleeding or non-
healing areas in your genital area should be reported to your healthcare provider.  
It is important that your LP is monitored and that you attend for follow-up visits 
with your healthcare provider at least once per year. 
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Appendix 2
Data Abstraction Form for Case Note audit and Review
Case note abstraction form - erosive lichen planus study
CENTRE ID: PATIENT REVIEW ID:
Section 1 - General details and disease history
Please complete for all patients with erosive lichen planus seen in your department in the
past 12 months.
GENERAL DETAILS
Centre ID
Patient ID
Age
Co morbidities
(possible exclusion
criteria for RCT)
฀ History of alcohol excess
฀ Renal impairment
฀ Pregnant/lactating
฀ Liver impairment
฀ Previous or current malignancy (cutaneous or internal)
Concurrent
medications?
Please indicate if
the patient is taking
any of the following:
(possible exclusion
criteria for RCT)
฀ Acitretin
฀ Aciclovir
฀ Digoxin
฀ Doxycycline
฀ Hydroxychloroquine
฀ Leflunomide
฀ Omeprazole
฀ Phenytoin
Case note abstraction form - erosive lichen planus study
CENTRE ID: PATIENT REVIEW ID:
GENERAL DETAILS
DISEASE HISTORY
Duration of disease
(years)
How was disease
severity recorded?
฀ Schematic diagram
฀ Description of symptoms
฀ Ability for sexual activity
฀ Visual analogue score
฀ DLQI
฀ Other skin sites recorded?
฀ Oral cavity examined?
Which specialties
are involved in
management
฀ GP
฀ General dermatology
฀ Dermatologist with a special interest
฀ Oral medicine
฀ Gynaecology
Was biopsy taken? ฀ Yes
฀ No
Biopsy result? ฀ Consistent with ELP
฀ No features of ELP but
ruled out other
pathology
฀ Inconclusive
Zoons Vulvitis
Case note abstraction form - erosive lichen planus study
CENTRE ID: PATIENT REVIEW ID:
GENERAL DETAILS
Sites affected - ฀ Skin
฀ Mouth
฀ Vulva
฀ Vagina
฀ Scalp
฀ Anus
฀ Oesophagus
฀ Not recorded
Case note abstraction form - erosive lichen planus study
CENTRE ID: PATIENT REVIEW ID:
Section 2 - Treatment history
For each patient please use this section to summarise their treatment regimens to date:
TREATMENT HISTORY
Treatment regimens
to date:
฀ Topical only (฀ Dermovate, ฀ Protopic)
฀ Systemic only
฀ Combination systemic/topical
CURRENT TREATMENT REGIMEN
Name treatment(s) Treatment
code(s)
Treatment
regimen/dose
Regimen code
(s)
Duration of
treatment (months)
Side effects (if any) Side effect
code (s)
Case note abstraction form - erosive lichen planus study
CENTRE ID: PATIENT REVIEW ID:
PAST TREATMENT REGIMEN 1
Name treatment(s) Treatment
code (s)
Treatment
regimen/dose
Regimen
code (s)
Duration of
treatment (months)
Side effects (if any) Side effect
code(s)
Reason treatment
stopped
฀ Treatment successful
฀ Treatment failed
฀ Side effects
฀ Patients choice
฀ Other (please state)
Case note abstraction form - erosive lichen planus study
CENTRE ID: PATIENT REVIEW ID:
PAST TREATMENT REGIMEN 2
Name treatment (s) Treatment
code (s)
Treatment
regimen/dose
Regimen code
(s)
Duration of
treatment (months)
Side effects (if any) Side effect
code(s)
Reason treatment
stopped:
฀ Treatment successful
฀ Treatment failed
฀ Side effects
฀ Patients choice
฀ Other (please state)
Case note abstraction form - erosive lichen planus study
CENTRE ID: PATIENT REVIEW ID:
PAST TREATMENT REGIMEN 3
Name treatment (s) Treatment
code (s)
Treatment
regimen/dose
Regimen code
(s)
Duration of
treatment (months)
Side effects (if any) Side effect
code(s)
Reason treatment
stopped:
฀ Treatment successful
฀ Treatment failed
฀ Side effects
฀ Patients choice
฀ Other (please state)
Case note abstraction form - erosive lichen planus study
CENTRE ID: PATIENT REVIEW ID:
PAST TREATMENT REGIMEN 4
Name treatment (s) Treatment
code (s)
Treatment
regimen/dose
Regimen
code (s)
Duration of
treatment (months)
Side effects (if any) Side effect
code(s)
Reason treatment
stopped:
฀ Treatment successful
฀ Treatment failed
฀ Side effects
฀ Patients choice
฀ Other (please state)
Case note abstraction form - erosive lichen planus study
CENTRE ID: PATIENT REVIEW ID:
PAST TREATMENT REGIMEN 5
Name treatment (s) Treatment
code (s)
Treatment
regimen/dose
Regimen code
(s)
Duration of
treatment (months)
Side effects (if any) Side effect
code(s)
Reason treatment
stopped:
฀ Treatment successful
฀ Treatment failed
฀ Side effects
฀ Patients choice
฀ Other (please state)
Case note abstraction form - erosive lichen planus study 
CENTRE ID:    PATIENT REVIEW ID:
 
Section 1 - General details and disease history 
 
 
Please complete for all patients with erosive lichen planus seen in your department in the 
past 12 months. 
 
 
GENERAL DETAILS 
Centre ID 
 
 
Patient ID 
 
 
Age 
 
 
Co morbidities  
(possible exclusion 
criteria for RCT)  
฀฀ History of alcohol excess 
 
฀฀ Renal impairment  
 
฀฀ Pregnant/lactating  
 
฀฀ Liver impairment 
 
฀฀ Previous or current malignancy (cutaneous or internal) 
Concurrent 
medications?  
Please indicate if 
the patient is taking 
any of the following: 
(possible exclusion 
criteria for RCT) 
 
 
฀฀ Acitretin 
 
฀฀ Aciclovir 
 
฀฀ Digoxin 
 
฀฀ Doxycycline 
 
฀฀ Hydroxychloroquine 
 
฀฀ Leflunomide 
 
฀฀ Omeprazole 
 
฀฀ Phenytoin 
 
 
 
 
 
Case note abstraction form - erosive lichen planus study 
CENTRE ID:    PATIENT REVIEW ID:
 
GENERAL DETAILS 
DISEASE HISTORY 
Duration of disease 
(years) 
 
 
How was disease 
severity recorded? 
฀฀ Schematic diagram 
 
฀฀ Description of symptoms 
 
฀฀ Ability for sexual activity 
 
฀฀ Visual analogue score 
 
฀฀ DLQI  
 
฀฀ Other skin sites recorded? 
 
฀฀ Oral cavity examined? 
Which specialties 
are involved in 
management 
฀฀ GP 
 
฀฀ General dermatology 
 
฀฀ Dermatologist with a special interest 
 
฀฀ Oral medicine 
 
฀฀ Gynaecology 
 
 
Was biopsy taken?  
 
  ฀฀ Yes 
 
  ฀฀ No 
Biopsy result? 
 ฀฀ Consistent with ELP 
 
 ฀฀ No features of ELP but    
ruled out other 
pathology 
 
฀฀ Inconclusive 
     =RRQ¶V9XOYLWLV 
Case note abstraction form - erosive lichen planus study 
CENTRE ID:    PATIENT REVIEW ID:
 
GENERAL DETAILS 
Sites affected - ฀฀ Skin 
 
฀฀ Mouth 
 
฀฀ Vulva 
 
฀฀ Vagina 
 
฀฀ Scalp 
 
฀฀ Anus 
 
฀฀ Oesophagus 
 
฀฀ Not recorded 
 
Case note abstraction form - erosive lichen planus study 
CENTRE ID:    PATIENT REVIEW ID:
 
 
Section 2 - Treatment history 
 
For each patient please use this section to summarise their treatment regimens to date: 
 
 
TREATMENT HISTORY 
Treatment regimens 
to date: 
฀฀ Topical only (฀฀ Dermovate, ฀฀ Protopic) 
 
฀฀ Systemic only 
 
฀฀ Combination systemic/topical 
 
CURRENT TREATMENT REGIMEN  
Name treatment(s) 
 
 Treatment 
code(s) 
 
Treatment 
regimen/dose 
   Regimen code 
(s) 
 
Duration of 
treatment (months) 
 
Side effects (if any) 
 
 Side effect 
code (s) 
 
Case note abstraction form - erosive lichen planus study 
CENTRE ID:    PATIENT REVIEW ID:
 
 
PAST TREATMENT REGIMEN 1 
Name treatment(s)  Treatment 
code (s) 
 
Treatment 
regimen/dose 
 Regimen 
code (s) 
 
Duration of 
treatment (months) 
 
Side effects (if any)  Side effect 
code(s) 
 
Reason treatment 
stopped 
 
 
 ฀฀ Treatment successful 
 
 ฀฀ Treatment failed 
 
 ฀฀ Side effects 
 
 ฀฀ 3DWLHQW¶VFKRLFH 
 
 ฀฀ Other (please state) 
 
 
   
   
Case note abstraction form - erosive lichen planus study 
CENTRE ID:    PATIENT REVIEW ID:
 
 
PAST TREATMENT REGIMEN 2 
Name treatment (s)  Treatment 
code (s) 
 
Treatment 
regimen/dose 
 Regimen code 
(s) 
 
Duration of 
treatment (months) 
 
Side effects (if any)  Side effect 
code(s) 
 
Reason treatment 
stopped:  
 
 
 ฀฀ Treatment successful 
 
 ฀฀ Treatment failed 
 
 ฀฀ Side effects 
 
 ฀฀ 3DWLHQW¶VFKRLFH 
 
 ฀฀ Other (please state) 
 
 
Case note abstraction form - erosive lichen planus study 
CENTRE ID:    PATIENT REVIEW ID:
 
 
PAST TREATMENT REGIMEN 3 
Name treatment (s)  Treatment 
code (s) 
 
Treatment 
regimen/dose 
 Regimen code 
(s) 
 
Duration of 
treatment (months) 
 
Side effects (if any)  Side effect 
code(s) 
 
Reason treatment 
stopped:  
 
 
 ฀฀ Treatment successful 
 
 ฀฀ Treatment failed 
 
 ฀฀ Side effects 
 
 ฀฀ 3DWLHQW¶VFKRLFH 
 
 ฀฀ Other (please state) 
 
 
Case note abstraction form - erosive lichen planus study 
CENTRE ID:    PATIENT REVIEW ID:
 
 
PAST TREATMENT REGIMEN 4 
Name treatment (s)  Treatment 
code (s) 
 
Treatment 
regimen/dose 
 Regimen 
code (s) 
 
Duration of 
treatment (months) 
 
Side effects (if any)  Side effect 
code(s) 
 
Reason treatment 
stopped:  
 
 
 ฀฀ Treatment successful 
 
 ฀฀ Treatment failed 
 
 ฀฀ Side effects 
 
 ฀฀ 3DWLHQW¶VFKRLFH 
 
 ฀฀ Other (please state) 
 
 
Case note abstraction form - erosive lichen planus study 
CENTRE ID:    PATIENT REVIEW ID:
 
 
PAST TREATMENT REGIMEN 5 
Name treatment (s)  Treatment 
code (s) 
 
Treatment 
regimen/dose 
 Regimen code 
(s) 
 
Duration of 
treatment (months) 
 
Side effects (if any)  Side effect 
code(s) 
 
Reason treatment 
stopped:  
 
 
 ฀฀ Treatment successful 
 
 ฀฀ Treatment failed 
 
 ฀฀ Side effects 
 
 ฀฀ 3DWLHQW¶VFKRLFH 
 
 ฀฀ Other (please state) 
 
 
 
Appendix 3:
Structured Interview Questionnaire
Vulval Erosive Lichen Planus
Structured Interviews
Interview Number: Date:
1. What are your current feelings on treating patients with vulval erosive lichen
planus?
(Assessing behaviour/experience)
2. Do you often follow patients up long term?
a. What is the reason for this?
(Assessing opinion/belief/experience)
3. How do you diagnose vulval erosive lichen planus (ELPV)?
a. Clinical features: please specify
(Assessing knowledge/experience)
b. Pathological features
(Assessing knowledge/experience)
4. Do you routinely biopsy patients with a clinical diagnosis of ELPV?
a. If no, in which circumstances would you perform a biopsy?
(Assessing experience)
5. Do you record clinical severity of ELPV? (Assessing experience)
a. How do you assess it?
b. Do you use any particular tools?
6. Do you assess impact of disease on the patient? (Assessing experience)
a. How do you assess it?
b. Do you use any particular tools?
7. Are there any specific outcomes you feel should be used for clinical trial purposes?
Opinion/belief
8. What is your treatment approach for patients with ELPV? (Assessing
knowledge/experience)
Vulval Erosive Lichen Planus
Structured Interviews
a. First line?
b. Second line?
c. How soon after commencing treatment do you follow up a patient to assess
whether treatment is working? How do you make that assessment?
d. What makes you move up the therapeutic ladder?
9. Which of the following drugs are you happy using within your general
dermatological practice? (Assessing experience)
a. Acitretin
b. Hydroxychloroquine
c. Methotrexate
d. Mycophenolate mofetil
e. Minocycline
f. Minocycline + nicotinamide
10. Are there any that you have never prescribed or do not prescribe? (Assessing
experience and opinion)
a. Are there specific reasons for this?
11. Would you prescribe these for patients with ELPV? (Assessing opinion)
12. Do you leave a specific washout period for these agents before commencing an
alternative systemic treatment?
(Assessing experience)
13. What do you think a wash out period should be for clinical trial purposes when
transitioning between therapies? (Assessing knowledge and opinion)
a. 1 month
b. 3 months
Vulval Erosive Lichen Planus
Structured Interviews
c. Other
14. i)Have any patients under your care experienced any significant adverse effects
(such as acute liver/renal/bone marrow failure, hypersensitivity, severe rash etc.)
when receiving the following treatments: (Assessing experience)
a. Acitretin
b. Hydroxychloroquine
c. Methotrexate
d. Mycophenolate mofetil
e. Minocycline
f. Minocycline + nicotinamide
ii) Have any of these adverse events stopped you from further prescribing the
agent(s)?
15. i. What is your standard dosing regimen for the following agents (i.e. as per
BAD/BNF guidelines, or do you have your own preferred dose escalation
regimen/max dose?) (Assessing experience and knowledge)
a. Acitretin
b. Hydroxychloroquine
c. Methotrexate
d. Mycophenolate mofetil
e. Minocycline
f. Minocycline + nicotinamide
ii. Is this different if you use these agents in the treatment of ELPV? (Assessing
opinion)
16. Are there any restrictions within your centre for prescribing the following
treatments? If so, please state what these restrictions are: (Assessing knowledge)
a. Acitretin
Vulval Erosive Lichen Planus
Structured Interviews
b. Hydroxychloroquine
c. Methotrexate
d. Mycophenolate mofetil
e. Minocycline
f. Minocycline + nicotinamide
17. If any of the aforementioned treatments were agents in a randomized controlled
trial for patients with ELPV, would this prevent your participation in the trial?
(Assessing opinion)
a. Which ones and why?
18. Do you routinely recommend soap substitution and regular use of an emollient for
patients with ELPV? (Assessing opinion/experience)
a. Which is your preferred agent?
b. Do you think the agent should be specified for patients included in an RCT or
should advice only be given about vulval skin care?
19. Do you think a therapeutic trial for ELP should include patients with genital OR
oral disease, or restrict to the genital population only? (Assessing opinion)
20. Do you have any further comments regarding systemic treatments for ELPV?
(Assessing opinion)
21. Would you be willing to be consulted about the design of a trial protocol for an
RCT in this area? (Assessing opinion)
22. Would you be willing to recruit patients to an RCT? (Assessing opinion)
23. Would you be put off recruiting into an RCT if one of the treatment arms was a
placebo? (Assessing opinion)
24. What sort of hospital do you work in? (Assessing background)
Vulval Erosive Lichen Planus
Structured Interviews
25. Do you have a dedicated vulval clinic/clinician with a subspecialist interest in vulval
disease? (Assessing background)
26. How many patients with vulval disease do you typically see each month? (Assessing
background)
a. How many have vulval ELP?
27. What specialty do you fall under? (Assessing background)
a. Dermatology
b. Gynaecology
c. Genitourinary medicine
d. Other
28. Are you a member of the ISSVD, BSSVD or any other specialist societies that have an
interest in vulval disease? (Assessing background)
Appendix 4
Electronic Delphi Consensus Exercise Round 1 Questionnaire
Page 1
Diagnostic Criteria for Vulval Erosive Lichen Planus
7KDQN\RXIRUSDUWLFLSDWLQJLQWKLV'HOSKL&RQVHQVXVH[HUFLVHWRUHDFKDQDJUHHPHQWRQGLDJQRVWLFFULWHULDIRUHURVLYHOLFKHQSODQXVDIIHFWLQJWKHYXOYD(/39,WLVKRSHGWKDW
WKHRXWFRPHRIWKLVSURMHFWZLOOKHOSSK\VLFLDQVLQWKHHDUO\UHFRJQLWLRQRI(/39DQGOHDGWRSURPSWWUHDWPHQWDQGDOOHYLDWLRQRIV\PSWRPV$GHILQHGVHWRIGLDJQRVWLFFULWHULD
ZLOODOVRDVVLVWUHFUXLWPHQWLQWRFOLQLFDOWULDOVWKDWDGYDQFHNQRZOHGJHRIWKLVGLIILFXOWFRQGLWLRQ

,QSUHSDUDWLRQIRUWKLVSURMHFWZHKDYHSHUIRUPHGDUHYLHZRIWKHOLWHUDWXUHWRVXPPDULVHGLDJQRVWLFFULWHULDWKDWKDYHEHHQXVHGLQSUHYLRXVVWXGLHVRI(/39:HKDYHDOVR
VSRNHQWRSK\VLFLDQVWKURXJKLQWHUYLHZVWRHVWDEOLVKWKHLUFXUUHQWSUDFWLFH7KLVTXHVWLRQQDLUHLVWKHUHIRUHEDVHGXSRQSXEOLVKHGOLWHUDWXUHDQGFXUUHQWFOLQLFDORSLQLRQ

7KHµ'HOSKL¶PHWKRGZKLFKZHDUHXVLQJIRUWKLVFRQVHQVXVZRUNZLOOEHUXQLQURXQGV

5RXQGWKHFXUUHQWURXQG\RXZLOOEHDVNHGWRDVVHVVDOLVWRISRWHQWLDOGLDJQRVWLFFULWHULDIRU(/39<RXZLOOKDYHWKHRSSRUWXQLW\WRDGGDQ\LWHPVWKDW\RXSHUFHLYHDUH
PLVVLQJ

5RXQG\RXZLOOUHFHLYHIHHGEDFNGHWDLOLQJWKHHQWLUHJURXS¶VUHVSRQVHV<RXZLOOKDYHWKHRSSRUWXQLW\WRUHIOHFWXSRQDQGPRGLI\\RXUDQVZHUVLI\RXZLVK

5RXQG\RXZLOOEHDVNHGWRUDQNWKHLWHPVWKDWKDYHUHDFKHGFRQVHQVXVLQWKHILUVWWZRURXQGVVRWKDWD
FRUHVHW
RIPDMRUDQGPLQRUGLDJQRVWLFFULWHULDIRU(/39FDQEH
GHWHUPLQHG

:HDSSUHFLDWHWKDWGXHWRWKHVNLOOPL[RISDUWLFLSDQWVVRPHTXHVWLRQVPD\DSSHDUPRUHUHOHYDQWWR\RXUGDLO\SUDFWLFHWKDQRWKHUV,WLVLPSRUWDQWWKDW\RXDQVZHUDOO
TXHVWLRQVHYHQLI\RXQHHGWRUHVSRQG
QRWVXUH
,WLVDOVRLPSRUWDQWWKDW\RXPDNHHYHU\HIIRUWWRFRPSOHWHDOOWKUHHURXQGVDVQRQUHVSRQVHPD\KDYHFRQVHTXHQFHVIRUWKH
HQGUHVXOWV(DFKURXQGZLOORQO\WDNHDIHZPLQXWHVWRFRPSOHWH

<RXZLOOEHDVNHGIRU\RXUQDPHDWWKHHQGRIWKHVXUYH\7KLVLVSXUHO\IRUDGPLQLVWUDWLYHSXUSRVHVDVRQO\UHVSRQGHUVFDQSDUWLFLSDWHLQVXEVHTXHQWURXQGV2QO\WKHVWXG\
DGPLQLVWUDWRUZLOOVHH\RXUQDPHDQGLWZLOOEHGHOHWHGRQFHWKHDQDO\VLVRIHDFKURXQGLVFRPSOHWH

2QFHDJDLQWKDQN\RXIRUSDUWLFLSDWLQJ

5RVDOLQG6LPSVRQ
5XWK0XUSK\

5RXQG,QWURGXFWLRQ

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7KHIROORZLQJTXHVWLRQVDUHUHJDUGLQJ&/,1,&$/FULWHULDIRUGLDJQRVLQJHURVLYHOLFKHQSODQXVRIWKHYXOYD
,Q\RXURSLQLRQKRZLPSRUWDQWDUHWKHIROORZLQJ&/,1,&$/FULWHULDWRPDNHWKHGLDJQRVLVRIHURVLYHOLFKHQSODQXVRIWKHYXOYD
$UHWKHUHDQ\DGGLWLRQDO&/,1,&$/LWHPVWKDW\RXSHUFHLYHWREHLPSRUWDQWLQGLDJQRVLQJHURVLYHOLFKHQSODQXVRIWKHYXOYD"
3OHDVHOLVW

5RXQG&OLQLFDOFULWHULD

9HU\LPSRUWDQW ,PSRUWDQW /HVVLPSRUWDQW 1RWLPSRUWDQW 1RWVXUH
:HOOGHPDUFDWHGHURVLRQVDWWKHYDJLQDOLQWURLWXV     
:HOOGHPDUFDWHGJOD]HGHU\WKHPDWRXVDUHDVDWWKHYDJLQDOLQWURLWXV     
6\PPHWULFDOGLVWULEXWLRQRIOHVLRQV     
+\SHUNHUDWRWLFZKLWHERUGHUWRHU\WKHPDWRXVDUHDVHURVLRQV     
:LFNKDP¶VVWULDHSUHVHQWLQDUHDVRIVXUURXQGLQJVNLQ     
6FDUULQJORVVRIQRUPDODUFKLWHFWXUHHJODELDODGKHVLRQVORVVRIODELDPLQRUDQDUURZLQJRILQWURLWXV
FOLWRUDOEXU\LQJ
    
3UHVHQFHRIDQHURVLYHYDJLQLWLV     
3UHVHQFHRIYDJLQDOGLVFKDUJH     
3DLQRQ4WLSSUHVVXUH     
,QYROYHPHQWRIRWKHUPXFRFXWDQHRXVVLWHVHJPRXWKVNLQVFDOSQDLOVH\HVRHVRSKDJXV     




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7KHIROORZLQJTXHVWLRQVDUHUHJDUGLQJ+,6723$7+2/2*,&$/FULWHULDIRUGLDJQRVLQJHURVLYHOLFKHQSODQXVRIWKHYXOYD
,Q\RXURSLQLRQKRZLPSRUWDQWDUHWKHIROORZLQJ+,6723$7+2/2*,&$/FULWHULDWRPDNHWKHGLDJQRVLVRIHURVLYHOLFKHQSODQXV
RIWKHYXOYD
$UHWKHUHDQ\DGGLWLRQDO+,6723$7+2/2*,&$/LWHPVWKDW\RXSHUFHLYHWREHLPSRUWDQWLQGLDJQRVLQJHURVLYHOLFKHQSODQXVRI
WKHYXOYD"3OHDVHOLVW

5RXQG3DWKRORJLFDOFULWHULD

9HU\LPSRUWDQW ,PSRUWDQW /HVVLPSRUWDQW 1RWLPSRUWDQW 1RWVXUH
3UHVHQFHRIDZHOOGHILQHGLQIODPPDWRU\EDQGLQWKHVXSHUILFLDOFRQQHFWLYHWLVVXHWKDWLQYROYHVWKH
GHUPRHSLGHUPDOMXQFWLRQ
    
3UHVHQFHRIDQLQIODPPDWRU\LQILOWUDWHWKDWFRQVLVWVSUHGRPLQDQWO\RIO\PSKRF\WHV     
6LJQVRIEDVDOFHOOOD\HUGHJHQHUDWLRQ     




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'R\RXKDYHDQ\IXUWKHUFRPPHQWVDERXWGLDJQRVWLFFULWHULDIRUHURVLYHOLFKHQSODQXVDIIHFWLQJWKHYXOYD"


5RXQG2WKHULQIRUPDWLRQ



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3OHDVHLQGLFDWH\RXUVSHFLDOW\RISUDFWLFH
3OHDVHLQGLFDWH\RXUFOLQLFDOJUDGH
+RZORQJKDYH\RXKHOGDVSHFLDOLVWLQWHUHVWLQYXOYDOVNLQGLVRUGHUV"

5RXQG'HPRJUDSKLFLQIRUPDWLRQ



'HUPDWRORJ\
*\QHFRORJ\
+LVWRSDWKRORJ\
*HQLWRXULQDU\PHGLFLQH9HQHURORJ\6H[XDOPHGLFLQH
2WKHUSOHDVHVSHFLI\


&RQVXOWDQW
5HVLGHQW6SHFLDOLVWUHJLVWUDU
1XUVHVSHFLDOLVW
2WKHU3OHDVHVSHFLI\


/HVVWKDQ\HDUV
\HDUV
\HDUV
\HDUV
0RUHWKDQ\HDUV
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3OHDVHLQGLFDWH\RXUFRXQWU\RISUDFWLFH

3OHDVHLQGLFDWH\RXUQDPHWKLVLVIRUDGPLQLVWUDWLYHSXUSRVHVDQGZLOOEHGHOHWHGRQFHDQDO\VLVLVFRPSOHWH




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7KDQN\RXIRUWDNLQJWKHWLPHWRVXEPLW\RXUDQVZHUV:HZLOOEHLQFRQWDFWZLWKWKHUHVXOWVRI5RXQGVKRUWO\7KLVUHVHDUFKLVEHLQJUXQIURPWKH&HQWUHRI(YLGHQFH%DVHG
'HUPDWRORJ\DWWKH8QLYHUVLW\RI1RWWLQJKDP

,I\RXKDYHDQ\TXHULHVSOHDVHFRQWDFW

URVDOLQGVLPSVRQ#QRWWLQJKDPDFXN

7KDQN\RX
Appendix 5
Electronic Delphi Consensus Exercise Round 2 Questionnaire
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'HDU3DUWLFLSDQW

:HOFRPHWR5RXQGRIWKH&RQVHQVXV([HUFLVHWRDJUHHGLDJQRVWLFFULWHULDIRUHURVLYHOLFKHQSODQXVDIIHFWLQJWKHYXOYD(/39<RXUFRQWLQXLQJLQSXWLVFUXFLDOWRKHOSLQJWKH
,QWHUQDWLRQDO&RPPXQLW\EHWWHUVWDQGDUGL]HPDQDJHPHQWRI(/39

,WLVLPSRUWDQWWKDW\RXDQVZHU$//5281'6DVDQ\GURSRXWRISDUWLFLSDQWVZLOO7+5($7(17+(6&,(17,),&&5(',%,/,7<RIWKHH[HUFLVH

,QOLJKWRIWKHUHVSRQVHVWR5RXQGWKHTXHVWLRQQDLUHKDVEHHQPRGLILHG6RPHZRUGLQJKDVEHHQDPHQGHGDQGVRPHTXHVWLRQVKDYHEHHQUHPRYHG:HQRZDVNIRU\RXU
EULHIUHVSRQVHVWR5RXQGWKLVVKRXOGOHVVWKDQPLQXWHV

5HVSRQVHVWR5RXQGKDYHEHHQDQDO\]HGDQGDUHGLVSOD\HGDVDSHUFHQWDJHDORQJWKHUHVSRQVHEDU:KHQDQVZHULQJWKHVHTXHVWLRQVDJDLQSOHDVHFRQVLGHUWKHFKDQJHV
ZHKDYHPDGHDQGWKHJURXS¶VRYHUDOOSUHYLRXVUHVSRQVH:HKRSHWKDWLQWKLVURXQGDPRYHWRZDUGVFRQVHQVXVZLOORFFXUIRUWKHGLDJQRVWLFFULWHULDWKDWSDUWLFLSDQWVEHOLHYH
DUHLPSRUWDQW

:HKDYHWDNHQLQWRDFFRXQWDGGLWLRQDOFRPPHQWVIURP5RXQGDVPXFKDVSRVVLEOHUHPHPEHUWKDWZHDUHWU\LQJWRDJUHHD',$*1267,&GDWDVHWEDVHGXSRQ&/,1,&$/
DQGRU+,6723$7+2/2*,&$/ILQGLQJV7KHUHIRUHVHFRQGDU\IHDWXUHVRIWKHGLVHDVHHJG\VSDUHXQLDSRRUUHVSRQVHWRWUHDWPHQWHWFDUHLQWHQWLRQDOO\127LQFOXGHGLQWKH
TXHVWLRQQDLUH

:KHQDQVZHULQJWKHTXHVWLRQVLWPD\EHKHOSIXOWRFRQVLGHUWKHWHUPV
YHU\LPSRUWDQW
DQG
LPSRUWDQW
V\QRQ\PRXVZLWK
PDMRUHVVHQWLDO
DQG
PLQRU
:HDSSUHFLDWHWKDWLWLV
GLIILFXOWWRTXDQWLI\WKHLPSRUWDQFHRIDSDUWLFXODUIHDWXUHEXWZHKRSHWRFRPHXSZLWKDOLVWRIFULWHULDWKDWDUH
HVVHQWLDO
IRUGLDJQRVLQJ(/39DQGDOLVWRI
RSWLRQDO
RWKHUVWKDW
DUHKHOSIXOEXWQRWHVVHQWLDO

7KDQN\RXIRU\RXUFRQWLQXHGLQSXW

5RVDOLQG6LPSVRQ
5XWK0XUSK\

5RXQG,QWURGXFWLRQ

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7KHTXHVWLRQVRQWKHIROORZLQJSDJHVDUHUHJDUGLQJ&/,1,&$/FULWHULDIRUGLDJQRVLQJHURVLYHOLFKHQSODQXVRIWKHYXOYD,WLVVWDWHGZKHWKHUWKHTXHVWLRQVDUHWKHVDPHRUKDYH
EHHQDPHQGHGIURP5RXQG

6RPHTXHVWLRQVKDYHEHHQUHPRYHGIURP5RXQG7KLVLVEHFDXVHLQ5RXQGWKH\UHDFKHGDFULWLFDOWKUHVKROGRIRSLQLRQDQGZHUHUDWHGDVHLWKHU
OHVVLPSRUWDQW
RU
QRW
LPSRUWDQW
E\SDUWLFLSDQWV7KHTXHVWLRQVWKDWKDYHEHHQUHPRYHGDUH

,Q\RXURSLQLRQKRZLPSRUWDQWLVLWWKDWOHVLRQVDUHV\PPHWULFDOWRPDNHWKHGLDJQRVLVRIHURVLYHOLFKHQSODQXVRIWKHYXOYD"

,Q\RXURSLQLRQKRZLPSRUWDQWLVWKHSUHVHQFHRIYDJLQDOGLVFKDUJHWRPDNHWKHGLDJQRVLVRIHURVLYHOLFKHQSODQXVRIWKHYXOYD"

,Q\RXURSLQLRQKRZLPSRUWDQWLVWKHSUHVHQFHRISDLQRQ4WLSSUHVVXUHWRPDNHWKHGLDJQRVLVRIHURVLYHOLFKHQSODQXVRIWKHYXOYD"
,I\RXGLVDJUHHZLWKWKHH[FOXVLRQRIDQ\WKHVHVWDWHPHQWVWKHQSOHDVHFRPPHQWEHORZ





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7KHZRUGLQJIRUWKLVTXHVWLRQKDVEHHQDPHQGHGDQGZHKDYHFRPELQHGWKHFOLQLFDOIHDWXUHVRIZHOOGHPDUFDWHGHURVLRQV25JOD]HGHU\WKHPDWRXVDUHDVLQWRRQHGLDJQRVWLF
FULWHULD7KHVHZHUHDVNHGDVWZRVHSDUDWHTXHVWLRQVLQ5RXQG

6FRUHVIURP5RXQGIRUHDFKRIWKHVHIHDWXUHVKDYHEHHQFRPELQHGDQGDUHGLVSOD\HGLQEUDFNHWV

,Q\RXURSLQLRQKRZLPSRUWDQWLVWKHIROORZLQJ&/,1,&$/IHDWXUHWRPDNHWKHGLDJQRVLVRIHURVLYHOLFKHQSODQXVRIWKHYXOYD

5RXQG&OLQLFDOFULWHULD

9HU\LPSRUWDQW ,PSRUWDQW /HVVLPSRUWDQW 1RWLPSRUWDQW 1RWVXUH
:HOOGHPDUFDWHGHURVLRQVRUJOD]HGHU\WKHPDWRXVDUHDVDWWKH
YDJLQDOLQWURLWXV
    

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7KHZRUGLQJIRUWKLVTXHVWLRQKDVEHHQDPHQGHGDQGZHKDYHFRPELQHGWKHFOLQLFDOIHDWXUHVRIDK\SHUNHUDWRWLFZKLWHERUGHU$1'25:LFNKDP
VVWULDHLQVXUURXQGLQJVNLQ
LQWRRQHGLDJQRVWLFFULWHULD7KHVHZHUHDVNHGDVWZRVHSDUDWHTXHVWLRQVLQ5RXQG

6FRUHVIURP5RXQGIRUHDFKRIWKHVHIHDWXUHVKDYHEHHQFRPELQHGDQGDUHGLVSOD\HGLQEUDFNHWV

,Q\RXURSLQLRQKRZLPSRUWDQWLVWKHIROORZLQJ&/,1,&$/IHDWXUHWRPDNHWKHGLDJQRVLVRIHURVLYHOLFKHQSODQXVRIWKHYXOYD

5RXQG&OLQLFDOFULWHULD

9HU\LPSRUWDQW ,PSRUWDQW /HVVLPSRUWDQW 1RWLPSRUWDQW 1RWVXUH
3UHVHQFHRIDK\SHUNHUDWRWLFZKLWHERUGHUWRHU\WKHPDWRXV
DUHDVHURVLRQV:LFNKDP
VVWULDHSUHVHQWLQVXUURXQGLQJVNLQ
    

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7KHZRUGLQJIRUWKLVTXHVWLRQUHPDLQVWKHVDPHDVLQ5RXQG6FRUHVIURP5RXQGDUHGLVSOD\HGLQEUDFNHWV

,Q\RXURSLQLRQKRZLPSRUWDQWLVWKHIROORZLQJ&/,1,&$/IHDWXUHWRPDNHWKHGLDJQRVLVRIHURVLYHOLFKHQSODQXVRIWKHYXOYD

5RXQG&OLQLFDOFULWHULD

9HU\LPSRUWDQW ,PSRUWDQW /HVVLPSRUWDQW 1RWLPSRUWDQW 1RWVXUH
6FDUULQJORVVRIQRUPDODUFKLWHFWXUHHJODELDODGKHVLRQVORVV
RIODELDPLQRUDQDUURZLQJRILQWURLWXVFOLWRUDOEXU\LQJ
    

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7KLVTXHVWLRQKDVEHHQDPHQGHGWREHPRUHVSHFLILF,Q5RXQGLWUHDG


3UHVHQFHRIDQHURVLYHYDJLQLWLV



6FRUHVIURPWKHRULJLQDO5RXQGTXHVWLRQDUHGLVOSD\HGLQEUDFNHWV
,Q\RXURSLQLRQKRZLPSRUWDQWLVWKHIROORZLQJ&/,1,&$/IHDWXUHWRPDNHWKHGLDJQRVLVRIHURVLYHOLFKHQSODQXVRIWKHYXOYD

5RXQG&OLQLFDOFULWHULD

9HU\LPSRUWDQW ,PSRUWDQW /HVVLPSRUWDQW 1RWLPSRUWDQW 1RWVXUH
3UHVHQFHRIYDJLQDOLQIODPPDWLRQYDJLQDOVFDUULQJ     

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7KHZRUGLQJIRUWKLVTXHVWLRQUHPDLQVWKHVDPHDVLQ5RXQG6FRUHVIURP5RXQGDUHGLVSOD\HGLQEUDFNHWV
,Q\RXURSLQLRQKRZLPSRUWDQWLVWKHIROORZLQJ&/,1,&$/IHDWXUHWRPDNHWKHGLDJQRVLVRIHURVLYHOLFKHQSODQXVRIWKHYXOYD

5RXQG&OLQLFDOFULWHULD

9HU\LPSRUWDQW ,PSRUWDQW /HVVLPSRUWDQW 1RWLPSRUWDQW 1RWVXUH
,QYROYHPHQWRIRWKHUPXFRFXWDQHRXVVLWHVHJPRXWK
VNLQVFDOSQDLOVRHVRSKDJXV
    

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7KHIROORZLQJTXHVWLRQVDUHDGGLWLRQDOWR5RXQGEDVHGXSRQSDUWLFLSDQWV
SUHYLRXVFRPPHQWV
,Q\RXURSLQLRQKRZLPSRUWDQWDUHWKHIROORZLQJ&/,1,&$/FULWHULDIRUGLDJQRVLQJHURVLYHOLFKHQSODQXVRIWKHYXOYD"

5RXQG$GGLWLRQDOFOLQLFDOFULWHULD

9HU\LPSRUWDQW ,PSRUWDQW /HVVLPSRUWDQW 1RWLPSRUWDQW 1RWVXUH
)LQGLQJVRQZHWPRXQWSUHSDUDWLRQ     
6\PSWRPVRISDLQEXUQLQJ     

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7KHTXHVWLRQVRQWKHIROORZLQJSDJHVDUHUHJDUGLQJ+,6723$7+2/2*,&$/FULWHULDIRUGLDJQRVLQJHURVLYHOLFKHQSODQXVRIWKHYXOYD1RTXHVWLRQVIURP5RXQGKDYHEHHQ
UHPRYHGIURPWKLVVHFWLRQ


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7KHZRUGLQJIRUWKLVTXHVWLRQUHPDLQVWKHVDPHDVLQ5RXQG6FRUHVIURP5RXQGDUHGLVSOD\HGLQEUDFNHWV


1%,WLVDVVXPHGWKDWELRSV\VSHFLPHQKDVEHHQWDNHQIURPWKH('*(2)$/(6,21IRUWKHGHVFULEHGKLVWRORJLFDOILQGLQJVWREHSUHVHQW
,Q\RXURSLQLRQKRZLPSRUWDQWLVWKHIROORZLQJ+,6723$7+2/2*,&$/IHDWXUHWRPDNHWKHGLDJQRVLVRIHURVLYHOLFKHQSODQXV
RIWKHYXOYD

5RXQG+LVWRSDWKRORJLFDOFULWHULD

9HU\LPSRUWDQW ,PSRUWDQW /HVVLPSRUWDQW 1RWLPSRUWDQW 1RWVXUH
3UHVHQFHRIDZHOOGHILQHGLQIODPPDWRU\EDQGLQWKH
VXSHUILFLDOFRQQHFWLYHWLVVXHWKDWLQYROYHVWKHGHUPRHSLGHUPR
MXQFWLRQ
    

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7KLVTXHVWLRQUHPDLQVWKHVDPHDVLQ5RXQG6FRUHVIURP5RXQGDUHGLVSOD\HGLQEUDFNHWV


1%,WLVDVVXPHGWKDWELRSV\VSHFLPHQKDVEHHQWDNHQIURPWKH('*(2)$/(6,21IRUWKHGHVFULEHGKLVWRORJLFDOILQGLQJVWREHSUHVHQW
,Q\RXURSLQLRQKRZLPSRUWDQWLVWKHIROORZLQJ+,6723$7+2/2*,&$/IHDWXUHWRPDNHWKHGLDJQRVLVRIHURVLYHOLFKHQSODQXV
RIWKHYXOYD

5RXQG+LVWRSDWKRORJLFDOFULWHULD

9HU\LPSRUWDQW ,PSRUWDQW /HVVLPSRUWDQW 1RWLPSRUWDQW 1RWVXUH
3UHVHQFHRIDQLQIODPPDWRU\LQILOWUDWHWKDWFRQVLVWV
35('20,1$17/<RIO\PSKRF\WHV
    

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7KHZRUGLQJIRUWKLVTXHVWLRQKDVEHHQDPHQGHG6SHFLILFIHDWXUHVGHVFULELQJNHUDWLQRF\WHGHVWUXFWLRQKDYHEHHQDGGHGLQWRWKHGHVFULSWLRQ

,Q5RXQGWKHTXHVWLRQUHDG


VLJQVRIEDVDOFHOOGHJHQHUDWLRQ


6FRUHVIURPWKHRULJLQDO5RXQGTXHVWLRQDUHGLVSOD\HGLQEUDFNHWV

1%,WLVDVVXPHGWKDWELRSV\VSHFLPHQKDVEHHQWDNHQIURPWKH('*(2)$/(6,21IRUWKHGHVFULEHGKLVWRORJLFDOILQGLQJVWREHSUHVHQW
,Q\RXURSLQLRQKRZLPSRUWDQWLVWKHIROORZLQJ+,6723$7+2/2*,&$/IHDWXUHWRPDNHWKHGLDJQRVLVRIHURVLYHOLFKHQSODQXV
RIWKHYXOYD

5RXQG+LVWRSDWKRORJLFDOFULWHULD

9HU\LPSRUWDQW ,PSRUWDQW /HVVLPSRUWDQW 1RWLPSRUWDQW 1RWVXUH
6LJQVRIEDVDOFHOOOD\HUGHJHQHUDWLRQHJWKHSUHVHQFHRI
&LYDWWHERGLHVDEQRUPDONHUDWLQRF\WHVRUEDVDODSRSWRVLV
    

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7KHIROORZLQJTXHVWLRQVDUHDGGLWLRQDOWR5RXQGEDVHGXSRQSDUWLFLSDQWV
SUHYLRXVFRPPHQWV1%,WLVDVVXPHGWKDWELRSV\VSHFLPHQKDVEHHQWDNHQIURPWKHHGJHRID
OHVLRQIRUWKHGHVFULEHGKLVWRORJLFDOILQGLQJVWREHSUHVHQW
,Q\RXURSLQLRQKRZLPSRUWDQWDUHWKHIROORZLQJ+,6723$7+2/2*,&$/FULWHULDIRUGLDJQRVLQJHURVLYHOLFKHQSODQXVRIWKH
YXOYD"
,Q\RXURSLQLRQ

5RXQG$GGLWLRQDOKLVWRSDWKRORJLFDOFULWHULD

9HU\LPSRUWDQW ,PSRUWDQW /HVVLPSRUWDQW 1RWLPSRUWDQW 1RWVXUH
(SLGHUPDOFKDQJHVHJZHGJHVKDSHGK\SHUJUDQXORVLVVDZWRRWKHGDFDQWKRVLV     
$EVHQFHRIGHUPDOK\DOLQDVDWLRQ     

9HU\LPSRUWDQW ,PSRUWDQW /HVVLPSRUWDQW 1RWLPSRUWDQW 1RWVXUH
+RZLPSRUWDQWDUH',5(&7,00812)/825(6&(1&(ILQGLQJVLQGLDJQRVLQJ
HURVLYHOLFKHQSODQXVRIWKHYXOYD"
    

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7KLVLVDQDGGLWLRQDOTXHVWLRQEDVHGXSRQFRPPHQWVIURP5RXQG
:KDWLVWKHEHVWQRPHQFODWXUHIRUWKHILQGLQJRISDLQIXOHURVLRQVJOD]HGHU\WKHPDWRXVOHVLRQVDWWKHYDJLQDOLQWURLWXV
YDJLQDOLQYROYHPHQW

5RXQG7HUPLQRORJ\


9XOYDOHURVLYHOLFKHQSODQXV
9XOYRYDJLQDOHURVLYHOLFKHQSODQXV
9XOYRYDJLQDOOLFKHQSODQXV
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3OHDVHLQGLFDWH\RXUVSHFLDOW\RISUDFWLFH
3OHDVHLQGLFDWH\RXUFOLQLFDOJUDGH
+RZORQJKDYH\RXKHOGDVSHFLDOLVWLQWHUHVWLQYXOYDOVNLQGLVRUGHUV"

5RXQG'HPRJUDSKLFLQIRUPDWLRQ



'HUPDWRORJ\
+LVWRSDWKRORJ\'HUPDWRSDWKRORJ\
*HQLWRXULQDU\PHGLFLQH9HQHURORJ\6H[XDOPHGLFLQH
*\QHFRORJ\2*
$VVRFLDWH6SHFLDOLVW
&RQVXOWDQW
1XUVHVSHFLDOLVW
3URIHVVRU$VVRFLDWH3URIHVVRU
5HVLGHQW6SHFLDOLVWUHJLVWUDU
2WKHU3OHDVHVSHFLI\


/HVVWKDQ\HDUV
\HDUV
\HDUV
\HDUV
0RUHWKDQ\HDUV
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3OHDVHLQGLFDWH\RXUFRXQWU\RISUDFWLFH

3OHDVHLQGLFDWH\RXUQDPHWKLVLVIRUDGPLQLVWUDWLYHSXUSRVHVDQGZLOOEHGHOHWHGRQFHDQDO\VLVLVFRPSOHWH




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7KDQN\RXIRUWDNLQJWKHWLPHWRVXEPLW\RXUDQVZHUV:HZLOOEHLQFRQWDFWZLWKWKHUHVXOWVRI5RXQGVKRUWO\7KLVUHVHDUFKLVEHLQJUXQIURPWKH&HQWUHRI(YLGHQFH%DVHG
'HUPDWRORJ\DWWKH8QLYHUVLW\RI1RWWLQJKDP

,I\RXKDYHDQ\TXHULHVSOHDVHFRQWDFW

URVDOLQGVLPSVRQ#QRWWLQJKDPDFXN
3OHDVHOHDYHDQ\DGGLWLRQDOFRPPHQWVKHUH


7KDQN\RX


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'HDU3DUWLFLSDQW


7KDQN\RXIRUUHWXUQLQJWRWKLVVXUYH\IRU5RXQG


,QWKLVVWDJHZHZRXOGOLNHWRQDUURZGRZQWKHLWHPVWKDWUHDFKHGDJUHHPHQWLQWKHSUHYLRXVURXQGVLQWRµHVVHQWLDO¶DQGµVXSSRUWLYH
GLDJQRVWLFFULWHULD:HDOVRZDQWWR
HVWDEOLVK+2:0$1<
VXSSRUWLYH
FULWHULDVKRXOGDFFRPSDQ\
HVVHQWLDO
FULWHULDLQDILQDOGLDJQRVWLFGDWDVHW



(VVHQWLDO
PHDQVWKDWDGLDJQRVWLFIHDWXUH0867EHSUHVHQWWRPDNHWKHGLDJQRVLV


6XSSRUWLYH
PHDQVWKDWWKHIHDWXUHGRHVQRWKDYHWREHSUHVHQWEXWDGGVZHLJKWWRRWKHUGLDJQRVWLFIHDWXUHVWKDWDUHSUHVHQW


$VPDOOQXPEHURIVWDWHPHQWVKDYHEHHQUHYLVHG:KHUHWKLVKDVKDSSHQHGZHKDYHLQGLFDWHGWKHSUHYLRXVZRUGLQJDQGKLJKOLJKWHGDQ\FKDQJHV


7RWU\DQGUHDFKFRQVHQVXVLQWKLVURXQGWKHUHVSRQVHRSWLRQVKDYHEHHQVHWDWµHVVHQWLDOVXSSRUWLYHQHLWKHU
RU
DJUHHGLVDJUHH
<RXZLOOKDYHWKHRSWLRQWRFRPPHQWDIWHU
HDFKLWHP


,WHPVWKDWGLGQRWUHDFKFRQVHQVXVLQ5RXQGKDYHEHHQH[FOXGHGIURP5RXQG<RXZLOOKDYHWKHRSSRUWXQLW\WRYLHZDQGFRPPHQWXSRQH[FOXGHGLWHPVLI\RXZLVK

:HKRSHWKDW\RXUDQVZHUVIURPWKLVURXQGZLOOIRUPDGHILQLWLYHGLDJQRVWLFGDWDVHWWKDWFDQEHXWLOLVHGLQFOLQLFDOSUDFWLFH

7KDQN\RXIRU\RXUFRQWLQXHGLQSXWLQWRWKLVSURMHFW


5RVDOLQG6LPSVRQ
5XWK0XUSK\

5RXQG,QWURGXFWLRQ

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,Q5RXQGZHDVNHGZKHWKHUSDUWLFLSDQWVWRFRPPHQWXSRQWKHQRPHQFODWXUHWKDWVKRXOGEHXVHGIRUWKHFRQGLWLRQ7KHRSWLRQVWKDWZHUHJLYHQZHUH


9XOYDOHURVLYHOLFKHQSODQXV

9XOYRYDJLQDOHURVLYHOLFKHQSODQXV

9XOYRYDJLQDOOLFKHQSODQXV


&RQVHQVXVZDVQRWUHDFKHGDQGPDQ\FRPPHQWHGWKDWWKHQRPHQFODWXUHGHSHQGVXSRQWKHLQGLYLGXDOFOLQLFDOFRQWH[W



)RUWKHSXUSRVHVRIWKLVH[HUFLVHZHZLOOFRQWLQXHWRXVHWKHWHUP
(526,9(/,&+(13/$1862)7+(98/9$
(/39DOWKRXJKZHDSSUHFLDWHWKDWQRWDOOSDWLHQWVZLOOKDYH
WUXHHURVLRQVDQGVRPHPD\KDYHLQYROYHPHQWPRUHH[WHQVLYHWKDQMXVWWKHYXOYD


,QSUDFWLFHLWVHHPVWKDWSK\VLFLDQVZLOOXVHWKHGLDJQRVWLFWHUP
HURVLYHOLFKHQSODQXVRIWKH>@
VXIIL[HGE\WKHVLWHVDIIHFWHGHJ(URVLYHOLFKHQSODQXVRIWKHYXOYDDQG
YDJLQD(URVLYHOLFKHQSODQXVRIWKHYXOYDDQGJLQJLYDHWF


7KHGLDJQRVWLFFULWHULDDJUHHGLQWKLVH[HUFLVHZLOOLGHQWLI\SDWLHQWVZLWKYXOYRYDJLQDOLQYROYHPHQWEXWVXEVHWVLQYROYLQJRWKHUPXFRVDOVXUIDFHVZLOOUHO\RQIXUWKHUFOLQLFDO
HYDOXDWLRQRIVLJQVDQGV\PSWRPVHJRUDORHVRSKDJHDOFHUYLFDODQGFRQMXQFWLYDOLQYROYHPHQW
3OHDVHDGGDQ\FRPPHQWVUHJDUGLQJQRPHQFODWXUHRIWKHFRQGLWLRQ


5RXQG7HUPLQRORJ\



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7KHTXHVWLRQVRQWKHIROORZLQJSDJHVDUHUHJDUGLQJ&/,1,&$/GLDJQRVWLFFULWHULD3OHDVHVWDWHZKHWKHU\RXEHOLHYHWKHGLDJQRVWLFLWHPVDUH
HVVHQWLDO
RU
VXSSRUWLYH
WRPDNH
WKHGLDJQRVLV

5HPHPEHU


(66(17,$/
PHDQVWKDWDGLDJQRVWLFIHDWXUH0867EHSUHVHQWWRPDNHWKHGLDJQRVLV


6833257,9(
PHDQVWKDWWKHIHDWXUHGRHVQRWKDYHWREHSUHVHQWEXWDGGVZHLJKWWRRWKHUGLDJQRVWLFIHDWXUHVWKDWDUHSUHVHQW



7KHZRUGLQJRIWKHVHTXHVWLRQVKDYHQRWFKDQJHGIURP5RXQG
+RZGR\RXUDWHWKHIROORZLQJIHDWXUHLQPDNLQJWKHGLDJQRVLVRI(/39"
+RZGR\RXUDWHWKHIROORZLQJIHDWXUHLQPDNLQJWKHGLDJQRVLVRI(/39"

5RXQG&OLQLFDOFULWHULD

(VVHQWLDO 6XSSRUWLYH 1HLWKHU
:HOOGHPDUFDWHGHURVLRQVRUJOD]HGHU\WKHPDWRXVDUHDVDWWKHYDJLQDOLQWURLWXV   

(VVHQWLDO 6XSSRUWLYH 1HLWKHU
3UHVHQFHRIDK\SHUNHUDWRWLFZKLWHERUGHUWRHU\WKHPDWRXVDUHDVHURVLRQV:LFNKDP
VVWULDHLQVXUURXQGLQJVNLQ   
&RPPHQWV


&RPPHQWV


2WKHU
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+RZGR\RXUDWHWKHIROORZLQJIHDWXUHLQPDNLQJWKHGLDJQRVLVRI(/39"
(VVHQWLDO 6XSSRUWLYH 1HLWKHU
6\PSWRPVRISDLQEXUQLQJ   

&RPPHQWV


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7KLVTXHVWLRQKDVEHHQUHSKUDVHGIURP5RXQG


,Q5RXQGWKHVWDWHPHQWUHDG


6FDUULQJORVVRIQRUPDODUFKLWHFWXUHHJODELDODGKHVLRQVORVVRIODELDPLQRUDQDUURZLQJRILQWURLWXVFOLWRUDOEXU\LQJ



9DJLQDOVFDUULQJKDVEHHQDGGHGWRWKLVVWDWHPHQW


3OHDVHVWDWHZKHWKHU\RXEHOLHYHWKHGLDJQRVWLFLWHPVDUH
HVVHQWLDO
RU
VXSSRUWLYH
WRPDNHWKHGLDJQRVLV
+RZGR\RXUDWHWKHIROORZLQJIHDWXUHLQPDNLQJWKHGLDJQRVLVRI(/39"

5RXQG$PHQGHGFOLQLFDOFULWHULD

(VVHQWLDO 6XSSRUWLYH 1HLWKHU
6FDUULQJORVVRIQRUPDODUFKLWHFWXUHHJODELDODGKHVLRQVORVVRIODELDPLQRUDQDUURZLQJRILQWURLWXVFOLWRUDOEXU\LQJYDJLQDOVFDUULQJ   

&RPPHQWV


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7KLVTXHVWLRQKDVEHHQUHSKUDVHGIURP5RXQGIRUFODULW\


,Q5RXQGWKHVWDWHPHQWUHDG


3UHVHQFHRIYDJLQDOLQIODPPDWLRQYDJLQDOVFDUULQJ



9DJLQDOVFDUULQJKDVEHHQLQFOXGHGLQ4XHVWLRQZKHUHVFDUULQJRIRWKHUDQDWRPLFDOVLWHVLVDOVRFRQVLGHUHG7KLVTXHVWLRQQRZUHODWHVWRLQIODPPDWRU\SURFHVVHVDIIHFWLQJ
WKHYDJLQDDVVFDUULQJLVFRQVLGHUHGHOVHZKHUH


3OHDVHVWDWHZKHWKHU\RXEHOLHYHWKHGLDJQRVWLFLWHPVDUH
HVVHQWLDO
RU
VXSSRUWLYH
WRPDNHWKHGLDJQRVLV
+RZGR\RXUDWHWKHIROORZLQJIHDWXUHLQPDNLQJWKHGLDJQRVLVRI(/39"

5RXQG$PHQGHGFOLQLFDOFULWHULD

(VVHQWLDO 6XSSRUWLYH 1HLWKHU
3UHVHQFHRIYDJLQDOLQIODPPDWLRQLQFOXGLQJGHVTXDPLWLYHLQIODPPDWRU\YDJLQLWLV',9   

&RPPHQWV


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7KLVTXHVWLRQKDVEHHQUHSKUDVHGIURP5RXQGIRUFODULW\


,Q5RXQGWKHVWDWHPHQWUHDG


,QYROYHPHQWRIRWKHUPXFRFXWDQHRXVVLWHVHJ6NLQVFDOSQDLOVPRXWKRHVRSKDJXV



$VWKHVNLQPD\EHDIIHFWHGE\OLFKHQVFOHURVXVLWLVQRWDGLVFULPLQDWLQJIDFWRUIRUOLFKHQSODQXV7KHUHIRUHWKLVKDVEHHQUHPRYHGIURPWKLVTXHVWLRQ


3OHDVHVWDWHZKHWKHU\RXEHOLHYHWKHGLDJQRVWLFLWHPVDUH
HVVHQWLDO
RU
VXSSRUWLYH
WRPDNHWKHGLDJQRVLV
+RZGR\RXUDWHWKHIROORZLQJIHDWXUHLQPDNLQJWKHGLDJQRVLVRI(/39"

5RXQG$PHQGHGFOLQLFDOFULWHULD

(VVHQWLDO 6XSSRUWLYH 1HLWKHU
,QYROYHPHQWRIRWKHUPXFRVDOVXUIDFHVHJ0RXWKRHVRSKDJXVFRQMXQFWLYDFHUYL[DQXVODU\Q[   

&RPPHQWV


Page 8
ELPV - Round 3
7KHTXHVWLRQVRQWKHIROORZLQJSDJHVDUHUHJDUGLQJ+,6723$7+2/2*,&$/FULWHULDIRUGLDJQRVLQJHURVLYHOLFKHQSODQXVRIWKHYXOYD


3OHDVHVWDWHZKHWKHU\RXEHOLHYHWKHIROORZLQJ+,6723$7+2/2*,&$/LWHPVDUH
HVVHQWLDO
RU
VXSSRUWLYH
WRPDNHWKHGLDJQRVLV


5HPHPEHU


(66(17,$/
PHDQVWKDWDGLDJQRVWLFIHDWXUH0867EHSUHVHQWWRPDNHWKHGLDJQRVLV


6833257,9(
PHDQVWKDWWKHIHDWXUHGRHVQRWKDYHWREHSUHVHQWEXWDGGVZHLJKWWRRWKHUGLDJQRVWLFIHDWXUHVWKDWDUHSUHVHQW


7KHZRUGLQJRIWKHVHTXHVWLRQVKDYHQRWFKDQJHGIURP5RXQG


1%,WLVDVVXPHGWKDWELRSV\VSHFLPHQKDVEHHQWDNHQIURPWKH('*(2)$/(6,21IRUWKHGHVFULEHGKLVWRORJLFDOILQGLQJVWREHSUHVHQW
+RZGR\RXUDWHWKHIROORZLQJIHDWXUHLQPDNLQJWKHGLDJQRVLVRI(/39"
+RZGR\RXUDWHWKHIROORZLQJ+,6723$7+2/2*,&$/IHDWXUHLQPDNLQJWKHGLDJQRVLVRI(/39"

5RXQG+LVWRSDWKRORJLFDOFULWHULD

(VVHQWLDO 6XSSRUWLYH 1HLWKHU
3UHVHQFHRIDZHOOGHILQHGLQIODPPDWRU\EDQGLQWKHVXSHUILFLDOFRQQHFWLYHWLVVXHWKDWLQYROYHVWKHGHUPRHSLGHUPRMXQFWLRQ   

(VVHQWLDO 6XSSRUWLYH 1HLWKHU
3UHVHQFHRIDQLQIODPPDWRU\EDQGWKDWFRQVLVWV35('20,1$17/<RIO\PSKRF\WHV   
&RPPHQWV


&RPPHQWV


Page 9
ELPV - Round 3
+RZGR\RXUDWHWKHIROORZLQJ+,6723$7+2/2*,&$/IHDWXUHLQPDNLQJWKHGLDJQRVLVRI(/39"
+RZGR\RXUDWHWKHIROORZLQJ+,6723$7+2/2*,&$/IHDWXUHLQPDNLQJWKHGLDJQRVLVRI(/39"

(VVHQWLDO 6XSSRUWLYH 1HLWKHU
6LJQVRIEDVDOFHOOOD\HUGHJHQHUDWLRQHJWKHSUHVHQFHRI&LYDWWHERGLHVDEQRUPDONHUDWLQRF\WHVRUEDVDODSRSWRVLV   
(VVHQWLDO 6XSSRUWLYH 1HLWKHU
$EVHQFHRIGHUPDOK\DOLQDVDWLRQ   

&RPPHQWV


&RPPHQWV


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7KHIROORZLQJTXHVWLRQVDLPWRHVWDEOLVKRSLQLRQRIZKHWKHUELRSV\LVPDQGDWRU\WRPDNHDGLDJQRVLVRI(/397KHVHTXHVWLRQVKDYHEHHQDGGHGVLQFH5RXQG
7KLVTXHVWLRQKDVEHHQDGGHGVLQFH5RXQG

5RXQG&OLQLFRSDWKRORJLFDOFRUUHODWLRQ

$JUHH 'LVDJUHH 1HLWKHU
$GLDJQRVLVRIHURVLYHOLFKHQSODQXVDIIHFWLQJWKHYXOYDVKRXOGVDWLVI\%27+FOLQLFDO$1'KLVWRSDWKRORJLFDOFULWHULD   
$ELRSV\RIVXVSHFWHG(/39LV$/:$<6UHTXLUHGZKHQWKHUHLVGLDJQRVWLFXQFHUWDLQW\RUFRQFHUQRIQHRSODVWLFFKDQJH   
$ELRSV\VKRXOG$/:$<6EHWDNHQEHIRUHVWDUWLQJV\VWHPLFWKHUDS\   

3OHDVHFRPPHQWRQDQ\RIWKHDERYHVWDWHPHQWVLI\RXZLVK


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6HYHUDOLWHPVIURP5RXQGGLG127UHDFKFRQVHQVXV7KHVHLWHPVKDYHEHHQH[FOXGHGIURPVFRULQJLQ5RXQG<RXKDYHWKHRSWLRQWRUHYLHZDQGFRPPHQWRQWKHVHLWHPV
LI\RXZLVK
2SWLRQV

5RXQG([FOXGHGLWHPV


,ZRXOGOLNHWRFRQWLQXHWRVHHWKHVWDWHPHQWVWKDWKDYHEHHQH[FOXGHG
,ZRXOGOLNHWRVNLSWKHVHVWDWHPHQWV
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7KHIROORZLQJLWHPVKDYHEHHQH[FOXGHGDVWKH\GLGQRWUHDFKFRQVHQVXVLQ5RXQG

)LQGLQJVRQZHWPRXQWSUHSDUDWLRQ


(SLGHUPDOFKDQJHVHJZHGJHVKDSHGK\SHUJUDQXORVLVVDZWRRWKHGDFDQWKRVLV


)LQGLQJVRQGLUHFWLPPXQRIOXRUHVFHQFH
3OHDVHDGGDQ\FRPPHQWVRQWKHH[FOXVLRQRIWKHVHLWHPV


5RXQG([FOXGHGLWHPV



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7KURXJKRXWWKLVVXUYH\\RXKDYHEHHQDVNHGWRUDWHFOLQLFDODQGKLVWRSDWKRORJLFDOIHDWXUHVDV
(66(17,$/
RU
6833257,9(



(VVHQWLDO
IHDWXUHV0867EHSUHVHQWWRPDNHWKHGLDJQRVLVZKHUHDV
VXSSRUWLYH
IHDWXUHVDGGZHLJKWWRDGLDJQRVLVEXWGRQRWQHFHVVDULO\KDYHWREHSUHVHQW


:HZDQW\RXWRWKLQNDERXW+2:0$1<RIWKHHVVHQWLDODQGVXSSRUWLYHIHDWXUHV\RXKDYHVHOHFWHGQHHGWREHSUHVHQWWRPDNHDGLDJQRVLVRI(/397KHFRPELQDWLRQRI
IHDWXUHVFDQLQFOXGH%27+FOLQLFDODQGKLVWRORJLFDOGRPDLQV3DUWLFLSDQWV
DQVZHUVIURPWKLVVHFWLRQZLOOEHXVHGWRZDUGVDGHILQLWLYHGLDJQRVWLFGDWDVHW


)RUH[DPSOHWRPDNHDGLDJQRVLVRIV\VWHPLFOXSXVHU\WKHPDWRVXVWKH$PHULFDQ5KHXPDWRORJ\$VVRFLDWLRQUHTXLUHDWOHDVWRXWRIVXSSRUWLYHFULWHULDWREHSUHVHQW
HDFKRIZKLFKDUHHTXDOO\ZHLJKWHG


:HZLOODVN\RXWRFRPPHQWXSRQKRZPDQ\
VXSSRUWLYH
IHDWXUHVPXVWEHSUHVHQWLQDGGLWLRQWRWKH
HVVHQWLDO
IHDWXUHVWKDW\RXLGHQWLILHGWRPDNHWKHGLDJQRVLVRI(/39,I
\RXKDYHQRWLGHQWLILHGDQ\
HVVHQWLDO
FULWHULDZHZLOODVNKRZPDQ\
VXSSRUWLYH
QHHGWREHSUHVHQW


1%<RXFDQDFFHVV\RXUSUHYLRXVDQVZHUVE\VHOHFWLQJ
SUHYLRXV
DWWKHERWWRPRIWKHSDJH1RGDWDZLOOEHORVWE\GRLQJWKLV

5RXQG)LQDOGLDJQRVWLFGDWDVHW

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7RPDNHWKHGLDJQRVLVRI(/39
7RPDNHWKHGLDJQRVLVRI(/39
,IQR
HVVHQWLDO
IHDWXUHVDUHSUHVHQWRU\RXKDYHQRWLGHQWLILHGDQ\
HVVHQWLDO
FULWHULDIURP\RXUSUHYLRXVDQVZHUV


$JUHH 'LVDJUHH
$//RI\RXULGHQWLILHG(66(17,$/FULWHULDVKRXOGEHPHW  

1RDGGLWLRQDO
VXSSRUWLYH
IHDWXUHVUHTXLUHG
2QHVXSSRUWLYH
IHDWXUH
7ZRVXSSRUWLYH
IHDWXUHV
7KUHHVXSSRUWLYH
IHDWXUHV
)RXUVXSSRUWLYH
IHDWXUHV
)LYHVXSSRUWLYH
IHDWXUHV
6L[VXSSRUWLYH
IHDWXUHV
,QDGGLWLRQWRWKH(66(17,$/FULWHULDZKDWLVWKH0,1,080QXPEHURI6833257,9(
FULWHULDWKDWVKRXOGEHSUHVHQW"1%7KHFULWHULDFDQLQFOXGHFOLQLFDODQGRUKLVWRORJLFDO
GRPDLQV
      

1RWDSSOLFDEOH
P\VHOHFWHG
HVVHQWLDOFULWHULD
PXVWEHSUHVHQW
2QHVXSSRUWLYH
IHDWXUH
7ZRVXSSRUWLYH
IHDWXUHV
7KUHHVXSSRUWLYH
IHDWXUHV
)RXUVXSSRUWLYH
IHDWXUHV
)LYHVXSSRUWLYH
IHDWXUHV
6L[VXSSRUWLYH
IHDWXUHV
:KDWLVWKH0,1,080QXPEHURI6833257,9(FULWHULDWKDWVKRXOGEHSUHVHQWWR
GLVJQRVH(/39"1%7KHFULWHULDFDQLQFOXGHFOLQLFDODQGRUKLVWRORJLFDOGRPDLQV$OO
VXSSRUWLYHFULWHULDDUHHTXDOO\ZHLJKWHG
      

,I\RX',6$*5((SOHDVHOHDYHDFRPPHQW
2WKHUSOHDVHVSHFLI\
2WKHUSOHDVHVSHFLI\
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2QFH5RXQGKDVEHHQDQDO\VHGZHZLOONQRZH[DFWO\ZKLFKGLDJQRVWLFFULWHULDKDYHUHDFKHGFRQVHQVXVIRU
HVVHQWLDO
DQG
VXSSRUWLYH
FULWHULD:HZLOODOVRNQRZZKDW
FRPELQDWLRQRI
HVVHQWLDO
DQG
VXSSRUWLYH
FULWHULDSDUWLFLSDQWVIHHODUHQHFHVVDU\WRGLDJQRVH(/39

:RXOG\RXOLNHWRVHHDQGKDYHWKHRSSRUWXQLW\WRFRPPHQWXSRQWKHILQDOGLDJQRVWLFGDWDVHW",I\RXDQVZHU
\HV
WKHQZHZLOOHPDLO\RXZLWKWKHUHVXOWVLQGXHFRXUVH
:RXOG\RXOLNHWRVHHDQGFRPPHQWXSRQWKHILQDOGLDJQRVWLFGDWDVHW"

5RXQGRSLQLRQRQIXUWKHUURXQGV


<HV
1R
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3OHDVHLQGLFDWH\RXUVSHFLDOW\RISUDFWLFH
3OHDVHLQGLFDWH\RXUFOLQLFDOJUDGH
+RZORQJKDYH\RXKHOGDVSHFLDOLVWLQWHUHVWLQYXOYDOVNLQGLVRUGHUV"

5RXQG'HPRJUDSKLFLQIRUPDWLRQ



'HUPDWRORJ\
+LVWRSDWKRORJ\'HUPDWRSDWKRORJ\
*HQLWRXULQDU\PHGLFLQH9HQHURORJ\6H[XDOPHGLFLQH
*\QHFRORJ\2*
$VVRFLDWH6SHFLDOLVW
&RQVXOWDQW
1XUVHVSHFLDOLVW
3URIHVVRU$VVRFLDWH3URIHVVRU
5HVLGHQW6SHFLDOLVWUHJLVWUDU
2WKHU3OHDVHVSHFLI\


/HVVWKDQ\HDUV
\HDUV
\HDUV
\HDUV
0RUHWKDQ\HDUV
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3OHDVHLQGLFDWH\RXUFRXQWU\RISUDFWLFH

3OHDVHLQGLFDWH\RXUQDPHWKLVLVIRUDGPLQLVWUDWLYHSXUSRVHV




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:HZRXOGOLNHWRDFNQRZOHGJHDOOSDUWLFLSDQWVFRPSOHWLQJ5RXQGLQDQ\VXEVHTXHQWSXEOLFDWLRQRUSUHVHQWDWLRQ:HZLOORQO\GRWKLVZLWK\RXUFRQVHQWDQGZLOO127OLQN\RXU
QDPHWRDQ\VSHFLILFFRPPHQWVRUDQVZHUV

$FNQRZOHGJHPHQW

)XWXUHDFNQRZOHGJHPHQWV


,FRQVHQWWRDFNQRZOHGJHPHQWLQDQ\IXWXUHSUHVHQWDWLRQRUSXEOLFDWLRQ
,ZLVKWRUHPDLQDQRQ\PRXVDQGGR127FRQVHQWWRDFNQRZOHGJHPHQWLQDQ\IXWXUHSXEOLFDWLRQRUSUHVHQWDWLRQ
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7KQN\RXIRUWDNLQJWKHWLPHWRVXEPLW\RXUDQVZHUV

7KLVVWXG\KDVEHHQFRRUGLQDWHGIURPWKH&HQWUHRI(YLGHQFH%DVHG'HUPDWRORJ\DWWKH8QLYHUVLW\RI1RWWLQJKDPDVSDUWRID'RFWRUDWH5HVHDUFK)HOORZVKLS

,I\RXKDYHDQ\TXHULHVSOHDVHFRQWDFW

URVDOLQGVLPSVRQ#QRWWLQJKDPDFXN

7KDQN\RX
Appendix 7
Electronic Delphi Consensus Exercise Feedback Questionnaire
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'HDU3DUWLFLSDQW

7KHSXUSRVHRIWKLVVKRUWVXUYH\LVIRU\RXWRUHYLHZDQGKDYH\RXUVD\LQWRWKHILQDOGLDJQRVWLFGDWDVHWIRUHURVLYHOLFKHQSODQXVDIIHFWLQJWKHYXOYD(/397KHQLQHLWHPVWKDW
PDNHXSWKHGDWDVHWKDYHEHHQVHOHFWHGIROORZLQJFRQVHQVXVIURPSDUWLFLSDQWVRYHUWKUHHURXQGV

7KLVVXUYH\KDVEHHQVHQWWR\RXDV\RXH[SUHVVHGDQLQWHUHVWWRVHHWKHILQDOUHVXOWV<RXUFRPPHQWVDUHUHDOO\LPSRUWDQWLQWKHILQDOLQWHUSUHWDWLRQRIWKHILQGLQJV

:HDUHSDUWLFXODUO\LQWHUHVWHGWRNQRZKRZPDQ\RIWKHQLQHLWHPV\RXWKLQNVKRXOGEHSUHVHQWWRGLDJQRVH(/39

0DQ\WKDQNVIRU\RXURSLQLRQ

5RVDOLQG6LPSVRQ
5XWK0XUSK\

)HHGEDFNVXUYH\,QWURGXFWLRQ

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7KHIROORZLQJOLVWRIQLQHLWHPVKDYHEHHQDJUHHGE\FRQVHQVXVDV
VXSSRUWLYH
IHDWXUHVWRGLDJQRVHHURVLYHOLFKHQSODQXVDIIHFWLQJWKHYXOYD,WHPVLYLUHSUHVHQWFOLQLFDOFULWHULD
DQGYLLL[UHSUHVHQWKLVWRSDWKRORJLFDOFULWHULD

L3UHVHQFHRIZHOOGHPDUFDWHGHURVLRQVHU\WKHPDWRXVDUHDVDWWKHYDJLQDOLQWURLWXV

LL3UHVHQFHRIVFDUULQJORVVRIQRUPDODUFKLWHFWXUH

LLL3UHVHQFHRIDK\SHUNHUDWRWLFERUGHUWRHU\WKHPDWRXVDUHDVHURVLRQV:LFNKDP¶VVWULDHLQVXUURXQGLQJVNLQ

LY,QYROYHPHQWRIRWKHUPXFRVDOVXUIDFHV

Y6\PSWRPVRISDLQEXUQLQJ

YL3UHVHQFHRIYDJLQDOLQIODPPDWLRQLQFOXGLQJGHVTXDPDWLYHLQIODPPDWRU\YDJLQLWLVOLNHFKDQJHV

YLL3UHVHQFHRIDZHOOGHILQHGLQIODPPDWRU\EDQGLQYROYLQJWKHGHUPRHSLGHUPRMXQFWLRQ

YLLL,QIODPPDWRU\LQILOWUDWHFRQVLVWVSUHGRPLQDQWO\RIO\PSKRF\WHV

L[6LJQVRIEDVDOOD\HUGHJHQHUDWLRQ
'R\RXDJUHHZLWKWKLVILQDOGLDJQRVWLFGDWDVHW"

)HHGEDFNVXUYH\)LQDOGLDJQRVWLFGDWDVHW
<HV
1R
3OHDVHOHDYHDQ\FRPPHQWVKHUH
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+RZPDQ\RIWKHVXSSRUWLYHIHDWXUHVOLVWHGDERYHVKRXOGEHSUHVHQWWRGLDJQRVHHURVLYHOLFKHQSODQXVDIIHFWLQJWKHYXOYD"
:KHQ\RXDQVZHUWKLVTXHVWLRQSOHDVHEHDULQPLQGRWKHUFRQGLWLRQVWKDWPD\FDXVHGLDJQRVWLFGLIILFXOW\WKHQXPEHURIFULWHULD
\RXFKRVHVKRXOGEHVXIILFLHQWWRH[FOXGHWKHVHDOWHUQDWLYHGLDJQRVHV
:KLFKRWKHUFRQGLWLRQVPD\IXOILOVRPHRIWKHVHFULWHULDDQGWKHUHIRUHFDXVHGLDJQRVWLFGLIILFXOW\"




2QHRUPRUH
7ZRRUPRUH
7KUHHRUPRUH
)RXURUPRUH
)LYHRUPRUH
6L[RUPRUH
6HYHQRUPRUH
(LJKWRUPRUH
1LQH
3OHDVHOHDYHDQ\DGGLWLRQDOFRPPHQWV
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7KDQN\RXIRUWDNLQJWKHWLPHWRVXEPLW\RXUDQVZHUV

7KLVVWXG\KDVEHHQFRRUGLQDWHGIURPWKH&HQWUHRI(YLGHQFH%DVHG'HUPDWRORJ\DWWKH8QLYHUVLW\RI1RWWLQJKDPDVSDUWRID'RFWRUDWH5HVHDUFK)HOORZVKLS

,I\RXKDYHDQ\TXHULHVSOHDVHFRQWDFW

URVDOLQGVLPSVRQ#QRWWLQJKDPDFXN

7KDQN\RX
Appendix 8
Medline Search Strategy for Systematic Review of Outcome Measures
for Vulval Skin Conditions
Appendix 8 
Medline Search  Strategy Systematic Review 
Medline RCT vulval disease search 18/7/12 
1. (vulval or vulvar or vulvo$).ti,ab. 
2. exp *Vulvitis/ 
3. exp Paget Disease, Extramammary/ or exp *Vulvar Neoplasms/ 
4. exp Vulvodynia/ 
5. exp Vulvar Vestibulitis/ 
6. or/1-5 
7. randomized controlled trial.pt. 
8. controlled clinical trial.pt. 
9. randomized.ab. 
10. placebo.ab. 
11. clinical trials as topic.sh. 
12. randomly.ab. 
13. trial.ti. 
14. 7 or 8 or 9 or 10 or 11 or 12 or 13 
15. (animals not (humans and animals)).sh. 
16. 14 not 15 
17. 6 and 16 
18. remove duplicates from 17 
 


Appendix 9
Focus Group Session 1 Prompt Sheet
   
ELPV FG Prompts Final version 1.0 19/11/2012 
To be printed on local headed notepaper
                               
 
Erosive Lichen Planus Focus Groups: 
Proposed Dialogue and Prompts 
 
The following dialogue and prompts are planned for use in the focus groups sessions. These have 
been kept relatively broad to begin with, to encourage free discussion, then will become more 
focussed upon specific topics where we require patient input.  
 
Focus Group Session 1 
Living with ELPV (Carron) 
฀ For the first 10-15 minutes I want you to talk openly ĂďŽƵƚ ǁŚĂƚ ŝƚ ?Ɛlike to live with 
erosive lichen planus. In particular, I would like to know how the condition impacts upon 
your life.  At the end of the discussion I will attempt to draw up a list of aspects which 
bother you the most and impact the greatest on your life. RS may interject with methods 
of measuring these outcomes 
 
If needed: 
o Which symptoms of ELPV bother you the most? Looking for 
pain/discomfort/soreness, appearance, scarring. May mention mouth symptoms, 
difficulty in daily activities (see below) 
o How does it affect your day to day life e.g. walking, sitting, going to the toilet, 
work, social life, sport and intimate relationships? Does it stop people doing these 
or does do they carry on despite being uncomfortable? 
o Does it affect you psychologically i.e. feeling low or depressed? 
o How do you find using the treatments e.g. easy or difficult to apply, time 
consuming, comfortable/uncomfortable? Some will be on tablets, others using 
creams. May want a show of hands and get people to talk about their different 
experiences 
o What one thing would you improve about living with erosive lichen planus or its 
treatment? i.e. what should we be asking you about in clinic to judge how well you 
are? 
o In your opinion what constitutes adequate control? V Important 
 
Outcome measures (Roz  ? ǁŝůůĐŽŵďŝŶĞǁŝƚŚĂƌƌŽŶ ?ƐƐĞĐƚŝŽŶĂďŽǀĞ ? 
฀ There are a number of different ways in which a doctor can assess whether treatment has 
been successful or not. For example by looking at the vulval skin and making a clinical 
assessment of whether it has improved or not, or by asking the patient to complete 
questionnaires. It is becoming more frequent to base treatment decisions on patient 
assessment of disease severity, using the results of these questionnaires. There are a 
number of different questionnairĞƐŽƌ ‘ƚŽŽůƐ ?ƚŚĂƚmay be used in the outpatient clinic, but 
none have been devised specifically for ELP or vulval skin conditions. Therefore, we want 
to hear your opinion on these commonly used tools and whether they cover relevant 
issues to your condition, or not. 
 
o Firstly in your own time, could you fill in these forms? Afterwards we will discuss 
the pros and cons of each one. 
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o We will also ask you to rank the tools in order of which are best and most user-
friendly to use 
o What do you think about the ways we should see if the medication has worked?  
Are there any things specifically that you think should be included? 
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Focus Group Session 2 
Additional points to clarify following FG session 1: 
฀ Talking about symptoms and main worries form ELP, you mentioned thĞƚĞƌŵ ‘&h^/KE ? ?Is this 
something you have picked up from doctors in clinic, or is it from the information sheets you 
have/internet  W the reason we ask is that it is quite a specific term and we refer to it as a form of 
ƐĐĂƌƌŝŶŐ ?tĞĂƌĞŶ ?ƚƐƵƌĞǁŚĞƚŚĞƌƉĂtients elsewhere in the country would use the same term 
ĂŶĚŝƚ ?ƐƚŚĞƌĞĨŽƌĞŝŵƉŽƌƚĂŶƚƚŽŬŶŽǁŝŶǁŚĂƚƐĞƚƚŝŶŐǇŽƵŚĂǀĞŚĞĂƌĚƚŚĞƚĞƌŵ. 
฀ You talked about psychological aspect being one of the worst  W is this because you are having to 
deal with a long-term condition that may not go away, in a similar way to diabetes or heart 
disease, or is it more than that given the location and nature of the condition? 
฀ We talked about adequate control and you seemed to say that you wanted comfort most of the 
time and to be able to do the things you want to do in comfort. Putting that into real terms, 
what would you consider a worthwhile improvement in your symptoms  W for example, if you 
are sore ever day, would soreness every other day be considered a worthwhile improvement? 
Or would you want to reduce symptoms to once or twice a week to consider it better? 
o How about taking a tablet medication  W how much better would you want your 
symptoms to get to consider taking a tablet worthwhile? 
฀ We also talked quite a bit about questionnaires that can be used to monitor your symptoms and 
progress and you were keen on the following: 
o Visual Analogue Scale for Soreness (0-10) 
o 0-10 scale for other symptoms individually  W itch and burn. Not so keen on a 3 point 
scale, but how about a compromise of 0-5 for overall disease control in your opinion? 
E.g 0-no disease, 1  W very mild, 2  W mild, 3-moderate, 4  W severe, 5-very severe 
o BUT how about a method of assessing overall control of your ELP  W which wording 
seems most appropriate 
 How would you rate your symptoms in the last week? 
 How much bother has your ELP caused in the last week? 
 How has your overall disease control been in the last week? 
o How would you like to rate the overall control (wording will depend upon which 
question is decided)  
 None/ a little/ moderate/ severe/ very severe 
 10 point scale  ? 0=no bother, 10=most bother you can imagine 
o KZ ?ĚŽǇŽƵĐŽŶƐŝĚĞƌƐĐŽƌŝŶŐƐŽƌĞŶĞƐƐĂƐƚŚĞŵŽƐƚŝŵƉŽƌƚĂŶƚǁĂǇƚŽŵĞĂƐƵƌĞ
control? 
o We talked quite a lot about day to day function, including sexual function  W one of 
the simpler scales seemed preferable to you, do you think we should ask patients 
about this in clinic  W how helpful to you is it to be asked, or would you rather we 
focused on quality of life and other day to day activities? 
o If you were in a study would you prefer to complete information, at the outpatient 
clinic (less frequent) or at home (e.g. mobile phone or computer or paper based?) 
which would be more frequent( but you would need to remember to do it), or by 
telephone call from the coordinator? 
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A brief powerpoint presentation will be given to give an overview of the proposed randomised 
controlled trial. Participants will then be asked to voice their thoughts on the overall design. If 
needed the following prompts will be used: 
Study design 
฀ What are your first, honest impressions? 
 
฀ What further information would you like to know if you were told about this in clinic? 
 
฀ Are any aspects of the study you particularly like? 
 
฀ Are there any parts of the study which concern you? (prompts: ask about timing and 
number of visits including telephone calls, questionnaires, disease state, medications, 
blood tests etc). 
 
฀ What things could be changed to make the study more attractive to potential participants? 
 
฀ What are your thoughts on the planned medications? Is there anything that should be put 
in the information leaflet that would allay your fears? 
 
฀ How would you feel about photographs being taken? (If they are not happy with this ask 
 ‘ŚŽǁ ǁŽƵůĚ ǇŽƵ ĨĞĞů ĂďŽƵƚ ŚĂǀŝŶŐ ĂŶ ŝŶĚĞƉĞŶĚĞŶƚ ĂƐƐĞƐƐŽƌĞǆĂŵŝŶĞ ƚŚĞŵ ĨŽƌ severity 
ĚƵƌŝŶŐƚŚĞŝƌĨŽůůŽǁƵƉĂƉƉŽŝŶƚŵĞŶƚ ? ? ? ro would you rather your own Doctor? 
 
฀ Overall is the proposed study acceptable to you as a patient and would you be willing to 
take part in a study like this? If not, what sort of study would you be willing to take part in? 
 
฀ Need to ascertain if any participants would be interested in helping with further work  W re 
discussing trial protocol, PIL lay review for trial, patient member of TSC and TMG, be 
interested in recruiting into trial? 
o Consent form already states they are happy to be contacted further 
 
 
Appendix 10
Outcome measure tools preferred by patients in focus groups
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Hospital Anxiety and
Depression Scale (HADS)
F
O
L
D
H
E
R
E
Clinicians are aware that emotions play an important part in most illnesses. If your clinician knows about
these feelings he or she will be able to help you more.
This questionnaire is designed to help your clinician to know how you feel. Read each item below and
underline the reply which comes closest to how you have been feeling in the past week. Ignore the
numbers printed at the edge of the questionnaire.
Don’t take too long over your replies, your immediate reaction to each item will probably be more
accurate than a long, thought-out response.
F
O
L
D
H
E
R
E
Now check that you have answered all the questions
A D
TOTAL
HADS copyright © R.P. Snaith and A.S. Zigmond, 1983, 1992, 1994.
Record form items originally published in Acta Psychiatrica Scandinavica, 67, 361–70,
copyright © Munksgaard International Publishers Ltd, Copenhagen, 1983.
This edition first published in 1994 by nferNelson Publishing Company Ltd,
9th Floor, 389 Chiswick High Road, London W4 4AL
GL Assessment is part of the Granada Group
This form may not be reproduced by any means without first obtaining permission from the publisher. Email: permissions@gl-assessment.co.uk
A D
I feel tense or ‘wound up’
3 Most of the time
2 A lot of the time
1 From time to time, occasionally
0 Not at all
I still enjoy the things I used to enjoy
0 Definitely as much
1 Not quite so much
2 Only a little
3 Hardly at all
I get a sort of frightened feeling as if
something awful is about to happen
3 Very definitely and quite badly
2 Yes, but not too badly
1 A little, but it doesn’t worry me
0 Not at all
I can laugh and see the funny side of things
0 As much as I always could
1 Not quite so much now
2 Definitely not so much now
3 Not at all
Worrying thoughts go through my mind
3 A great deal of the time
2 A lot of the time
1 Not too often
0 Very little
I feel cheerful
3 Never
2 Not often
1 Sometimes
0 Most of the time
I can sit at ease and feel relaxed
0 Definitely
1 Usually
2 Not often
3 Not at all
A D
I feel as if I am slowed down
Nearly all the time 3
Very often 2
Sometimes 1
Not at all 0
I get a sort of frightened feeling like
‘butterflies’ in the stomach
Not at all 0
Occasionally 1
Quite often 2
Very often 3
I have lost interest in my appearance
Definitely 3
I don’t take as much care as I should 2
I may not take quite as much care 1
I take just as much care as ever 0
I feel restless as if I have to be on the move
Very much indeed 3
Quite a lot 2
Not very much 1
Not at all 0
I look forward with enjoyment to things
As much as I ever did 0
Rather less than I used to 1
Definitely less than I used to 2
Hardly at all 3
I get sudden feelings of panic
Very often indeed 3
Quite often 2
Not very often 1
Not at all 0
I can enjoy a good book or radio or
television programme
Often 0
Sometimes 1
Not often 2
Very seldom 3
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Vulval-specific Skindex-29
HOW OFTEN DURING THE PAST 4
WEEKS DO THESE STATEMENTS
DESCRIBE YOU?
NEVER
1
RARELY
2
SOMETIMES
3
OFTEN
4
ALL THE
TIME
5
1 My vulva hurts Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
2 My vulvar condition affects how well
I sleep Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
3 I worry that my vulvar condition
may be serious Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
4 My vulvar condition makes it hard to
do work or hobbies Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
5 My vulvar condition affects my social
life Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
6 My vulvar condition makes me feel
depressed Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
7 My vulva burns or stings Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
8 I tend to stay at home because of
my vulvar condition Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
9 I worry about getting scars from my
vulvar condition Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
10 My vulva itches Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
11 My vulvar condition affects how
close I can be with those I love Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
12 I am ashamed of my vulvar
condition Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
13 I worry that my vulvar condition
may get worse Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
14 I tend to do things by myself
because of my vulvar condition Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
HOW OFTEN DURING THE PAST 4
WEEKS DO THESE STATEMENTS
NEVER RARELY SOMETIMES OFTEN ALL THE
These questions concern your feelings over the past 4 weeks about your vulvar condition.
Check the answer that comes closest to the way you have been feeling.
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Skindex Questionnaire
DESCRIBE YOU? 1 2 3 4 TIME
5
15 I am angry about my vulvar
condition Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
16 Water bothers my vulvar condition
(i.e. bathing) Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
17 My vulvar condition makes showing
affection difficult Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
18 I worry about side effects from
vulvar medications/treatments Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
19 My vulva is irritated Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
20 My vulvar condition affects my
interactions with others Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
21 I am embarrassed by my vulvar
condition Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
22 My vulvar condition is a problem for
the people I love Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
23 I am frustrated by my vulvar
condition Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
24 My vulva is sensitive Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
25 My vulvar condition affects my
desire to be with people Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
26 I am humiliated by my vulvar
condition Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
27 My vulva bleeds Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
28 I am annoyed by my vulvar
condition Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
29 My vulvar condition interferes with
my sex life Ŀ1 Ŀ2 Ŀ3 Ŀ4 Ŀ5
Participant ID: Participant initials:
Date of completion
D D M M M Y Y
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(SF-36v2® Health Survey Standard, United Kingdom (English))
Your Health and Well-Being
This survey asks for your views about your health. This information will help
keep track of how you feel and how well you are able to do your usual
activities. Thank you for completing this survey!
For each of the following questions, please tick the one box that best describes
your answer.
1. In general, would you say your health is:
Excellent Very good Good Fair Poor    
1 2 3 4 5
2. Compared to one year ago, how would you rate your health in general
now?
Much better
now than one
year ago
Somewhat
better
now than one
year ago
About the
same as
one year ago
Somewhat
worse
now than one
year ago
Much worse
now than one
year ago
    
1 2 3 4 5
Participant ID: Participant initials:
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3. The following questions are about activities you might do during a typical
day. Does your health now limit you in these activities? If so, how much?
Yes,
limited
a lot
Yes,
limited
a little
No, not
limited
at all  
a Vigorous activities, such as running, lifting
heavy objects, participating in strenuous sports ...................... 1 ............. 2 ............. 3
b Moderate activities, such as moving a table, pushing
a vacuum cleaner, bowling, or playing golf............................. 1 ............. 2 ............. 3
c Lifting or carrying groceries .................................................... 1 ............. 2 ............. 3
d Climbing several flights of stairs ............................................. 1 ............. 2 ............. 3
e Climbing one flight of stairs .................................................... 1 ............. 2 ............. 3
f Bending, kneeling, or stooping ................................................ 1 ............. 2 ............. 3
g Walking more than a mile........................................................ 1 ............. 2 ............. 3
h Walking several hundred yards................................................ 1 ............. 2 ............. 3
i Walking one hundred yards ..................................................... 1 ............. 2 ............. 3
j Bathing or dressing yourself .................................................... 1 ............. 2 ............. 3
Participant ID: Participant initials:
Page 3 of 6
SF-36v2® Health Survey  1992, 2002, 2009 Medical Outcomes Trust and QualityMetric Incorporated. All rights reserved.
SF-36® is a registered trademark of Medical Outcomes Trust.
(SF-36v2® Health Survey Standard, United Kingdom (English))
4. During the past 4 weeks, how much of the time have you had any of the
following problems with your work or other regular daily activities as a
result of your physical health?
All of
the time
Most of
the time
Some of
the time
A little of
the time
None of
the time    
a Cut down on the amount of
time you spent on work or
other activities.................................. 1.............. 2 .............. 3.............. 4 ............. 5
b Accomplished less than you
would like ........................................ 1.............. 2 .............. 3.............. 4 ............. 5
c Were limited in the kind of
work or other activities .................... 1.............. 2 .............. 3.............. 4 ............. 5
d Had difficulty performing the
work or other activities (for
example, it took extra effort) ........... 1.............. 2 .............. 3.............. 4 ............. 5
5. During the past 4 weeks, how much of the time have you had any of the
following problems with your work or other regular daily activities as a
result of any emotional problems (such as feeling depressed or anxious)?
All of
the time
Most of
the time
Some of
the time
A little of
the time
None of
the time    
a Cut down on the amount of
time you spent on work or
other activities.................................. 1.............. 2 .............. 3.............. 4 ............. 5
b Accomplished less than you
would like ........................................ 1.............. 2 .............. 3.............. 4 ............. 5
c Did work or other activities
less carefully than usual................... 1.............. 2 .............. 3.............. 4 ............. 5
Participant ID: Participant initials:
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6. During the past 4 weeks, to what extent has your physical health or
emotional problems interfered with your normal social activities with
family, friends, neighbours, or groups?
Not at all Slightly Moderately Quite a bit Extremely    
1 2 3 4 5
7. How much bodily pain have you had during the past 4 weeks?
None Very mild Mild Moderate Severe Very severe     
1 2 3 4 5 6
8. During the past 4 weeks, how much did pain interfere with your normal
work (including both work outside the home and housework)?
Not at all A little bit Moderately Quite a bit Extremely    
1 2 3 4 5
Participant ID: Participant initials:
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9. These questions are about how you feel and how things have been with you
during the past 4 weeks. For each question, please give the one answer that
comes closest to the way you have been feeling. How much of the time
during the past 4 weeks…
10. During the past 4 weeks, how much of the time has your physical health or
emotional problems interfered with your social activities (like visiting with
friends, relatives, etc.)?
All of
the time
Most of
the time
Some of
the time
A little of
the time
None of
the time    
1 2 3 4 5
All of
the time
Most of
the time
Some of
the time
A little of
the time
None of
the time    
a Did you feel full of life? .................. 1 .............. 2 .............. 3 .............. 4 .............. 5
b Have you been very nervous? .......... 1 .............. 2.............. 3 .............. 4.............. 5
c Have you felt so down in the
dumps that nothing could
cheer you up? ................................... 1 .............. 2 .............. 3 .............. 4 .............. 5
d Have you felt calm and
peaceful? .......................................... 1 .............. 2.............. 3 .............. 4.............. 5
e Did you have a lot of energy? .......... 1 .............. 2 .............. 3 .............. 4 .............. 5
f Have you felt downhearted
and low?........................................... 1 .............. 2.............. 3 .............. 4.............. 5
g Did you feel worn out? .................... 1 .............. 2.............. 3 .............. 4.............. 5
h Have you been happy? ..................... 1 .............. 2.............. 3 .............. 4.............. 5
i Did you feel tired? ........................... 1 .............. 2 .............. 3 .............. 4 .............. 5
Participant ID: Participant initials:
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11. How TRUE or FALSE is each of the following statements for you?
Definitely
true
Mostly
true
Don’t
know
Mostly
false
Definitely
false    
a I seem to get ill more
easily than other people .................. 1 .............. 2 ............. 3 .............. 4.............. 5
b I am as healthy as
anybody I know............................... 1 .............. 2 ............. 3 .............. 4.............. 5
c I expect my health to
get worse......................................... 1 .............. 2 ............. 3 .............. 4.............. 5
d My health is excellent ..................... 1 .............. 2 ............. 3 .............. 4.............. 5
Thank you for completing these questions!

Appendix 11
Categories from Thematic Analysis of Focus Groups
 Level I Level II Level III Level IV 
Management experiences       
  Experiences of Clinical examination     
    Fear of physical examination   
        
  Lack of faith in non-specialists     
  Wanting to be managed by female doctors     
  Negative experiences     
  Treatments     
    Negative experiences   
    Difficulty in managing as asked by Dr   
  Adequate control     
  Co-existing diagnoses and subsequent problems     
        
        
Misunderstandings       
  General public misunderstanding     
  Healthcare workers misunderstanding     
        
  Patient misunderstanding about disease Wanting to be managed by female doctors  
(i.e. feeling that male doctors misunderstand 
them) 
  
    (Leading to) Fear - Anxiety   
        
  Patient misunderstanding about management     
    Inquisitive (wanting to know more)   
      Inquisitive about the disease 
      Inquisitive about treatments 
Route/pathway to diagnosis       
  Diagnostic tests     
    Fear of procedures   
  Improvements in diagnosis     
  Inconsistency in care received     
 Level I Level II Level III Level IV 
  Incorrect diagnosis made     
  Time taken for diagnosis to be made     
        
        
Effects of disease on the patient Symptoms     
    Dryness Effect on daily activities 
    Itching   
    Pain v soreness   
    Triggers_pattens of disease   
      Fear of deterioration 
      Seasonal variation 
  Duration of disease     
  Sites affected     
        
        
Problems caused by the condition Anxiety     
  Effect on daily activities     
    Clothing   
    Eating   
    Mobility_physical activity   
    Sitting   
    Sleep   
    Urination   
        
  Effect on intimite relationships     
    Emotional side of intimacy   
    Guilt   
    Physical side of intimacy   
    Takes pressure off partner   
        
  Quality of life     
 Level I Level II Level III Level IV 
        
Psychological effects       
  Distress     
  Feeling guilty     
  Low mood     
  Stoicism     
    Acceptance of disease over time   
  Fear     
    Fear - Anxiety   
    Fear of physical examination   
    Fear of deterioration   
  Embarrasment     
    Ashamed by what is happening to them   
    Embarassed in public by symptoms   
    Embarassed to talk to doctors   
        
  Coping mechanisms     
    Coping by humorising the situation   
    Physical coping techniques   
Support available for patients       
  Concerned about impacting on other people     
  Wanting reassurance     
  Information available     
    Internet   
    Healthcare professionals   
      Lack of understanding and poor 
informationavailable  
leads to patients being inquisitive but 
also leads to lack  
of faith and psychological effects 
Terminology       
  Anatomy     
 Level I Level II Level III Level IV 
  Fusion_scarring     
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Thematic Map from Focus Group Results

